AU2015200064A1 - Modulation of hsp47 expression - Google Patents

Abstract

Compositions, methods and kits for modulating expression of target genes are provided herein. In various aspects and embodiments, compositions, methods and kits provided herein modulate expression of heat shock protein 47 (hsp47 or SERPINH1). Said compositions, kits or methods may involve use of short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that bind hsp47. Also provided are compositions, methods and kits for treating and/or preventing diseases, conditions or disorders associated with hsp47. WO 2011/072082 PCT/US2010/059578 1.4 H 293_gfp 12 293_hsp47gfp#2 E 293_gp46gfp #1 5 1.0 HT1080_gfp HT1080_hsp47gfp M HT1080_gp46gfp .0.6 E hTERTgfp hTERT hsp47gfp 0 m NRKgfp S0.2 NRKgp46gfp Treatment: 1. cells only 2. RNAiMAX 3. RNAiMAX +- scrambled siRNA 4. RNAiMAX +v siGFP

Description

AUSTRALIA Patents Act 1990 NITTO DENKO CORPORATION COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Modulation of hsp47 expression The following statement is a full description of this invention including the best method of performing it known to us: 1 MODULATION OF HSP47 EXPRESSION RELATED PATENT APPLICATIONS [0001] This application is a divisional application of Australian Patent Application No. 2010328104, which corresponds to International Application No. PCT/US2010/059578 filed 8 December 2010, which claims priority from U.S. Provisional Application Serial Nos. 61/372,072, filed 9 August 2010, 61/307,412, filed 23 February 2010; and 61/285,149, filed 9 December 2009 the contents of each of which are incorporated herein by reference in their entirety and for all purposes. SEQUENCE LISTING [0002] The instant application contains a Sequence Listing which is entitled 220-PCT1_ST25_07-Dec-10.txt, said ASCII copy, created on December 7, 2010 and is 533kb in size, is hereby incorporated by reference in its entirety. FIELD OF THE INVENTION [0003] Provided herein are compositions and methods for modulating expression of hsp47. BACKGROUND OF THE INVENTION [0004] Sato, Y., et al. disclose the administration of vitamin A-coupled liposomes to deliver small interfering RNA (siRNA) against gp46, the rat homolog of human heat shock protein 47, to liver cirrhosis rat animal models. Sato, Y., et al., Nature Biotechnology, vol. 26(4), p. 431-442 (2008). [0005] Chen, J-J., et al. disclose transfecting human keloid samples with HSP47-shRNA (small hairpin RNA) to examine proliferation of keloid fibroblast cells. Chen, J-J., et al., British Journal of Dermatology, vol. 156, p. 1188-1195 (2007). [0006] PCT Patent Publication No. WO 2006/068232 discloses an astrocyte specific drug carrier which includes a retinoid derivative and/or a vitamin A analog. 1A SUMMARY OF THE INVENTION [0007] Compositions, methods and kits for modulating expression of target genes are provided herein. In various aspects and embodiments, compositions, methods and kits provided herein modulate expression of heat shock protein 47 (hsp47), also known as 1B SERPINH1. The compositions, methods and kits may involve use of nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that bind a nucleotide sequence (such as an mRNA sequence) encoding hsp47, for example, the mRNA coding sequence for human hsp47 exemplified by SEQ ID NO: 1. In certain preferred embodiments, the compositions, methods and kits disclosed herein inhibit expression of hsp47. For example, siNA molecules (e.g., RISC length dsNA molecules or Dicer length dsNA molecules) are provided that reduce or inhibit hsp47 expression. Also provided are compositions, methods and kits for treating and/or preventing diseases, conditions or disorders associated with hsp47, such as liver fibrosis, cirrhosis, pulmonary fibrosis including lung fibrosis (including ILF), kidney fibrosis resulting from any condition (e.g., CKD including ESRD), peritoneal fibrosis, chronic hepatic damage, fibrillogenesis, fibrotic diseases in other organs, abnormal scarring (keloids) associated with all possible types of skin injury accidental and iatrogenic (operations); scleroderma; cardiofibrosis, failure of glaucoma filtering operation; and intestinal adhesions. [00081 In one aspect, provided are nucleic acid molecules (e.g., siNA molecules) in which (a) the nucleic acid molecule includes a sense strand and an antisense strand; (b) each strand of the nucleic acid molecule is independently 15 to 49 nucleotides in length; (c) a 15 to 49 nucleotide sequence of the antisense strand is complementary to a sequence of an mRNA encoding human hsp47 (e.g., SEQ ID NO: 1); and (d) a 15 to 49 nucleotide sequence of the sense strand is complementary to the a sequence of the antisense strand and includes a 15 to 49 nucleotide sequence of an mRNA encoding human hsp47 (e.g., SEQ ID NO: 1). [0009] In certain embodiments, the sequence of the antisense strand that is complementary to a sequence of an mRNA encoding human hsp47 includes a sequence complimentary to a sequence between nucleotides 600-800; or 801-899; or 900-1000; or 1001 1300 of SEQ ID NO: 1; or between nucleotides 650-730; or 900-975 of SEQ ID NO: 1. In some embodiments, the antisense strand includes a sequence that is complementary to a sequence of an mRNA encoding human hsp47 corresponding to nucleotides 674-693 of SEQ ID NO: I or a portion thereof; or nucleotides 698-716 of SEQ ID NO: 1 or a portion thereof; or nucleotides 698-722 of SEQ ID NO: I or a portion thereof; or nucleotides 701-720 of SEQ ID NO: I or a portion thereof; or nucleotides 920-939 of SEQ ID NO: I or a portion thereof; or nucleotides 963-982 of SEQ ID NO: I or a portion thereof; or nucleotides 947-972 of SEQ ID NO: I or a portion thereof; or nucleotides 948-966 of SEQ ID NO: 1 or a portion thereof; 2 WO 2011/072082 PCT/US2010/059578 or nucleotides 945-969 of SEQ ID NO: 1 or a portion thereof; or nucleotides 945-963 of SEQ ID NO: I or a portion thereof. [0010] In certain embodiments, the antisense strand of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes a sequence corresponding to SEQ ID NO: 4 or a portion thereof; or SEQ ID NO: 6 or a portion thereof; or SEQ ID NO: 8 or a portion thereof; or SEQ ID NO: 10 or a portion thereof; or SEQ ID NO: 12 or a portion thereof; or SEQ ID NO: 14 or a portion thereof; or SEQ ID NO: 16 or a portion thereof; or SEQ ID NO: 18 or a portion thereof; or SEQ ID NO: 20 or a portion thereof; or SEQ ID NO: 22 or a portion thereof; or SEQ ID NO: 24 or a portion thereof; or SEQ ID NO: 26 or a portion thereof; or SEQ ID NO: 28 or a portion thereof; or SEQ ID NO: 30 or a portion thereof; or SEQ ID NO: 32 or a portion thereof; or SEQ ID NO: 34 or a portion thereof; or SEQ ID NO: 36 or a portion thereof; or SEQ ID NO: 38 or a portion thereof; or SEQ ID NO: 40 or a portion thereof; or SEQ ID NO: 42 or a portion thereof; or SEQ ID NO: 44 or a portion thereof; or SEQ ID NO: 46 or a portion thereof; or SEQ ID NO: 48 or a portion thereof; or SEQ ID NO: 50 or a portion thereof; or SEQ ID NO: 52 or a portion thereof; or SEQ ID NO: 54 or a portion thereof; or SEQ ID NO: 56 or a portion thereof; or SEQ ID NO: 58 or a portion thereof. In certain embodiments, the sense strand of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes a sequence corresponding to SEQ ID NO: 3 or a portion thereof; or SEQ ID NO: 5 or a portion thereof; or SEQ ID NO: 7 or a portion thereof; or SEQ ID NO: 9 or a portion thereof; or SEQ ID NO: 11 or a portion thereof; or SEQ ID NO: 13 or a portion thereof; or SEQ ID NO: 15 or a portion thereof; or SEQ ID NO: 17 or a portion thereof; or SEQ ID NO: 19 or a portion thereof; or SEQ ID NO: 21 or a portion thereof; or SEQ ID NO: 23 or a portion thereof; or SEQ ID NO: 25 or a portion thereof; or SEQ ID NO: 27 or a portion thereof; or SEQ ID NO: 29 or a portion thereof; or SEQ ID NO: 31 or a portion thereof; or SEQ ID NO: 33 or a portion thereof; or SEQ ID NO: 35 or a portion thereof; or SEQ ID NO: 37 or a portion thereof; or SEQ ID NO: 39 or a portion thereof; or SEQ ID NO: 41 or a portion thereof; or SEQ ID NO: 43 or a portion thereof; or SEQ ID NO: 45 or a portion thereof; or SEQ ID NO: 47 or a portion thereof; or SEQ ID NO: 49 or a portion thereof; or SEQ ID NO: 51 or a portion thereof; or SEQ ID NO: 53 or a portion thereof; or SEQ ID NO: 55 or a portion thereof; or SEQ ID NO: 57 or a portion thereof. [0011] In certain preferred embodiments, the antisense strand of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes a sequence corresponding to any one of 3 the antisense sequences shown on Table A-I 9. In certain preferred embodiments the antisense strand and the sense strand are selected from the sequence pairs shown in Table A-19. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_4, SERPINHI_12, SERPINHI_18, SERPINHI 30, SERPINHI_58 and SERPINHI_88. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_4 (SEQ ID NOS:195 and 220), SERPINHI 12 (SEQ ID NOS:196 and 221), SERPINHi30 (SEQ ID NOS:199 and 224), and SERPINHI_58 (SEQ ID NOS:208 and 233). [0012] In some embodiments the antisense and sense strands of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the sequence pairs set forth in SERPINHI_4 (SEQ IDNOS:195 and 220). In some embodiments of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the antisense and sense strands of the sequence pairs set forth in SERPINHI_12 (SEQ ID NOS:196 and 221). In some embodiments the antisense and sense strands of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the sequence pairs set forth in SERPINH1_30 (SEQ ID NOS:199 and 224). In some embodiments of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the antisense and sense strands of the sequence pairs set forth in SERPINHI_58 (SEQ ID NOS:208 and 233). [0013] In certain embodiments, the antisense strand of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes a sequence corresponding to any one of the antisense sequences shown on any one of Tables B or C. [0014] In certain preferred embodiments, the antisense strand of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes a sequence corresponding to any one of the antisense sequences shown on Table A-18. In certain preferred embodiments the antisense strand and the sense strand are selected from the sequence pairs shown in Table A-I 8. In some embodiments of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the antisense and sense strands selected from the sequence pairs set forth in SERPINHI_2 (SEQ ID NOS: 60 and 127), SERPINHI6 (SEQ ID NOS: 63 and 130), SERPINHIl1 (SEQ ID NOS: 68 and 135), SERPINHI_13 (SEQ ID NOS: 69 and 136), SERPINH1_45 (SEQ ID NOS: 97 and 164), SERPINHI_45a (SEQ ID NOS: 98 and 165), SERPINH I_51 (SEQ ID NOS: 101 and 168), SERPINHI_52 (SEQ ID NOS:102 and 169) or SERPINHI_86 (SEQ ID NOS: 123 and 190). In some preferred embodiments the antisense 4 and sense strands are selected from the sequence pairs set forth in SERPINHI_2 (SEQ ID NOS: 60 and 127), SERPINH16 (SEQ ID NOS: 63 and 130), SERPINHI_45a (SEQ ID NOS: 98 and 165), and SERPINHl_51 (SEQ ID NOS: 101 and 168). [00151 In some preferred embodiments, a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the antisense and sense strands selected from the sequence pairs set forth in SERPINHi_2 (SEQ ID NOS: 60 and 127). In some embodiments the antisense and sense strands include the sequence pairs set forth in SERPINHI_6 (SEQ ID NOS: 63 and 130). In some embodiments of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes the antisense and sense strands of the sequence pairs set forth in SERPINHI_11 (SEQ ID NOS: 68 and 135). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI_13 (SEQ ID NOS: 69 and 136). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI_45 (SEQ ID NOS: 97 and 164). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI_45a (SEQ ID NOS: 98 and 165). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINH1 _51 (SEQ ID NOS: 101 and 168). [0016] In certain embodiments, the antisense strand of a nucleic acid molecule (e.g., a siNA molecule) as disclosed herein includes a sequence corresponding to any one of the antisense sequences shown on any one of Tables D or E. [00171 In various embodiments of nucleic acid molecules (e.g., siNA molecules) as disclosed herein, the antisense strand may be 15 to 49 nucleotides in length (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 or 49 nucleotides in length); or 17-35 nucleotides in length; or 17-30 nucleotides in length; or 15-25 nucleotides in length; or 18-25 nucleotides in length; or 18-23 nucleotides in length; or 19-21 nucleotides in length; or 25-30 nucleotides in length; or 26-28 nucleotides in length. In some embodiments of nucleic acid molecules (e.g., siNA molecules) as disclosed herein, the antisense strand may be 19 nucleotides in length. Similarly the sense strand of nucleic acid molecules (e.g., siNA molecules) as disclosed herein may be 15 to 49 nucleotides in length (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 or 49 nucleotides in length); or 17 35 nucleotides in length; or 17-30 nucleotides in length; or 15-25 nucleotides in length; or 18 25 nucleotides in length; or 18-23 nucleotides in length; or 19-21 nucleotides in length; or 25 5 WO 2011/072082 PCT/US2010/059578 30 nucleotides in length; or 26-28 nucleotides in length. In some embodiments of nucleic acid molecules (e.g., siNA molecules) as disclosed herein, the sense strand may be 19 nucleotides in length. In some embodiments of nucleic acid molecules (e.g., siNA molecules) as disclosed herein, the antisense strand and the sense strand may be 19 nucleotides in length. The duplex region of the nucleic acid molecules (e.g., siNA molecules) as disclosed herein may be 15-49 nucleotides in length (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 or49 nucleotides in length), 15-35 nucleotides in length; or 15-30 nucleotides in length; or about 15-25 nucleotides in length; or 17-25 nucleotides in length; or 17-23 nucleotides in length; or 17-21 nucleotides in length; or 25-30 nucleotides in length; or 25-28 nucleotides in length. In various embodiments of nucleic acid molecules (e.g., siNA molecules) as disclosed herein, the duplex region may be 19 nucleotides in length. [0018] In certain embodiments, the sense and antisense strands of a nucleic acid (e.g., an siNA nucleic acid molecule) as provided herein are separate polynucleotide strands. In some embodiments, the separate antisense and sense strands form a double stranded structure via hydrogen bonding, for example, Watson-Crick base pairing. In some embodiments the sense and antisense strands are two separate strands that are covalently linked to each other. In other embodiments, the sense and antisense strands are part of a single polynucleotide strand having both a sense and antisense region; in some preferred embodiments the polynucleotide strand has a hairpin structure. [00191 In certain embodiments, the nucleic acid molecule (e.g., siNA molecule) is a double stranded nucleic acid (dsNA) molecule that is symmetrical with regard to overhangs, and has a blunt end on both ends. In other embodiments the nucleic acid molecule (e.g., siNA molecule) is a dsNA molecule that is symmetrical with regard to overhangs, and has an overhang on both ends of the dsNA molecule; preferably the molecule has overhangs of 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides; preferably the molecule has 2 nucleotide overhangs. In some embodiments the overhangs are 5' overhangs; in alternative embodiments the overhangs are 3' overhangs. In certain embodiments, the overhang nucleotides are modified with modifications as disclosed herein. In some embodiments the overhang nucleotides are 2' deoxynucleotides. [00201 In certain preferred embodiments, the nucleic acid molecule (e.g., siNA molecule) is a dsNA molecule that is asymmetrical with regard to overhangs, and has a blunt end on one 6 WO 2011/072082 PCT/US2010/059578 end of the molecule and an overhang on the other end of the molecule. In certain embodiments the overhang is 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides; preferably the overhang is 2 nucleotides. In some preferred embodiments an asymmetrical dsNA molecule has a 3' overhang (for example a two nucleotide 3'-overhang) on one side of a duplex occurring on the sense strand; and a blunt end on the other side of the molecule. In some preferred embodiments an asymmetrical dsNA molecule has a 5'-overhang (for example a two nucleotide 5'-overhang) on one side of a duplex occurring on the sense strand; and a blunt end on the other side of the molecule. In other preferred embodiments an asymmetrical dsNA molecule has a 3'-overhang (for example a two nucleotide 3'-overhang) on one side of a duplex occurring on the antisense strand; and a blunt end on the other side of the molecule. In some preferred embodiments an asymmetrical dsNA molecule has a 5'-overhang (for example a two nucleotide 5'-overhang) on one side of a duplex occurring on the antisense strand; and a blunt end on the other side of the molecule. In certain preferred embodiments, the overhangs are 2'-deoxynucleotides. [0021] In some embodiments, the nucleic acid molecule (e.g., siNA molecule) has a hairpin structure (having the sense strand and antisense strand on one polynucleotide), with a loop structure on one end and a blunt end on the other end. In some embodiments, the nucleic acid molecule has a hairpin structure, with a loop structure on one end and an overhang end on the other end (for example a 1, 2, 3, 4, 5, 6, 7, or 8 nucleotide overhang); in certain embodiments, the overhang is a 3'-overhang; in certain embodiments the overhang is a 5' overhang; in certain embodiments the overhang is on the sense strand; in certain embodiments the overhang is on the antisense strand. [0022] In some preferred embodiments, the nucleic acid molecule is selected from the nucleic acid molecules shown on Table I. [0023] The nucleic acid molecules (e.g., siNA molecule) disclosed herein may include one or more modifications or modified nucleotides such as described herein. For example, a nucleic acid molecule (e.g., siNA molecule) as provided herein may include a modified nucleotide having a modified sugar; a modified nucleotide having a modified nucleobase; or a modified nucleotide having a modified phosphate group. Similarly, a nucleic acid molecule (e.g., siNA molecule) as provided herein may include a modified phosphodiester backbone and/or may include a modified terminal phosphate group. 7 [00241 Nucleic acid molecules (e.g., siNA molecules) as provided may have one or more nucleotides that include a modified sugar moiety, for example as described herein. In some preferred embodiments the modified sugar moiety is selected from the group consisting of 2' 0-methyl, 2'-methoxyethoxy, 2'-deoxy, 2'-fluoro, 2'-allyl, 2'-0-[2-(methylamino)-2 oxoethyl], 4'-thio, 4'-(CH 2

)

2 -0-2'-bridge, 2'-locked nucleic acid, and 2'-0-(N methylcarbamate). [00251 Nucleic acid molecules (e.g., siNA molecules) as provided may have one or more modified nucleobase(s) for example as described herein, which preferably may be one selected from the group consisting of xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, and acyclonucleotides. [0026] Nucleic acid molecules (e.g., siNA molecules) as provided may have one or more modifications to the phosphodiester backbone, for example as described herein. In some preferred embodiments the phosphodiester bond is modified by substituting the phosphodiester bond with a phosphorothioate, 3'-(or -5')deoxy-3'-(or -5')thio phosphorothioate, phosphorodithioate, phosphoroselenates, 3'-(or -5')deoxy phosphinates, borano phosphates, 3'-(or -5')deoxy-3'-(or 5'-)amino phosphoramidates, hydrogen phosphonates, borano phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phosphotriester or phosphorus linkages. [0027] In various embodiments, the provided nucleic acid molecules (e.g., siNA molecules) may include one or more modifications in the sense strand but not the antisense strand. In some embodiments the provided nucleic acid molecules (e.g., siNA molecules) include one or more modifications in the antisense strand but not the sense strand. In some embodiments the provided nucleic acid molecules (e.g., siNA molecules) include one or more modifications in the both the sense strand and the antisense strand. [0028] In some embodiments in which the provided nucleic acid molecules (e.g., siNA molecules) have modifications, the sense strand includes a pattern of alternating modified and unmodified nucleotides, and/or the antisense strand includes a pattern of alternating modified 8 and unmodified nucleotides; in some preferred versions of such embodiments the modification is a 2'-O-methyl (2' methoxy or 2'OMe) sugar moiety. The pattern of alternating modified and unmodified nucleotides may start with a modified nucleotide at the 5' end or 3' end of one of the strands; for example the pattern of alternating modified and unmodified nucleotides may start with a modified nucleotide at the 5' end or 3' end of the sense strand and/or the pattern of alternating modified and unmodified nucleotides may start with a modified nucleotide at the 5' end or 3' end of the antisense strand. When both the antisense and sense strand include a pattern of alternating modified nucleotides, the pattern of modified nucleotides may be configured such that modified nucleotides in the sense strand are opposite modified nucleotides in the antisense strand; or there may be a phase shift in the pattern such that modified nucleotides of the sense strand are opposite unmodified nucleotides in the antisense strand and vice-versa. [00291 The nucleic acid molecules (e.g., siNA molecules) as provided herein may include 1-3 (i.e., 1, 2 or 3) deoxynucleotides at the 3' end of the sense and/or antisense strand. [0030] The nucleic acid molecules (e.g., siNA molecules) as provided herein may include a phosphate group at the 5' end of the sense and/or antisense strand. In one aspect, provided are double stranded nucleic acid molecules having the structure (Al): (Al) 5' (N)x - Z 3' (antisense strand) 3' Z'-(N')y -z" 5' (sense strand) wherein each of N and N' is a nucleotide which may be unmodified or modified, or an unconventional moiety; wherein each of (N)x and (N')y is an oligonucleotide in which each consecutive N or N' is joined to the next N or N' by a covalent bond; wherein each of Z and Z' is independently present or absent, but if present independently includes 1-5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of(N')y; wherein each of x and y is independently an integer between 18 and 40; wherein the sequence of (N')y is complementary to the sequence of (N)x; and wherein (N)x 9 WO 2011/072082 PCT/US2010/059578 includes an antisense sequence to SEQ ID NO: 1. In some embodiments (N)x includes an antisense oligonucleotide present in Table A-19. In other embodiments (N)x is selected from an antisense oligonucleotide present in Tables B or C. [0031] In some embodiments the covalent bond joining each consecutive N or N' is a phosphodiester bond. [0032] In some embodiments x = y and each of x and y is 19, 20, 21, 22 or 23. In various embodiments x = y =19. [0033] In some embodiments of nucleic acid molecules (e.g., siNA molecules) as disclosed herein, the double stranded nucleic acid molecule is a siRNA, siNA or a miRNA. [0034] In some embodiments, the antisense and sense strands are selected from the sequence pairs set forth in SERPINH1_4 (SEQ ID NOS:195 and 220), SERPINHI_12 (SEQ ID NOS:196 and 221), SERPINHI_30 (SEQ ID NOS:199 and 224), and SERPINH1_58 (SEQ ID NOS:208 and 233). [0035] In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI_4 (SEQ ID NOS:195 and 220). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINH _12 (SEQ ID NOS:196 and 221). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINH1_30 (SEQ ID NOS:199 and 224). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI58 (SEQ ID NOS:208 and 233). [0036] In some embodiments the double stranded nucleic acid molecules comprise a DNA moiety or a mismatch to the target at position 1 of the antisense strand (5' terminus). Such a structure is described herein. According to one embodiment provided are modified nucleic acid molecules having a structure (A2) set forth below: (A2) 5' N 1 -(N)x - Z 3' (antisense strand) 3' Z'-N 2 -(N')y -z" 5' (sense strand) wherein each of N 2 , N and N' is an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of (N)x and (N')y is an oligonucleotide in which each consecutive N or N' is joined to the adjacent N or N' by a covalent bond; 10 WO 2011/072082 PCT/US2010/059578 wherein each of x and y is independently an integer between 17 and 39; wherein the sequence of (N')y has complementarity to the sequence of (N)x and (N)x has complementarity to a consecutive sequence in a target RNA; wherein N' is covalently bound to (N)x and is mismatched to the target RNA or is a complementary DNA moiety to the target RNA; wherein NJ is a moiety selected from the group consisting of natural or modified uridine, deoxyribouridine, ribothymidine, deoxyribothymidine, adenosine or deoxyadenosine; wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N - (N')y; and wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides, consecutive non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present. [00371 In some embodiments the sequence of (N')y is fully complementary to the sequence of (N)x. In various embodiments sequence of N 2 -(N')y is complementary to the sequence of Nl-(N)x. In some embodiments (N)x comprises an antisense that is fully complementary to about 17 to about 39 consecutive nucleotides in a target RNA. In other embodiments (N)x comprises an antisense that is substantially complementary to about 17 to about 39 consecutive nucleotides in a target RNA. [0038] In some embodiments N' and N 2 form a Watson-Crick base pair. In some embodiments Ni and N 2 form a non-Watson-Crick base pair. In some embodiments a base pair is formed between a ribonucleotide and a deoxyribonucleotide. [0039] In some embodiments x =y=1 8 , x =y=1 9 or x =y=20. In preferred embodiments x=y=18. When x=18 in N-(N)x , N' refers to position land positions 2-19 are included in

(N)

18 . When y--18 in N 2 -(N')y, N 2 refers to position 19 and positions 1-18 are included in

(N')

18 . [0040] In some embodiments N' is covalently bound to (N)x and is mismatched to the target RNA. In various embodiments N is covalently bound to (N)x and is a DNA moiety complementary to the target RNA. 11 [00411 In some embodiments a uridine in position I of the antisense strand is substituted with an N' selected from adenosine, deoxyadenosine, deoxyuridine (dU), ribothymidine or deoxythymidine. In various embodiments N' is selected from adenosine, deoxyadenosine or deoxyuridine. [00421 In some embodiments guanosine in position I of the antisense strand is substituted with an N' selected from adenosine, deoxyadenosine, uridine, deoxyuridine, ribothymidine or deoxythymidine. In various embodiments N' is selected from adenosine, deoxyadenosine, uridine or deoxyuridine. [00431 In some embodiments cytidine in position 1 of the antisense strand is substituted with an N' selected from adenosine, deoxyadenosine, uridine, deoxyuridine, ribothymidine or deoxythymidine. In various embodiments N' is selected from adenosine, deoxyadenosine, uridine or deoxyuridine. [00441 In some embodiments adenosine in position 1 of the antisense strand is substituted with an N' selected from deoxyadenosine, deoxyuridine, ribothymidine or deoxythymidine. In various embodiments N' selected from deoxyadenosine or deoxyuridine. [0045] In some embodiments N' and N 2 form a base pair between uridine or deoxyuridine, and adenosine or deoxyadenosine. In other embodiments N' and N 2 form a base pair between deoxyuridine and adenosine. [0046] In some embodiments the double stranded nucleic acid molecule is a siRNA, siNA or a miRNA. The double stranded nucleic acid molecules as provided herein are also refered to as "duplexes". [0047] In some embodiments (N)x includes and antisense oligonucleotide present in Table A-18. In some embodiments x=y=18 and NI-(N)x includes an antisense oligonucleotide present in Table A-18. In some embodiments x=y=19 or x=y=20. In certain preferred embodiments x =y= 18. In some embodiments x=y= 18 and the sequences of Ni -(N)x and N2 (N')y are selected from the pair of oligonucleotides set forth in Table A-18. In some embodiments x=y=18 and the sequences of NI-(N)x and N2-(N')y are selected from the pair of oligonucleotides set forth in Tables D and E. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2 (SEQ ID NOS: 60 and 127), SERPINH_6 (SEQ ID NOS: 63 and 130), SERPINHII I (SEQ ID NOS: 68 and 135), 12 SERPINHI _13 (SEQ ID NOS: 69 and 136), SERPINHI_45 (SEQ ID NOS: 97 and 164), SERPINHI_45a (SEQ ID NOS: 98 and 165), SERPINHIl51 (SEQ ID NOS: 101 and 168), SERPINH1_51a (SEQ ID NOS: 105 and 172), SERPINHI_52 (SEQ ID NOS:102 and 169) or SERPINHI_86 (SEQ ID NOS: 123 and 190). In some preferred embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI _2 (SEQ ID NOS: 60 and 127), SERPINH_6 (SEQ ID NOS: 63 and 130), SERPINHI_45a (SEQ ID NOS: 98 and 165), SERPINH1 _51 (SEQ ID NOS: 101 and 168) and SERPINH1 _51a (SEQ ID NOS: 105 and 172). [0048] In some preferred embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINH1_2 (SEQ ID NOS: 60 and 127). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI 6 (SEQ ID NOS: 63 and 130). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHi_11(SEQ ID NOS: 68 and 135). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHi_13 (SEQ ID NOS: 69 and 136). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINH1_45 (SEQ ID NOS: 97 and 164). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI _45a (SEQ ID NOS: 98 and 165). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI_51 (SEQ ID NOS: 101 and 168). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI 51a (SEQ lID NOS: 105 and 172). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINH1_52 (SEQ ID NOS:102 and 169). In some embodiments the antisense and sense strands are the sequence pairs set forth in SERPINHI_86 (SEQ ID NOS: 123 and 190). In some preferred embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH16 (SEQ ID NOS: 63 and 130), SERPINHI_45a (SEQ ID NOS: 98 and 165), SERPINH1_51 (SEQ ID NOS: 101 and 168) and SERPINH1_5 1a (SEQ ID NOS: 105 and 172). [00491 In some embodiments NI and N2 form a Watson-Crick base pair. In other embodiments NI and N2 form a non-Watson-Crick base pair. In some embodiments NI is a modified riboadenosine or a modified ribouridine. [0050] In some embodiments NI and N2 form a Watson-Crick base pair. In other embodiments NI and N2 form a non-Watson-Crick base pair. In certain embodiments NI is 13 WO 2011/072082 PCT/US2010/059578 selected from the group consisting of riboadenosine, modified riboadenosine, deoxyriboadenosine, modified deoxyriboadenosine. In other embodiments NI is selected from the group consisting of ribouridine, deoxyribouridine, modified ribouridine, and modified deoxyribouridine. [0051] In certain embodiments position 1 in the antisense strand (5' terminus) includes deoxyribouridine (dU) or adenosine. In some embodiments NI is selected from the group consisting of riboadenosine, modified riboadenosine, deoxyriboadenosine, modified deoxyriboadenosine and N2 is selected from the group consisting of ribouridine, deoxyribouridine, modified ribouridine, and modified deoxyribouridine. In certain embodiments NI is selected from the group consisting of riboadenosine and modified riboadenosine and N2 is selected from the group consisting of ribouridine and modified ribouridine. [0052] In certain embodiments NI is selected from the group consisting of ribouridine, deoxyribouridine, modified ribouridine, and modified deoxyribouridine and N2 is selected from the group consisting of riboadenosine, modified riboadenosine, deoxyriboadenosine, modified deoxyriboadenosinc. In certain embodiments NI is selected from the group consisting of ribouridine and deoxyribouridine and N2 is selected from the group consisting of riboadenosine and modified riboadenosine. In certain embodiments Ni is ribouridine and N2 is riboadenosine. In certain embodiments NI is deoxyribouridine and N2 is riboadenosine. [0053] In some embodiments of Structure (A2), NI includes 2'OMe sugar-modified ribouracil or 2'OMe sugar-modified riboadenosine. In certain embodiments of structure (A), N2 includes a TOMe sugar modified ribonucleotide or deoxyribonucleotide. [0054] In some embodiments of Structure (A2), NI includes 2'OMe sugar-modified ribouracil or 2'OMe sugar-modified ribocytosine. In certain embodiments of structure (A), N2 includes a 2'OMe sugar modified ribonucleotide. [0055] In some embodiments each of N and N' is an unmodified nucleotide. In some embodiments at least one of N or N' includes a chemically modified nucleotide or an unconventional moiety. In some embodiments the unconventional moiety is selected from a mirror nucleotide, an abasic ribose moiety and an abasic deoxyribose moiety. In some embodiments the unconventional moiety is a mirror nucleotide, preferably an L-DNA moiety. 14 In some embodiments at least one of N or N' includes a 2'OMe sugar-modified ribonucleotide. [00561 In some embodiments the sequence of (N')y is fully complementary to the sequence of (N)x. In other embodiments the sequence of (N')y is substantially complementary to the sequence of (N)x. 10057] In some embodiments (N)x includes an antisense sequence that is fully complementary to about 17 to about 39 consecutive nucleotides in a target mRNA. In other embodiments (N)x includes an antisense sequence that is substantially complementary to about 17 to about 39 consecutive nucleotides in a target mRNA. [0058] In some embodiments of Structure Al and Structure A2 the compound is blunt ended, for example wherein both Z and Z' are absent. In an alternative embodiment, at least one of Z or Z' is present. Z and Z' independently include one or more covalently linked modified and/ or unmodified nucleotides, including deoxyribonucleotides and ribonucleotides, or an unconventional moiety for example inverted abasic deoxyribose moiety or abasic ribose moiety; a non-nucleotide C3, C4 or C5 moiety, an amino-6 moiety, a mirror nucleotide and the like. In some embodiments each of Z and Z' independently includes a C3 moiety or an amino C6 moiety. In some embodiments Z' is absent and Z is present and includes a non-nucleotide C3 moiety. In some embodiments Z is absent and Z' is present and includes a non-nucleotide C3 moiety. [00591 In some embodiments of Structure Al and Structure A2, each N consists of an unmodified ribonucleotide. In some embodiments of Structure Al and Structure A2, each N' consists of an unmodified nucleotide. In preferred embodiments, at least one of N and N' is a modified ribonucleotide or an unconventional moiety. [0060] In other embodiments the compound of Structure Al or Structure A2 includes at least one ribonucleotide modified in the sugar residue. In some embodiments the compound includes a modification at the 2' position of the sugar residue. In some embodiments the modification in the 2' position includes the presence of an amino, a fluoro, an alkoxy or an alkyl moiety. In certain embodiments the 2' modification includes an alkoxy moiety. In preferred embodiments the alkoxy moiety is a methoxy moiety (also known as 2'-O-methyl; 2'OMe; 2'-OCH3). In some embodiments the nucleic acid compound includes 2'OMe sugar modified alternating ribonucleotides in one or both of the antisense and the sense strands. In 15 other embodiments the compound includes 2'OMe sugar modified ribonucleotides in the antisense strand, (N)x or N1-(N)x, only. In certain embodiments the middle ribonucleotide of the antisense strand; e.g. ribonucleotide in position 10 in a 19-mer strand is unmodified. In various embodiments the nucleic acid compound includes at least 5 alternating 2'OMe sugar modified and unmodified ribonucleotides. In additional embodiments the compound of Structure Al or Structure A2 includes modified ribonucleotides in alternating positions wherein each ribonucleotide at the 5' and 3' termini of (N)x or N1-(N)x are modified in their sugar residues, and each ribonucleotide at the 5' and 3' termini of (N')y or N2-(N')y are unmodified in their sugar residues. [0061] In some embodiments the double stranded molecule includes one or more of the following modifications a) N in at least one of positions 5, 6, 7, 8, or 9 from the 5' terminus of the antisense strand is selected from a 2'5' nucleotide or a mirror nucleotide; b) N' in at least one of positions 9 or 10 from the 5' terminus of the sense strand is selected from a 2'5' nucleotide and a pseudoUridine; and c) N' in 4, 5, or 6 consecutive positions at the 3' terminus positions of (N')y comprises a 2'5' nucleotide. [00621 In some embodiments the double stranded molecule includes a combination of the following modifications a) the antisense strand includes a 2'5' nucleotide or a mirror nucleotide in at least one of positions 5, 6, 7, 8, or 9 from the 5' terminus; and b) the sense strand includes at least one of a 2'5' nucleotide and a pseudoUridine in positions 9 or 10 from the 5' terminus. [0063] In some embodiments the double stranded molecule includes a combination of the following modifications a) the antisense strand includes a 2'5' nucleotide or a mirror nucleotide in at least one of positions 5, 6, 7, 8, or 9 from the 5' terminus; and c) the sense strand includes 4, 5, or 6 consecutive 2'5' nucleotides at the 3' penultimate or 3' terminal positions. 16 [0064] In some embodiments, the sense strand [(N)x or N1-(N)x] includes 1, 2, 3, 4, 5, 6, 7, 8, or 9 2'OMe sugar modified ribonucleotides. In some embodiments, the antisense strand includes 2'OMe modified ribonucleotides at positions 2, 4, 6, 8, 11, 13, 15, 17 and 19. In other embodiments antisense strand includes 2'OMe modified ribonucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19. In other embodiments the antisense strand includes 2'OMe modified ribonucleotides at positions 3, 5, 7, 9, 11, 13, 15, 17 and 19. In some embodiments the antisense strand includes one or more 2'OMe sugar modified pyrimidines. In some embodiments all the pyrimidine nucleotides in the antisense strand are 2'OMe sugar modified. In some embodiments the sense strand includes 2'OMe sugar modified pyrimidines. [00651 In some embodiments of Structure Al and Structure A2, neither the sense strand nor the antisense strand is phosphorylated at the 3' and 5' termini. In other embodiments one or both of the sense strand or the antisense strand are phosphorylated at the 3' termini. [00661 In some embodiments of Structure Al and Structure A2 (N')y includes at least one unconventional moiety selected from a mirror nucleotide, a 2'5' nucleotideand a TNA. In some embodiments the unconventional moiety is a mirror nucleotide. In various embodiments the mirror nucleotide is selected from an L-ribonucleotide (L-RNA) and an L deoxyribonucleotide (L-DNA). In preferred embodiments the mirror nucleotide is L-DNA. In certain embodiments the sense strand comprises an unconventional moiety in position 9 or 10 (from the 5' terminus). In preferred embodiments the sense strand includes an unconventional moiety in position 9 (from the 5' terminus). In some embodiments the sense strand is 19 nucleotides in length and comprises 4, 5, or 6 consecutive unconventional moieties in positions 15, (from the 5' terminus). In some embodiments the sense strand includes 4 consecutive 2'5' ribonucleotides in positions 15, 16, 17, and 18. In some embodiments the sense strand includes 5 consecutive 2'5' ribonucleotides in positions 15, 16, 17, 18 and 19. In various embodiments the sense strand further comprises Z'. In some embodiments Z' includes a C30H moiety or a C3Pi moiety. [00671 In some embodiments of Structure Al (N')y includes at least one L-DNA moiety. In some embodiments x=y=19 and (N')y, consists of unmodified ribonucleotides at positions 1-17 and 19 and one L-DNA at the 3' penultimate position (position 18). In other embodiments x=y=19 and (N')y consists of unmodified ribonucleotides at positions 1-16 and 19 and two consecutive L-DNA at the 3' penultimate position (positions 17 and 18). In various embodiments the unconventional moiety is a nucleotide joined to an adjacent 17 WO 2011/072082 PCT/US2010/059578 nucleotide by a 2'-5' internucleotide phosphate linkage. According to various embodiments (N')y includes 2, 3, 4, 5, or 6 consecutive ribonucleotides at the 3' terminus linked by 2'-5' internucleotide linkages. In one embodiment, four consecutive nucleotides at the 3' terminus of (N')y are joined by three 2'-5' phosphodiester bonds, wherein one or more of the 2'-5' nucleotides which form the 2'-5' phosphodiester bonds further includes a 3'-O-methyl (3'OMe) sugar modification. Preferably the 3' terminal nucleotide of (N')y includes a 2'OMe sugar modification. In certain embodiments x=y-19 and (N')y includes two or more consecutive nucleotides at positions 15, 16, 17, 18 and 19 include a nucleotide joined to an adjacent nucleotide by a 2'-5' intemucleotide bond (2'-5' nucleotide). In various embodiments the nucleotide forming the 2'-5' internucleotide bond includes a 3' deoxyribose nucleotide or a 3' methoxy nucleotide (3' H or 3'OMe in place of a 3' OH). In some embodiments x=y=19 and (N')y includes 2'-5' nucleotides at positions 15, 16 and 17 such that adjacent nucleotides are linked by a 2'-5' internucleotide bond between positions 15-16, 16-17 and 17-18; or at positions, 15, 16, 17, 18, and 19 such that adjacent nucleotides are linked by a 2'-5' internucleotide bond between positions 15-16, 16-17, 17-18 and 18-19 and a 3'OH is available at the 3' terminal nucleotide or at positions 16, 17 and 18 such that adjacent nucleotides are linked by a 2'-5' internucleotide bond between positions 16-17, 17-18 and 18 19. In some embodiments x=y=19 and (N')y includes 2'-5'nucleotides at positions 16 and 17 or at positions 17 and 18 or at positions 15 and 17 such that adjacent nucleotides are linked by a 2'-5' intermucleotide bond between positions 16-17 and 17-18 or between positions 17-18 and 18-19 or between positions 15-16 and 17-18, respectively. In other embodiments the pyrimidine ribonucleotides (rU, rC) in (N')y are substituted with nucleotides joined to the adjacent nucleotide by a 2'-5' internucleotide bond. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINH1 4, SERPINH1 12, SERPINH1_18, SERPINH1_30, SERPINH1_58 or SERPINH1_88, and x=y=19 and (N')y comprises five consecutive nucleotides at the 3' terminus joined by four 2'-5' linkages, specifically the linkages between the nucleotides position 15-16, 16-17, 17-18 and 18-19. [00681 In some embodiments the linkages include phosphodiester bonds. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINH1_4, SERPINH1_12, SERPINHI_18, SERPINHI30, SERPINHI_58 or SERPINHI_88 and x=y=19 and (N')y comprises five consecutive nucleotides at the 3' terminus joined by four 2'-5' linkages and optionally further includes Z' and z' independently selected from an inverted abasic moiety and a C3 alkyl [C3; 1,3-propanediol 18 WO 2011/072082 PCT/US2010/059578 mono(dihydrogen phosphate)] cap. The C3 alkyl cap is covalently linked to the 3' or 5' terminal nucleotide. In some embodiments the 3' C3 terminal cap further comprises a 3' phosphate. In some embodiments the 3' C3 terminal cap further comprises a 3' terminal hydroxy group. [0069] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI 4, SERPINHI 12, SERPINHI 18, SERPINHI_30, SERPINH1_58 or SERPINH1_88 and x=y-19 and (N')y includes an L-DNA position 18; and (N')y optionally further includes Z' and z' independently selected from an inverted abasic moiety and a C3 alkyl [C3; 1,3-propanediol mono(dihydrogen phosphate)] cap. [0070] In some embodiments (N')y includes a 3' terminal phosphate. In some embodiments (N')y includes a 3' terminal hydroxyl. [0071] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI 4, SERPINHI 12, SERPINHI 18, SERPINHI_30, SERPINH1_58 or SERPINH1_88 and x=y-19 and (N)x includes 2'OMe sugar modified ribonucleotides at positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or at positions 2, 4, 6, 8, 11, 13, 15, 17, 19. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI4, SERPINHI-12, SERPINHI-18, SERPINHI-_30, SERPINHI_58 and SERPINH1_88 and x=y=19 and (N)x includes 2'OMe sugar modified pyrimidines. In some embodiments all pyrimidines in (N)x include the 2'OMe sugar modification. [0072] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI2, SERPINHI_6, SERPINHI_11, SERPINHI_13, SERPINHI45, SERPINHI45a, SERPINHI51, SERPIN51a, SERPINHI52 or SERPINHI_86 and x=y=18 and N2 is a riboadenosine moiety. [0073] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI2, SERPINH1_6, SERPINHi_11, SERPINHi_13, SERPINHI 45, SERPINHI 45a, SERPINHi 51, SERPIN51a, SERPINHi 52 or SERPINHI_86 and x=y=18, and N2-(N')y includes five consecutive nucleotides at the 3' terminus joined by four 2'-5' linkages, specifically the linkages between the nucleotides position 15-16, 16-17, 17-18 and 18-19. In some embodiments the linkages include phosphodiester bonds. 19 [0074] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPINHI_6, SERPINHI_11, SERPINHI_13, SERPINHI_45, SERPINHI_45a, SERPINH1_51, SERPINH1_51a, SERPINHI_52 or SERPINHi_86 and x=y=18 and N2-(N')y includes five consecutive nucleotides at the 3' terminus joined by four 2'-5' linkages and optionally further includes Z' and z' independently selected from an inverted abasic moiety and a C3 alkyl [C3; 1,3-propanediol mono(dihydrogen phosphate)] cap. [00751 In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPINHI_6, SERPINHi_11, SERPINHi_13, SERPINH1_45, SERPINHI_45a, SERPINHI_51, SERPINH1_51a, SERPINH1_52 or SERPINHI_86 and x=y=1 8 and N 2 -(N')y includes an L-DNA position 18; and (N')y optionally further includes Z' and z' independently selected from an inverted abasic moiety and a C3 alkyl [C3; 1,3-propanediol mono(dihydrogen phosphate)] cap. [00761 In some embodiments N 2 -(N')y comprises a 3' terminal phosphate. In some embodiments N2-(N')y comprises a 3' terminal hydroxyl. [0077] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPINHI_6, SERPINHI_11, SERPINHI_13, SERPINHI_45, SERPINHI_45a, SERPINH1_51, SERPINHI_51a, SERPINHI_52 or SERPINHI_86 and x=y=18 and N 1 -(N)x includes 2'OMe sugar modified ribonucleotides in positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or in positions 1, 3, 5, 9, 11, 13, 15, 17, 19, or in positions 3, 5, 9, 11, 13, 15, 17, or in positions 2, 4, 6, 8, 11, 13, 15, 17, 19. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPINHI_6, SERPINHI1 1, SERPINHI 13, SERPINH1_45, SERPINHI_45a, SERPINHI_51, SERPINHI1_51a, SERPINHI_52 or SERPiNHI_86 and x=y=1 8 and N 1 -(N)x includes 2'OMe sugar modified ribonucleotides at positions 11, 13, 15, 17 and 19 (from 5' terminus). In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPLNHI_6, SERPINHI_11, SERPINHI_13, SERPINH1-45, SERPINH1_45a, SERPINHI_51, SERPINHI_51 a, SERPINHI 52 or SERPINHI_86 and x=y=18 and Nl-(N)x includes 2'OMe sugar modified ribonucleotides in positions 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or in positions 3, 5, 7, 9, 11, 13, 15, 17, 19. In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPINHI_6, SERPINHI_11, SERPINHI_13, 20 SERPINHI_45, SERPINH1_45a, SERPINHI_51, SERPINHI_51a, SERPINHI _52 or SERPINHI_86 and x=y=1 8 and N1-(N)x includes 2'OMe sugar modified ribonucleotides in positions positions 2, 4, 6, 8, 11, 13, 15, 17, 19. [0078] In some embodiments the antisense and sense strands are selected from the sequence pairs set forth in SERPINHI_2, SERPINHI_6, SERPINH1_11, SERPINHi_13, SERPINHI_45, SERPINHI_45a, SERPINHI_51, SERPINHI_51a, SERPINHI_52 or SERPINHI_86 and x=y=18 and N1-(N)x includes 2'OMe sugar modified pyrimidines. In some embodiments all pyrimidines in (N)x include the 2'OMe sugar modification. In some embodiments the antisense strand further includes an L-DNA or a 2'-5' nucleotide in position 5, 6 or 7 (5'>3'). In other embodiments the antisense strand further includes a ribonucleotide which generates a 2'5' internucleotide linkage in between the ribonucleotides in positions 5-6 or 6-7 (5'>3') [00791 In additional embodiments NI -(N)x further includes Z wherein Z includes a non nucleotide overhang. In some embodiments the non-nucleotide overhang is C3 -C3 [1,3 propanediol mono(dihydrogen phosphate)]2. [0080] In some embodiments of Structure A2, (N')y includes at least one L-DNA moiety. In some embodiments x=y=18 and (N')y consists of unmodified ribonucleotides at positions 1-16 and 18 and one L-DNA at the 3' penultimate position (position 17). In other embodiments x=y=18 and (N')y consists of unmodified ribonucleotides at position 1-15 and 18 and two consecutive L-DNA at the 3' penultimate position (positions 16 and 17). In various embodiments the unconventional moiety is a nucleotide joined to an adjacent nucleotide by a 2'-5' internucleotide phosphate linkage. According to various embodiments (N')y includes 2, 3, 4, 5, or 6 consecutive ribonucleotides at the 3' terminus linked by 2'-5' internucleotide linkages. In one embodiment, four consecutive nucleotides at the 3' terminus of (N')y are joined by three 2'-5' phosphodiester bonds, wherein one or more of the 2'-5' nucleotides which form the 2'-5' phosphodiester bonds further includes a 3'-O-methyl (3'OMe) sugar modification. Preferably the 3' terminal nucleotide of (N')y includes a 2'OMe sugar modification. In certain embodiments x=y=18 and in (N')y two or more consecutive nucleotides at positions 14, 15, 16, 17, and 18 include a nucleotide joined to an adjacent nucleotide by a 2'-5' internucleotide bond. In various embodiments the nucleotide forming the 2'-5' internucleotide bond includes a 3' deoxyribose nucleotide or a 3' methoxy nucleotide. In some embodiments x=y=18 and (N')y includes nucleotides joined to the 21 adjacent nucleotide by a 2'-5' internucleotide bond between positions 15-16, 16-17 and 17-18 or between positions 16-17 and 17-18. In some embodiments x=y=18 and (N')y includes nucleotides joined to the adjacent nucleotide by a 2'-5' internucleotide bond between positions 14-15, 15-16, 16-17, and 17-18 or between positions 15-16, 16-17, and 17-18 or between positions 16-17 and 17-18 or between positions 17-18 or between positions 15-16 and 17-18. In other embodiments the pyrimidine ribonucleotides (rU, rC) in (N')y are substituted with nucleotides joined to the adjacent nucleotide by a 2'-5' internucleotide bond. [0081] In some embodiments the antisense and sense strands are selected from the oligonucleotide pairs set forth in Table A-1 8 and identified herein as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH16 (SEQ ID NOS: 63 and 130), SERPINHI__45a (SEQ ID NOS: 98 and 165), SERPINH1_51 (SEQ ID NOS: 101 and 168) and SERPINHI_ la (SEQ ID NOS: 105 and 172). 100821 In some embodiments the double stranded nucleic acid molecule includes the antisense strand set forth in SEQ ID NO:127 and sense strand set forth in SEQ ID NO:60; identified herein as SERPINHI_2. In some embodiments the double stranded nucleic acid molecule has the structure 5' UAUAGCACCCAUGUGUCUC -Z 3' (antisense SEQ IDNO:127) lll ll l11111111 l l 3' Z -AUAUCGUGGGUACACAGAG - z" 5' (sense SEQ ID NO:60) wherein each " " represents base pairing between the ribonucleotides; wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [00831 In some embodiments provided is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO: 127) includes one or more 2'OMe sugar modified pyrimidines and or purines, a 2'-5' ribonucleotide in position 5, 6, 7 or 8, and a 3' terminal nucleotide or non-nucleotide overhang. In some embodiments the sense strand (SEQ ID 22 NO:60) includes 4 or 5 consecutive 2'5' nucleotides at the 3' terminal or penultimate positions, a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus and a cap moiety covalently attached at the 5' terminus. In other embodiments the sense strand (SEQ ID NO:60) includes one or more 2'OMe pyrimidine, a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus and a cap moiety covalemtly attached at the 5' terminus. [0084] In some embodiments provided is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 15, 17 and 19, a 2'-5' ribonucleotide at position 7, and a C3Pi-C30H moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO:60) is selected from a sense strand which includes a) 2'-5' ribonucleotides at positions 15, 16, 17, 18 and 19, a C30H 3' terminal non-nucleotide overhang; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or b) 2'-5' ribonucleotides at positions 15, 16, 17, 18 and 19, a 3' terminal phosphate; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or c) 2'OMe sugar modified ribonucleotides at positions (5'>3') 5, 7, 13, and 16; a 2'5' ribonucleotide at position 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or d) 2'OMe sugar modified ribonucleotides at positions (5'>3') 7, 13, 16 and 18; a 2'5' ribonucleotide at position 9; a C30H moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or e) 2'-5' ribonucleotides at positions 15, 16, 17, 18, and 19: a C3-Pi moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0085] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO: 127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide at position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO:60) includes 2'-5' ribonucleotides at positions 15, 16, 17, 18, and 19: a C3 3' terminal overhang; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. 23 WO 2011/072082 PCT/US2010/059578 [0086] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide at position 7 and a C3Pi-C3OH, 3' terminal overhang; and the sense strand (SEQ ID NO:60) includes 2'-5' ribonucleotides at positions 15, 16, 17, 18, and 19: a 3' terminal phosphate; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0087] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 15, 17, 19 , a 2'-5' ribonucleotide at position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO:60) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 5, 7, 13, and 16; a 2'-5' ribonucleotide at position 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0088] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 15, 17, 19 , a 2'-5' ribonucleotide at position 7 and a C3Pi-C3OH moicty covalently attached to the 3' terminus; and the sense strand (SEQ ID NO:60) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 7, 13, 16 and 18; a 2'-5' ribonucleotide at position 9; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0089] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide at position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO:60) includes 2'-5' ribonucleotides at positions 15, 16, 17, 18, and 19: a C3-Pi moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0090] In some embodiments provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO: 127) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 13, 15, 17, 19 and a C3-C3 3' terminal overhang; and the sense strand (SEQ ID NO:60) includes 2'OMe sugar modified 24 WO 2011/072082 PCT/US2010/059578 ribonucleotides at positions (5'>3') 7, 9, 13, 16 and 18; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0091] In some embodiments provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:60) includes 2'-5' ribonucleotides at positions 15, 16, 17, 18, and 19: a 3' terminal phosphate and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus and the antisense strand (SEQ ID NO: 127) includes an antisense strand selected from one of a) 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 and a C3Pi-C30H moiety covalently attached to the 3' terminus; or b) 2'OMe sugar modified ribonucleotides at positions (5'>3') 1, 3, 6, 8, 10, 12, 14, 17, 18 and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0092] In some embodiments provided herein is a double stranded nucleic acid molecule which includes the antisense strand set forth in SEQ ID NO: 130 and the sense strand set forth in SEQ ID NO:63; identified herein as SERPINHI_6. In some embodiments the duplex comprises the structure 5' UACUCGUCUCGCAUCUUGU -Z 3' (antisense SEQ ID NO:130) | | | | | | | | | | | | | | | | | | | 3' Z' -AUGAGCAGAGCGUAGAACA -z" 5' (sense SEQ ID NO:63) wherein each "| " represents base parining between the ribonucleotides; wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [0093] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:63) includes one or more 2'OMe sugar modified pyrimidines; a 3' terminal nucleotide or non-nucleotide overhang; and cap moiety covalently attached at the 5' terminus. In some embodiments the antisense strand (SEQ ID NO:130) includes one or 25 WO 2011/072082 PCT/US2010/059578 more 2'OMe sugar modified pyrimidine, a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus and a cap moiety covalently attached at the 5' terminus. [0094] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:63) includes 2'OMe sugar modified ribonucleotides at positions (5'>3') 2, 14 and 18; a C30H or C3Pi moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:130) is selected from an antisense strand which includes a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15 and 17; a 2'-5' ribonucleotide at position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 7, 9, 12, 13 and 17; a 2' 5' ribonucleotide at position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus; or c) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 13, 15 and 17; a 2' 5' ribonucleotide at position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus; or d) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 13, 15 and 17; a dU in position 1; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0095] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:63) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:130) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0096] In some embodiments provided is a duplex oligonucleotide molecule wherein the sense strand (SEQ ID NO:63) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18 and optionally in position 2; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' 26 WO 2011/072082 PCT/US2010/059578 terminus; and the antisense strand (SEQ ID NO: 130) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 7, 9, 12, 13, and 17; a 2'-5' ribonucleotide at position 7; and a C3:Pi-C3OH moiety covalently attached to the 3' terminus. [0097] In some embodiments provided is a duplex oligonucleotide molecule wherein the sense strand (SEQ ID NO:63) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO: 130) is selected from an antisense strand which includes a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3Pi or C3Pi-C3OH moiety covalently attached to the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 7, 9, 12, 13, and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3Pi or C3Pi-C3OH moiety covalently attached to the 3' terminus. [0098] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:63) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:130) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0099] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:63) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:130) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5,7, 9, 12, 13, and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH 3' terminal overhang. 27 WO 2011/072082 PCT/US2010/059578 [0100] In some embodiments the duplex includes the antisense strand set forth in SEQ ID NO:165 and sense strand set forth in SEQ ID NO:98; identified herein as SERPINHI_45a. In some embodiments the duplex comprises the structure 5' AGGAAGUUGAUCUUGGAGU -Z 3' (antisense SEQ ID NO: 165) | | | | | | | | | | | | | | | | | | | 3' Z'-UCCUUCAACUAGAACCUCA -z" 5' (sense SEQ ID NO:98) wherein each "| " represents base parining between the ribonucleotides; wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [0101] In some embodiments the sense strand (SEQ ID NO:98) includes 2'-5' ribonucleotides in positions (5'>3') 15, 16, 17, and 18 or 15, 16, 17, 18, and 19: a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus, and a cap moiety covalently attached at the 5' terminus. In some embodiments the antisense strand (SEQ ID NO:165) includes 2'OMe sugar modified pyrimidine and or purines, a 2'-5' nucleotide in position 5, 6, 7, or 8 (5'>3');, and a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus. [0102] In some embodiments the sense strand (SEQ ID NO:98) includes 2'-5' ribonucleotides in positions (5'>3') 15, 16, 17, 18, and 19: a C3Pi or C3-OH 3' terminal non nucleotide moiety and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:165) includes an antisense strand selected from one of a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2'-5' ribonucleotide in position 7 and a C3Pi-C3Pi or C3Pi-C3OH 3' terminal overhang; or 28 WO 2011/072082 PCT/US2010/059578 b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 4, 6, 8, 11, 13, 15, 17 and 19 and a C3Pi-C3Pi or C3Pi-C30H 3' terminal overhang; c) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5' ribonucleotide in position 7 and a C3Pi-C3Pi or C3Pi-C3OH 3' terminal overhang; or d) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19 and a C3Pi-C3Pi or C3Pi-C3OH 3' terminal overhang. [0103] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:98) includes 2'-5' ribonucleotides in positions (5'>3') 15, 16, 17, 18, and 19: a C3-OH 3' terminal moiety and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:165) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2'-5' ribonucleotide in position 7 and a C3Pi-COH 3' terminal overhang. [0104] In some embodiments the double stranded nucleic acid molecule includes the antisense strand set forth in SEQ ID NO:168 and sense strand set forth in SEQ ID NO:101; identified herein as SERPINHI_51. In some embodiments the duplex comprises the structure 5' JCACCCAUGUGUCUCAGGA -Z 3' (antisense SEQ ID NO: 168) | | | | | | | | | | | | | | | | | | | 3' Z' -AGUGGGUACACAGAGUCCU -z" 5' (sense SEQ ID NO:101) wherein each "| " represents base parining between the ribonucleotides; wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [0105] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:101) includes 2'OMe sugar modified pyrimidines, optionally a 2'-5' ribonucleotide in position 9 or 10; a nucleotide or non-nucleotide moiety covalently 29 WO 2011/072082 PCT/US2010/059578 attached at the 3' terminus and optionally a cap moiety covalently attached at the 5' terminus. In some embodiments the antisense strand (SEQ ID NO: 168) includes 2'OMe sugar modified pyrimidine and or purines, a2'-5' nucleotide in position 5, 6, 7, or 8 (5'>3');, and a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus. [0106] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:101) includes 2'OMe sugar modified pyrimidines in positions (5'>3') 4, 11, 13, and 17, optionally a 2'-5' ribonucleotide in position 9 or 10, a C3Pi or C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO: 168) is selected from an antisense strand which includes a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 8, and 15, a 2'5' ribonucleotide in position 6 or 7; a C3Pi-C3OH overhang covalently attached at the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 13 and 15, a 2'5' ribonucleotide in position 6 or 7; a C3Pi-C3OH overhang covalently attached at the 3' terminus; or c) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 11 and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C3OH overhang covalently attached at the 3' terminus; or d) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 8, 12, 13, and 15; a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [01071 Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:101) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, optionally a 2'-5' ribonucleotide in position 9, a C3-OH non-nucleotide moiety covalently attached at the 3' and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO: 168) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 8, and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [01081 Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:101) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, optionally a 2'-5' ribonucleotide in position 9, a C3-OH non-nucleotide 30 WO 2011/072082 PCT/US2010/059578 moiety covalently attached at the 3' and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO: 168) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 13 and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [0109] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO: 101) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, a 2'-5' ribonucleotide in position 9, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:168) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 11 and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [0110] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:101) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, a 2'-5' ribonucleotide in position 9, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:168) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 8, 12, 13, and 15; a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [01111 In some embodiments the double stranded nucleic acid molecule includes the antisense strand set forth in SEQ ID NO:172 and sense strand set forth in SEQ ID NO:105; identified herein as SERPINH1_51 a. In some embodiments the duplex comprises the structure 5' ACACCCAUGUGUCUCAGGA -Z 3' (antisense SEQ ID NO:172) lllllllllllllllllll 3' Z' -UGUGGGUACACAGAGUCCU -z" 5' (sense SEQ ID NO:105) wherein each " "represents base parining between the ribonucleotides; wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and 31 WO 2011/072082 PCT/US2010/059578 wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [0112] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:105) includes 2'OMe sugar modified pyrimidines, optionally a 2'-5' ribonucleotide in position 9 or 10; a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus and optionally a cap moiety covalently attached at the 5' terminus. In some embodiments the antisense strand (SEQ ID NO:172) includes 2'OMe sugar modified pyrimidine and or purines, a 2'-5' nucleotide in position 5, 6, 7, or 8 (5'>3'); and a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus. [0113] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:105) includes 2'OMe sugar modified pyrimidines in positions (5'>3') 4, 11, 13, and 17, optionally a 2'-5' ribonucleotide in position 9 or 10, a C3Pi or C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:172) is selected from an antisense strand which includes a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 8, and 15, a 2'5' ribonucleotide in position 6 or 7; a C3Pi-C30H moiety covalently attached at the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 8, 13 and 15, a 2'5' ribonucleotide in position 6 or 7; a C3Pi-C30H moiety covalently attached at the 3' terminus; or c) 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 8, 11 and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus; or d) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 8, 12, 13, and 15; a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [0114] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:105) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, optionally a 2'-5' ribonucleotide in position 9, a C3-OH non-nucleotide moiety covalently attached at the 3' and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:172) includes 32 WO 2011/072082 PCT/US2010/059578 2'OMe sugar modified ribonucleotides in positions (5'>3') 8, and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C30H moiety covalently attached at the 3' terminus. [0115] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:105) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, optionally a 2'-5' ribonucleotide in position 9, a C3-OH non-nucleotide moiety covalently attached at the 3' and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5 terminus; and the antisense strand (SEQ ID NO:172) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 8, 13 and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C30H moiety covalently attached at the 3' terminus. [01161 Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:105) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, a 2'-5' ribonucleotide in position 9, a C3-OH non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:172) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 8, 11 and 15, a 2'5' ribonucleotide in position 6; a C3Pi-C30H moiety covalently attached at the 3' terminus. [01171 Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:105) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, a 2'-5' ribonucleotide in position 9, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:172) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 8, 12, 13, and 15; a 2'5' ribonucleotide in position 6; a C3Pi-C3OH moiety covalently attached at the 3' terminus. [01181 In some embodiments the antisense and sense strands are selected from the oligonucleotide pairs set forth in Table A-19 and identified herein as SERPINH1_4 (SEQ ID NOS: 195 and 220) and SERPINHI_12 (SEQ ID NOS: 196 and 221). [0119] In some embodiments the double stranded nucleic acid molecule includes the antisense strand set forth in SEQ ID NO:220 and sense strand set forth in SEQ ID NO:194; identified herein as SERPINHI_4. In some embodiments the double stranded nucleic acid molecule has the structure 33 WO 2011/072082 PCT/US2010/059578 5' AAUAGCACCCAUGUGUCUC -Z 3' (antisense SEQ ID NO:220) | | | | | | | | | | | | | | | | | | | 3' Z' -UUAUCGUGGGUACACAGAG - z" 5' (sense SEQ ID NO:195) wherein each "| " represents base parining between the ribonucleotides; wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [0120] In some embodiments provided is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 15, 17 and 19, a 2'-5' ribonucleotide in position 7, and a C3Pi C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO:195) is selected from a sense strand which includes a) 2'-5' ribonucleotides in positions 15, 16, 17, 18 and 19, a C30H moiety covalently attached to the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or b) 2'-5' ribonucleotides in positions 15, 16, 17, 18 and 19, a 3' terminal phosphate; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or c) 2'OMe sugar modified ribonucleotides in positions (5'>3') 5, 7, 13, and 16; a 2'5' ribonucleotide in position 18; a C30H moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or d) 2'OMe sugar modified ribonucleotides in positions (5'>3') 7, 13, 16 and 18; a 2'5' ribonucleotide in position 9; a C30H moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; or 34 WO 2011/072082 PCT/US2010/059578 e) 2'-5' ribonucleotides in positions 15, 16, 17, 18, and 19: a C3Pi moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0121] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide in position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO: 195) includes 2'-5' ribonucleotides in positions 15, 16, 17, 18, and 19: a C3 moiety covalently attached to the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0122] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 15, 17, 19 , a 2'-5' ribonucleotide in position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO: 195) includes 2'-5' ribonucleotides in positions 15, 16, 17, 18, and 19: a 3' terminal phosphate; and an inverted abasic dcoxyribonucleotide moiety covalently attached at the 5' terminus. [01231 Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide in position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO: 195) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 5, 7, 13, and 16; a 2'-5' ribonucleotide in position 18; a C3OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonuelcotide moiety covalently attached at the 5' terminus. [01241 Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide in position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO: 195) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 7, 13, 16 and 18; a 2'-5' ribonucleotide in position 9; a C3OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. 35 WO 2011/072082 PCT/US2010/059578 [0125] Provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 15, 17, 19, a 2'-5' ribonucleotide in position 7 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO: 195) includes 2'-5' ribonucleotides in positions 15, 16, 17, 18, and 19: a C3Pi moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0126] In some embodiments provided herein is a double stranded nucleic acid molecule wherein the antisense strand (SEQ ID NO:220) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15, 17, 19 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; and the sense strand (SEQ ID NO: 195) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 7, 9, 13, 16 and 18; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus. [0127] In some embodiments provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:195) includes 2'-5' ribonucleotides in positions 15, 16, 17, 18, and 19: a 3' terminal phosphate and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus and the antisense strand (SEQ ID NO:220) includes an antisense strand selected from one of a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 7, 9, 11, 13, 15, 17, 19 and a C3Pi-C3OH moiety covalently attached to the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 6, 8, 10, 12, 14, 17, 18 and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0128] In some embodiments provided herein is a double stranded nucleic acid molecule which includes the antisense strand set forth in SEQ ID NO: 130 and the sense strand set forth in SEQ ID NO:63; identified herein as SERPINHi12. In some embodiments the duplex comprises the structure 5' AACUCGUCUCGCAUCUUGU -Z 3' (antisense SEQ ID NO:221) | | | | | | | | | | | | | | | | | | | 3' Z' -UUGAGCAGAGCGUAGAACA -z" 5' (sense SEQ ID NO:196) wherein each" "represents base parining between the ribonucleotides; 36 WO 2011/072082 PCT/US2010/059578 wherein each of A, C, G, U is independently an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1 5 consecutive nucleotides or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N2-(N')y. [0129] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:196) includes one or more 2'OMe sugar modified pyrimidines; a 3' terminal nucleotide or non-nucleotide overhang; and a cap moiety covalently attached at the 5' terminus. In some embodiments the antisense strand (SEQ ID NO:221) includes one or more 2'OMe sugar modified pyrimidines, a nucleotide or non-nucleotide moiety covalently attached at the 3' terminus, and a cap moiety covalently attached at the 5' terminus. [0130] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:196) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 14 and 18; a C3OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:221) is selected from an antisense strand which includes a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 13, 15 and 17; a 2' 5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 7, 9, 12, 13 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0131] In some embodiments provided is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:196) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:221) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 13, 15 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi C30H moiety covalently attached to the 3' terminus. 37 [0132] In some embodiments provided is a duplex oligonucleotide molecule wherein the sense strand (SEQ ID NO: 196) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18 and optionally in position 2; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:221) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 7, 9, 12, 13, and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [0133] In some embodiments provided is a duplex oligonucleotide molecule wherein the sense strand (SEQ ID NO:196) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:221) is selected from an antisense strand which includes a) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 9, 11, 13, 15 and 17; a 2' 5' ribonucleotide in position 7; and a C3Pi-C30H moiety covalently attached to the 3' terminus; or b) 2'OMe sugar modified ribonucleotides in positions (5'>3') 3, 5, 7, 9, 12, 13 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached to the 3' terminus. [01341 Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO: 196) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:221) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, 15 and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C30H moiety covalently attached to the 3' terminus. [0135] Provided herein is a double stranded nucleic acid molecule wherein the sense strand (SEQ ID NO:196) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 14 and 18; a C3-OH moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand (SEQ ID NO:221) includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 38 5,7, 9, 12, 13, and 17; a 2'-5' ribonucleotide in position 7; and a C3Pi-C30H moiety covalently attached to the 3' terminus. [01361 In further embodiments of Structures Al and A2 (N')y includes 1-8 modified ribonucleotides wherein the modified ribonucleotide is a DNA nucleotide. In certain embodiments (N')y includes 1, 2, 3, 4, 5, 6, 7, or up to 8 DNA moieties. [01371 In some embodiments either Z or Z' is present and independently includes two non-nucleotide moieties. [0138] In additional embodiments Z and Z' are present and each independently includes two non-nucleotide moieties. [01391 In some embodiments each of Z and Z' includes an abasic moiety, for example a deoxyriboabasic moiety (referred to herein as "dAb") or riboabasic moiety (referred to herein as "rAb"). In some embodiments each of Z and/or Z' includes two covalently linked abasic moieties and is for example dAb-dAb or rAb-rAb or dAb-rAb or rAb-dAb, wherein each moiety is covalently attached to an adjacent moiety, preferably via a phospho-based bond. In some embodiments the phospho-based bond includes a phosphorothioate, a phosphonoacetate or a phosphodiester bond. In preferred embodiments the phospho-based bond includes a phosphodiester bond. [01401 In some embodiments each of Z and/or Z' independently includes an alkyl moiety, optionally propane [(CH2) 3] moiety (C3) or a derivative thereof including propanol (C3-OH) and phospho derivative of propanediol ("C3-3'Pi"). In some embodiments each of Z and/or Z' includes two alkyl moieties covalently linked to the 3' terminus of the antisense strand or sense strand via a phosphodiester or phosphorothioate linkage and covalently linked to one another via a phosphodiester or phosphorothioate linkage and in some examples is C3Pi-C3Pi or C3Pi-C30H. The 3' terminus of the antisense strand and/or the 3' terminus of the sense strand is covalently attached to a C3 moiety via a phospho-based bond and the C3 moiety is covalently conjugated to a C3-OH moiety via a phospho-based bond. In some embodiments the phospho-based bonds include a phosphorothioate, a phosphonoacetate or a phosphodiester bond. In preferred embodiments the phospho-based bond includes a phosphodiester bond. [01411 In various embodiments of Structure Al or Structure A2, Z and Z' are absent. In other embodiments Z or Z' is present. In some embodiments each of Z and/or Z' 39 independently includes a C2, C3, C4, C5 or C6 alkyl moiety, optionally a C3 [propane, (CH2) 3 -] moiety or a derivative thereof including propanol (C3-OH/C30H), propanediol, and phosphodiester derivative of propanediol ("C3Pi"). In preferred embodiments each of Z and/or Z' includes two hydrocarbon moieties and in some examples is C3Pi-C30H or C3Pi-C3Pi. Each C3 is covalently conjugated to an adjacent C3 via a covalent bond, preferably a phospho based bond. In some embodiments the phospho-based bond is a phosphorothioate, a phosphonoacetate or a phosphodiester bond. 101421 In specific embodiments x=y=19 and Z comprises at least one C3 alkyl overhang. In some embodiments the C3-C3 overhang is covalently attached to the 3' terminus of (N)x or (N')y via a covalent linkage, preferably a phosphodiester linkage. In some embodiments the linkage between a first C3 and a second C3 is a phosphodiester linkage. In some embodiments the 3' non-nucleotide overhang is C3Pi-C3Pi. In some embodiments the 3' non-nucleotide overhang is C3Pi-C3Ps. In some embodiments the 3' non-nucleotide overhang is C3Pi-C30H (OH is hydroxy). In some embodiments the 3' non-nucleotide overhang is C3Pi-C30H. [01431 In various embodiments the alkyl moiety comprises an alkyl derivative including a C3 alkyl, C4 alkyl, C5 alky or C6 alkyl moiety comprising a terminal hydroxyl, a terminal amino, or terminal phosphate group. In some embodiments the alkyl moiety is a C3 alkyl or C3 alkyl derivative moiety. In some embodiments the C3 alkyl moiety comprises propanol, propylphosphate, propylphosphorothioate or a combination thereof. The C3 alkyl moiety is covalently linked to the 3' terminus of (N')y and/or the 3' terminus of (N)x via a phosphodiester bond. In some embodiments the alkyl moiety comprises propanol, propyl phosphate or propyl phosphorothioate. In some embodiments each of Z and Z' is independently selected from propanol, propyl phosphate, propyl phosphorothioate, combinations thereof or multiples thereof in particular 2 or 3 covalently linked propanol, propyl phosphate, propyl phosphorothioate or combinations thereof. In some embodiments each of Z and Z' is independently selected from propyl phosphate, propyl phosphorothioate, propyl phospho-propanol; propyl phospho-propyl phosphorothioate; propylphospho-propyl phosphate; (propyl phosphate)3, (propyl phosphate) 2 -propanol, (propyl phosphate) 2 - propyl phosphorothioate. Any propane or propanol conjugated moiety can be included in Z or Z'. 40 WO 2011/072082 PCT/US2010/059578 [0144] The structures of exemplary 3' terminal non-nucleotide moieties are as follows: B emu 0 ~3' terminus-C3Pi. 3' terminus-C3-OH o~\ce O O OH O O O O' ' -1-, O B 3' terminus-C3Pi-C30H O O 3 terminus-C3Pi-C3Pi Oe O 3' terminus-C3Pi-C3P-C30H [01451 In some embodiments each of Z and Z' is independently selected from propanol, propyl phosphate, propyl phosphorothioate, combinations thereof or multiples thereof. [0146] In some embodiments each of Z and Z' is independently selected from propyl phosphate, propyl phosphorothioate, propyl phospho-propanol; propyl phospho-propyl phosphorothioate; propylphospho-propyl phosphate; (propyl phosphate)3, (propyl phosphate)2-propanol, (propyl phosphate)2- propyl phosphorothioate. Any propane or propanol conjugated moiety can be included in Z or Z'. 41 WO 2011/072082 PCT/US2010/059578 [0147] In additional embodiments each of Z and/or Z' includes a combination of an abasic moiety and an unmodified deoxyribonucleotide or ribonucleotide or a combination of a hydrocarbon moiety and an unmodified deoxyribonucleotide or ribonucleotide or a combination of an abasic moiety (deoxyribo or ribo) and a hydrocarbon moiety. In such embodiments, each of Z and/or Z' includes C3-rAb or C3-dAb wherein each moiety is covalently bond to the adjacent moiety vi a phospho-based bond, preferably a phosphodiester, phosphorothioate or phosphonoacetate bond. [0148] In certain embodiments nucleic acid molecules as disclosed herein include a sense oligonucleotide sequence selected from any one of Oligo #s 2-67 or 68-92, shown infra in Tables A-18 and A-19, respectfully. [0149] In certain preferred embodiments compounds provided include Compound_1, Compound_2, Compound 3, Compound 4, Compound 5, Compound_6 , Compound_7, Compound 8 and Compound 9 as described herein. [0150] In some embodiments (such as, for example, Compound_1, Compound 5 and Compound_6 as described herein) provided are 19 mer double stranded nucleic acid molecules wherein the antisense strand is SEQ ID NO:127 and the sense strand is SEQ ID NO:60. In certain embodiments, provided are 19 mer double stranded nucleic acid molecules wherein the antisense strand is SEQ ID NO: 127 and includes 2'OMe sugar modified ribonucleotides, a 2'-5' ribonucleotide in at least one of positions 1, 5, 6, or 7, and a 3' terminal non-nucleotide moiety covalently attached to the 3' terminus; and the sense strand is SEQ ID NO:60 and includes at least one 2'5' ribonucleotide or 2'OMe modified ribonucleotide, a non-nucleotide moiety covalently attached at the 3' terminus and a cap moiety covalently attached at the 5' terminus. In some embodiments, provided are 19 mer double stranded nucleic acid molecule wherein the antisense strand is SEQ ID NO:127 and includes 2'OMe sugar modified ribonucleotides at positions 3, 5, 9, 11, 13, 15, 17, and 19 (5'>3'), a 2'-5' ribonucleotide in position 7, and a 3' terminal C30H non-nucleotide moiety covalently attached at the 3' terminus; and the sense strand is SEQ ID NO:60 and includes 5 consecutive 2'5' ribonucleotides in the 3' terminal positions 15, 16, 17, 18, and 19 (5'>3') , a C3Pi non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic moiety covalently attached at the 5' terminus. 42 WO 2011/072082 PCT/US2010/059578 [0151] In one embodiment provided is Compound_1 that is a 19 mer double stranded nucleic acid molecule wherein the antisense strand is SEQ ID NO:127 and includes 2'OMe sugar modified ribonucleotides at positions 3, 5, 9, 11, 13, 15, 17, and 19 (5'>3'), a 2'-5' ribonucleotide in position 7, and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3' terminus; and the sense strand is SEQ ID NO:60 and includes 5 consecutive 2'5' ribonucleotides in the 3' terminal positions 15, 16, 17, 18, and 19 (5'>3'), a C3Pi non nucleotide moiety covalently attached at the 3' terminus and an inverted abasic moiety covalently attached at the 5' terminus; and that further includes a 2'OMe sugar modified ribonuclcotide at position 1 of the antisense strand. [01521 In one embodiment, provided is Compound_6 that is a 19 mer double stranded nucleic acid molecule wherein the antisense strand is SEQ ID NO:127 and includes 2'OMe sugar modified ribonucleotides at positions 3, 5, 9, 11, 13, 15, 17, and 19 (5'>3'), a 2'-5' ribonucleotide in position 7, and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3' terminus; and the sense strand is SEQ ID NO:60 and includes 5 consecutive 2'5' ribonucleotides in the 3' terminal positions 15, 16, 17, 18, and 19 (5'>3') , a C3Pi non nucleotide moiety covalently attached at the 3' terminus and an inverted abasic moiety covalently attached at the 5' terminus; and that further includes a 2'5' ribonucleotide at position 1 of the antisense strand. [0153] In one embodiment, provided is Compound 5 that is a 19 mer double stranded nucleic acid molecule wherein the antisense strand is SEQ ID NO:127 and includes 2'OMe sugar modified ribonucleotides in positions 1, 3, 5, 9, 11, 13, 15, 17, and 19 (5'>3'), a 2'-5' ribonucleotide in position 7, and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3' terminus; and the sense strand is SEQ ID NO:60 and includes 2'OMc sugar modified ribonucleotides in positions (5'>3') 7, 13, 16 and 18, a 2'5' ribonucleotide at position 9, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic moiety covalently attached at the 5' terminus. [0154] In some embodiments (such as, for example, Compound 2, and Compound 7 as described herein) provided are 19 mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:63 and the antisense strand is SEQ ID NO:130. In some embodiments provided are 19-mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:63 and includes 2'OMe sugar modified pyrimidine ribonucleotides; a non-nucleotide moiety covalently attached at the 3' terminus; and a cap moiety covalently 43 WO 2011/072082 PCT/US2010/059578 attached at the 5' terminus; and the antisense strand is SEQ ID NO:130 and includes 2'OMe sugar modified ribonucleotides; a 2'-5' ribonucleotide at position 7; and a non-nucleotide moiety covalently attached at the 3' terminus. In some embodiments provided are 19-mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:63 and includes 2'OMe sugar modified ribonucleotides, a non-nucleotide moiety covalently attached at the 3' terminus, and a cap moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:130 and includes 2'OMe sugar modified ribonucleotides; a 2'-5' ribonucleotide in at least one of positions 5, 6 or 7; and a non-nucleotide moiety covalently attached at the 3' terminus. [01551 In one embodiment, provided is Compound_2 that is a 19-mer double stranded nucleic acid molecule wherein the sense strand is SEQ ID NO:63 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 14 and 18; a C30H moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:130 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 12, 13, and 17; a 2'-5' ribonucleotide in at least one of positions 5, 6 or 7; and C3Pi-C3OH non-nucleotide moiety covalently attached at the 3' terminus. [0156] In one embodiment, provided is Compound_7 that is a 19-mer double stranded nucleic acid molecule wherein the sense strand is SEQ ID NO:63 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 14 and 18; a C30H moiety covalently attached at the 3' terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:130 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 3, 5, 9, 11, 13, and 17; a 2'-5' ribonucleotide at position 7; and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3' terminus. [0157] In some embodimens (such as, for example, Compound_3 as described herein) provided are 19 mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:98 and the antisense strand is SEQ ID NO:165. In some embodiments, provided are 19-mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:98 and includes 2'-5' ribonucleotides in positions at the 3' terminus: a non-nucleotide moiety covalently attached at the 3' terminus and a cap moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:165 and includes 2'OMe sugar modified 44 WO 2011/072082 PCT/US2010/059578 ribonucleotides; a 2'-5' ribonucleotide in at least one of positions 5, 6 or 7 and a non nucleotide moiety covalently attached at the 3' terminus. In one embodiment, provided is Compound_3 that is a 19-mer double stranded nucleic acid molecule wherein the sense strand is SEQ ID NO:98 and includes 2'-5' ribonucleotides in positions (5'>3') 15, 16, 17, 18, and 19: a C3-OH 3' moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:165 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2'-5' ribonucleotide in position 7 and a C3Pi-C3OH covalently attached at the 3' terminus. [0158] In some embodiments (such as, for example, Compound 4, Compound_8 and Compound_9 described herein) provided are 19-mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:101 and the antisense strand is SEQ ID NO: 168. In some embodiments provided are 19-mer double stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:101 and includes 2'OMe sugar modified pyrimidine ribonucleotides, an optional 2'-5' ribonucleotide in one of position 9 or 10, a non-nucleotide moiety covalently attached at the 3' terminus and a cap moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO: 168 and includes 2'OMe sugar modified ribonucleotides, a 2'5' ribonucleotide in at least one of positions 5, 6, or 7; and a non nucleotide moiety covalently attached at the 3' terminus. [0159] In one embodiment, provided is Compound 4 that is a 19-mer double stranded nucleic acid molecule wherein sense strand is SEQ ID NO:101 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, a 2'-5' ribonucleotide in position 9, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:168 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 11 and 15, a 2'5' ribonucleotide in position 6; a 3' C3Pi-C3OH overhang covalently attached at the 3' terminus. [0160] In one embodiment, provided is Compound_8 that is a 19-mer double stranded nucleic acid molecule wherein sense strand is SEQ ID NO:101 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 4, 11, 13, and 17, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO:168 and 45 includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 13 and 15, a 2'5' ribonucleotide in position 6; and a 3' C3Pi-C3OH overhang covalently attached at the 3' terminus. [01611 In one embodiment, provided is Compound_9 that is a 19-mer double stranded nucleic acid molecule wherein the sense strand is SEQ ID NO:101 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 2, 4, 11, 13, and 17, a C30H non-nucleotide moiety covalently attached at the 3' terminus and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5' terminus; and the antisense strand is SEQ ID NO: 168 and includes 2'OMe sugar modified ribonucleotides in positions (5'>3') 1, 4, 8, 11 and 15, a 2'5' ribonucleotide in position 6; a 3' C3Pi-C3OH non-nucleotide moiety covalently attached at the 3' terminus. [0162] In another aspect, provided are methods for reducing the expression of hsp47 in a cell by introducing into a cell a nucleic acid molecule as provided herein in an amount sufficient to reduce expression of hsp47. In one embodiment, the cell is hepatic stellate cell. In another embodiment, the cell is a stellate cell in renal or pulmonary tissue. In certain embodiments, the method is performed in vitro, in other embodiments, the method is performed in vivo. [01631 In yet another aspect, provided are methods for treating an individual suffering from a disease associated with hsp47. The methods include administering to the individual a nucleic acid molecule such as provided herein in an amount sufficient to reduce expression of hsp47. In certain embodiments the disease associated with hsp47 is a disease selected from the group consisting of liver fibrosis, cirrhosis, pulmonary fibrosis including lung fibrosis (including ILF), any condition causing kidney fibrosis (e.g., CKD including ESRD), peritoneal fibrosis, chronic hepatic damage, fibrillogenesis, fibrotic diseases in other organs, abnormal scarring (keloids) associated with all possible types of skin injury accidental and jatrogenic (operations); scleroderma; cardiofibrosis, failure of glaucoma filtering operation; and intestinal adhesions. In some embodiments, the compounds may be useful in treating organ-specific indications, for example indications including those shown in Table 2 below: 46 WO 2011/072082 PCT/US2010/059578 Table 2 Organ Indication Skin Pathologic scarring as keloid and hypertrophic scar Surgical scarring Injury scarring keloid, or nephrogenic fibrosing dermatopathy Peritoneum Peritoneal fibrosis Adhesions Peritoneal Sclerosis associated with continual ambulatory peritoneal dialysis (CAPD) Liver Cirrhosis including post-hepatitis C cirrhosis, primary biliary cirrhosis Liver fibrosis, e.g. Prevention of Liver Fibrosis in Hepatitis C carriers schistomasomiasis cholangitis Liver cirrhosis due to Hepatitis C post liver transplant or Non-Alcoholic Steatohepatitis (NASH) Pancreas inter(pcri)lobular fibrosis (as in alcoholic chronic pancreatitis), periductal fibrosis (as in hereditary pancreatitis), periductal and interlobular fibrosis (as in autoimmune pancreatitis), diffuse inter- and intralobular fibrosis (as in obstructive chronic pancreatitis) Kidney Chronic Kidney Disease (CKD) of any etiology. Treatment of early stage CKD (elevated SCr) in diabetic patients ("prevent" further deterioration in renal function) kidney fibrosis associated with lupus glomeruloschelerosis Diabetic Nephropathy Heart Congestive heart failure, Endomyocardial fibrosis, cardiofibrosis fibrosis associated with myocardial infarction Lung Asthma, Idiopathic pulmonary fibrosis (IPF); Interstitial lung fibrosis (ILF) Radiation Pneumonitis leading to Pulmonary Fibrosis (e.g. due to cancer treating radiation) Bone marrow Myeloproliferative disorders: Myelofibrosis (MF), Polycythemia vera (PV), Essential thrombocythemia (ET) idiopathic myelofibrosis drug induced myelofibrosis. Eye Anterior segment: Corneal opacification e,g, following inherited dystrophies, herpetic keratitis or pterygia; Glaucoma Posterior segment fibrosis and traction retinal detachment, a complication of advanced diabetic retinopathy (DR); Fibrovascular scarring and gliosis in the retina; Under the retina fibrosis for example subsequent to subretinal hemorrhage associated with neovascular AMD Retro-orbital fibrosis, postcataract surgery, proliferative vitreoretinopathy. Ocular cicatricial pemphigoid Intestine Intestinal fibrosis, Crohn's disease Vocal cord Vocal cord scarring, vocal cord mucosal fibrosis, laryngeal fibrosis 47 Vasculature Atherosclerosis, postangioplasty arterial restenosis Multisystemic Scleroderma systemic sclerosis; multifocal fibrosclerosis; sclerodermatous graft versus-host disease in bone marrow transplant recipients, and nephrogenic systemic fibrosis (exposure to gadolinium-based contrast agents (GBCAs), 30% of MRIs) Malignancies of Metastatic and invasive cancer by inhibiting function of activated tumor various origin associated myofibroblasts [0164] In some embodiments the preferred indications include, Liver cirrhosis due to Hepatitis C post liver transplant; Liver cirrhosis due to\ Non-Alcoholic Steatohepatitis (NASH); Idiopathic Pulmonary Fibrosis; Radiation Pneumonitis leading to Pulmonary Fibrosis,; Diabetic Nephropathy; Peritoneal Sclerosis associated with continual ambulatory peritoneal dialysis (CAPD) and Ocular cicatricial pemphigoid. [0165] Fibrotic Liver indications include Alcoholic Cirrhosis, Hepatitis B cirrhosis, Hepatitis C cirrhosis, Hepatitis C (Hep C) cirrhosis post orthotopic liver transplant (OLTX), NASH/NAFLD, Primary biliary cirrhosis (PBC), Primary sclerosing cholangitis (PSC), Biliary atresia, alphal antitrypsin deficiency (A IAD), Copper storage diseases (Wilson's disease), Fructosemia, Galactosemia, Glycogen storage diseases (especially types III, IV, VI, IX, and X), Iron-overload syndromes (hemochromatosis), Lipid abnormalities (e.g., Gaucher's disease). Peroxisomal disorders (eg, Zellweger syndrome), Tyrosinemia, Congenital hepatic fibrosis, Bacterial Infections (eg, brucellosis), Parasitic (eg, echinococcosis), Budd-Chiari syndrome (hepatic veno-occlusive disease). [0166] Pulmonary Indications indications include Idiopathic Pulmonary Fibrosis, Silicosis, Pneumoconiosis, Bronchopulmonary Dysplasia in newborn following neonatal respiratory distress syndrome, Bleomycin/chemo lung injury, Bronchiolitis Obliterans (BOS) post lung transplant, Chronic obstructive pulmonary disorder (COPD), Cystic Fibrosis, Asthma. [01671 Cardiac indications include Cardiomyopathy, Atherosclerosis (Bergers disease, etc), Endomyocardial fibrosis, Atrial Fibrillation, Scarring post Myocardial Infarction (MI) 10168] Other Thoracic indications include Radiation-induced capsule tissue reactions around textured breast implants and Oral submucosal fibrosis. 48 [01691 Renal indications include Autosomal Dominant Polycystic Kidney Disease (ADPKD), Diabetic nephropathy (diabetic glomerulosclerosis), FSGS (collapsing vs. other histologic variants), IgA Nephropathy (Berger Disease), Lupus Nephritis, Wegner's disease, Scleroderma, Goodpasture Syndrome, tubulointerstitial fibrosis: drug induced (protective) pencillins, cephalosporins, analgesic nephropathy, Membranoproliferative glomerulonephritis (MPGN), Henoch-Schonlein Purpura, Congenital nephropathies: Medullary Cystic Disease, Nail-Patella Syndrome and Alport Syndrome. [01701 Bone Marrow indications include lymphangioleiomyomatosis (LAM), Chronic graft vs. host disease, Polycythemia vera, Essential thrombocythemia, Myelofibrosis. [0171] Ocular indications include Retinopathy of Prematurity (RoP), Ocular cicatricial pemphigoid, Lacrimal gland fibrosis, Retinal attachment surgery, Corneal opacity, Herpetic keratitis, Pterygia, Glaucoma, Age-related macular degeneration (AMD/ARMD), Retinal fibrosis associated Diabetes mellitus (DM) retinopathy [01721 Gynecological indications include Endometriosis add on to hormonal therapy for prevention of scarring, post STD fibrosis/salpingitis, 10173] Systemic indications include Dupuytren's disease, palmar fibromatosis, Peyronie's disease, Ledderhose disease, keloids, multifocal fibrosclerosis, nephrogenic systemic fibrosis, nephrogenic myelofibrosis (anemia). [01741 Injury Associated Fibrotic Diseases include Bum (chemical included) induced skin & soft tissue scarring and contraction, Radiation induce skin & organ scarring post cancer therapeutic radiation treatment, Keloid (skin). [01751 Surgical indications include peritoneal fibrosis post peritoneal dialysis catheter, corneal implant, cochlear implant, other implants , silicone implants in breasts, chronic sinusitis; adhesions, pseudointimal hyperplasia of dialysis grafts. [0176] Other indications include Chronic Pancreatitis. [0177] In some embodiments provided is a method for treatment of a subject suffering from liver fibrosis comprising administering to the subject an effective amount of a nucleic acid molecule disclosed herein, thereby treating liver fibrosis. In some embodiments the 49 WO 2011/072082 PCT/US2010/059578 subject is suffering from cirrhosis of the liver due to hepatitis. In some embodiments the subject is suffering from cirrhosis of the liver due to NASH. [0178] In some embodiments provided is the use of a nucleic acid molecule disclosed herein for the manufacture of a medicament to treat liver fibrosis. In some embodiments the liver fibrosis is due to hepatitis. In some embodiments the liver fibrosis is due to NASH. [0179] In some embodiments provided is a method for remodeling of scar tissue comprising administering to a subject in need thereof an effective amount of a nucleic acid molecule disclosed herein, thereby effecting scar tissue remodeling. In some embodiments the scar tissue is in the liver. In some embodiments the subject is suffering from cirrhosis of the liver due to hepatitis. In some embodiments the subject is suffering from cirrhosis of the liver due to NASH. [0180] In some embodiments provided is a method for effecting fibrosis regression comprising administering to a subject in need thereof an effective amount of a nucleic acid molecule disclosed herein, thereby effecting fibrosis regression. [0181] In some embodiments provided is a method for reduction of scar tissue in a subject comprising the step of administering to the subject an effective amount of a nucleic acid molecule disclosed herein to reduce the scar tissue. In some embodiments provided is a method for reducing scar tissue in a subject comprising the step of topically applying to scar tissue an effective amount of a nucleic acid molecule disclosed herein to reduce scar tissue. [0182] In some embodiments provided is a method for improving the appearance of scar tissue comprising the step of topically applying to scar tissue an effective amount of a nucleic acid molecule disclosed herein to improve the appearance of the scar tissue. [0183] In some embodiments provided is a method for treatment of a subject suffering from lung fibrosis comprising administering to the subject an effective amount of a nucleic acid molecule disclosed herein, thereby treating the lung fibrosis. In some embodiments the subject is suffering from interstitial lung fibrosis (ILF). In some embodiments the subject is suffering from Radiation Pneumonitis leading to Pulmonary Fibrosis. In some embodiments the subject is suffering from drug induced lung fibrosis. [0184] In some embodiments provided is the use of a nucleic acid molecule disclosed herein for the manufacture of a medicament to treat lung fibrosis. In some embodiments the 50 lung fibrosis is ILF. In some embodiments the lung fibrosis is drug- or radiatio- induced lung fibrosis. [01851 In one aspect, provided are pharmaceutical compositions that include a nucleic acid molecule (e.g., an siNA molecule) as described herein in a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical formulation includes, or involves, a delivery system suitable for delivering nucleic acid molecules (e.g., siNA molecules) to an individual such as a patient; for example delivery systems described in more detail below. [01861 In a related aspect, provided are compositions or kits that include a nucleic acid molecule (e.g., an siNA molecule) packaged for use by a patient. The package may be labeled or include a package label or insert that indicates the content of the package and provides certain information regarding how the nucleic acid molecule (e.g., an siNA molecule) should be or can be used by a patient, for example the label may include dosing information and/or indications for use. In certain embodiments the contents of the label will bear a notice in a form prescribed by a government agency, for example the United States Food and Drug administration. In certain embodiments, the label may indicate that the nucleic acid molecule (e.g., an siNA molecule) is suitable for use in treating a patient suffering from a disease associated with hsp47; for example, the label may indicate that the nucleic acid molecule (e.g., an siNA molecule) is suitable for use in treating fibroids; or for example the label may indicate that the nucleic acid molecule (e.g., an siNA molecule) is suitable for use in treating a disease selected from the group consisting of fibrosis, liver fibrosis, cirrhosis, pulmonary fibrosis, kidney fibrosis, peritoneal fibrosis, chronic hepatic damage, and fibrillogenesis. 101871 As used herein, the term "heat shock protein 47" or "hsp47" or "HSP47" are used interchangeably and refer to any heat shock protein 47, peptide, or polypeptide having any hsp47 protein activity. Heat shock protein 47 is a serine proteinase inhibitor (serpin) also known, for example, as serpin peptidase inhibitor, clade H, member I (SERPINH1), SERPINH2, collagen binding protein I (CBPI), CBP2, gp46; arsenic-transactivated protein 3 (AsTP3); HSP47; proliferation-inducing gene 14 (PIG 14); PPROM; rheumatoid arthritis antigen A-47 (RA-A47); colligin-1; and colligin-2. In certain preferred embodiments, "hsp47" refers to human hsp47. Heat shock protein 47 (or more particularly human hsp47) may have an amino acid sequence that is the same, or substantially the same, as SEQ ID NO. 2 (Figure 7). 51 WO 2011/072082 PCT/US2010/059578 [0188] As used herein the term "nucleotide sequence encoding hsp47" means a nucleotide sequence that codes for an hsp47 protein or portion thereof. The term "nucleotide sequence encoding hsp47" is also meant to include hsp47 coding sequences such as hsp47 isoforms, mutant hsp47 genes, splice variants of hsp47 genes, and hsp47 gene polymorphisms. A nucleic acid sequence encoding hsp47 includes mRNA sequences encoding hsp47, which can also be referred to as "hsp47 mRNA." An exemplary sequence of human hsp47 mRNA is SEQ ID. NO. 1. [0189] As used herein, the term "nucleic acid molecule" or "nucleic acid" are used interchangeably and refer to an oligonucleotide, nucleotide or polynucleotide. Variations of "nucleic acid molecule" are described in more detail herein. A nucleic acid molecule encompasses both modified nucleic acid molecules and unmodified nucleic acid molecules as described herein. A nucleic acid molecule may include deoxyribonucleotides, ribonucleotides, modified nucleotides or nucleotide analogs in any combination. [0190] As used herein, the term "nucleotide" refers to a chemical moiety having a sugar (or an analog thereof, or a modified sugar), a nucleotide base (or an analog thereof, or a modified base), and a phosphate group (or analog thereof, or a modified phosphate group). A nucleotide encompasses both modified nucleotides or unmodified nucleotides as described herein. As used herein, nucleotides may include deoxyribonucleotides (e.g., unmodified deoxyribonucleotides), ribonucleotides (e.g., unmodified ribonucleotides), and modified nucleotide analogs including, inter alia, locked nucleic acids and unlocked nucleic acids, peptide nucleic acids, L-nucleotides (also referred to as mirror nucleotides), ethylene-bridged nucleic acid (ENA), arabinoside, PACE, nucleotides with a 6 carbon sugar, as well as nucleotide analogs (including abasic nucleotides) often considered to be non-nucleotides. In some embodiments, nucleotides may be modified in the sugar, nucleotide base and/or in the phosphate group with any modification known in the art, such as modifications described herein. A "polynucleotide" or "oligonucleotide" as used herein refer to a chain of linked nucleotides; polynucleotides and oligonucleotides may likewise have modifications in the nucleotide sugar, nucleotide bases and phosphate backbones as are well known in the art and/or are disclosed herein. [0191] As used herein, the term "short interfering nucleic acid", "siNA", or "short interfering nucleic acid molecule" refers to any nucleic acid molecule capable of modulating gene expression or viral replication. Preferably siNA inhibits or down regulates gene 52 expression or viral replication. siNA includes without limitation nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. As used herein, "short interfering nucleic acid", "siNA", or "short interfering nucleic acid molecule" has the meaning described in more detail elsewhere herein. [0192] As used herein, the term "complementary" means that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic acid molecules disclosed herein, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp. 123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377; Turner et al., 1987, J. Am. Chem. Soc. 109:3783 3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, or 10 nucleotides out of a total of 10 nucleotides in the first oligonucleotide being based paired to a second nucleic acid sequence having 10 nucleotides represents 50%, 60%, 70%, 80%, 90%, and 100% complementary respectively). "Fully complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. In one embodiment, a nucleic acid molecule disclosed herein includes about 15 to about 35 or more (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 or more) nucleotides that are complementary to one or more target nucleic acid molecules or a portion thereof. [0193] As used herein, the term "sense region" refers to a nucleotide sequence of a siNA molecule complementary (partially or fully) to an antisense region of the siNA molecule. The sense strand of a siNA molecule can include a nucleic acid sequence having homology with a target nucleic acid sequence. As used herein, "sense strand" refers to nucleic acid molecule that includes a sense region and may also include additional nucleotides. 53 WO 2011/072082 PCT/US2010/059578 [0194] As used herein, the term "antisense region" refers to a nucleotide sequence of a siNA molecule complementary (partially or fully) to a target nucleic acid sequence. The antisense strand of a siNA molecule can optionally include a nucleic acid sequence complementary to a sense region of the siNA molecule. As used herein, "antisense strand" refers to nucleic acid molecule that includes an antisense region and may also include additional nucleotides. [0195] As used herein, the term "RNA" refers to a molecule that includes at least one ribonucleotide residue. [0196] As used herein, the term "duplex region" refers to the region in two complementary or substantially complementary oligonucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a duplex between oligonucleotide strands that are complementary or substantially complementary. For example, an oligonucleotide strand having 21 nucleotide units can base pair with another oligonucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the "duplex region" consists of 19 base pairs. The remaining base pairs may, for example, exist as 5' and 3' overhangs. Further, within the duplex region, 100% complementarity is not required; substantial complementarity is allowable within a duplex region. Substantial complementarity refers to complementarity between the strands such that they are capable of annealing under biological conditions. Techniques to empirically determine if two strands are capable of annealing under biological conditions are well know in the art. Alternatively, two strands can be synthesized and added together under biological conditions to determine if they anneal to one another. [0197] As used herein, the terms "non-pairing nucleotide analog" means a nucleotide analog which includes a non-base pairing moiety including but not limited to: 6 des amino adenosine (Nebularine), 4-Me-indole, 3-nitropyrrole, 5-nitroindole, Ds, Pa, N3-Me ribo U, N3-Me riboT, N3-Me dC, N3-Me-dT, N1-Me-dG, Ni-Me-dA, N3-ethyl-dC, N3-Me dC. In some embodiments the non-base pairing nucleotide analog is a ribonucleotide. In other embodiments it is a deoxyribonucleotide. [0198] As used herein, the term, "terminal functional group" includes without limitation a halogen, alcohol, amine, carboxylic, ester, amide, aldehyde, ketone, ether groups. 54 WO 2011/072082 PCT/US2010/059578 [0199] An "abasic nucleotide" or "abasic nucleotide analog" is as used herein may also be often referred to herein and in the art as a pseudo-nucleotide or an unconventional moiety. While a nucleotide is a monomeric unit of nucleic acid, generally consisting of a ribose or deoxyribose sugar, a phosphate, and a base (adenine, guanine, thymine, or cytosine in DNA; adenine, guanine, uracil, or cytosine in RNA). an abasic or pseudo-nucleotide lacks a base, and thus is not strictly a nucleotide as the term is generally used in the art. Abasic deoxyribose moieties include for example, abasic deoxyribose-3'-phosphate; 1,2-dideoxy-D ribofuranose-3 -phosphate; 1,4-anhydro-2-deoxy-D-ribitol-3-phosphate. Inverted abasic deoxyribose moieties include inverted deoxyriboabasic; 3',5' inverted deoxyabasic 5' phosphate. [0200] The term "capping moiety" (z") as used herein includes a moiety which can be covalently linked to the 5' terminus of (N')y and includes abasic ribose moiety, abasic deoxyribose moiety, modifications abasic ribose and abasic deoxyribose moieties including 2' o alkyl modifications; inverted abasic ribose and abasic deoxyribose moieties and modifications thereof; C6-imino-Pi; a mirror nucleotide including L-DNA and L-RNA; 5'OMc nucleotide; and nucleotide analogs including 4',5'-methylene nucleotide; 1-(p-D erythrofuranosyl)nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate; 12-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; alpha-nucleotide; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted abasic moiety; 1,4-butanediol phosphate; 5'-amino; and bridging or non bridging methylphosphonate and 5' mercapto moieties. [0201] Certain capping moieties may be abasic ribose or abasic deoxyribose moieties; inverted abasic ribose or abasic deoxyribose moieties; C6-amino-Pi; a mirror nucleotide including L-DNA and L-RNA. The nucleic acid molecules as disclosed herein may be synthesized using one or more inverted nucleotides, for example inverted thymidine or inverted adenine (for example see Takei, et al., 2002. JBC 277(26):23800-06). [0202] The term "unconventional moiety" as used herein refers to non-nucleotide moieties including an abasic moiety, an inverted abasic moiety, a hydrocarbon (alkyl) moiety and derivatives thereof, and further includes a deoxyribonucleotide, a modified deoxyribonucleotide, a mirror nucleotide (L-DNA or L-RNA), a non-base pairing nucleotide 55 WO 2011/072082 PCT/US2010/059578 analog and a nucleotide joined to an adjacent nucleotide by a 2'-5' internucleotide phosphate bond; bridged nucleic acids including LNA and ethylene bridged nucleic acids, linkage modified (e.g. PACE) and base modified nucleotides as well as additional moieties explicitly disclosed herein as unconventional moieties. [0203] As used herein, the term "inhibit", "down-regulate", or "reduce" with respect to gene expression means the expression of the gene, or level of RNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits (e.g., mRNA), or activity of one or more proteins or protein subunits, is reduced below that observed in the absence of an inhibitory factor (such as a nucleic acid molecule, e.g., an siNA, for example having structural features as described herein); for example the expression may be reduced to 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less than that observed in the absence of an inhibitor. BRIEF DESCRIPTION OF THE FIGURES [0204] Fig. 1 is a bar graph showing the effect of GFP siNA on various reporter cell lines. Cell lines were established by lenti-viral induction of human HSP47 cDNA-GFP or rat GP46 cDNA-GFP construct into HEK293, human fibrosarcoma cell line HT1080, human HSC line hTERT or NRK cell line. Negative control siNA or siNA against GFP was introduced into the cells and GFP fluorescence was measured. The results showed that siNA against GFP knocks down the fluorescence to different extent in different cell lines. 293_HSP47-GFP and 293_GP46-GFP cell lines were selected for siHsp47 screening due to their easiness of being transfected and sensitivity to fluorescence knockdown. [0205] Fig. 2 is a series of bar graphs showing the cytotoxicity and knockdown efficiency of various siHsp47s in 293_HSP47-GFP and 293_GP46-GFP cell lines. The result showed that siHsp47-C, siHsp47-2 and siHsp47-2d efficiently knockdown both human HSP47 and rat GP46 (the human hsp47 homolog) without substantial cytotoxicity. siGp46A against GP46 does not knock down human HSP47. Additionally, the newly designed siHsp47s outperformed siGp46A in knocking down rat GP46. [0206] Fig. 3 is a bar graph showing the knock down effect of various siHsp47s on hsp47 mRNA, measured by TaqMan® qPCR using the human HSC cell line hTERT. The Y axis represents the remaining mRNA level of hsp47. HSP47-C was most effective among all the hsp47 siNAs tested. 56 [0207] Fig. 4 is a bar graph showing the effect of different hsp47 siNAs on collagen I expression in hTERT cells. The collagen I mRNA levels were measured by real-time quantitative PCR using TaqMan@ probe. The Y axis represents the remaining mRNA expression level of collagen I. The result showed that collagen I mRNA level is significantly reduced in the cells treated with some of the candidates (siHsp47-2, siHsp47-2d, and their combination with siHsp47-1). [02081 Fig. 5 shows the decrease in fibrotic areas of the liver in animals treated with siHSP47. [02091 Fig. 6 is an exemplary nucleic acid sequence of human hsp47 mRNA cDNA (SEQ ID NO: 1; based on the cDNA disclosed in GenBank accession number: NM_001235). 10210] Fig. 7 is an exemplary amino acid sequence of human hsp47 (SEQ ID NO:2). 102111 Fig. 8 is protein coding nucleic acid sequence of human hsp47 cDNA (SEQ ID NO:59), which corresponds to nucleotides 230-1486 of SEQ ID NO: 1. [0212] Figs. 9A-91 show plasma stability of Compound_l, Compound 2, Compound_3, Compound_4, Compound_5, Compound_6, Compound_7, Compound_8 and Compound_9, respectively, as detected by ethidium bromide staining. [02131 Figs. 1 OA- 101 show ontarget/off-target activity of Compound_1, Compound_2 , Compound_3, Compound_4, Compound_5, Compound_6 , Compound_7, Compound_8 and Compound_9, respectively. AS_CM shows activity of antisense strand of compound to a plasmid comprising a full match insert; AS_SM shows activity of antisense strand of compound to a plasmid comprising seed sequence insert; S_CM shows activity of sense strand of compound to a plasmid comprising a full match insert. All assays were performed in human cells, except for data shown in Fig. IOF which was performed in rat REF52 cells. DETAILED DESCRIPTION OF THE INVENTION RNA Interference and siNA Nucleic Acid Molecules [02141 RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Zamore et al., 2000, Cell, 101, 25-33; Fire et al., 1998, Nature, 391, 806; Hamilton et al., 1999, Science, 286, 950 57 WO 2011/072082 PCT/US2010/059578 951; Lin et al., 1999, Nature, 402, 128-129; Sharp, 1999, Genes & Dev., 13:139-141; and Strauss, 1999, Science, 286, 886). The corresponding process in plants (Heifetz et al., International PCT Publication No. WO 99/61631) is often referred to as post-transcriptional gene silencing (PTGS) or RNA silencing. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes (Fire et al., 1999, Trends Genet., 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon clements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized. This mechanism appears to be different from other known mechanisms involving double stranded RNA specific ribonucleases, such as the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L (see for example U.S. Pat. Nos. 6,107,094; 5,898,031; Clemens et al., 1997, J. Interferon & Cytokine Res., 17, 503-524; Adah et al., 2001, Curr. Med. Chem., 8, 1189). [0215] The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as dicer (Bass, 2000, Cell, 101, 235; Zamore et al., 2000, Cell, 101, 25-33; Hammond et al., 2000, Nature, 404, 293). Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Zamore et al., 2000, Cell, 101, 25-33; Bass, 2000, Cell, 101, 235; Berstein et al., 2001, Nature, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and include about 19 base pair duplexes (Zamore et al., 2000, Cell, 101, 25-33; Elbashir et al., 2001, Genes Dev., 15, 188). Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner et al., 2001, Science, 293, 834). The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir et al., 2001, Genes Dev., 15, 188). 58 [02161 RNAi has been studied in a variety of systems. Fire et al., 1998, Nature, 391, 806, were the first to observe RNAi in C. elegans. Bahramian and Zarbl, 1999, Molecular and Cellular Biology, 19, 274-283 and Wianny and Goetz, 1999, Nature Cell Biol., 2, 70, describe RNAi mediated by dsRNA in mammalian systems. Hammond et al., 2000, Nature, 404, 293, describe RNAi in Drosophila cells transfected with dsRNA. Elbashir et al., 2001, Nature, 411, 494 and Tuschl et al., International PCT Publication No. WO 01/75164, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in Drosophila embryonic lysates (Elbashir et al., 2001, EMBO J., 20, 6877 and Tuschl et al., International PCT Publication No. WO 01/75164) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. [02171 Nucleic acid molecules (for example having structural features as disclosed herein) may inhibit or down regulate gene expression or viral replication by mediating RNA interference "RNAi" or gene silencing in a sequence-specific manner (see e.g., Zamore et al., 2000, Cell, 101, 25-33; Bass, 2001, Nature, 411, 428-429; Elbashir et al., 2001, Nature, 411, 494-498; and Kreutzer et al., International PCT Publication No. WO 00/44895; Zernicka Goetz et al., International PCT Publication No. WO 01/3 6646; Fire, International PCT Publication No. WO 99/32619; Plaetinck et al., International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 0 1/29058; Deschamps Depaillette, International PCT Publication No. WO 99/07409; and Li et al., International PCT Publication No. WO 00/44914; Allshire, 2002, Science, 297, 1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein, 2002, Science, 297, 2215-2218; and Hall et al., 2002, Science, 297, 2232-2237; Hutvagner and Zamore, 2002, Science, 297, 2056-60; McManus et al., 2002, RNA, 8, 842-850; Reinhart et al., 2002, Gene & Dev., 16, 1616-1626; and Reinhart & Bartel, 2002, Science, 297, 1831). [0218] An siNA nucleic acid molecule can be assembled from two separate polynucleotide strands, where one strand is the sense strand and the other is the antisense strand in which the antisense and sense strands are self-complementary (i.e. each strand includes nucleotide sequence that is complementary to nucleotide sequence in the other strand); such as where the antisense strand and sense strand form a duplex or double stranded structure having any length and structure as described herein for nucleic acid molecules as provided, for example wherein the double stranded region (duplex region) is about 15 to about 59 WO 2011/072082 PCT/US2010/059578 49 (e.g., about 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 base pairs); the antisense strand includes nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule (i.e., hsp47 mRNA) or a portion thereof and the sense strand includes nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof (e.g., about 17 to about 49 or more nucleotides of the nucleic acid molecules herein are complementary to the target nucleic acid or a portion thereof). [0219] In certain aspects and embodiments a nucleic acid molecule (e.g., a siNA molecule) provided herein may be a "RISC length" molecule or may be a Dicer substrate as described in more detail below. [0220] An siNA nucleic acid molecule may include separate sense and antisense sequences or regions, where the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linkers molecules as is known in the art, or are alternately non covalently linked by ionic interactions, hydrogen bonding, van der Waals interactions, hydrophobic interactions, and/or stacking interactions. Nucleic acid molecules may include a nucleotide sequence that is complementary to nucleotide sequence of a target gene. Nucleic acid molecules may interact with nucleotide sequence of a target gene in a manner that causes inhibition of expression of the target gene. [0221] Alternatively, an siNA nucleic acid molecule is assembled from a single polynucleotide, where the self-complementary sense and antisense regions of the nucleic acid molecules are linked by means of a nucleic acid based or non-nucleic acid-based linker(s), i.e., the antisense strand and the sense strand are part of one single polynucleotide that having an antisense region and sense region that fold to form a duplex region (for example to form a "hairpin" structure as is well known in the art). Such siNA nucleic acid molecules can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region includes nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence (e.g., a sequence of hsp47 mRNA). Such siNA nucleic acid molecules can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region includes nucleotide sequence that is 60 WO 2011/072082 PCT/US2010/059578 complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active nucleic acid molecule capable of mediating RNAi. [0222] The following nomenclature is often used in the art to describe lengths and overhangs of siNA molecules and may be used throughout the specification and Examples. Names given to duplexes indicate the length of the oligomers and the presence or absence of overhangs. For example, a "21+2" duplex contains two nucleic acid strands both of which are 21 nucleotides in length, also termed a 21-mer siRNA duplex or a 21-mer nucleic acid and having a 2 nucleotides 3'-overhang. A "21-2" design refers to a 21-mer nucleic acid duplex with a 2 nucleotides 5'-overhang. A 21-0 design is a 21-mer nucleic acid duplex with no overhangs (blunt). A "21+2UU" is a 21-mer duplex with 2- nucleotides 3'-overhang and the terminal 2 nucleotides at the 3'-ends are both U residues (which may result in mismatch with target sequence). The aforementioned nomenclature can be applied to siNA molecules of various lengths of strands, duplexes and overhangs (such as 19-0, 21+2, 27+2, and the like). In an alternative but similar nomenclature, a "25/27" is an asymmetric duplex having a 25 base sense strand and a 27 base antisense strand with a 2- nucleotides 3'-overhang. A "27/25" is an asymmetric duplex having a 27 base sense strand and a 25 base antisense strand. Chemical Modifications [0223] In certain aspects and embodiments, nucleic acid molecules (e.g., siNA molecules) as provided herein include one or more modifications (or chemical modifications). In certain embodiments, such modifications include any changes to a nucleic acid molecule or polynucleotide that would make the molecule different than a standard ribonucleotide or RNA molecule (i.e., that includes standard adenosine, cytosine, uracil, or guanosine moieties); which may be referred to as an "unmodified" ribonucleotide or unmodified ribonucleic acid. Traditional DNA bases and polynucleotides having a 2'-deoxy sugar represented by adenosine, cytosine, thymine, or guanosine moieties may be referred to as an "unmodified deoxyribonucleotide" or "unmodified deoxyribonucleic acid"; accordingly, the term "unmodified nucleotide" or "unmodified nucleic acid" as used herein refers to an "unmodified ribonucleotide" or "unmodified ribonucleic acid" unless there is a clear indication to the contrary. Such modifications can be in the nucleotide sugar, nucleotide base, nucleotide phosphate group and/or the phosphate backbone of a polynucleotide. 61 [0224] In certain embodiments modifications as disclosed herein may be used to increase RNAi activity of a molecule and/or to increase the in vivo stability of the molecules, particularly the stability in serum, and/or to increase bioavailability of the molecules. Non limiting examples of modifications include without limitation intemucleotide or internucleoside linkages; deoxynucleotides or dideoxyribonucleotides at any position and strand of the nucleic acid molecule; nucleic acid (e.g., ribonucleic acid) with a modification at the 2'-position preferably selected from an amino, fluoro, methoxy, alkoxy and alkyl; 2' deoxyribonucleotides, 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, "acyclic" nucleotides, 5-C-methyl nucleotides, biotin group, and terminal glyceryl and/or inverted deoxy abasic residue incorporation, sterically hindered molecules, such as fluorescent molecules and the like. Other nucleotides modifiers could include 3'-deoxyadenosine (cordycepin), 3'-azido-3'-deoxythymidine (AZT), 2',3' dideoxyinosine (ddl), 2',3'-dideoxy-3'-thiacytidine (3TC), 2',3'-didehydro-2',3' dideoxythymidi- ne (d4T) and the monophosphate nucleotides of 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxy-3'-thiacytidine (3TC) and 2',3'-didehydro-2',3'-dide-oxythymidine (d4T). Further details on various modifications are described in more detail below. [02251 Modified nucleotides include those having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, Principles of Nucleic Acid Structure, Springer-Verlag ed., 1984). Non-limiting examples of nucleotides having a northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2'-O, 4'-C-methylene-(D ribofuranosyl) nucleotides); 2'-methoxyethoxy (MOE) nucleotides; 2'-methyl-thio-ethyl, 2' deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-chloro nucleotides, 2'-azido nucleotides, and 2'-0 methyl nucleotides. Locked nucleic acids, or LNA's are described, for example, in Elman et al., 2005; Kurreck et al., 2002; Crinelli et al., 2002; Braasch and Corey, 2001; Bondensgaard et al., 2000; Wahlestedt et al., 2000; and International Patent Publication Nos. WO 00/47599, WO 99/14226, and WO 98/39352 and WO 2004/083430. In one embodiment, an LNA is incorporated at the 5' terminus of the sense strand. [0226] Chemical modifications also include unlocked nucleic acids, or UNAs, which are non-nucleotide, acyclic analogues, in which the C2'-C3' bond is not present (although UNAs are not truly nucleotides, they are expressly included in the scope of "modified" nucleotides or modified nucleic acids as contemplated herein). In particular embodiments, nucleic acid molecules with an overhang may be modified to have UNAs at the overhang positions (i.e., 2 nucleotide overhang). In other embodiments, UNAs are included at the 3'- or 5'- ends. A 62 UNA may be located anywhere along a nucleic acid strand, i.e. in position 7. Nucleic acid molecules may contain one or more UNA. Exemplary UNAs are disclosed in Nucleic Acids Symposium Series No. 52 p. 133-134 (2008). In certain embodiments a nucleic acid molecule (e.g., a siNA molecule) as described herein include one or more UNAs; or one UNA. In some embodiments, a nucleic acid molecule (e.g., a siNA molecule) as described herein that has a 3'-overhang include one or two UNAs in the 3' overhang. In some embodiments a nucleic acid molecule (e.g., a siNA molecule) as described herein includes a UNA (for example one UNA) in the antisense strand; for example in position 6 or position 7 of the antisense strand. Chemical modifications also include non-pairing nucleotide analogs, for example as disclosed herein. Chemical modifications further include unconventional moieties as disclosed herein. [02271 Chemical modifications also include terminal modifications on the 5' and/or 3' part of the oligonucleotides and are also known as capping moieties. Such terminal modifications are selected from a nucleotide, a modified nucleotide, a lipid, a peptide, and a sugar. [0228] Chemical modifications also include six membered "six membered ring nucleotide analogs." Examples of six-membered ring nucleotide analogs are disclosed in Allart, et al (Nucleosides & Nucleotides, 1998, 17:1523-1526,; and Perez-Perez, et al., 1996, Bioorg. and Medicinal Chem Letters 6:1457-1460) Oligonucleotides including 6-membered ring nucleotide analogs including hexitol and altritol nucleotide monomers are disclosed in International patent application publication No. WO 2006/047842. [0229] Chemical modifications also include "mirror" nucleotides which have a reversed chirality as compared to normal naturally occurring nucleotide; that is a mirror nucleotide may be an "L-nucleotide" analogue of naturally occurring D-nucleotide (see US Patent No. 6,602,858). Mirror nucleotides may further include at least one sugar or base modification and/or a backbone modification, for example, as described herein, such as a phosphorothioate or phosphonate moiety. US Patent No. 6,602,858 discloses nucleic acid catalysts including at least one L-nucleotide substitution. Mirror nucleotides include for example L-DNA (L deoxyriboadenosine-3'-phosphate (mirror dA); L-deoxyribocytidine-3'-phosphate (mirror dC); L-deoxyriboguanosine-3'-phosphate (mirror dG); L-deoxyribothymidine-3'-phosphate (mirror image dT)) and L-RNA (L-riboadenosine-3'-phosphate (mirror rA); L-ribocytidine 63 WO 2011/072082 PCT/US2010/059578 3'-phosphate (mirror rC); L-riboguanosine-3'-phosphate (mirror rG); L-ribouracil-3' phosphate (mirror dU). [0230] In some embodiments, modified ribonucleotides include modified deoxyribonucleotides, for example 5'OMe DNA (5-methyl-deoxyriboguanosine-3'-phosphate) which may be useful as a nucleotide in the 5' terminal position (position number 1); PACE (deoxyriboadenosine 3' phosphonoacetate, deoxyribocytidine 3' phosphonoacetate, deoxyriboguanosine 3' phosphonoacetate, deoxyribothymidine 3' phosphonoacetate. [0231] Modifications may be present in one or more strands of a nucleic acid molecule disclosed herein, e.g., in the sense strand, the antisense strand, or both strands. In certain embodiments, the antisense strand may include modifications and the sense strand my only include unmodified RNA. Nucleobases [0232] Nuclcobases of the nucleic acid disclosed herein may include unmodified ribonucleotides (purines and pyrimidines) such as adenine, guanine, cytosine, uracil. The nucleobases in one or both strands can be modified with natural and synthetic nucleobases such as, thymine, xanthine, hypoxanthine, inosine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, any "universal base" nucleotides; 2-propyl and other alkyl derivatives of adenine and guanine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, amino, thiol, thioalkyl, hydroxyl and other 8-substituted adenines and guanines, 5 trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine, deazapurines, heterocyclic substituted analogs of purines and pyrimidines, e.g., aminoethyoxy phenoxazine, derivatives of purines and pyrimidines (e.g., 1-alkyl-, 1-alkenyl-, heteroaromatic- and 1 alkynyl derivatives) and tautomers thereof, 8-oxo-N6-methyladenine, 7-diazaxanthine, 5 methylcytosine, 5-methyluracil, 5-(1-propynyl)uracil, 5-(1-propynyl) cytosine and 4,4 ethanocytosine). Other examples of suitable bases include non-purinyl and non-pyrimidinyl bases such as 2-aminopyridine and triazines. Sugar moieties [0233] Sugar moieties in nucleic acid disclosed herein may include 2'-hydroxyl pentofuranosyl sugar moiety without any modification. Alternatively, sugar moieties can be 64 modified such as, 2'-deoxy-pentofuranosyl sugar moiety, D-ribose, hexose, modification at the 2' position of the pentofuranosyl sugar moiety such as 2'-O-alkyl (including 2'-O-methyl and 2'-O-ethyl), i.e., 2'-alkoxy, 2'-amino, 2'-O-allyl, 2'-S-alkyl, 2'-halogen (including 2'-fluoro, chloro, and bromo), 2'-methoxyethoxy, 2'-O-methoxyethyl, 2'-O-2-methoxyethyl, 2'-allyloxy (-OCH2CH=CH2), 2'-propargyl, 2'-propyl, ethynyl, ethenyl, propenyl, CF, cyano, imidazole, carboxylate, thioate, Cl to Cl 0 lower alkyl, substituted lower alkyl, alkaryl or aralkyl, OCF3, OCN, 0-, S-, or N- alkyl; 0-, S, or N-alkenyl; SOCH3; SO2CH3; ON02; N02, N3; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino or substituted silyl, as, among others, for example as described in European patents EP 0 586 520 B 1 or EP 0 618 925 Bl. [02341 Alkyl group includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., Cl-C6 for straight chain, C3-C6 for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term Cl -C6 includes alkyl groups containing I to 6 carbon atoms. The alkyl group can be substituted alkyl group such as alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. 102351 Alkoxy group includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy 65 groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc. [02361 In some embodiments, the pentofuranosyl ring may be replaced with acyclic derivatives lacking the C2'-C3'-bond of the pentofuranosyl ring. For example, acyclonucleotides may substitute a 2-hydroxyethoxymethyl group for-the 2' deoxyribofuranosyl sugar normally present in dNMPs. [0237] Halogens include fluorine, bromine, chlorine, iodine. Backbone 10238] The nucleoside subunits of the nucleic acid disclosed herein may be linked to each other by phosphodiester bond. The phosphodiester bond may be optionally substituted with other linkages. For example, phosphorothioate, thiophosphate-D-ribose entities, triester, thioate, 2'-5' bridged backbone (may also be referred to as 5'-2' or 2'5' nucleotide or 2'5' ribonucleotide), PACE, 3'-(or -5')deoxy-3'-(or -5')thio-phosphorothioate, phosphorodithioate, phosphoroselenates, 3'-(or -5')deoxy phosphinates, borano phosphates, 3'-(or -5')deoxy-3'-(or 5'-)amino phosphoramidates, hydrogen phosphonates, phosphonates, borano phosphate esters, phosphoramidates, alkyl or aryl phosphonates and phosphotriester modifications such as alkylphosphotriesters, phosphotriester phosphorus linkages, 5'-ethoxyphosphodiester, P alkyloxyphosphotriester, methylphosphonate, and nonphosphorus containing linkages for example, carbonate, carbamate, silyl, sulfur, sulfonate, sulfonamide, formacetal, thioformacetyl, oxime, methyleneimino, methylenemethylimino, methylenehydrazo, methylenedimethylhydrazo and methyleneoxymethylimino linkages. 66 [02391 Nucleic acid molecules disclosed herein may include a peptide nucleic acid (PNA) backbone. The PNA backbone includes repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. The various bases such as purine, pyrimidine, natural and synthetic bases are linked to the backbone by methylene carbonyl bonds. Terminal Phosphates 102401 Modifications can be made at terminal phosphate groups. Non-limiting examples of different stabilization chemistries can be used, e.g., to stabilize the 3'-end of nucleic acid sequences, including (1) [3'-3']-inverted deoxyribose; (2) deoxyribonucleotide; (3) [5'-3']-3' deoxyribonucleotide; (4) [5'-3']-ribonucleotide; (5) [5'-3']-3'-O-methyl ribonucleotide; (6) 3' glyceryl; (7) [3'-5']-3'-deoxyribonucleotide; (8) [3'-3']-deoxyribonucleotide; (9) [5'-2'] deoxyribonucleotide; and (10) [5'-3']-dideoxyribonucleotide. In addition, unmodified backbone chemistries can be combined with one or more different backbone modifications described herein. [0241] Exemplary chemically modified terminal phosphate groups include those shown below: -oP-CH 2 - O-P-NH -CF2 -NH -~ 0 O- -o0- ~o-P-O- O-P-o - o--- o- -o o -S OMe Me CH 2

NH

2

-

0 - - 1 - 11 0-0 - O-P--O- O-P-0 I I H H C 0-11-0- 0-1-CH- Sulfonic acid equivalent or 0 0 Vanadyl equivalent with any combination of other modifications herein Conjugates [02421 Modified nucleotides and nucleic acid molecules (e.g., siNA molecules) as provided herein may include conjugates, for example, a conjugate covalently attached to the 67 chemically-modified nucleic acid molecule. Non-limiting examples of conjugates include conjugates and ligands described in Vargeese et al., U.S. Ser. No. 10/427,160. The conjugate may be covalently attached to a nucleic acid molecule (such as an siNA molecule) via a biodegradable linker. The conjugate molecule may be attached at the 3'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified nucleic acid molecule. The conjugate molecule may be attached at the 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified nucleic acid molecule. The conjugate molecule may be attached both the 3'-end and 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified nucleic acid molecule, or any combination thereof. In one embodiment, a conjugate molecule may include a molecule that facilitates delivery of a chemically-modified nucleic acid molecule into a biological system, such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified nucleic acid molecule is a polyethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake. Examples of specific conjugate molecules contemplated by the instant invention that can be attached to chemically-modified nucleic acid molecules are described in Vargeese et al., U.S. Ser. No. 10/201,394. Linkers [02431 A nucleic acid molecule provided herein (e.g., an siNA) may include a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the nucleic acid to the antisense region of the nucleic acid. A nucleotide linker can be a linker of > 2 nucleotides in length, for example about 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. The nucleotide linker can be a nucleic acid aptamer. By "aptamer" or "nucleic acid aptamer" as used herein refers to a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that includes a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule (such as hsp47 mRNA) where the target molecule does not naturally bind to a nucleic acid. For example, the aptamer can be used to bind to a ligand binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art. See e.g., Gold et al.; 1995, Annu. Rev. Biochem., 64, 763; Brody and Gold, 2000, J. Biotechnol., 74, 5; Sun, 2000, Curr. Opin. Mol. Ther., 2, 100; Kusser, 2000, J. Biotechnol., 74, 27; 68 WO 2011/072082 PCT/US2010/059578 Hermann and Patel, 2000, Science, 287, 820; and Jayasena, 1999, Clinical Chemistry, 45, 1628. [0244] A non-nucleotide linker may include an abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g. polyethylene glycols such as those having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, Nucleic Acids Res. 1990, 18:6353 and Nucleic Acids Res. 1987, 15:3113; Cload and Schepartz, J. Am. Chem. Soc. 1991, 113:6324; Richardson and Schepartz, J. Am. Chem. Soc. 1991, 113:5109; Ma et al., Nucleic Acids Res. 1993, 21:2585 and Biochemistry 1993, 32:175 1; Durand et al., Nucleic Acids Res. 1990, 18:6353; McCurdy et al., Nucleosides & Nucleotides 1991, 10:287; Jschke et al., Tetrahedron Lett. 1993, 34:301; Ono et al., Biochemistry 1991, 30:9914; Arnold et al., International Publication No. WO 89/02439; Usman et al., International Publication No. WO 95/0673 1; Dudycz et al., International Publication No. WO 95/11910 and Ferentz and Verdine, J. Am. Chem. Soc. 1991, 113:4000. 5' Ends, 3' Ends and Overhans [0245] Nucleic acid molecules disclosed herein (e.g., siNA molecules) may be blunt ended on both sides, have overhangs on both sides or a combination of blunt and overhang ends. Overhangs may occur on either the 5'- or 3'- end of the sense or antisense strand. [0246] 5'- and/or 3'- ends of double stranded nucleic acid molecules (e.g., siNA) may be blunt ended or have an overhang. The 5'-end may be blunt ended and the 3'-end has an overhang in either the sense strand or the antisense strand. In other embodiments, the 3'-end may be blunt ended and the 5'-end has an overhang in either the sense strand or the antisense strand. In yet other embodiments, both the 5'- and 3'- end are blunt ended or both the 5'- and 3'- ends have overhangs. [0247] The 5'- and/or 3'-end of one or both strands of the nucleic acid may include a free hydroxyl group. The 5'- and/or 3'-end of any nucleic acid molecule strand may be modified to include a chemical modification. Such modification may stabilize nucleic acid molecules, e.g., the 3'-end may have increased stability due to the presence of the nucleic acid molecule modification. Examples of end modifications (e.g., terminal caps) include, but are not limited to, abasic, deoxy abasic, inverted (deoxy) abasic, glyceryl, dinucleotide, acyclic nucleotide, amino, fluoro, chloro, bromo, CN, CF, methoxy, imidazole, carboxylate, thioate, C1 to C10 69 lower alkyl, substituted lower alkyl, alkaryl or aralkyl, OCF3, OCN, 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; SOCH3; SO2CH3; ON02; N02, N3; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino or substituted silyl, as, among others, described in European patents EP 586,520 and EP 618,925 and other modifications disclosed herein. 10248] Nucleic acid molecules include those with blunt ends, i.e., ends that do not include any overhanging nucleotides. A nucleic acid molecule can include one or more blunt ends. The blunt ended nucleic acid molecule has a number of base pairs equal to the number of nucleotides present in each strand of the nucleic acid molecule. The nucleic acid molecule can include one blunt end, for example where the 5'-end of the antisense strand and the 3'-end of the sense strand do not have any overhanging nucleotides. Nucleic acid molecule may include one blunt end, for example where the 3'-end of the antisense strand and the 5'-end of the sense strand do not have any overhanging nucleotides. A nucleic acid molecule may include two blunt ends, for example where the 3'-end of the antisense strand and the 5'-end of the sense strand as well as the 5'-end of the antisense strand and 3'-end of the sense strand do not have any overhanging nucleotides. Other nucleotides present in a blunt ended nucleic acid molecule can include, for example, mismatches, bulges, loops, or wobble base pairs to modulate the activity of the nucleic acid molecule to mediate RNA interference. [0249] In certain embodiments of the nucleic acid molecules (e.g., siNA molecules) provided herein, at least one end of the molecule has an overhang of at least one nucleotide (for example 1 to 8 overhang nucleotides). For example, one or both strands of a double stranded nucleic acid molecule disclosed herein may have an overhang at the 5'-end or at the 3'-end or both. An overhang may be present at either or both the sense strand and antisense strand of the nucleic acid molecule. The length of the overhang may be as little as one nucleotide and as long as I to 8 or more nucleotides (e.g., 1, 2, 3, 4, 5, 6, 7 or 8 nucleotides); in some preferred embodiments an overhang is 2, 3, 4, 5, 6, 7 or 8 nucleotides; for example an overhang may be 2 nucleotides. The nucleotide(s) forming the overhang may include deoxyribonucleotide(s), ribonucleotide(s), natural and non-natural nucleobases or any nucleotide modified in the sugar, base or phosphate group such as disclosed herein. A double stranded nucleic acid molecule may have both 5'- and 3'-overhangs. The overhangs at the 5' and 3'-end may be of different lengths. An overhang may include at least one nucleic acid modification which may be deoxyribonucleotide. One or more deoxyribonucleotides may be at the 5'-terminal. The 3'-end of the respective counter-strand of the nucleic acid molecule may not have an overhang, more preferably not a deoxyribonucleotide overhang. The one or 70 more deoxyribonucleotide may be at the 3'-terminal. The 5'-end of the respective counter strand of the dsRNA may not have an overhang, more preferably not a deoxyribonucleotide overhang. The overhang in either the 5'- or the 3'-end of a strand may be I to 8 (e.g., about 1, 2, 3, 4, 5, 6, 7 or 8) unpaired nucleotides, preferably, the overhang is 2-3 unpaired nucleotides; more preferably 2 unpaired nucleotides. Nucleic acid molecules may include duplex nucleic acid molecules with overhanging ends of about I to about 20 (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 1, 15, 16, 17, 18, 19 or 20); preferably 1-8 (e.g., about 1, 2, 3, 4, 5, 6, 7 or 8) nucleotides, for example, about 21-nucleotide duplexes with about 19 base pairs and 3' terminal mononucleotide, dinucleotide, or trinucleotide overhangs. Nucleic acid molecules herein may include duplex nucleic acid molecules with blunt ends, where both ends are blunt, or alternatively, where one of the ends is blunt. Nucleic acid molecules disclosed herein can include one or more blunt ends, i.e. where a blunt end does not have any overhanging nucleotides. In one embodiment, the blunt ended nucleic acid molecule has a number of base pairs equal to the number of nucleotides present in each strand of the nucleic acid molecule. The nucleic acid molecule may include one blunt end, for example where the 5'-end of the antisense strand and the 3'-end of the sense strand do not have any overhanging nucleotides. The nucleic acid molecule may include one blunt end, for example where the 3'-end of the antisense strand and the 5'-end of the sense strand do not have any overhanging nucleotides. A nucleic acid molecule may include two blunt ends, for example where the 3'-end of the antisense strand and the 5'-end of the sense strand as well as the 5'-end of the antisense strand and 3'-end of the sense strand do not have any overhanging nucleotides. . In certain preferred embodiments the nucleic acid compounds are blunt ended. Other nucleotides present in a blunt ended siNA molecule can include, for example, mismatches, bulges, loops, or wobble base pairs to modulate the activity of the nucleic acid molecule to mediate RNA interference. [02501 In many embodiments one or more, or all, of the overhang nucleotides of a nucleic acid molecule (e.g., a siNA molecule) as described herein are modified such as described herein; for example one or more, or all, of the nucleotides may be 2'-deoxynucleotides. Amount, Location and Patterns of Modifications. [02511 Nucleic acid molecules (e.g., siNA molecules) disclosed herein may include modified nucleotides as a percentage of the total number of nucleotides present in the nucleic acid molecule. As such, a nucleic acid molecule may include about 5% to about 100% 71 modified nucleotides (e.g., about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides). The actual percentage of modified nucleotides present in a given nucleic acid molecule will depend on the total number of nucleotides present in the nucleic acid. If the nucleic acid molecule is single stranded, the percent modification can be based upon the total number of nucleotides present in the single stranded nucleic acid molecule. Likewise, if the nucleic acid molecule is double stranded, the percent modification can be based upon the total number of nucleotides present in the sense strand, antisense strand, or both the sense and antisense strands. [0252] Nucleic acid molecules disclosed herein may include unmodified RNA as a percentage of the total nucleotides in the nucleic acid molecule. As such, a nucleic acid molecule may include about 5% to about 100% modified nucleotides (e.g., about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of total nucleotides present in a nucleic acid molecule. [02531 A nucleic acid molecule (e.g., an siNA molecule) may include a sense strand that includes about 1 to about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 2'-O-methyl, 2' deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand; and wherein the antisense strand includes about I to about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2' deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. A nucleic acid molecule may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense nucleic acid strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2' fluoro nucleotides, with or without about I to about 5 or more, for example about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3' end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand. 72 WO 2011/072082 PCT/US2010/059578 [0254] A nucleic acid molecule may include about 1 to about 5 or more (specifically about 1, 2, 3, 4, 5 or more) phosphorothioate internucleotide linkages in each strand of the nucleic acid molecule. [0255] A nucleic acid molecule may include 2'-5' internucleotide linkages, for example at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of one or both nucleic acid sequence strands. In addition, the 2'-5' internucleotide linkage(s) can be present at various other positions within one or both nucleic acid sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siNA molecule can include a 2'-5' internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siNA molecule can include a 2'-5' internucleotide linkage. [0256] A chemically-modified short interfering nucleic acid (siNA) molecule may include an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2 '-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides). [0257] A chemically-modified short interfering nucleic acid (siNA) molecule may include an antisense region, wherein any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2 '-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides). [0258] A chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against hsp47 inside a cell or reconstituted in vitro system may include a sense region, wherein one or more pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine 73 WO 2011/072082 PCT/US2010/059578 nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and one or more purine nucleotides present in the sense region are 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides), and an antisense region, wherein one or more pyrimidine nucleotides present in the antisense region are 2'-deoxy-2 '-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-0-methyl purine nucleotides). The sense region and/or the antisense region can have a terminal cap modification, such as any modification, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense and/or antisense sequence. The sense and/or antisense region can optionally further include a 3'-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxynueleotides. The overhang nucleotides can further include one or more (e.g., about 1, 2, 3, 4 or more) phosphorothioate, phosphonoacetate, and/or thiophosphonoacetate internucleotide linkages. The purine nucleotides in the sense region may alternatively be 2'-0-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides) and one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-0-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-0 methyl purine nucleotides). One or more purine nucleotides in the sense region may alternatively be purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides) and any purine nucleotides present in the antisense region are 2'-0-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-0-methyl purine nucleotides). One or more purine nucleotides in the sense region and/or present in the antisense region may alternatively selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-0-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4' 74 thionucleotides, and 2'-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides). [0259] In some embodiments, a nucleic acid molecule (e.g., a siNA molecule) as described herein includes a modified nucleotide (for example one modified nucleotide) in the antisense strand; for example in position 6 or position 7 of the antisense strand. [02601 Modification Patterns and Alternating Modifications [0261] Nucleic acid molecules (e.g., siNA molecules) provided herein may have patterns of modified and unmodified nucleic acids. A pattern of modification of the nucleotides in a contiguous stretch of nucleotides may be a modification contained within a single nucleotide or group of nucleotides that are covalently linked to each other via standard phosphodiester bonds or, at least partially, through phosphorothioate bonds. Accordingly, a "pattern" as contemplated herein, does not necessarily need to involve repeating units, although it may. Examples of modification patterns that may be used in conjunction with the nucleic acid molecules (e.g., siNA molecules) provided herein include those disclosed in Giese, US Patent No. 7,452,987. For example, nucleic acid molecules (e.g., siNA molecules) provided herein include those having modification patterns such as, similar to, or the same as, the patterns shown diagrammatically in figure 2 of the Giese US Patent No. 7,452,987. 102621 A modified nucleotide or group of modified nucleotides may be at the 5'-end or 3'-end of the sense or antisense strand, a flanking nucleotide or group of nucleotides is arrayed on both sides of the modified nucleotide or group, where the flanking nucleotide or group either is unmodified or does not have the same modification of the preceding nucleotide or group of nucleotides. The flanking nucleotide or group of nucleotides may, however, have a different modification. This sequence of modified nucleotide or group of modified nucleotides, respectively, and unmodified or differently modified nucleotide or group of unmodified or differently modified nucleotides may be repeated one or more times. [0263] In some patterns, the 5'-terminal nucleotide of a strand is a modified nucleotide while in other patterns the 5'-terminal nucleotide of a strand is an unmodified nucleotide. In some patterns, the 5'- end of a strand starts with a group of modified nucleotides while in other patterns, the 5'-terminal end is an unmodified group of nucleotides. This pattern may be either on the first stretch or the second stretch of the nucleic acid molecule or on both. 75 [02641 Modified nucleotides of one strand of the nucleic acid molecule may be complementary in position to the modified or unmodified nucleotides or groups of nucleotides of the other strand. [02651 There may be a phase shift between modifications or patterns of modifications on one strand relative to the pattern of modification of the other strand such that the modification groups do not overlap. In one instance, the shift is such that the modified group of nucleotides of the sense strand corresponds to the unmodified group of nucleotides of the antisense strand and vice versa. [02661 There may be a partial shift of the pattern of modification such that the modified groups overlap. The groups of modified nucleotides in any given strand may optionally be the same length, but may be of different lengths. Similarly, groups of unmodified nucleotides in any given strand may optionally be the same length, or of different lengths. [02671 In some patterns, the second (penultimate) nucleotide at the terminus of the strand, is an unmodified nucleotide or the beginning of group of unmodified nucleotides. Preferably, this unmodified nucleotide or unmodified group of nucleotides is located at the 5'-end of the either or both the sense and antisense strands and even more preferably at the terminus of the sense strand. An unmodified nucleotide or unmodified group of nucleotide may be located at the 5'-end of the sense strand. In a preferred embodiment the pattern consists of alternating single modified and unmodified nucleotides. [02681 In some double stranded nucleic acid molecules, a 2'-O-methyl modified nucleotide and a non-modified nucleotide, preferably a nucleotide which is not 2'-O-methyl modified, are incorporated on both strands in an alternating fashion, resulting in a pattern of alternating 2'-O-methyl modified nucleotides and nucleotides that are either unmodified or at least do not include a 2'-O-methyl modification. In certain embodiments, the same sequence of 2'-O-methyl modification and non-modification exists on the second strand; in other embodiments the alternating 2'-O-methyl modified nucleotides are only present in the sense strand and are not present in the antisense strand; and in yet other embodiments the alternating 2'-O-methyl modified nucleotides are only present in the antisense strand and are not present in the sense strand. In certain embodiments, there is a phase shift between the two strands such that the 2'-O-methyl modified nucleotide on the first strand base pairs with a non-modified nucleotide(s) on the second strand and vice versa. This particular arrangement, i.e. 76 base pairing of 2'-O-methyl modified and non-modified nucleotide(s) on both strands is particularly preferred in certain embodiments. In certain embodiments, the pattern of alternating 2'-O-methyl modified nucleotides exists throughout the entire nucleic acid molecule; or the entire duplex region. In other embodiments the pattern of alternating 2'-0 methyl modified nucleotides exists only in a portion of the nucleic acid; or the entire duplex region. [02691 In "phase shift" patterns, it may be preferred if the antisense strand starts with a 2'-O-methyl modified nucleotide at the 5' end whereby consequently the second nucleotide is non-modified, the third, fifth, seventh and so on nucleotides are thus again 2'-O-methyl modified whereas the second, fourth, sixth, eighth and the like nucleotides are non-modified nucleotides. Exemplary Modification Locations and Patterns [02701 While exemplary patterns are provided in more detail below, all permutations of patterns with of all possible characteristics of the nucleic acid molecules disclosed herein and those known in the art are contemplated (e.g., characteristics include, but are not limited to, length of sense strand, length of antisense strand, length of duplex region, length of overhang, whether one or both ends of a double stranded nucleic acid molecule is blunt or has an overhang, location of modified nucleic acid, number of modified nucleic acids, types of modifications, whether a double overhang nucleic acid molecule has the same or different number of nucleotides on the overhang of each side, whether a one or more than one type of modification is used in a nucleic acid molecule, and number of contiguous modified/unmodified nucleotides). With respect to all detailed examples provided below, while the duplex region is shown to be 19 nucleotides, the nucleic acid molecules provided herein can have a duplex region ranging from I to 49 nucleotides in length as each strand of a duplex region can independently be 17-49 nucleotides in length. Exemplary patterns are provided herein. 10271] Nucleic acid molecules may have a blunt end (when n is 0) on both ends that include a single or contiguous set of modified nucleic acids. The modified nucleic acid may be located at any position along either the sense or antisense strand. Nucleic acid molecules may include a group of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 77 46, 47, 48 or 49 contiguous modified nucleotides. Modified nucleic acids may make up 1%, 2%, 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 100% of a nucleic acid strand. Modified nucleic acids of the examples immediately below may be in the sense strand only, the antisense strand only, or in both the sense and antisense strand. 10272] General nucleic acid patterns are shown below where X = sense strand nucleotide in the duplex region; Xa = 5'-overhang nucleotide in the sense strand; Xb = 3'-overhang nucleotide in the sense strand; Y = antisense strand nucleotide in the duplex region; Ya = 3' overhang nucleotide in the antisense strand; Yb = 5'-overhang nucleotide in the antisense strand; and M = a modified nucleotide in the duplex region. Each a and b are independently 0 to 8 (e.g., 0, 1, 2, 3, 4, 5, 6, 7 or 8). Each X, Y, a and b are independently modified or unmodified. The sense and antisense strands can are each independently 17-49 nucleotides in length. The examples provided below have a duplex region of 19 nucleotides; however, nucleic acid molecules disclosed herein can have a duplex region anywhere between 17 and 49 nucleotides and where each strand is independently between 17 and 49 nucleotides in length. 5' XaXXXXXXXXXXXXXXXXXXXXb 3' YbYYYYYYYYYYYYYYYYYYYYa [02731 Further exemplary nucleic acid molecule patterns are shown below where X unmodified sense strand nucleotides; x = an unmodified overhang nucleotide in the sense strand; Y = unmodified antisense strand nucleotides; y = an unmodified overhang nucleotide in the antisense strand; and M = a modified nucleotide. The sense and antisense strands can are each independently 17-49 nucleotides in length. The examples provided below have a duplex region of 19 nucleotides; however, nucleic acid molecules disclosed herein can have a duplex region anywhere between 17 and 49 nucleotides and where each strand is independently between 17 and 49 nucleotides in length. 5' MXXXXXXXXXMXXXXXXXXXM, 3' MnYYYYYYYYYYYYYYYYYYYMa 5' XXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYMYYYYYYYYY 5' XXXXXXXXMMXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYY 78 WO 2011/072082 PCT/US2010/059578 5' XXXXXXXXXXXXXXXXXXX 3' YYYYYYYYMMYYYYYYYYY 5' XXXXXXXXXMXXXXXXXXX 3' YYYYYYYYYMYYYYYYYYY 5' XXXXXMXXXXXXXXXXXXX 3' YYYYYYYYYMYYYYYYYYY 5' MXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYMYYYYYY 5' XXXXXXXXXXXXXXXXXXM 3' YYYYYMYYYYYYYYYYYYY 5' XXXXXXXXXMXXXXXXXX 3' MYYYYYYYYYYYYYYYYY 5' XXXXXXXMXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYM 5' XXXXXXXXXXXXXMXXXX 3' MYYYYYYYYYYYYYYYYY 5' MMMMMMMMMMMMMMMMMM 3' MMMMMMMMMMMMMMMMM [0274] Nucleic acid molecules may have blunt ends on both ends with alternating modified nucleic acids. The modified nucleic acids may be located at any position along either the sense or antisense strand. 5' MXMXMXMXMXMXMXMXMXM 3' YMYMYMYMYMYMYMYMYMY 5' XMXMXMXMXMXMXMXMXMX 3' MYMYMYMYMYMYMYMYMYM 5' MMXMMXMMXMMXMMXMMXM 3' YMMYMMYMMYMMYMMYMMY 5f' XMMXMMXMMXMMXMMXMMX 3' MMYMMYMMYMMYMMYMMYM 5' MOMXMM4MXMMMXDMMXOM4M 3' YMMMYMMMYMMYMMYMM 79 WO 2011/072082 PCT/US2010/059578 5' XMMXMMMXMMMXMMMXMM 3' OYMMMYb4YMMMYbM [0275] Nucleic acid molecules with a blunt 5'-end and 3'-end overhang end with a single modified nucleic acid. [0276] Nucleic acid molecules with a 5'-end overhang and a blunt 3'-end with a single modified nucleic acid. [0277] Nucleic acid molecules with overhangs on both ends and all overhangs are modified nucleic acids. In the pattern immediately below, M is n number of modified nucleic acids, where n is an integer from 0 to 8 (i.e., 0, 1, 2, 3, 4, 5, 6, 7 and 8). 5' XXXXXXXXXXXXXXXXXXXM 3' MYYYYYYYYYYYYYYYYYYY [0278] Nucleic acid molecules with overhangs on both ends and some overhang nucleotides are modified nucleotides. In the patterns immediately below, M is n number of modified nucleotides, x is n number of unmodified overhang nucleotides in the sense strand, y is n number of unmodified overhang nucleotides in the antisense strand, where each n is independently an integer from 0 to 8 (i.e., 0, 1, 2, 3, 4, 5, 6, 7 and 8), and where each overhang is maximum of 20 nucleotides; preferably a maximum of 8 nucleotides (modified and/or unmodified). 5' XXXXXXXXXXXXXXXXXXXM 3' yYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMx 3' yYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMxM 3' yYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMxMx 3' yYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMxMxM 3' yYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMxMxMx 3' yYYYYYYYYYYYYYYYYYYY 80 WO 2011/072082 PCT/US2010/059578 5' XXXXXXXXXXXXXXXXXXXMxMxMxM 3' yYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMxMxMxMx 3' yYYYYYYYYYYYYYYYYYYY 5' MXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' xMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' MxMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' xMxMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' MxMxMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' xMxMxMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' MxMxMxMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' xMxMxMxMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYy 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYM 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMy 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMyM 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMyMy 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMyMyM 81 WO 2011/072082 PCT/US2010/059578 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMyMyMy 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMyMyMyM 5' xXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYYMyMyMyMy 5' XXXXXXXXXXXXXXXXXXXx 3' MYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' yMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' MyMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' yMyMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' MyMyMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' yMyMyMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' MyMyMyMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXx 3' yMyMyMyMYYYYYYYYYYYYYYYYYYY [0279] Modified nucleotides at the 3' end of the sense region. 5' XXXXXXXXXXXXXXXXXXXM 3' YYYYYYYYYYYYyYYYYYY 5' XXXXXXXXXXXXXXXXXXXMM 3' YYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMMM 3' YYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMMM 82 WO 2011/072082 PCT/US2010/059578 3' YYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMMMMM 3' YYYYYYYYYYYYyYYYYYY 5' XXXXXXXXXXXXXXXXXXXMMMMMM 3' YYYYYYYYYYYYyYYYYYY 5' XXXXXXXXXXXXXXXXXXXMMMMMMMM 3' YYYYYYYYYYYYyYYYYYY 5' XXXXXXXXXXXXXXXXXXXMMMMMMMM 3' YYYYYYYYYYYYyYYYYYY [02801 Overhang at the 5' end of the sense region. 5' MXXXXXXXXXXXXXXXXXXX 3' YYYYYYYyYYYYyYYYYYY 5' MMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYyYYYYYY 5' MMMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYY 5' MMMMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYyYYYYYY 5' MMMMMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYY 5' MMMMMMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYyYYYYYY 5' MMMMMMMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYyYYYYYY 5' MMMMMMMMXXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYYYYyYYYYYY [0281] Overhang at the 3' end of the antisense region. 5' xxxxxxxxxxxxxxxxxxx 3' MYYYYYYYYYYYYYYYYYYY 83 WO 2011/072082 PCT/US2010/059578 5' XXXXXXXXXXXXXXXXXXX 3' MMYYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMMMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMMMMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMMMMMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMMMMMMYYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMMMMMMMYYYYYYYYYYYYYYYYYYY [0282] Modified nucleotide(s) within the sense region 5' XXXXXXXXXMXXXXXXXXX 3' YYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' YYYYYYYYYMYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXXMM 3' YYYYYYYYYYYYYYYYYYY 5' XXXXXXXXXXXXXXXXXXX 3' MMYYYYYYYYYYYYYYYYYYY [0283] Exemplary nucleic acid molecules are provided below along with the equivalent general structure in line with the symbols used above: [0284] siHSP47-C siRNA to human and rat hsp47 having a 19 nucleotide (i.e., 19mer) duplex region and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' GGACAGGCCUCJACAACUAdTdT 3' 3' dTdTCCUGUCCGGAGAUGUUGAU 5' 84 WO 2011/072082 PCT/US2010/059578 5' XXXXXXXXXXXXXXXXXXXMM 3' MMYYYYYYYYYYYYYYYYYYY [0285] siHSP47-Cd siRNA to human and rat hsp47 having a 25-mer duplex region, a 2 nucleotide overhang at the 3'-end of the antisense strand and 2 modified nucleotides at the 5' terminal and penultimate positions of the sense strand. 5' GGACAGGCCUCUACAACUACUACdGdA 3' 3' UUCCUGUCCGGAGAUGUUGAUGAUGCU 5' 5' XXXXXXXXXXXXXXXXXXXXXXXMM 3' 3' yyYYYYYYYYYYYYYYYYYYYYYYYYY 5' [0286] siHSP47-1 siRNA to human and rat hsp47 cDNA 719-737 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' CAGGCCUCUACAACUACUAdTdT 3' 3' dTdTGUCCGGAGAUGUUGAUGAU 5' 5' XXXXXXXXXXXXXXXXXXXMM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' [0287] siHSP47-ld siRNA to human hsp47 cDNA 719-743 having a 25-mer with a blunt end at the 3'-end of the sense strand and a 2 nucleotide overhang at the 3'-end of the antisense strand, and 2 modified nucleotides at the 5'- terminal and penultimate positions of the sense strand. 5' CAGGCCUCUACAACUACUACGACdGdA 3' 3' UUGUCCGGAGAUGUUGAUGAUGCUGCU 5' 5' XXXXXXXXXXXXXXXXXXXXXXXMM 3' 3' yyYYYYYYYYYYYYYYYYYYYYYYYYY 5' [0288] siHSP47-2 siRNA to human hsp47 cDNA 469-487 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' GAGCACUCCAAGAUCAACUdTdT 3' 3' dTdTCUCGUGAGGUUCUAGUUGA 5' 85 WO 2011/072082 PCT/US2010/059578 5' XXXXXXXXXXXXXXXXXXXMM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' [0289] siHSP47-2d siRNA to human hsp47 cDNA 469-493 having a 25-mer duplex region with a blunt end at the 3'-end of the sense strand and a 2 nucleotide overhang at the 3' end of the antisense strand, and 2 modified nucleotides at the 5'- terminal and penultimate positions of the sense strand. 5' GAGCACUCCAAGAUCAACUUCCGdCdG 3' 3' UUCUCGUGAGGUUCUAGUUGAAGGCGC 5' 5' XXXXXXXXXXXXXXXXXXXXXXXMM 3' 3' yyYYYYYYYYYYYYYYYYYYYYYYYYY 5' [0290] siHSP47-2d rat siRNA to rat Gp46 cDNA 466-490 having a 25-mer duplex region with a blunt end at the 3'-end of the sense strand and a 2 nucleotide overhang at the 3'-end of the antisense strand, and 2 modified nucleotides at the 5'- terminal and penultimate positions of the sense strand. 5' GAACACUCCAAGAUCAACUUCCGdAdG 3' 3' UUCUUGUGAGGUUCUAGUUGAAGGCUC 5' 5' XXXXXXXXXXXXXXXXXXXXXXXMM 3' 3' yyYYYYYYYYYYYYYYYYYYYYYYYYY 5' [0291] siHSP47-3 siRNA to human hsp47 cDNA 980-998 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' CTGAGGCCATTGACAAGAAdTdT 3' 3' dTdTGACUCCGGUAACUGUUCUU 5' 5' XXXXXXXXXXXXXXXXXXXMM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' [0292] siHSP47-3d siRNA to human hsp47 cDNA 980-1004 having a 25-mer duplex region with a blunt end at the 3'-end of the sense strand and a 2 nucleotide overhang at the 3' end of the antisense strand, and 2 modified nucleotides at the 5'- terminal and penultimate positions of the sense strand. 86 WO 2011/072082 PCT/US2010/059578 5' CTGAGGCCATTGACAAGAACAAGdGdC 3' 3' UUGACUCCGGUAACUGUUCUUGUUCCG 5' 5' XXXXXXXXXXXXXXXXXXXXXXXMM 3' 3' yyYYYYYYYYYYYYYYYYYYYYYYYYY 5' [0293] siHSP47-4 siRNA to human hsp47 cDNA 735-753 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' CUACGACGACGAGAAGGAAdTdT 3' 3' dTdTGAUGCUGCUGCUCUUCCUU 5' 5' XXXXXXXXXXXXXXXXXXXMM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' [0294] siHSP47-4d siRNA to human hsp47 cDNA 735-759 having a 25-mer duplex region with a blunt end at the 3'-end of the sense strand and a 2 nucleotide overhang at the 3' end of the antisense strand, and 2 modified nucleotides at the 5'- terminal and penultimate positions of the sense strand. 5' CUACGACGACGAGAAGGAAAAGCdTdG 3' 3' UUGAUGCUGCUGCUCUUCCUUUUCGAC 5' 5' XXXXXXXXXXXXXXXXXXXXXXXMM 3' 3' yyYYYYYYYYYYYYYYYYYYYYYYYYY 5' [0295] siHSP47-5 siRNA to human hsp47 cDNA 621-639 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' GCCACACUGGGAUGAGAAAdTdT 3' 3' dTdTCGGUGUGACCCUACUCUUU 5' 5' XXXXXXXXXXXXXXXXXXXMIM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' [0296] siHSP47-6 siRNA to human hsp47 cDNA 446-464 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 87 WO 2011/072082 PCT/US2010/059578 5' GCAGCAAGCAGCACUACAAdTdT 3' 3' dTdTCGUCGUUCGUCGUGAUGUU 5' 5' XXXXXXXXXXXXXXXXXXXMM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' [0297] siHSP47-7 siRNA to human hsp47 cDNA 692-7 10 having a 19-mer duplex region, and modified 2 nucleotide (i.e., deoxynucleotide) overhangs at the 3'-ends of the sense and antisense strands. 5' CCGUGGGUGUCAUGAUGAUdTdT 3' 3' dTdTGGCACCCACAGUACUACUA 5' 5' XXXXXXXXXXXXXXXXXXXMM 3' 3' MMYYYYYYYYYYYYYYYYYYY 5' Nicks and Gaps in Nucleic Acid Strands [0298] Nucleic acid molecules (e.g., siNA molecules) provided herein may have a strand, preferably the sense strand, that is nicked or gapped. As such, nucleic acid molecules may have three or more strand, for example, such as a meroduplex RNA (mdRNA) disclosed in International Patent Application No. PCT/US07/081836. Nucleic acid molecules with a nicked or gapped strand may be between about 1-49 nucleotides, or may be RISC length (e.g., about 15 to 25 nucleotides) or Dicer substrate length (e.g., about 25 to 30 nucleotides) such as disclosed herein. [0299] Nucleic acid molecules with three or more strands include, for example, an 'A' (antisense) strand, 'S1' (second) strand, and 'S2' (third) strand in which the 'Si' and 'S2' strands are complementary to and form base pairs with non-overlapping regions of the 'A' strand (e.g., an mdRNA can have the form of A:S1S2). The S1, S2, or more strands together form what is substantially similar to a sense strand to the 'A' antisense strand. The double stranded region formed by the annealing of the 'S1' and 'A' strands is distinct from and non overlapping with the double-stranded region formed by the annealing of the 'S2' and 'A' strands. An nucleic acid molecule (e.g., an siNA molecule) may be a "gapped" molecule, meaning a "gap" ranging from 0 nucleotides up to about 10 nucleotides (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides). Preferably, the sense strand is gapped. In some embodiments, the A:S 1 duplex is separated from the A:S2 duplex by a gap resulting from at least one unpaired nucleotide (up to about 10 unpaired nucleotides) in the 'A' strand that is positioned between 88 the A:SI duplex and the A:S2 duplex and that is distinct from any one or more unpaired nucleotide at the 3'-end of one or more of the 'A', 'Sl', or 'S2 strands. The A:SI duplex may be separated from the A:B2 duplex by a gap of zero nucleotides (i.e., a nick in which only a phosphodiester bond between two nucleotides is broken or missing in the polynucleotide molecule) between the A:SI duplex and the A:S2 duplex-which can also be referred to as nicked dsRNA (ndsRNA). For example, A:SlS2 may include a dsRNA having at least two double-stranded regions that combined total about 14 base pairs to about 40 base pairs and the double-stranded regions are separated by a gap of about 0 to about 10 nucleotides, optionally having blunt ends, or A:SIS2 may include a dsRNA having at least two double-stranded regions separated by a gap of up to 10 nucleotides wherein at least one of the double-stranded regions includes between about 5 base pairs and 13 base pairs. Dicer Substrates [0300] In certain embodiments, the nucleic acid molecules (e.g., siNA molecules) provided herein may be a precursor "Dicer substrate" molecule, e.g., double stranded nucleic acid, processed in vivo to produce an active nucleic acid molecules, for example as described in Rossi, US Patent App. No. 20050244858. In certain conditions and situations, it has been found that these relatively longer dsRNA siNA species, e.g., of from about 25 to about 30 nucleotides, can give unexpectedly effective results in terms of potency and duration of action. Without wishing to be bound by any particular theory, it is thought that the longer dsRNA species serve as a substrate for the enzyme Dicer in the cytoplasm of a cell. In addition to cleaving double stranded nucleic acid into shorter segments, Dicer may facilitate the incorporation of a single-stranded cleavage product derived from the cleaved dsRNA into the RNA-induced silencing complex (RISC complex) that is responsible for the destruction of the cytoplasmic RNA derived from the target gene. [03011 Dicer substrates may have certain properties which enhance its processing by Dicer. Dicer substrates are of a length sufficient such that it is processed by Dicer to produce an active nucleic acid molecule and may further include one or more of the following properties: (i) the dsRNA is asymmetric, e.g., has a 3' overhang on the first strand (antisense strand) and (ii) the dsRNA has a modified 3' end on the second strand (sense strand) to direct orientation of Dicer binding and processing of the dsRNA to an active siRNA. In certain embodiments, the longest strand in the Dicer substrate may be 24-30 nucleotides. 89 [0302] Dicer substrates may be symmetric or asymmetric. The Dicer substrate may have a sense strand includes 22-28 nucleotides and the antisense strand may include 24-30 nucleotides; thus, in some embodiments the resulting Dicer substrate may have an overhang on the 3' end of the antisense strand. Dicer substrate may have a sense strand 25 nucleotides in length, and the antisense strand having 27 nucleotides in length with a 2 base 3'-overhang. The overhang may be 1-3 nucleotides, for example 2 nucleotides. The sense strand may also have a 5' phosphate. [03031 An asymmetric Dicer substrate may further contain two deoxynucleotides at the 3'-end of the sense strand in place of two of the ribonucleotides. Some exemplary Dicer substrates lengths and structures are 21+0, 21+2, 21-2, 22+0, 22+1, 22-1, 23+0, 23+2, 23-2, 24+0, 24+2, 24-2, 25+0, 25+2, 25-2, 26+0, 26+2, 26-2, 27+0, 27+2, and 27-2. [0304] The sense strand of a Dicer substrate may be between about 22 to about 30 (e.g., about 22, 23, 24, 25, 26, 27, 28, 29 or 30); about 22 to about 28; about 24 to about 30; about 25 to about 30; about 26 to about 30; about 26 and 29; or about 27 to about 28 nucleotides in length. In certain preferred embodiments Dicer substrates contain sense and antisense strands, that are at least about 25 nucleotides in length and no longer than about 30 nucleotides; between about 26 and 29 nucleotides; or 27 nucleotides in length. The sense and antisense strands may be the same length (blunt ended), different lengths (have overhangs), or a combination. The sense and antisense strands may exist on the same polynucleotide or on different polynucleotides. A Dicer substrate may have a duplex region of about 19, 20, 21, 22, 23, 24, 25 or 27 nucleotides. [03051 Like other siNA molecules provided herein, the antisense strand of a Dicer substrate may have any sequence that anneals to the antisense strand under biological conditions, such as within the cytoplasm of a eukaryotic cell. 10306] Dicer substrates may have any modifications to the nucleotide base, sugar or phosphate backbone as known in the art and/or as described herein for other nucleic acid molecules (such as siNA molecules). In certain embodiments, Dicer substrates may have a sense strand modified for Dicer processing by suitable modifiers located at the 3' end of the sense strand, i.e., the dsRNA is designed to direct orientation of Dicer binding and processing. Suitable modifiers include nucleotides such as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotides and the like and sterically hindered molecules, such as fluorescent 90 molecules and the like. Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for-the 2'-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotides modifiers that could be used in Dicer substrate siNA molecules include 3'-deoxyadenosine (cordycepin), 3' azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxy-3'-thiacytidine (3TC), 2',3'-didehydro-2',3'-dideoxythymidi- ne (d4T) and the monophosphate nucleotides of 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxy-3'-thiacytidine (3TC) and 2',3'-didehydro 2',3'-dide-oxythymidine (d4T). In one embodiment, deoxynucleotides are used as the modifiers. When nucleotide modifiers are utilized, they may replace ribonucleotides (e.g., 1-3 nucleotide modifiers, or 2 nucleotide modifiers are substituted for the ribonucleotides on the 3' end of the sense strand) such that the length of the Dicer substrate does not change. When sterically hindered molecules are utilized, they may be attached to the ribonucleotide at the 3' end of the antisense strand. Thus, in certain embodiments the length of the strand does not change with the incorporation of the modifiers. In certain embodiments, two DNA bases in the dsRNA are substituted to direct the orientation of Dicer processing of the antisense strand. In a further embodiment , two terminal DNA bases are substituted for two ribonucleotides on the 3'-end of the sense strand forming a blunt end of the duplex on the 3' end of the sense strand and the 5' end of the antisense strand, and a two-nucleotide RNA overhang is located on the 3'-end of the antisense strand. This is an asymmetric composition with DNA on the blunt end and RNA bases on the overhanging end. [03071 In certain embodiments modifications are included in the Dicer substrate such that the modification does not prevent the nucleic acid molecule from serving as a substrate for Dicer. In one embodiment, one or more modifications are made that enhance Dicer processing of the Dicer substrate. One or more modifications may be made that result in more effective RNAi generation. One or more modifications may be made that support a greater RNAi effect. One or more modifications are made that result in greater potency per each Dicer substrate to be delivered to the cell. Modifications may be incorporated in the 3'-terminal region, the 5' terminal region, in both the 3'-terminal and 5'-terminal region or at various positions within the sequence. Any number and combination of modifications can be incorporated into the Dicer substrate so long as the modification does not prevent the nucleic acid molecule from serving as a substrate for Dicer. Where multiple modifications are present, they may be the same or different. Modifications to bases, sugar moieties, the phosphate backbone, and their combinations are contemplated. Either 5'-terminus can be phosphorylated. 91 [0308] Examples of Dicer substrate phosphate backbone modifications include phosphonates, including methylphosphonate, phosphorothioate, and phosphotriester modifications such as alkylphosphotriesters, and the like. Examples of Dicer substrate sugar moiety modifications include 2'-alkyl pyrimidine, such as 2'-O-methyl, 2'-fluoro, amino, and deoxy modifications and the like (see, e.g., Amarzguioui et al., 2003). Examples of Dicer substrate base group modifications include abasic sugars, 2'-O-alkyl modified pyrimidines, 4 thiouracil, 5-bromouracil, 5-iodouracil, and 5-(3-aminoallyl)-uracil and the like. Locked nucleic acids, or LNA's, could also be incorporated. [03091 The sense strand may be modified for Dicer processing by suitable modifiers located at the 3' end of the sense strand, i.e., the Dicer substrate is designed to direct orientation of Dicer binding and processing. Suitable modifiers include nucleotides such as deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotides and the like and sterically hindered molecules, such as fluorescent molecules and the like. Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for-the 2'-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotides modifiers could include 3'-deoxyadenosine (cordycepin), 3'-azido 3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxy-3'-thiacytidine (3TC), 2',3'-didehydro-2',3'-dideoxythymidi- ne (d4T) and the monophosphate nucleotides of 3' azido-3'-deoxythymidine (AZT), 2',3'-dideoxy-3'-thiacytidine (3TC) and 2',3'-didehydro 2',3'-dide-oxythymidine (d4T). In one embodiment, deoxynucleotides are used as the modifiers. When nucleotide modifiers are utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers are substituted for the ribonucleotides on the 3' end of the sense strand. When sterically hindered molecules are utilized, they are attached to the ribonucleotide at the 3' end of the antisense strand. Thus, the length of the strand does not change with the incorporation of the modifiers. In another embodiment, the invention contemplates substituting two DNA bases in the Dicer substrate to direct the orientation of Dicer processing of the antisense strand. In a further embodiment of the present invention, two terminal DNA bases are substituted for two ribonucleotides on the 3'-end of the sense strand forming a blunt end of the duplex on the 3' end of the sense strand and the 5' end of the antisense strand, and a two nucleotide RNA overhang is located on the 3'-end of the antisense strand. This is an asymmetric composition with DNA on the blunt end and RNA bases on the overhanging end. [0310] The antisense strand may be modified for Dicer processing by suitable modifiers located at the 3' end of the antisense strand, i.e., the dsRNA is designed to direct orientation of Dicer binding and processing. Suitable modifiers include nucleotides such as 92 WO 2011/072082 PCT/US2010/059578 deoxyribonucleotides, dideoxyribonucleotides, acyclonucleotides and the like and sterically hindered molecules, such as fluorescent molecules and the like. Acyclonucleotides substitute a 2-hydroxyethoxymethyl group for the 2'-deoxyribofuranosyl sugar normally present in dNMPs. Other nucleotide modifiers could include 3'-deoxyadenosine (cordycepin), 3'-azido 3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxy-3'-thiacytidine (3TC), 2',3'-didehydro-2',3'-dideoxythymidi- ne (d4T) and the monophosphate nucleotides of 3' azido-3'-deoxythymidine (AZT), 2',3'-dideoxy-3'-thiacytidine (3TC) and 2',3'-didehydro 2',3'-dide- oxythymidine (d4T). In one embodiment, deoxynucleotides are used as the modifiers. When nucleotide modifiers are utilized, 1-3 nucleotide modifiers, or 2 nucleotide modifiers are substituted for the ribonucleotides on the 3' end of the antisense strand. When sterically hindered molecules are utilized, they are attached to the ribonucleotide at the 3' end of the antisense strand. Thus, the length of the strand does not change with the incorporation of the modifiers. In another embodiment, the invention contemplates substituting two DNA bases in the dsRNA to direct the orientation of Dicer processing. In a further invention, two terminal DNA bases are located on the 3' end of the antisense strand in place of two ribonucleotides forming a blunt end of the duplex on the 5' end of the sense strand and the 3' end of the antisense strand, and a two-nucleotide RNA overhang is located on the 3'-end of the sense strand. This is an asymmetric composition with DNA on the blunt end and RNA bases on the overhanging end. [0311] Dicer substrates with a sense and an antisense strand can be linked by a third structure. The third structure will not block Dicer activity on the Dicer substrate and will not interfere with the directed destruction of the RNA transcribed from the target gene. The third structure may be a chemical linking group. Suitable chemical linking groups are known in the art and can be used. Alternatively, the third structure may be an oligonucleotide that links the two oligonucleotides of the dsRNA is a manner such that a hairpin structure is produced upon annealing of the two oligonucleotides making up the Dicer substrate. The hairpin structure preferably does not block Dicer activity on the Dicer substrate or interfere with the directed destruction of the RNA transcribed from the target gene. [0312] The sense and antisense strands of the Dicer substrate are not required to be completely complementary. They only need to be substantially complementary to anneal under biological conditions and to provide a substrate for Dicer that produces an siRNA sufficiently complementary to the target sequence. 93 WO 2011/072082 PCT/US2010/059578 [0313] Dicer substrate can have certain properties that enhance its processing by Dicer. The Dicer substrate can have a length sufficient such that it is processed by Dicer to produce an active nucleic acid molecules (e.g., siRNA) and may have one or more of the following properties: (i) the Dicer substrate is asymmetric, e.g., has a 3' overhang on the first strand (antisense strand) and (ii) the Dicer substrate has a modified 3' end on the second strand (sense strand) to direct orientation of Dicer binding and processing of the Dicer substrate to an active siRNA. The Dicer substrate can be asymmetric such that the sense strand includes 22 28 nucleotides and the antisense strand includes 24-30 nucleotides. Thus, the resulting Dicer substrate has an overhang on the 3' end of the antisense strand. The overhang is 1-3 nucleotides, for example 2 nucleotides. The sense strand may also have a 5' phosphate. [0314] A Dicer substrate may have an overhang on the 3' end of the antisense strand and the sense strand is modified for Dicer processing. The 5' end of the sense strand may have a phosphate. The sense and antisense strands may anneal under biological conditions, such as the conditions found in the cytoplasm of a cell. A region of one of the strands, particularly the antisense strand, of the Dicer substrate may have a sequence length of at least 19 nucleotides, wherein these nucleotides are in the 21-nucleotide region adjacent to the 3' end of the antisense strand and are sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene. A Dicer substrate may also have one or more of the following additional properties: (a) the antisense strand has a right shift from a corresponding 21 -mer (i.e., the antisense strand includes nucleotides on the right side of the molecule when compared to the corresponding 21 -mer), (b) the strands may not be completely complementary, i.e., the strands may contain simple mismatch pairings and (c) base modifications such as locked nucleic acid(s) may be included in the 5' end of the sense strand. [0315] An antisense strand of a Dicer substrate nucleic acid molecule may be modified to include 1-9 ribonucleotides on the 5' -end to give a length of 22-28 nucleotides. When the antisense strand has a length of 21 nucleotides, then 1-7 ribonucleotides, or 2-5 ribonucleotides and or 4 ribonucleotides may be added on the 3'-end. The added ribonucleotides may have any sequence. Although the added ribonucleotides may be complementary to the target gene sequence, full complementarity between the target sequence and the antisense strands is not required. That is, the resultant antisense strand is sufficiently complementary with the target sequence. A sense strand may then have 24-30 nucleotides. The sense strand may be substantially complementary with the antisense strand to anneal to the antisense strand under biological conditions. In one embodiment, the antisense strand may 94 WO 2011/072082 PCT/US2010/059578 be synthesized to contain a modified 3' -end to direct Dicer processing. The sense strand may have a 3' overhang. The antisense strand may be synthesized to contain a modified 3' -end for Dicer binding and processing and the sense strand has a 3' overhang. Heat Shock Protein 47 [0316] Heat shock protein 47 (HSP47) is a collagen-specific molecular chaperone and resides in the endoplasmic reticulum. It interacts with procollagen during the process of folding, assembling and transporting from the endoplasmic reticulum (Nagata Trends Biochem Sci 1996; 21:22-6; Razzaque et al. 2005; Contrib Nephrol 2005; 148: 57-69; Koide et al. 2006 J. Biol. Chem.; 281: 3432-38; Leivo et al. Dev. Biol. 1980; 76:100-114; Masuda et al. J. Clin. Invest. 1994; 94:2481-2488; Masuda et al. Cell Stress Chaperones 1998; 3:256 264). HSP47 has been reported to have an upregulated expression in various tissue fibrosis (Koide et al. J Biol Chem 1999; 274: 34523-26), such as liver cirrhosis (Masuda et al. J Clin Invest 1994; 94:2481-8), pulmonary fibrosis (Razzaque et al. Virchows Arch 1998; 432:455 60; Kakugawa et al. Eur Respir J 2004; 24: 57-65), and glomerulosclerosis (Moriyama et al. Kidney Int 1998; 54: 110-19). Exemplary nucleic acid sequence of target human hsp47 cDNA is disclosed in GenBank accession number: NM_001235 and the corresponding mRNA sequence, for example as listed as SEQ ID NO: 1. One of ordinary skill in the art would understand that a given sequence may change over time and to incorporate any changes needed in the nucleic acid molecules herein accordingly. [0317] The specific association of HSP47 with a diverse range of collagen types makes HSP47 a potential target for the treatment of fibrosis. Inhibition of hsp47 expression may prevent extracellular collagen I secretion. Sato et al. (Nat Biotechnol 2008; 26:431-442) explored this possibility by using siRNA for the inhibition hsp47 expression and preventing the progression of hepatic fibrosis in rats. Similarly, Chen et al. (Br J Dermatol 2007; 156: 1188-1195) and Wang et al. (Plast. Reconstr Surg 2003; 111: 1980-7) investigated the inhibition hsp47 expression by RNA interference technology. [0318] Methods and Compositions for Inhibiting hsp47 [0319] Provided are compositions and methods for inhibition of hsp47 expression by using small nucleic acid molecules, such as short interfering nucleic acid (siNA), interfering RNA (RNAi), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate 95 WO 2011/072082 PCT/US2010/059578 RNA interference against hsp47 gene expression. The composition and methods disclosed herein are also useful in treating various fibrosis such as liver fibrosis, lung fibrosis, and kidney fibrosis. [0320] Nucleic acid molecule(s) and/or methods of the invention are used to down regulate the expression of gene(s) that encode RNA referred to, by example, Genbank Accession NM 001235. [0321] Compositions, methods and kits provided herein may include one or more nucleic acid molecules (e.g., siNA) and methods that independently or in combination modulate (e.g., downregulate) the expression of hsp47 protein and/or genes encoding hsp47 proteins, proteins and/or genes encoding hsp47 associated with the maintenance and/or development of diseases, conditions or disorders associated with hsp47, such as liver fibrosis, cirrhosis, pulmonary fibrosis, kidney fibrosis, peritoneal fibrosis, chronic hepatic damage, and fibrillogenesis (e.g., genes encoding sequences comprising those sequences referred to by GenBank Accession Nos. NM_001235), or a hsp47 gene family member where the genes or gene family sequences share sequence homology. The description of the various aspects and embodiments is provided with reference to exemplary gene hsp47. However, the various aspects and embodiments are also directed to other related hsp47 genes, such as homolog genes and transcript variants, and polymorphisms (e.g., single nucleotide polymorphism, (SNPs)) associated with certain hsp47 genes. As such, the various aspects and embodiments are also directed to other genes that are involved in hsp47 mediated pathways of signal transduction or gene expression that are involved, for example, in the maintenance or development of diseases, traits, or conditions described herein. These additional genes can be analyzed for target sites using the methods described for the hsp47 gene herein. Thus, the modulation of other genes and the effects of such modulation of the other genes can be performed, determined, and measured as described herein. [0322] In one embodiment, compositions and methods provided herein include a double stranded short interfering nucleic acid (siNA) molecule that down-regulates expression of a hsp47 gene (e.g., human hsp47 exemplified by SEQ ID NO: 1), where the nucleic acid molecule includes about 15 to about 49 base pairs. [0323] In one embodiment, a nucleic acid disclosed may be used to inhibit the expression of the hsp47 gene or a hsp47 gene family where the genes or gene family sequences share 96 WO 2011/072082 PCT/US2010/059578 sequence homology. Such homologous sequences can be identified as is known in the art, for example using sequence alignments. Nucleic acid molecules can be designed to target such homologous sequences, for example using perfectly complementary sequences or by incorporating non-canonical base pairs, for example mismatches and/or wobble base pairs, that can provide additional target sequences. In instances where mismatches are identified, non-canonical base pairs (for example, mismatches and/or wobble bases) can be used to generate nucleic acid molecules that target more than one gene sequence. In a non-limiting example, non-canonical base pairs such as UU and CC base pairs are used to generate nucleic acid molecules that are capable of targeting sequences for differing hsp47 targets that share sequence homology. As such, one advantage of using siNAs disclosed herein is that a single nucleic acid can be designed to include nucleic acid sequence that is complementary to the nucleotide sequence that is conserved between the homologous genes. In this approach, a single nucleic acid can be used to inhibit expression of more than one gene instead of using more than one nucleic acid molecule to target the different genes. [0324] Nucleic acid molecules may be used to target conserved sequences corresponding to a gene family or gene families such as hsp47 family genes. As such, nucleic acid molecules targeting multiple hsp47 targets can provide increased therapeutic effect. In addition, nucleic acid can be used to characterize pathways of gene function in a variety of applications. For example, nucleic acid molecules can be used to inhibit the activity of target gene(s) in a pathway to determine the function of uncharacterized gene(s) in gene function analysis, mRNA function analysis, or translational analysis. The nucleic acid molecules can be used to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The nucleic acid molecules can be used to understand pathways of gene expression involved in, for example fibroses such as liver, kidney or pulmonary fibrosis, and/or inflammatory and proliferative traits, diseases, disorders, and/or conditions. [0325] In one embodiment, the compositions and methods provided herein include a nucleic acid molecule having RNAi activity against hsp47 RNA, where the nucleic acid molecule includes a sequence complementary to any RNA having hsp47 encoding sequence, such as those sequences having sequences as shown in Table I. In another embodiment, a nucleic acid molecule may have RNAi activity against hsp47 RNA, where the nucleic acid molecule includes a sequence complementary to an RNA having variant hsp47 encoding sequence, for example other mutant hsp47 genes not shown in Table I but known in the art to 97 WO 2011/072082 PCT/US2010/059578 be associated with the maintenance and/or development of fibrosis. Chemical modifications as shown in Table I or otherwise described herein can be applied to any nucleic acid construct disclosed herein. In another embodiment, a nucleic acid molecule disclosed herein includes a nucleotide sequence that can interact with nucleotide sequence of a hsp47 gene and thereby mediate silencing of hsp47 gene expression, for example, wherein the nucleic acid molecule mediates regulation of hsp47 gene expression by cellular processes that modulate the chromatin structure or methylation patterns of the hsp47 gene and prevent transcription of the hsp47 gene. [0326] Nucleic acid molecules disclosed herein may have RNAi activity against hsp47 RNA, where the nucleic acid molecule includes a sequence complementary to any RNA having hsp47 encoding sequence, such as those sequences having GenBank Accession Nos. NM_001235. Nucleic acid molecules may have RNAi activity against hsp47 RNA, where the nucleic acid molecule includes a sequence complementary to an RNA having variant hsp47 encoding sequence, for example other mutant hsp47 genes known in the art to be associated with the maintenance and/or development of fibrosis. Nucleic acid molecules disclosed herein include a nucleotide sequence that can interact with nucleotide sequence of a hsp47 gene and thereby mediate silencing of hsp47 gene expression, e.g., where the nucleic acid molecule mediates regulation of hsp47 gene expression by cellular processes that modulate the chromatin structure or methylation patterns of the hsp47 gene and prevent transcription of the hsp47 gene. Methods of Treatment [0327] The specific association of HSP47 with a diverse range of collagen types makes hsp47 a target for the treatment of fibrosis. Inhibition of hsp47 expression may prevent extracellular collagen I secretion. Sato et al. (Nat Biotechnol 2008; 26:431-442) explored this possibility by using siRNA for the inhibition hsp47 expression and preventing the progression of hepatic fibrosis in rats. Similarly, Chen et al. (Br J Dermatol 2007; 156: 1188-1195) and Wang et al. (Plast. Reconstr Surg 2003; 111: 1980-7) investigated the inhibition hsp47 expression by RNA interference technology. [0328] In one embodiment, nucleic acid molecules may be used to down regulate or inhibit the expression of hsp47 and/or hsp47 proteins arising from hsp47 and/or hsp47 haplotype polymorphisms that are associated with a disease or condition, (e.g., fibrosis). 98 WO 2011/072082 PCT/US2010/059578 Analysis of hsp47 and/or hsp47 genes, or hsp47 and/or hsp47 protein or RNA levels can be used to identify subjects with such polymorphisms or those subjects who are at risk of developing traits, conditions, or diseases described herein. These subjects are amenable to treatment, for example, treatment with nucleic acid molecules disclosed herein and any other composition useful in treating diseases related to hsp47 and/or hsp47 gene expression. As such, analysis of hsp47 and/or hsp47 protein or RNA levels can be used to determine treatment type and the course of therapy in treating a subject. Monitoring of hsp47 and/or hsp47 protein or RNA levels can be used to predict treatment outcome and to determine the efficacy of compounds and compositions that modulate the level and/or activity of certain hsp47 and/or hsp47 proteins associated with a trait, condition, or disease. [0329] Provided are compositions and methods for inhibition of hsp47 expression by using small nucleic acid molecules as provided herein, such as short interfering nucleic acid (siNA), interfering RNA (RNAi), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference against hsp47 gene expression. The composition and methods disclosed herein are also useful in treating various fibrosis such as liver fibrosis, lung fibrosis, and kidney fibrosis. [0330] The nucleic acid molecules disclosed herein individually, or in combination or in conjunction with other drugs, can be use for preventing or treating diseases, traits, conditions and/or disorders associated with hsp47, such as liver fibrosis, cirrhosis, pulmonary fibrosis, kidney fibrosis, peritoneal fibrosis, chronic hepatic damage, and fibrillogenesis. [0331] The nucleic acid molecules disclosed herein are able to inhibit the expression of hsp47 in a sequence specific manner. The nucleic acid molecules may include a sense strand and an antisense strand which include contiguous nucleotides that are at least partially complementary (antisense) to a hsp47 mRNA. [0332] In some embodiments, dsRNA specific for hsp47 can be used in conjunction with other dsRNA specific for other molecular chaperones that assist in the folding of newly synthesized proteins such as, calnexin, calreticulin, BiP (Bergeron et al. Trends Biochem. Sci. 1994; 19:124-128; Herbert et al. 1995; Cold Spring Harb. Symp. Quant. Biol. 60:405-415) [0333] Fibrosis can be treated by RNA interference using nucleic acid molecules as disclosed herein. Exemplary fibrosis include liver fibrosis, peritoneal fibrosis, lung fibrosis, 99 WO 2011/072082 PCT/US2010/059578 kidney fibrosis. The nucleic acid molecules disclosed herein may inhibit the expression of hsp47 in a sequence specific manner. [0334] Treatment of fibrosis can be monitored by determining the level of extracellular collagen using suitable techniques known in the art such as, using anti-collagen I antibodies. Treatment can also be monitored by determining the level of hsp47 mRNA or the level of HSP47 protein in the cells of the affected tissue. Treatment can also be monitored by non invasive scanning of the affected organ or tissue such as by computer assisted tomography scan, magnetic resonance elastography scans. [0335] A method for treating or preventing hsp47 associated disease or condition in a subject or organism may include contacting the subject or organism with a nucleic acid molecule as provided herein under conditions suitable to modulate the expression of the hsp47 gene in the subject or organism. [0336] A method for treating or preventing fibrosis in a subject or organism may include contacting the subject or organism with a nucleic acid molecule under conditions suitable to modulate the expression of the hsp47 gene in the subject or organism. [0337] A method for treating or preventing one or more fibroses selected from the group consisting of liver fibrosis, kidney fibrosis, and pulmonary fibrosis in a subject or organism may include contacting the subject or organism with a nucleic acid molecule under conditions suitable to modulate the expression of the hsp47 gene in the subject or organism. Fibrotic Diseases [0338] Fibrotic diseases are generally characterized by the excess deposition of a fibrous material within the extracellular matrix, which contributes to abnormal changes in tissue architecture and interferes with normal organ function. [0339] All tissues damaged by trauma respond by the initiation of a wound-healing program. Fibrosis, a type of disorder characterized by excessive scarring, occurs when the normal self-limiting process of wound healing response is disturbed, and causes excessive production and deposition of collagen. As a result, normal organ tissue is replaced with scar tissue, which eventually leads to the functional failure of the organ. 100 [0340] Fibrosis may be initiated by diverse causes and in various organs. Liver cirrhosis, pulmonary fibrosis, sarcoidosis, keloids and kidney fibrosis are all chronic conditions associated with progressive fibrosis, thereby causing a continuous loss of normal tissue function. [0341] Acute fibrosis (usually with a sudden and severe onset and of short duration) occurs as a common response to various forms of trauma including accidental injuries (particularly injuries to the spine and central nervous system), infections, surgery, ischemic illness (e.g. cardiac scarring following heart attack), burns, environmental pollutants, alcohol and other types of toxins, acute respiratory distress syndrome, radiation and chemotherapy treatments. [0342] Fibrosis, a fibrosis related pathology or a pathology related to aberrant crosslinking of cellular proteins may all be treated by the siRNAs disclosed herein. Fibrotic diseases or diseases in which fibrosis is evident (fibrosis related pathology) include both acute and chronic forms of fibrosis of organs, including all etiological variants of the following: pulmonary fibrosis, including interstitial lung disease and fibrotic lung disease, liver fibrosis, cardiac fibrosis including myocardial fibrosis, kidney fibrosis including chronic renal failure, skin fibrosis including scleroderma, keloids and hypertrophic scars; myelofibrosis (bone marrow fibrosis); all types of ocular scarring including proliferative vitreoretinopathy (PVR) and scarring resulting from surgery to treat cataract or glaucoma; inflammatory bowel disease of variable etiology, macular degeneration, Grave's ophthalmopathy, drug induced ergotism, keloid scars, scleroderma, psoriasis, glioblastoma in Li-Fraumeni syndrome, sporadic glioblastoma, myleoid leukemia, acute myelogenous leukemia, myelodysplastic syndrome, myeloproferative syndrome, gynecological cancer, Kaposi's sarcoma, Hansen's disease, and collagenous colitis . [0343] In various embodiments, the compounds (nucleic acid molecules) as disclosed herein may be used to treat fibrotic diseases, for example as disclosed herein, as well as many other diseases and conditions apart from fibrotic diseases, for example such as disclosed herein. Other conditions to be treated include fibrotic diseases in other organs - kidney fibrosis for any reason (CKD including ESRD); lung fibrosis (including ILF); myelofibrosis, abnormal scarring (keloids) associated with all possible types of skin injury accidental and jatrogenic (operations); scleroderma; cardiofibrosis, failure of glaucoma filtering operation; intestinal adhesions. 101 Ocular surgery and fibrotic complications [0344] Contracture of scar tissue resulting from eye surgery may often occur. Glaucoma surgery to create new drainage channels often fails due to scarring and contraction of tissues and the generated drainage system may be blocked requiring additional surgical intervention. Current anti-scarring regimens (Mitomycin C or 5FU) are limited due to the complications involved (e.g. blindness) e.g. see Cordeiro MF, et al., Human anti-transforming growth factor beta2 antibody: a new glaucoma anti-scarring agent Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2225-34. There may also be contraction of scar tissue formed after corneal trauma or corneal surgery, for example laser or surgical treatment for myopia or refractive error in which contraction of tissues may lead to inaccurate results. Scar tissue may be formed on/in the vitreous humor or the retina, for example, and may eventually causes blindness in some diabetics, and may be formed after detachment surgery, called proliferative vitreoretinopathy (PVR). PVR is the most common complication following retinal detachment and is associated with a retinal hole or break. PVR refers to the growth of cellular membranes within the vitreous cavity and on the front and back surfaces of the retina containing retinal pigment epithelial (RPE) cells. These membranes, which are essentially scar tissues, exert traction on the retina and may result in recurrences of retinal detachment, even after an initially successful retinal detachment procedure. [0345] Scar tissue may be formed in the orbit or on eye and eyelid muscles after squint, orbital or eyelid surgery, or thyroid eye disease, and where scarring of the conjunctiva occurs as may happen after glaucoma surgery or in cicatricial disease, inflammatory disease, for example, pemphigoid, or infective disease, for example, trachoma. A further eye problem associated with the contraction of collagen-including tissues is the opacification and contracture of the lens capsule after cataract extraction. Important role for MMPs has been recognized in ocular diseases including wound healing, dry eye, sterile corneal ulceration, recurrent epithelial erosion, corneal neovascularization, pterygium, conjunctivochalasis, glaucoma, PVR, and ocular fibrosis. Liver fibrosis 10346] Liver fibrosis (LF) is a generally irreversible consequence of hepatic damage of several etiologies. In the Western world, the main etiologic categories are: alcoholic liver disease (30-50%), viral hepatitis (30%), biliary disease (5-10%), primary hemochromatosis 102 WO 2011/072082 PCT/US2010/059578 (5%), and drug-related and cryptogenic cirrhosis of, unknown etiology, (10-15%). Wilson's disease, a,-antitrypsin deficiency and other rare diseases also have liver fibrosis as one of the symptoms. Liver cirrhosis, the end stage of liver fibrosis, frequently requires liver transplantation and is among the top ten causes of death in the Western world. Kidney fibrosis and related conditions. Chronic Renal Failure (CRF) [03471 Chronic renal failure is a gradual and progressive loss of the ability of the kidneys to excrete wastes, concentrate urine, and conserve electrolytes. CRF is slowly progressive. It most often results from any disease that causes gradual loss of kidney function, and fibrosis is the main pathology that produces CRF. Diabetic nephropathy [0348] Diabetic nephropathy, hallmarks of which are glomerulosclerosis and tubulointerstitial fibrosis, is the single most prevalent cause of end-stage renal disease in the modern world, and diabetic patients constitute the largest population on dialysis. Such therapy is costly and far from optimal. Transplantation offers a better outcome but suffers from a severe shortage of donors. Chronic Kidney Disease [0349] Chronic kidney disease (CKD) is a worldwide public health problem and is recognized as a common condition that is associated with an increased risk of cardiovascular disease and chronic renal failure (CRF). [0350] The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation (NKF) defines chronic kidney disease as either kidney damage or a decreased kidney glomerular filtration rate (GFR) for three or more months. Other markers of CKD are also known and used for diagnosis. In general, the destruction of renal mass with irreversible sclerosis and loss of nephrons leads to a progressive decline in GFR. Recently, the K/DOQI published a classification of the stages of CKD, as follows: Stage 1: Kidney damage with normal or increased GFR (>90 mL/min/1.73 m2) Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2) Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2) 103 WO 2011/072082 PCT/US2010/059578 Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2) Stage 5: Kidney failure (GFR <15 mL/min/ 1.73 m2 or dialysis) [0351] In stages 1 and 2 CKD, GFR alone does not confirm the diagnosis. Other markers of kidney damage, including abnormalities in the composition of blood or urine or abnormalities in imaging tests, may be relied upon. Pathophysiologv of CKD [0352] Approximately 1 million nephrons are present in each kidney, each contributing to the total GFR. Irrespective of the etiology of renal injury, with progressive destruction of nephrons, the kidney is able to maintain GFR by hyperfiltration and compensatory hypertrophy of the remaining healthy nephrons. This nephron adaptability allows for continued normal clearance of plasma solutes so that substances such as urea and creatinine start to show significant increases in plasma levels only after total GFR has decreased to 50%, when the renal reserve has been exhausted. The plasma creatinine value will approximately double with a 50% reduction in GFR. Therefore, a doubling in plasma creatinine from a baseline value of 0.6 mg/dL to 1.2 mg/dL in a patient actually represents a loss of 50% of functioning nephron mass. [0353] The residual nephron hyperfiltration and hypertrophy, although beneficial for the reasons noted, is thought to represent a major cause of progressive renal dysfunction. This is believed to occur because of increased glomerular capillary pressure, which damages the capillaries and leads initially to focal and segmental glomerulosclerosis and eventually to global glomerulosclerosis. This hypothesis has been based on studies of five-sixths nephrectomized rats, which develop lesions that are identical to those observed in humans with CKD. [0354] The two most common causes of chronic kidney disease are diabetes and hypertension. Other factors include acute insults from nephrotoxins, including contrasting agents, or decreased perfusion; Proteinuria; Increased renal ammoniagenesis with interstitial injury; Hyperlipidemia; Hyperphosphatemia with calcium phosphate deposition; Decreased levels of nitrous oxide and smoking. [0355] In the United States, the incidence and prevalence of CKD is rising, with poor outcomes and high cost to the health system. Kidney disease is the ninth leading cause of 104 WO 2011/072082 PCT/US2010/059578 death in the US. The high rate of mortality has led the US Surgeon General's mandate for America's citizenry, Healthy People 2010, to contain a chapter focused on CKD. The objectives of this chapter are to articulate goals and to provide strategies to reduce the incidence, morbidity, mortality, and health costs of chronic kidney disease in the United States. [0356] The incidence rates of end-stage renal disease (ESRD) have also increased steadily internationally since 1989. The United States has the highest incident rate of ESRD, followed by Japan. Japan has the highest prevalence per million population, followed by the US. [0357] The mortality rates associated with hemodialysis are striking and indicate that the life expectancy of patients entering into hemodialysis is markedly shortened. At every age, patients with ESRD on dialysis have significantly increased mortality when compared with nondialysis patients and individuals without kidney disease. At age 60 years, a healthy person can expect to live for more than 20 years, whereas the life expectancy of a 60-year-old patient starting hemodialysis is closer to 4 years (Aurora and Verelli, May 21, 2009. Chronic Renal Failure: Treatment & Medication. Emedicine. lttp:/emedicine.medscape.com/article/238798 treatment). Pulmonary fibrosis [0358] Interstitial pulmonary fibrosis (IPF) is scarring of the lung caused by a variety of inhaled agents including mineral particles, organic dusts, and oxidant gases, or by unknown reasons (idiopathic lung fibrosis). The disease afflicts millions of individuals worldwide, and there are no effective therapeutic approaches. A major reason for the lack of useful treatments is that few of the molecular mechanisms of disease have been defined sufficiently to design appropriate targets for therapy (Lasky JA., Brody AR. (2000), "Interstitial fibrosis and growth factors", Environ Health Perspect.;108 Suppl 4:751-62). Cardiac fibrosis [0359] Heart failure is unique among the major cardiovascular disorders in that it alone is increasing in prevalence while there has been a striking decrease in other conditions. Some of this can be attributed to the aging of the populations of the United States and Europe. The ability to salvage patients with myocardial damage is also a major factor, as these patients 105 WO 2011/072082 PCT/US2010/059578 may develop progression of left ventricular dysfunction due to deleterious remodelling of the heart. [0360] The normal myocardium is composed of a variety of cells, cardiac myocytes and noncardiomyocytes, which include endothelial and vascular smooth muscle cells and fibroblasts. [0361] Structural remodeling of the ventricular wall is a key determinant of clinical outcome in heart disease. Such remodeling involves the production and destruction of extracellular matrix proteins, cell proliferation and migration, and apoptotic and necrotic cell death. Cardiac fibroblasts are crucially involved in these processes, producing growth factors and cytokines that act as autocrine and paracrine factors, as well as extracellular matrix proteins and proteinases. Recent studies have shown that the interactions between cardiac fibroblasts and cardiomyocytes are essential for the progression of cardiac remodeling of which the net effect is deterioration in cardiac function and the onset of heart failure (Manabe I, et al., (2002), "Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy", Circ Res. 13;91(12):1103-13). Burns and scars [0362] A particular problem which may arise, particularly in fibrotic disease, is contraction of tissues, for example contraction of scars. Contraction of tissues including extracellular matrix components, especially of collagen-including tissues, may occur in connection with many different pathological conditions and with surgical or cosmetic procedures. Contracture, for example, of scars, may cause physical problems, which may lead to the need for medical treatment, or it may cause problems of a purely cosmetic nature. Collagen is the major component of scar and other contracted tissue and as such is the most important structural component to consider. Nevertheless, scar and other contracted tissue also includes other structural components, especially other extracellular matrix components, for example, elastin, which may also contribute to contraction of the tissue. [0363] Contraction of collagen-including tissue, which may also include other extracellular matrix components, frequently occurs in the healing of bums. The bums may be chemical, thermal or radiation burns and may be of the eye, the surface of the skin or the skin and the underlying tissues. It may also be the case that there are bums on internal tissues, for example, caused by radiation treatment. Contraction of burnt tissues is often a problem and 106 WO 2011/072082 PCT/US2010/059578 may lead to physical and/or cosmetic problems, for example, loss of movement and/or disfigurement. [0364] Skin grafts may be applied for a variety of reasons and may often undergo contraction after application. As with the healing of burnt tissues the contraction may lead to both physical and cosmetic problems. It is a particularly serious problem where many skin grafts are needed as, for example, in a serious burns case. [03651 Contraction is also a problem in production of artificial skin. To make a true artificial skin it is necessary to have an epidermis made of epithelial cells (keratinocytes) and a dermis made of collagen populated with fibroblasts. It is important to have both types of cells because they signal and stimulate each other using growth factors. The collagen component of the artificial skin often contracts to less than one tenth of its original area when populated by fibroblasts. [0366] Cicatricial contraction, contraction due to shrinkage of the fibrous tissue of a scar, is common. In some cases the scar may become a vicious cicatrix, a scar in which the contraction causes serious deformity. A patient's stomach may be effectively separated into two separate chambers in an hour-glass contracture by the contraction of scar tissue formed when a stomach ulcer heals. Obstruction of passages and ducts, cicatricial stenosis, may occur due to the contraction of scar tissue. Contraction of blood vessels may be due to primary obstruction or surgical trauma, for example, after surgery or angioplasty. Stenosis of other hollow visci, for examples, ureters, may also occur. Problems may occur where any form of scarring takes place, whether resulting from accidental wounds or from surgery. Conditions of the skin and tendons which involve contraction of collagen-including tissues include post-trauma conditions resulting from surgery or accidents, for example, hand or foot tendon injuries, post-graft conditions and pathological conditions, such as scleroderma, Dupuytren's contracture and epidermolysis bullosa. Scarring and contraction of tissues in the eye may occur in various conditions, for example, the sequelae of retinal detachment or diabetic eye disease (as mentioned above). Contraction of the sockets found in the skull for the eyeballs and associated structures, including extra-ocular muscles and eyelids, may occur if there is trauma or inflammatory damage. The tissues contract within the sockets causing a variety of problems including double vision and an unsightly appearance. 107 WO 2011/072082 PCT/US2010/059578 [0367] For further information on different types of fibrosis see: Molina V, et al., (2002), "Fibrotic diseases", Harefuah, 141(11): 973-8, 1009; Yu L, et al., (2002), "Therapeutic strategies to halt renal fibrosis", Curr Opin Pharmacol. 2(2):177-8 1; Keane WF and Lyle PA. (2003), "Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study", Am J Kidney Dis. 41(3 Suppl 2): S22-5; Bohle A, et al., (1989), "The pathogenesis of chronic renal failure", Pathol Res Pract. 185(4):421-40; Kikkawa R, et al., (1997), "Mechanism of the progression of diabetic nephropathy to renal failure", Kidney Int Supply. 62:S39-40; Bataller R, and Brenner DA. (2001), "Hepatic stellate cells as a target for the treatment of liver fibrosis", Semin Liver Dis. 21(3):437-51; Gross TJ and Hunninghake GW, (2001) "Idiopathic pulmonary fibrosis", N Engl J Med. 345(7):517-25; Frohlich ED. (2001) "Fibrosis and ischemia: the real risks in hypertensive heart disease", Am J Hypertens;14(6 Pt 2):194S-199S; Friedman SL. (2003), "Liver fibrosis - from bench to bedside", J Hepatol. 38 Suppl 1:S38-53; Albanis E, et al., (2003), "Treatment of hepatic fibrosis: almost there", Curr Gastroenterol Rep. 5(1):48-56; (Weber KT. (2000), "Fibrosis and hypertensive heart disease", Cuff Opin Cardiol. 15(4):264-72). Delivery of Nucleic Acid Molecules and Pharmaceutical Formulations [0368] Nucleic acid molecules may be adapted for use to prevent or treat fibroses (e.g., liver, kidney, peritoneal, and pulmonary) diseases, traits, conditions and/or disorders, and/or any other trait, disease, disorder or condition that is related to or will respond to the levels of hsp47 in a cell or tissue, alone or in combination with other therapies. A nucleic acid molecule may include a delivery vehicle, including liposomes, for administration to a subject, carriers and diluents and their salts, and/or can be present in pharmaceutically acceptable formulations. [0369] Nucleic acid molecules disclosed herein may be delivered or administered directly with a carrier or diluent but not any delivery vehicle that acts to assist, promote or facilitate entry to the cell, including viral vectors, viral particles, liposome formulations, lipofectin or precipitating agents and the like. [0370] Nucleic acid molecules may be delivered or administered to a subject by direct application of the nucleic acid molecules with a carrier or diluent or any other delivery vehicle that acts to assist, promote or facilitate entry into a cell, including viral sequences, viral particular, liposome formulations, lipofectin or precipitating agents and the like. Polypeptides 108 that facilitate introduction of nucleic acid into a desired subject such as those described in US. Application Publication No. 20070155658 (e.g., a melamine derivative such as 2,4,6 Triguanidino Triazine and 2,4,6- Triamidosarcosyl Melamine, a polyarginine polypeptide, and a polypeptide including alternating glutamine and asparagine residues). [0371] Methods for the delivery of nucleic acid molecules are described in Akhtar et al., Trends Cell Bio., 2: 139 (1992); Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, (1995), Maurer et al., Mol. Membr. Biol., 16: 129-140 (1999); Hofland and Huang, Handb. Exp. Pharmacol., 137: 165-192 (1999); and Lee et al., ACS Symp. Ser., 752: 184-192 (2000); U.S. Pat. Nos. 6,395,713; 6,235,310; 5,225,182; 5,169,383; 5,167,616; 4,959217; 4.925,678; 4,487,603; and 4,486,194 and Sullivan et al., PCT WO 94/02595; PCT WO 00/03683 and PCT WO 02/08754; and U.S. Patent Application Publication No. 2003077829. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as biodegradable polymers, hydrogels, cyclodextrins (see e.g., Gonzalez et al., Bioconjugate Chem., 10: 1068 1074 (1999); Wang et al., International PCT publication Nos. WO 03/47518 and WO 03/46185), poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see for example U.S. Pat. No. 6,447,796 and U.S. Application Publication No. 2002130430), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication No. WO 00/53722). Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Direct injection of the nucleic acid molecules of the invention, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free technologies such as those described in Conry et al., Clin. Cancer Res., 5: 2330-2337 (1999) and Barry et al., International PCT Publication No. WO 99/31262. The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, modulate the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a subject. [0372] Nucleic acid molecules may be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through direct dermal application, transdermal application, or injection, with or without their incorporation 109 WO 2011/072082 PCT/US2010/059578 in biopolymers. The nucleic acid molecules of the invention may include sequences shown in Tables I. Examples of such nucleic acid molecules consist essentially of sequences provided in Table I. [0373] Delivery systems include surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al. Chem. Rev. 1995, 95, 2601-2627; Ishiwata et al., Chem. Pharm. Bull. 1995, 43, 1005-1011). [0374] Nucleic acid molecules may be formulated or complexed with polyethylenimine (e.g., linear or branched PEI) and/or polyethylenimine derivatives, including for example polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine (PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL) derivatives, grafted PEIs such as galactose PEI, cholesterol PEI, antibody derivatized PEI, and polyethylene glycol PEI (PEG-PEI) derivatives thereof (see for example Ogris et al., 2001, AAPA PharmSci, 3, 1-11; Furgeson et al., 2003, Bioconjugate Chem., 14, 840-847; Kunath et al., 2002, Pharmaceutical Research, 19, 810-817; Choi et al., 2001, Bull. Korean Chem. Soc., 22, 46-52; Bettinger et al., 1999, Bioconjugate Chem., 10, 558-561; Peterson et al., 2002, Bioconjugate Chem., 13, 845-854; Erbacher et al., 1999, Journal of Gene Medicine Preprint, 1, 1-18; Godbey et al., 1999., PNAS USA, 96, 5177-5181; Godbey et al., 1999, Journal of Controlled Release, 60, 149-160; Diebold et al., 1999, Journal of Biological Chemistry, 274, 19087-19094; Thomas and Klibanov, 2002, PNAS USA, 99, 14640-14645; Sagara, U.S. Pat. No. 6,586,524 and United States Patent Application Publication No. 20030077829. [0375] Nucleic acid molecules may be complexed with membrane disruptive agents such as those described in U.S. Patent Application Publication No. 20010007666. The membrane disruptive agent or agents and the nucleic acid molecule may also be complexed with a cationic lipid or helper lipid molecule, such as those lipids described in U.S. Pat. No. 6,235,310. [0376] The nucleic acid molecules may be administered via pulmonary delivery, such as by inhalation of an aerosol or spray dried formulation administered by an inhalation device or 110 WO 2011/072082 PCT/US2010/059578 nebulizer, providing rapid local uptake of the nucleic acid molecules into relevant pulmonary tissues. Solid particulate compositions containing respirable dry particles of micronized nucleic acid compositions can be prepared by grinding dried or lyophilized nucleic acid compositions, and then passing the micronized composition through, for example, a 400 mesh screen to break up or separate out large agglomerates. A solid particulate composition comprising the nucleic acid compositions of the invention can optionally contain a dispersant which serves to facilitate the formation of an aerosol as well as other therapeutic compounds. A suitable dispersant is lactose, which can be blended with the nucleic acid compound in any suitable ratio, such as a 1 to 1 ratio by weight. [0377] Aerosols of liquid particles may include a nucleic acid molecules disclosed herein and can be produced by any suitable means, such as with a nebulizer (see e.g., U.S. Pat. No. 4,501,729). Nebulizers are commercially available devices which transform solutions or suspensions of an active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas, typically air or oxygen, through a narrow venturi orifice or by means of ultrasonic agitation. Suitable formulations for use in nebulizers include the active ingredient in a liquid carrier in an amount of up to 40% w/w preferably less than 20% w/w of the formulation. The carrier is typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, e.g., sodium chloride or other suitable salts. Optional additives include preservatives if the formulation is not prepared sterile, e.g., methyl hydroxybenzoate, anti-oxidants, flavorings, volatile oils, buffering agents and emulsifiers and other formulation surfactants. The aerosols of solid particles including the active composition and surfactant can likewise be produced with any solid particulate aerosol generator. Aerosol generators for administering solid particulate therapeutics to a subject produce particles which are respirable, as explained above, and generate a volume of aerosol containing a predetermined metered dose of a therapeutic composition at a rate suitable for human administration. One illustrative type of solid particulate aerosol generator is an insufflator. Suitable formulations for administration by insufflation include finely comminuted powders which can be delivered by means of an insufflator. In the insufflator, the powder, e.g., a metered dose thereof effective to carry out the treatments described herein, is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened in situ and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump. The powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active 111 ingredient, a suitable powder diluent, such as lactose, and an optional surfactant. The active ingredient typically includes from 0.1 to 100% w/w of the formulation. A second type of illustrative aerosol generator includes a metered dose inhaler. Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquefied propellant. During use these devices discharge the formulation through a valve adapted to deliver a metered volume to produce a fine particle spray containing the active ingredient. Suitable propellants include certain chlorofluorocarbon compounds, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane and mixtures thereof. The formulation can additionally contain one or more co-solvents, for example, ethanol, emulsifiers and other formulation surfactants, such as oleic acid or sorbitan trioleate, anti-oxidants and suitable flavoring agents. Other methods for pulmonary delivery are described in, e.g., US Patent Application No. 20040037780, and U.S. Pat. Nos. 6,592,904; 6,582,728; 6,565,885. PCT Patent Publiction No. W02008/132723 relates to aerosol delivery of oligonucleotides in general, and of siRNA in particular, to the respiratory system. [03781 Nucleic acid molecules may be administered to the central nervous system (CNS) or peripheral nervous system (PNS). Experiments have demonstrated the efficient in vivo uptake of nucleic acids by neurons. See e.g., Sommer et al., 1998, Antisense Nuc. Acid Drug Dev., 8, 75; Epa et al., 2000, Antisense Nuc. Acid Drug Dev., 10, 469; Broaddus et al., 1998, J. Neurosurg., 88(4), 734; Karle et al., 1997, Eur. J. Pharmocol., 340(2/3), 153; Bannai et al., 1998, Brain Research, 784(1,2), 304; Rajakumar et al., 1997, Synapse, 26(3), 199; Wu-pong et al., 1999, BioPharm, 12(1), 32; Bannai et al., 1998, Brain Res. Protoc., 3(1), 83; and Simantov et al., 1996, Neuroscience, 74(1), 39. Nucleic acid molecules are therefore amenable to delivery to and uptake by cells in the CNS and/or PNS. 103791 Delivery of nucleic acid molecules to the CNS is provided by a variety of different strategies. Traditional approaches to CNS delivery that can be used include, but are not limited to, intrathecal and intracerebroventricular administration, implantation of catheters and pumps, direct injection or perfusion at the site of injury or lesion, injection into the brain arterial system, or by chemical or osmotic opening of the blood-brain barrier. Other approaches can include the use of various transport and carrier systems, for example through the use of conjugates and biodegradable polymers. Furthermore, gene therapy approaches, e.g., as described in Kaplitt et al., U.S. Pat. No. 6,180,613 and Davidson, WO 04/013280, can be used to express nucleic acid molecules in the CNS. 112 [0380] Delivery systems may include, for example, aqueous and nonaqueous gels, creams, multiple emulsions, microemulsions, liposomes, ointments, aqueous and nonaqueous solutions, lotions, aerosols, hydrocarbon bases and powders, and can contain excipients such as solubilizers, permeation enhancers (e.g., fatty acids, fatty acid esters, fatty alcohols and amino acids), and hydrophilic polymers (e.g., polycarbophil and polyvinylpyrolidone). In one embodiment, the pharmaceutically acceptable carrier is a liposome or a transdermal enhancer. Examples of liposomes which can be used in this invention include the following: (1) CellFectin, 1:1.5 (M/M) liposome formulation of the cationic lipid N,NI,NII,NIII-tetramethyl N,NI,NII,NIII-tetrapalmityl-y-spermine and dioleoyl phosphatidylethanolamine (DOPE) (GIBCO BRL); (2) Cytofectin GSV, 2:1 (M/M) liposome formulation of a cationic lipid and DOPE (Glen Research); (3) DOTAP (N-[ 1 -(2,3-dioleoyloxy)-N,N,N-tri-methyl ammoniummethylsulfate) (Boehringer Manheim); and (4) Lipofectamine, 3:1 (M/M) liposome formulation of the polycationic lipid DOSPA, the neutral lipid DOPE (GIBCO BRL) and Di Alkylated Amino Acid (DiLA2). 10381] Delivery systems may include patches, tablets, suppositories, pessaries, gels and creams, and can contain excipients such as solubilizers and enhancers (e.g., propylene glycol, bile salts and amino acids), and other vehicles (e.g., polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethylcellulose and hyaluronic acid). [03821 Nucleic acid molecules may be formulated or complexed with polyethylenimine (e.g., linear or branched PEI) and/or polyethylenimine derivatives, including for example grafted PEIs such as galactose PEI, cholesterol PEI, antibody derivatized PEI, and polyethylene glycol PEI (PEG-PEI) derivatives thereof (see for example Ogris et al., 2001, AAPA PharmSci, 3, 1-11; Furgeson et al., 2003, Bioconjugate Chem., 14, 840-847; Kunath et al., 2002, Pharmaceutical Research, 19, 810-817; Choi et al., 2001, Bull. Korean Chem. Soc., 22, 46-52; Bettinger et al., 1999, Bioconjugate Chem., 10, 558-561; Peterson et al., 2002, Bioconjugate Chem., 13, 845-854; Erbacher et al., 1999, Journal of Gene Medicine Preprint, 1, 1-18; Godbey et al., 1999., PNAS USA, 96, 5177-5181; Godbey et al., 1999, Journal of Controlled Release, 60, 149-160; Diebold et al., 1999, Journal of Biological Chemistry, 274, 19087-19094; Thomas and Klibanov, 2002, PNAS USA, 99, 14640-14645; and Sagara, U.S. Pat. No. 6,586,524. 113 WO 2011/072082 PCT/US2010/059578 [0383] Nucleic acid molecules may include a bioconjugate, for example a nucleic acid conjugate as described in Vargeese et al., U.S. Ser. No. 10/427,160; U.S. Pat. No. 6,528,631; U.S. Pat. No. 6,335,434; U.S. Pat. No. 6,235,886; U.S. Pat. No. 6,153,737; U.S. Pat. No. 5,214,136; U.S. Pat. No. 5,138,045. [0384] Compositions, methods and kits disclosed herein may include an expression vector that includes a nucleic acid sequence encoding at least one nucleic acid molecule of the invention in a manner that allows expression of the nucleic acid molecule. Methods of introducing nucleic acid molecules or one or more vectors capable of expressing the strands of dsRNA into the environment of the cell will depend on the type of cell and the make up of its environment. The nucleic acid molecule or the vector construct may be directly introduced into the cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, or may be introduced by bathing an organism or a cell in a solution containing dsRNA. The cell is preferably a mammalian cell; more preferably a human cell. The nucleic acid molecule of the expression vector can include a sense region and an antisense region. The antisense region can include a sequence complementary to a RNA or DNA sequence encoding hsp47 and the sense region can include a sequence complementary to the antisense region. The nucleic acid molecule can include two distinct strands having complementary sense and antisense regions. The nucleic acid molecule can include a single strand having complementary sense and antisense regions. [0385] Nucleic acid molecules that interact with target RNA molecules and down-regulate gene encoding target RNA molecules (e.g., target RNA molecules referred to by Genbank Accession numbers herein) may be expressed from transcription units inserted into DNA or RNA vectors. Recombinant vectors can be DNA plasmids or viral vectors. Nucleic acid molecule expressing viral vectors can be constructed based on, but not limited to, adeno associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the nucleic acid molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the nucleic acid molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of nucleic acid molecule expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell. 114 WO 2011/072082 PCT/US2010/059578 [0386] Expression vectors may include a nucleic acid sequence encoding at least one nucleic acid molecule disclosed herein, in a manner which allows expression of the nucleic acid molecule. For example, the vector may contain sequence(s) encoding both strands of a nucleic acid molecule that include a duplex. The vector can also contain sequence(s) encoding a single nucleic acid molecule that is self-complementary and thus forms a nucleic acid molecule. Non-limiting examples of such expression vectors are described in Paul et al., 2002, Nature Biotechnology, 19, 505; Miyagishi and Taira, 2002, Nature Biotechnology, 19, 497; Lee et al., 2002, Nature Biotechnology, 19, 500; and Novina et al., 2002, Nature Medicine, advance online publication doi:10.1038/nm725. Expression vectors may also be included in a mammalian (e.g., human) cell. [0387] An expression vector may include a nucleic acid sequence encoding two or more nucleic acid molecules, which can be the same or different. Expression vectors may include a sequence for a nucleic acid molecule complementary to a nucleic acid molecule referred to by a Genbank Accession number NM_001235, for example those shown in Table I. [0388] An expression vector may encode one or both strands of a nucleic acid duplex, or a single self-complementary strand that self hybridizes into a nucleic acid duplex. The nucleic acid sequences encoding nucleic acid molecules can be operably linked in a manner that allows expression of the nucleic acid molecule (see for example Paul et al., 2002, Nature Biotechnology, 19, 505; Miyagishi and Taira, 2002, Nature Biotechnology, 19, 497; Lee et al., 2002, Nature Biotechnology, 19, 500; and Novina et al., 2002, Nature Medicine, advance online publication doi: 10.103 8/nm725). [0389] An expression vector may include one or more of the following: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) an intron and d) a nucleic acid sequence encoding at least one of the nucleic acid molecules, wherein said sequence is operably linked to the initiation region and the termination region in a manner that allows expression and/or delivery of the nucleic acid molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3' side of the sequence encoding the nucleic acid molecule; and/or an intron (intervening sequences). 115 WO 2011/072082 PCT/US2010/059578 [0390] Transcription of the nucleic acid molecule sequences can be driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, Proc. Natl. Acad. Sci. USA, 87, 6743-7; Gao and Huang 1993, Nucleic Acids Res., 21, 2867-72; Lieber et al., 1993, Methods Enzymol., 217, 47-66; Zhou et al., 1990, Mol. Cell. Biol., 10, 4529-37). Several investigators have demonstrated that nucleic acid molecules expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992, Antisense Res. Dev., 2, 3-15; Ojwang et al., 1992, Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Yu et al., 1993, Proc. Natl. Acad. Sci. USA, 90, 6340-4; L'Huillier et al., 1992, EMBO J., 11, 4411-8; Lisziewicz et al., 1993, Proc. Natl. Acad. Sci. U.S.A, 90, 8000-4; Thompson et al., 1995, Nucleic Acids Res., 23, 2259; Sullenger & Cech, 1993, Science, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as siNA in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994, Nucleic Acid Res., 22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997, Gene Ther., 4, 45; Beigelman et al., International PCT Publication No. WO 96/18736. The above nucleic acid transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (see Couture and Stinchcomb, 1996 supra). [0391] Nucleic acid molecule may be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, Science, 229, 345; McGarry and Lindquist, 1986, Proc. Natl. Acad. Sci., USA 83, 399; Scanlon et al., 1991, Proc. Natl. Acad. Sci. USA, 88, 10591-5; Kashani-Sabet et al., 1992, Antisense Res. Dev., 2, 3-15; Dropulic et al., 1992, J. Virol., 66, 1432-41; Weerasinghe et al., 1991, J. Virol., 65, 5531-4; Ojwang et al., 1992, Proc. Natl. Acad. Sci. USA, 89, 10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Sarver et al., 1990 Science, 247, 1222-1225; Thompson et al., 1995, Nucleic Acids Res., 23, 2259; Good et 116 WO 2011/072082 PCT/US2010/059578 al., 1997, Gene Therapy, 4, 45. Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992, Nucleic Acids Symp. Ser., 27, 15-6; Taira et al., 1991, Nucleic Acids Res., 19, 5125-30; Ventura et al., 1993, Nucleic Acids Res., 21, 3249-55; Chowrira et al., 1994, J. Biol. Chem., 269, 25856. [0392] A viral construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of dsRNA construct encoded by the expression construct. [0393] Methods for oral introduction include direct mixing of RNA with food of the organism, as well as engineered approaches in which a species that is used as food is engineered to express an RNA, then fed to the organism to be affected. Physical methods may be employed to introduce a nucleic acid molecule solution into the cell. Physical methods of introducing nucleic acids include injection of a solution containing the nucleic acid molecule, bombardment by particles covered by the nucleic acid molecule, soaking the cell or organism in a solution of the RNA, or electroporation of cell membranes in the presence of the nucleic acid molecule. [0394] Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical mediated transport, such as calcium phosphate, and the like. Thus the nucleic acid molecules may be introduced along with components that perform one or more of the following activities: enhance RNA uptake by the cell, promote annealing of the duplex strands, stabilize the annealed strands, or other-wise increase inhibition of the target gene. [0395] The nucleic acid molecules or the vector construct can be introduced into the cell using suitable formulations. One preferable formulation is with a lipid formulation such as in LipofectamineTM 2000 (Invitrogen, CA, USA), vitamin A coupled liposomes (Sato et al. Nat Biotechnol 2008; 26:431-442, PCT Patent Publication No. WO 2006/068232). Lipid formulations can also be administered to animals such as by intravenous, intramuscular, or intraperitoneal injection, or orally or by inhalation or other methods as are known in the art. When the formulation is suitable for administration into animals such as mammals and more 117 specifically humans, the formulation is also pharmaceutically acceptable. Pharmaceutically acceptable formulations for administering oligonucleotides are known and can be used. In some instances, it may be preferable to formulate dsRNA in a buffer or saline solution and directly inject the formulated dsRNA into cells, as in studies with oocytes. The direct injection of dsRNA duplexes may also be done. For suitable methods of introducing dsRNA see U.S. published patent application No. 2004/0203145, 20070265220 which are incorporated herein by reference. [0396] Polymeric nanocapsules or microcapsules facilitate transport and release of the encapsulated or bound dsRNA into the cell. They include polymeric and monomeric materials, especially including polybutylcyanoacrylate. A summary of materials and fabrication methods has been published (see Kreuter, 1991). The polymeric materials which are formed from monomeric and/or oligomeric precursors in the polymerization/nanoparticle generation step, are per se known from the prior art, as are the molecular weights and molecular weight distribution of the polymeric material which a person skilled in the field of manufacturing nanoparticles may suitably select in accordance with the usual skill. [03971 Nucleic acid molecules may be formulated as a microemulsion. A microemulsion is a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution. Typically microemulsions are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a 4th component, generally an intermediate chain-length alcohol to form a transparent system. [0398] Surfactants that may be used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML3 10), tetraglycerol monooleate (M03 10), hexaglycerol monooleate (P0310), hexaglycerol pentaoleate (P05 00), decaglycerol monocaprate (MCA750), decaglycerol monooleate (M0750), decaglycerol sequioleate (S0750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, I -propanol, and I -butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. 10399] Water Soluble Crosslinked Polymers 118 [04001 Delivery formulations can include water soluble degradable crosslinked polymers that include one or more degradable crosslinking lipid moiety, one or more PEI moiety, and/or one or more mPEG (methyl ether derivative of PEG (methoxypoly (ethylene glycol)). [0401] Degradable lipid moieties preferably include compounds having the following structural motif: O N O 0 R (A) [0402] In the above formula, ester linkages are biodegradable groups, R represents a relatively hydrophobic "lipo" group, and the structural motif shown occurs m times where m is in the range of about I to about 30. For example, in certain embodiments R is selected from the group consisting of C2-C50 alkyl, C2-C50 heteroalkyl, C2 - C50 alkenyl, C2 - C50 heteroalkenyl, C5-C50 aryl; C2-C50 heteroaryl; C2-C50 alkynyl, C2-C50 heteroalkynyl, C2 C50 carboxyalkenyl, and C2 - C50 carboxyheteroalkenyl. In preferred embodiments, R is a saturated or unsaturated alkyl having 4 to 30 carbons, more preferably 8 to 24 carbons or a sterol, preferably a cholesteryl moiety. In preferred embodiments, R is oleic, lauric, myristic, palmitic margaric, stearic, arachidic, behenic, or lignoceric. In a most preferred embodiment, R is oleic. [04031 The N in formula (A) may have an electron pair or a bond to a hydrogen atom. When N has an electron pair, the recurring unit may be cationic at low pH. [04041 The degradable crosslinking lipid moiety may be reacted with a polyethyleneimine (PEI) as shown in Scheme A below: 119 Scheme A O NO 0 0 R PEI -(-PEI O N 00 0 R II [04051 In scheme (A), R has the same meanings as described above. The PEI may contain recurring units of formula (B) in which x is an integer in the range of about I to about 100 and y is an integer in the range of about I to about 100. -f-NHCH 2

CH

2 -- (-NCH 2

CH

2 ) x I

CH

2

CH

2

NH

2 (B) [04061 The reaction illustrated in Scheme A may be carried out by intermixing the PEI and the diacrylate (I) in a mutual solvent such as ethanol, methanol or dichloromethane with stirring, preferably at room temperature for several hours, then evaporating the solvent to recover the resulting polymer. While not wishing to be bound to any particular theory, it is believed that the reaction between the PEI and diacrylate (I) involves a Michael reaction between one or more amines of the PEI with double bond(s) of the diacrylate (see J. March, Advanced Organic Chemistry 3rd Ed., pp. 711-712 (1985)). The diacrylate shown in Scheme A may be prepared in the manner as described in US Application No. 11/216,986 (US Publication No. 2006/0258751). [04071 The molecular weight of the PEI is preferably in the range of about 200 to 25,000 Daltons more preferably 400 to 5,000 Daltons, yet more preferably 600 to 2000 Daltons. PEI may be either branched or linear. [04081 The molar ratio of PEI to diacrylate is preferably in the range of about 1:2 to about 1:20. The weight average molecular weight of the cationic lipopolymer may be in the range 120 WO 2011/072082 PCT/US2010/059578 of about 500 Daltons to about 1,000,000 Daltons preferably in the range of about 2,000 Daltons to about 200,000 Daltons. Molecular weights may be determined by size exclusion chromatography using PEG standards or by agarose gel electrophoresis. [0409] The cationic lipopolymer is preferably degradable, more preferably biodegradable, e.g., degradable by a mechanism selected from the group consisting of hydrolysis, enzyme cleavage, reduction, photo-cleavage, and sonication. While not wishing to be bound to any particular theory, but it is believed that degradation of the cationic lipopolymer of formula (II) within the cell proceeds by enzymatic cleavage and/or hydrolysis of the ester linkages. [0410] Synthesis may be carried out by reacting the degradable lipid moiety with the PEI moiety as described above. Then the mPEG (methyl ether derivative of PEG (methoxypoly (ethylene glycol)), is added to form the degradable crosslinked polymer. In preferred embodiments, the reaction is carried out at room temperature. The reaction products may be isolated by any means known in the art including chromatographic techniques. In a preferred embodiment, the reaction product may be removed by precipitation followed by centrifugation. Dosages [0411] The useful dosage to be administered and the particular mode of administration will vary depending upon such factors as the cell type, or for in vivo use, the age, weight and the particular animal and region thereof to be treated, the particular nucleic acid and delivery method used, the therapeutic or diagnostic use contemplated, and the form of the formulation, for example, suspension, emulsion, micelle or liposome, as will be readily apparent to those skilled in the art. Typically, dosage is administered at lower levels and increased until the desired effect is achieved. [0412] When lipids are used to deliver the nucleic acid, the amount of lipid compound that is administered can vary and generally depends upon the amount of nucleic acid being administered. For example, the weight ratio of lipid compound to nucleic acid is preferably from about 1:1 to about 30:1, with a weight ratio of about 5:1 to about 10:1 being more preferred. [0413] A suitable dosage unit of nucleic acid molecules may be in the range of 0.001 to 0.25 milligrams per kilogram body weight of the recipient per day, or in the range of 0.01 to 121 WO 2011/072082 PCT/US2010/059578 20 micrograms per kilogram body weight per day, or in the range of 0.01 to 10 micrograms per kilogram body weight per day, or in the range of 0.10 to 5 micrograms per kilogram body weight per day, or in the range of 0.1 to 2.5 micrograms per kilogram body weight per day. [0414] Suitable amounts of nucleic acid molecules may be introduced and these amounts can be empirically determined using standard methods. Effective concentrations of individual nucleic acid molecule species in the environment of a cell may be about 1 femtomolar, about 50 femtomolar, 100 femtomolar, 1 picomolar, 1.5 picomolar, 2.5 picomolar, 5 picomolar, 10 picomolar, 25 picomolar, 50 picomolar, 100 picomolar, 500 picomolar, 1 nanomolar, 2.5 nanomolar, 5 nanomolar, 10 nanomolar, 25 nanomolar, 50 nanomolar, 100 nanomolar, 500 nanomolar, 1 micromolar, 2.5 micromolar, 5 micromolar, 10 micromolar, 100 micromolar or more. 10415] Dosage may be from 0.01 pg to 1 g per kg of body weight (e.g., 0.1 pg, 0.25 pg, 0.5 pg, 0.75 jg, 1 pg, 2.5 pg, 5 pig, 10 pg, 25 pig, 50 pg, 100 jig, 250 jg, 500 ig, 1 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg, or 500 mg per kg). [0416] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per subject per day). The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient. [04171 It is understood that the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy. [04181 Pharmaceutical compositions that include the nucleic acid molecule disclosed herein may be administered once daily, qid, tid, bid, QD, or at any interval and for any duration that is medically appropriate. However, the therapeutic agent may also be dosed in dosage units containing two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In that case, the nucleic acid molecules contained in each snh-dose may he corresnondinvly smal' in order to achieve the total daily dosage unit 122 WO 2011/072082 PCT/US2010/059578 conventional sustained release formulation which provides sustained and consistent release of the dsRNA over a several day period. Sustained release formulations are well known in the art. The dosage unit may contain a corresponding multiple of the daily dose. The composition can be compounded in such a way that the sum of the multiple units of a nucleic acid together contain a sufficient dose. Pharmaceutical compositions, kits, and containers [0419] Also provided are compositions, kits, containers and formulations that include a nucleic acid molecule (e.g., an siNA molecule) as provided herein for reducing expression of hsp47 for administering or distributing the nucleic acid molecule to a patient. A kit may include at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers can be formed from a variety of materials such as glass, metal or plastic. The container can hold amino acid sequence(s), small molecule(s), nucleic acid sequence(s), cell population(s) and/or antibody(s). In one embodiment, the container holds a polynucleotide for use in examining the mRNA expression profile of a cell, together with reagents used for this purpose. In another embodiment a container includes an antibody, binding fragment thereof or specific binding protein for use in evaluating hsp47 protein expression cells and tissues, or for relevant laboratory, prognostic, diagnostic, prophylactic and therapeutic purposes; indications and/or directions for such uses can be included on or with such container, as can reagents and other compositions or tools used for these purposes. Kits may further include associated indications and/or directions; reagents and other compositions or tools used for such purpose can also be included. [0420] The container can alternatively hold a composition that is effective for treating, diagnosis, prognosing or prophylaxing a condition and can have a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agents in the composition can be a nucleic acid molecule capable of specifically binding hsp47 and/or modulating the function of hsp47. [0421] A kit may further include a second container that includes a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution and/or dextrose solution. It can further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, stirrers, needles, syringes, and/or package inserts with indications and/or instructions for use. 123 [04221 The units dosage ampoules or multidose containers, in which the nucleic acid molecules are packaged prior to use, may include an hermetically sealed container enclosing an amount of polynucleotide or solution containing a polynucleotide suitable for a pharmaceutically effective dose thereof, or multiples of an effective dose. The polynucleotide is packaged as a sterile formulation, and the hermetically sealed container is designed to preserve sterility of the formulation until use. [04231 The container in which the polynucleotide including a sequence encoding a cellular immune response element or fragment thereof is contained may include a package that is labeled, and the label may bear a notice in the form prescribed by a governmental agency, for example the Food and Drug Administration, which notice is reflective of approval by the agency under Federal law, of the manufacture, use, or sale of the polynucleotide material therein for human administration. 104241 Federal law requires that the use of pharmaceutical compositions in the therapy of humans be approved by an agency of the Federal government. In the United States, enforcement is the responsibility of the Food and Drug Administration, which issues appropriate regulations for securing such approval, detailed in 21 U.S.C. § 301-392. Regulation for biologic material, including products made from the tissues of animals is provided under 42 U.S.C. § 262. Similar approval is required by most foreign countries. Regulations vary from country to country, but individual procedures are well known to those in the art and the compositions and methods provided herein preferably comply accordingly. 10425] The dosage to be administered depends to a large extent on the condition and size of the subject being treated as well as the frequency of treatment and the route of administration. Regimens for continuing therapy, including dose and frequency may be guided by the initial response and clinical judgment. The parenteral route of injection into the interstitial space of tissues is preferred, although other parenteral routes, such as inhalation of an aerosol formulation, may be required in specific administration, as for example to the mucous membranes of the nose, throat, bronchial tissues or lungs. [04261 As such, provided herein is a pharmaceutical product which may include a polynucleotide including a sequence encoding a cellular immune response element or fragment thereof in solution in a pharmaceutically acceptable injectable carrier and suitable for introduction interstitially into a tissue to cause cells of the tissue to express a cellular 124 immune response element or fragment thereof, a container enclosing the solution, and a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of manufacture, use, or sale of the solution of polynucleotide for human administration. Indications 10427] The nucleic acid molecules disclosed herein can be used to treat diseases, conditions or disorders associated with hsp47, such as liver fibrosis, cirrhosis, pulmonary fibrosis, kidney fibrosis, peritoneal fibrosis, chronic hepatic damage, and fibrillogenesis and any other disease or conditions that are related to or will respond to the levels of hsp47 in a cell or tissue, alone or in combination with other therapies. As such, compositions, kits and methods disclosed herein may include packaging of a nucleic acid molecule disclosed herein that includes a label or package insert. The label may include indications for use of the nucleic acid molecules such as use for treatment or prevention of liver fibrosis, peritoneal fibrosis, kidney fibrosis and pulmonary fibrosis, and any other disease or conditions that are related to or will respond to the levels of hsp47 in a cell or tissue, alone or in combination with other therapies. A label may include an indication for use in reducing expression of hsp47. A "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications, other therapeutic products to be combined with the packaged product, and/or warnings concerning the use of such therapeutic products, etc. [04281 Those skilled in the art will recognize that other anti-fibrosis treatments, drugs and therapies known in the art can be readily combined with the nucleic acid molecules herein (e.g. siNA molecules) and are hence contemplated herein. [04291 The methods and compositions provided herein will now be described in greater detail by reference to the following non-limiting examples. EXAMPLE 1 Selecting hsp47 Nucleic Acid Molecule Sequences: [0430] Nucleic acid molecules (e.g., siNA 5 25 nucleotides) against Hsp47 were designed using several computer programs including siRNA at Whitehead (Whitehead Institute for 125 Biomedical Research), IDT siRNA Design (Integrated DNA Technologies), BLOCK-iT RNAi Designer (Invitrogen), siDESIGN Center (Dharmacon), and BIOPREDsi (Friedrich Miescher Institute for Biomedical Research, part of the Novartis Research Foundation, available at http://www.biopredsi.org/start.html). The sequences of top scored siRNAs from these programs were compared and selected (see Table 1) based on the algorithms as well as the sequence homology between human and rat. Candidate sequences were validated by in vitro knocking down assays. 10431] Several parameters were considered for selecting a nucleic acid molecule (e.g., a 21-mer siRNA) sequence. Exemplary parameters include: 1) thermodynamic stability (RISC favors the strand with less stable 5' end) 2) 30-52% GC content 3) positional nucleotide preference: (C/G)NNNNNNNN(A/U) 1 ONNNNNNNN(A/U), where N is any nucleotide 4) devoid of putative immunostimulatory motifs 5) 2-nucleotide 3' overhang 6) position of siRNA within the transcript (preferably within cDNA region) 7) sequence specificity (checked by using BLAST) 8) variations in single nucleotide by checking SNP database [04321 siRNA sequences having < 25 nucleotides were designed based on the foregoing methods. Corresponding Dicer substrate siRNA (e.g., > 26 nucleotides) were designed based on the smaller sequences and extend the target site of the siNA <25 nucleotide by adding 4 bases to the 3'-end of the sense strand and 6 bases to the 5'-end of the antisense strand. The Dicer substrates that were made generally have a 25 base sense strand a 27 base antisense strand with an asymmetric blunt ended and 3'-overhang molecule. The sequences of the sense and the anti-sense strand without base modification (base sequence) and with modifications (experimental sequence) are provided in Table 1. EXAMPLE 2 [04331 In order to screen for the potency of various siNA molecules against both the human and rat hsp47 genes, various reporter cell lines were established by lenti-viral induction of human HSP47 cDNA-green fluorescent protein (GFP) or rat GP46 cDNA-GFP construct into 293, HT1080, human HSC line hTERT, or NRK cell lines. These cell lines were further 126 WO 2011/072082 PCT/US2010/059578 evaluated by siRNA against GFP. The remaining fluorescence signal was measured and normalized to scrambled siRNA (Ambion) and subsequently normalized to cell viability. The results showed that siRNA against GFP knocks down the fluorescence to different extent in different cell lines (Fig. 1). 293_HSP47-GFP and 293_GP46-GFP cell lines were selected for siHsp47 screening due to their ease of transfection and sensitivity to fluorescence knockdown. siRNA transfection: [04341 Cells were transfected with 1.5 pmol per well of siNA against GFP in 96-well tissue culture plates using Lipofectamine RNAiMAX (Invitrogen) in a reverse transfection manner. Cells were seeded at 6,000 cells per well and mixed with the siNA complexs. Fluorescence readings were taken after 72 hours incubation on a Synergy 2 Multi-Mode Microplate Reader (BioTek). Cell viability assay: [0435] Cells treated with or without siNA were measured for viability after 72 hours incubation using CellTiter-Glo Luminescent Cell Viability Assay Kit according to the manual (Promega). The readings were normalized to samples treated with scrambled siNA molecules. EXAMPLE 3 Evaluation of inhibitory efficiency of siHsp47 on hsp47 expression in reporter cell lines [0436] siNAs against hsp47 were evaluated for their inhibitory efficiency in 293_HSP47 GFP and 293_GP46-GFP cell lines by evaluating the change in fluorescent signal from the reporter GFP. The experiments were carried out as described in Example 2. The fluorescent signals were normalized to fluorescent signals from cells treated with scrambled siRNA (Ambion) which served as a control. The results indicate that the tested hsp47 siNA molecules were effective in inhibiting hsp47 mRNA in both cell lines. However, siNA against GP46 mRNA (as published in the 2008 Sato et al paper) was effective only in the 293_GP46-GFP cell line. The results are shown in Fig. 2 A-B. [0437] The 293_HSP47-GFP and 293_GP46-GFP cell lines treated with siRNA against hsp47 and gp46 were evaluated for viability using the methods described in Example 2. The cell viability was normalized to cells treated with scrambled siRNA (Ambion). The results indicate that the cell viability was not affected significantly by the treatment with siNA 127 molecules. However, the cell viability of 293_HSP47-GFP cell lines treated with different hsp47 siNA molecules varied depending on the siNA molecules used, while the viability of 293_GP46-GFP cell lines were similar. Viability for 293 HSP47-GFP cells were lower for siHsp47-6 and Hsp47-7 treated cells than the rest. The results are shown in Fig. 2C-D. EXAMPLE 4 Evaluation of siHsp47 inhibitory effect on hsp47 mRNA by TaqMan@ qPCR 104381 In Example 3, the knock down efficiency of siHsp47s in reporter cell lines was evaluated by change in fluorescent signal. To validate the results at the mRNA level, siRNAs targeting endogenous hsp47 were transfected into cells of the human HSC cell line hTERT using Lipofectamine RNAiMAX (Invitrogen) in a reverse transfection manner as described in Example 2. [0439] The hsp47 mRNA level was evaluated for knock down efficiency of the various tested siHsp47 siNA molecules. Briefly, mRNA were isolated from hTERT cells 72 hours after transfection using an RNeasy mini kit (Qiagen). The level of hsp47 mRNA was determined by reverse transcription coupled with quantitative PCR using TaqMan@ probes. Briefly, cDNA synthesis was carried out using High-Capacity cDNA Reverse Transcription Kit (ABI) according to the manufacturer's instruction, and subjected to TaqMan Gene Expression Assay (ABI, hsp47 assay ID HsO1060395_gl). The level of hsp47 mRNA was normalized to the level of GAPDH mRNA according to the manufacturer's instruction (ABI). The results indicate that siHsp47-C was the most effective among all the hsp47 siRNAs, siHsp47-2 and siHsp47-2d were the next most effective. The combinations of siHsp47-1 with siHsp47-2 or siHsp47-1 with siHsp47-2d were more effective than siHsp47-1 alone. The results are shown in Fig. 3. EXAMPLE 5 Validation of siHsp47 knock down effect at the protein level [04401 The inhibitory effect of different Hsp47 siNA molecules (siHsp47) on hsp47 mRNA expression were validated at the protein level by measuring the HSP47 in hTERT cells transfected with different siHsp47. Transfection of hTERT cells with different siHsp47 were performed as described in Example 2. Transfected hTERT cells were lysed and the cell lysate were clarified by centrifugation. Proteins in the clarified cell lysate were resolved by SDS polyacrylamide gel electrophoresis. The level of HSP47 protein in the cell lysate were 128 determined using an anti-HSP47 antibody (Assay Designs) as the primary antibody, Goat anti mouse IgG conjugated with HRP (Millipore) as the secondary antibody, and subsequently detected by Supersignal West Pico Chemiluminescence kit (Pierce). Anti-actin antibody (Abcam) was used as a protein loading control. The result showed significant decrease in the level of Hsp47 protein in cells treated with siHsp47-C, siHsp47-2d, alone or combination of siHsp47-1 with siHsp47-2d. EXAMPLE 6 Downregulation of Collagen I expression by hsp47 siRNA [0441] To determine the effect of siHsp47 on collagen I expression level, collagen I mRNA level in hTERT cells treated with different siRNA against hsp47 was measured. Briefly, hTERT cells were transfected with different siHsp47 as described in Example 2. The cells were lysed after 72 hours and mRNA were isolated using RNeasy mini kit according to the manual (Qiagen). The level of collagen I mRNA was determined by reverse transcription coupled with quantitative PCR using TaqMan@ probes. Briefly, cDNA synthesis was carried out using High-Capacity cDNA Reverse Transcription Kit (ABI) according to the manual, and subjected to TaqMan Gene Expression Assay (ABI, COL1Al assay ID Hs01076780_g1). The level of collagen I mRNA was normalized to the level of GAPDH mRNA according to the manufacturer's instruction (ABI). The signals were normalized to the signal obtained from cells transfected with scrambled siNA. The result indicated that collagen I mRNA level is significantly reduced in the cells treated with some of the candidates siHsp47-2, siHsp47-2d, and their combination with siHsp47-1 and shown in Fig. 4. EXAMPLE 7 Immunofluorescence staining of hsp47 siRNA treated hTERT cells 10442] To visualize the expression of two fibrosis markers, collagen I and alpha-smooth muscle actin (SMA), in hTERT cells transfected with or without siHsp47, the cells were stained with rabbit anti-collagen I antibody (Abcam) and mouse anti-alpha-SMA antibody (Sigma). Alexa Fluor 594 goat anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen (Molecular Probes)) were used as secondary antibodies to visualize collagen I (green) and alpha-SMA (red). Hoescht was used to visualize nuleus (blue). The results indicate correlation between siRNA knocking down of some of the target genes and collagen/SMA expression. 129 WO 2011/072082 PCT/US2010/059578 EXAMPLE 8 In vivo testing of siHSP47 in animal models of liver fibrosis [0443] siRNA for rat liver cirrhosis treatment The siRNA duplex sequence for HSP47 (siHSP47C) is as listed below. Sense (5'->3') ggacaggccucuacaacuaTT Antisense (5'->3') uaguuguagaggccuguccTT [0444] 10 mg/ml siRNA stock solution was prepared by dissolving in nuclease free water (Ambion). For treatment of cirrhotic rats, siRNA was formulated with vitamin A-coupled liposome as described by Sato et al (Sato Y. et al. Nature Biotechnology 2008. Vol.26, p431) in order to target activated hepatic stellate cells that produce collagen. The vitamin A (VA) liposome-siRNA formulation consists of 0.33 pmol/ml of VA, 0.33 pmol/ml of liposome (Coatsome EL-01-D, NOF Corporation) and 0.5 gg/gl of siRNA in 5% glucose solution. [0445] The liver cirrhosis animal model was reported by Sato et al (Sato Y. et al. Nature Biotechnology 2008. Vol.26, p 4 31). 4 week-old male SD rats were induced with liver cirrhosis with 0.5% dimethylnitrosoamine (DMN) (Wako Chemicals, Japan) in phosphate buffered saline (PBS). A dose of 2 ml/kg per body weight was administered intraperitoneally for 3 consecutive days per week on days 0, 2, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 34, 36, 38 and 40 [0446] siRNA treatment: siRNA treatment was carried out from day 32 and for 5 intravenous injections. In detail, rats were treated with siRNA on day-32, 34, 36, 38 and 40. Then rats were sacrificed on day-42 or 43. 3 different siRNA doses (1.5mg siRNA per kg body weight, 2.25mg siRNA per kg body weight, 3.0mg siRNA per kg body weight) were tested. Detail of tested groups and number of animals in each group are as follows: 1) Cirrhosis was induced by DMN injection, then 5% glucose was injected instead of siRNA) (n=10) 2) VA-Lip-siHSP47C 1.5 mg/kg (n=10) 3) VA-Lip-siHSP47C 2.25 mg/kg (n=10) 4) VA-Lip-siHSP47C 3.0 mg/Kg (n=10) 130 5) Sham (PBS was injected instead of DMN. 5%Glucose was injected instead of siRNA) (n=6) 6) No treatment control (Intact) (n=6) VA-Lip refers to vitamin A - liposome complex. 104471 Evaluation of therapeutic efficacy: On day 43, 2 out of 10 animals in the "diseased rat" group and 1 out of 10 animals in "VA-Lip-siHSP47C siRNA 1.5 mg/kg" died due to development of liver cirrhosis. The remainder of the animals survived. After rats were sacrificed, liver tissues were fixed in 10% formalin. Then, the left lobe of each liver was embedded in paraffin for histology. Tissue slides were stained with Sirius red, and hematoxylin and eosin (HE). Sirius red staining was employed to visualize collagen-deposits and to determine the level of cirrhosis. HE staining was for nuclei and cytoplasm as counter staining. Each slide was observed under microscope (BZ-8000, Keyence Corp. Japan) and percentage of Sirius red-stained area per slide was determined by image analysis software attached to the microscope. At least 4 slides per each liver were prepared for image analysis, and whole area of each slide (slice of liver) was captured by camera and analyzed. Statistical analysis was carried out by Student's t-test. [04481 Results: Figure 5 shows the fibrotic areas. The area of fibrosis in "diseased rats" was higher than in the "sham" or "no treatment control" groups. Therefore, DMN treatment induced collagen deposition in the liver, which was a typical observation of liver fibrosis. However, the area of fibrosis was significantly reduced by the treatment of siRNA targeting HSP47 gene, compared with "disease rat" group (Figure 5). This result indicates that siRNA as disclosed herein has a therapeutic efficacy in actual disease. [04491 Additional siRNA compounds are tested in the liver fibrosis animal model, and were shown to reduce the fibrotic area in the liver. EXAMPLE 9 Generation of sequences for active double stranded RNA compounds to HSP47/SERPINH1 and production of the siRNAs shown in tables A-18, A-19, and B-E. [0450] Using proprietary algorithms and the known sequence of the target genes, the sequences of many potential siRNAs were generated. The sequences that have been generated using this method are complementary to the corresponding mRNA sequence. 131 WO 2011/072082 PCT/US2010/059578 [0451] Duplexes are generated by annealing complementary single stranded oligonucleotides. In a laminar flow hood, a ~500pM Stock Solution of single stranded oligonucleotide is prepared by diluting in WFI (water for injection, Norbrook). Actual ssRNA concentrations are determined by diluting each 500ptM ssRNA 1:200 using WFI, and measuring the OD using Nano Drop. The procedure is repeated 3 times and the average concentration is calculated. The Stock Solution was then diluted to a final concentration of 250pM. Complementary single strands were annealed by heating to 850C and allowing to cool to room temperature over at least 45 minutes. Duplexes were tested for complete annealing by testing 5l on a 20% polyacrylamide gel and staining. Samples were stored at 800C. [0452] Tables A-18, A-19 and B-E provide siRNAs for HSP47/SERPINH1. For each gene there is a separate list of 19-mer siRNA sequences, which are prioritized based on their score in the proprietary algorithm as the best sequences for targeting the human gene expression. [0453] The following abbreviations are used in the Tables A-18, A-19 and B-E herein: "other spec or Sp." refers to cross species identity with other animals: D-dog, Rt-rat, Rb Rabbit, Rh-rhesus monkey, P- Pig, M-Mouse; ORF: open reading frame. 19-mers, and 18+ 1 mers refer to oligomers of 19 and 18+1 (U in position 1 of Antisense, A in position 19 of sense strand) ribonucleic acids in length, respectively. In vitro testing of the siRNA compounds for the target genes Low- Throughput- Screen (LTS).for siRNA oligos directed to human and rat SERPINHI gene. [0454] Cell Lines: Human prostate adenocarcinoma PC3 cells (ATCC, Cat# CRL-1435) were grown in RPMI medium supplemented with 10% FBS and 2mM L-Glutamine and human epithelial cervical cancer HeLa cells (ATCC, Cat#CCL-2) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 2mM L glutamine. Cells were maintained at 37 0 C in 5% C02. [0455] About 2X105 human PC-3 cells endogenously expressing SERPINH1 gene, were inoculated in 1.5 mL growth medium in order to reach 30-50% confluence after 24 hours. Cells were transfected with LipofectamineTM2000 reagent to a final concentration of 0.01-5 132 WO 2011/072082 PCT/US2010/059578 nM per transfected cells. Cells were incubated at 37±1'C, 5% CO 2 for 48 hours. siRNA transfected cells were harvested and RNA was isolated using EZ-RNA kit [Biological Industries (#20-410-100)]. [0456] Reverse transcription was performed as follows: Synthesis of cDNA was performed and human SERPINH1 mRNA levels were determined by Real Time qPCR and normalized to those of the Cyclophilin A (CYNA, PPIA) mRNA for each sample. siRNA activity was determined based on the ratio of the SERPINHI mRNA quantity in siRNA treated samples versus non-transfected control samples. [0457] The most active sequences were selected from further assays. From Table A- 18 siRNA compounds SERPINHI_2, SERPINHI6, SERPINHI_13, SERPINHI_45 SERPINHI 45a,, SERPINHI 51, SERPINHI 51a, SERPINHI 52 and SERPINHI 86 were selected as preferred compounds. From Table A-19 siRNA compounds SERPINHI_4, SERPINHI12, SERPINH1_18, SERPINHI_30, SERPINHI_58 and SERPINHI_88 were selected as preferred compounds. [0458] Other preferred compounds include SERPINHI50, SERPINHI_67, SERPINH1_73, SERPINH1_74. IC50 values for the LTS selected SERPINH1 siRNA oligos [0459] About 2X10 5 human PC-3 or 0.9X10 5 rat REF52 cells endogenously expressing SERPINH1 gene, were inoculated in 1.5 mL growth medium in order to reach 30-50% confluence. Cells were transfected with SERPINHI double stranded RNA compounds (i.e. SERPINH1_2, 4, 6, 12, 13, 18, 45, 51, 58, 88) with LipofectamineTM2000 reagent to reach final transfection concentrations ranging between 0.0029 -100 nM. As negative control cells are treated with LipofectamineTM2000 reagent or with Synthetic randomized-sequence, non targeting siRNA at final concentrations of 20-100 nM. Cy3-labeled siRNA transfected cells were used as positive control for transfection efficiency. [0460] Cells were incubated at 37±1'C, 5% C02 for 48 hours. siRNA transfected cells were harvested and RNA was isolated using EZ-RNA kit [Biological Industries (#20-410 100) Reverse transcription: Synthesis of cDNA is performed and human SERPINHI mRNA levels weredetermined by Real Time qPCR and normalized to those of the Cyclophilin A (CYNA, PPIA) mRNA for each sample. 133 WO 2011/072082 PCT/US2010/059578 [0461] The IC50 value of the tested RNAi activity was determined by constructing a dose response curve using the activity results obtained with the various final siRNA concentrations. The dose response curve was constructed by plotting the relative amount of residual SERPINHI mRNA versus the logarithm of transfected siRNA concentration. The curve is calculated by fitting the best sigmoid curve to the measured data. The method for the sigmoid fit is also known as a 3-point curve fit. Y=Bot+ 100 - Bot Y + 1 0 (LogIC50-X)xHiSope where Yis the residual SERPINHI mRNA response, Xis the logarithm of transfected siRNA concentration, Bot is the Y value at the bottom plateau, LogIC50 is the Xvalue when Y is halfway between bottom and top plateaus and HillSlope is the steepness of the curve. [04621 The percent of inhibition of gene expression using specific siRNAs was determined using qPCR analysis of target gene in cells expressing the endogenous gene. Other siRNA compounds according to Tables A-18, A-19 and B-E are tested in vitro where it is shown that these siRNA compounds inhibit gene expression. Activity is shown as percent residual mRNA; accordingly, a lower value reflects better activity. [0463] In order to test the stability of the siRNA compounds in serum, specific siRNA molecules were incubated in four different batches of human serum (100% concentration) at 37'C for up to 24 hours. Samples are collected at 0.5, 1, 3, 6, 8, 10, 16 and 24 hours. The migration patterns as an indication of were determined at each collection time by polyacrylamide gel electrophoresis (PAGE). [04641 Table 3 shows IC50 (or activity where IC50 not calculated) in human cell line for unmodified double stranded nucleic acid compounds (sense and antisense strand unmodified, dTdT 3' terminal overhangs) selected from Tables A-18 and A-19. 134 WO 2011/072082 PCT/US2010/059578 Table 3 siRNA AntiSense structure IC50 O.1nM 0.5nM 5nM 1st position SERPINHI_6_S709 U A2 0.019 SERPINHi12_S709 A Al 0.065 SERPINH1_23_S709 U A2 0.377 SERPINH1_54_S709 A Al 0.522 SERPINHi_37_S709 U A2 0.11 SERPINH1_73_S709 A Al 0.189 SERPINHi_24_S709 U A2 0.271 SERPINH1_55_S709 A Al 0.268 SERPINHi_60_S709 U A2 0.163 SERPTNH1_88_S709 A Al 0.135 SERPINHi_11_S709 U A2 0.079 SERPINHi_30_S709 A Al 0.093 SERPINHi_25_S709 U A2 0.229 SERPINHi_56_S709 A Al 0.469 SERPINHI_5_S709 U A2 0.178 SERPINHi_81_S709 G Al 1.404 SERPINHI_52_S709 U A2 0.06 SERPINHi_58_S709 A Al 0.304 SERPJNHi_2_S709 U A2 0.008 SERPINH1_4_S709 A Al 0.006 SERPINHi43_S709 U A2 1.403 SERPINHi_67_S709 A Al 2.39 SERPINHi_16_S709 U A2 134 95 16 SERPINHi_46_S709 A Al 112 84 28 SERPINH1_8_S709 U A2 103 90 39 SERPINHi_85_S709 C Al 166 109 59 SERPINHi_45_S709 U A2 0.029 SERPINHI_45aS1354 A A2 0.051 135 siRNA Knock Down activity: [0465] About 2x105 human PC-3 cells endogenously expressing SERPINHI gene were seeded per well in 6 well plates and allowed to grow for about 24hr to 30-70% confluency. Cells were transfected with the siRNAs being tested at different concentrations using the LipofectamineTM2000 reagent (Invitrogen). The cells were incubated at 37 0 C in a 5% C02 incubator for either 48h or 72h. At 48-72h after transfection cells were harvested and cell RNA was extracted. Cy3-labeled siRNA duplexes were used as a positive control for transfection efficiency. Mock cells treated with LipofectamineTM2000 reagent defined as "Control not active samples" (negative control) and cells treated with a known active siRNA (HSP47-C) at final concentration of 5nM defined as "Control active samples" (positive control). Z' and controls fold {Fold=mean (Negative)/mean (Positive)} are the means to describe the assay efficiency. [0466] The percent inhibition of target gene expression by each siRNA tested was determined by qPCR analysis of a target mRNA from cells. Reverse transcription was performed by synthesizing cDNA from the cells and determining target gene mRNA levels by Real Time qPCR. Measured cell mRNA levels were normalized to those of the Cyclophilin A (CYNA, PPIA) mRNA for each sample. siRNA activity was determined based on the ratio of the target gene mRNA quantity siRNA-treated samples versus non-transfected control samples. Z' and controls fold {Fold=mean (Negative)/mean(Positive)} are the means to describe the assay efficiency. [0467] The qPCR results are those that passed QC standards, i.e. the value of the standard curve slope was in the interval [-4, -3], R2 >0.99, no primer dimers. Results that did not pass the QC requirements were disqualified from analysis. [0468] IC50 value of the tested RNAi activity was determined by constructing a dose response curve using the activity results obtained with the various final siRNA concentrations. The dose response curve was constructed by plotting the relative amount of residual SERPINHI mRNA versus the logarithm of transfected siRNA concentration, asdescribed above. On-target and off-target testing of double stranded RNA molecules: 104691 The psiCHECK system enables evaluation of the guide strand (GS) (antisense) and the passenger strand (PS) (sense strand) to elicit targeted (on-target) and off-targeted 136 WO 2011/072082 PCT/US2010/059578 effects, by monitoring the changes in expression levels of their target sequences. Four psiCHECKTM-2-based (Promega) constructs were prepared for the evaluation of target activity and potential off-target activity of each test molecule GS and PS strands. In each of the constructs one copy or three copies of either the full target or the seed-target sequence, of test molecule PS or GS, was cloned into the multiple cloning site located downstream of the Renilla luciferase translational stop codon in the 3'-UTR region. [0470] The resulting vectors were termed: [0471] 1- GS-CM (guide strand, complete-match) vector containing one copy of the full target sequence (nucleotide sequence fully complementary to the whole 19-base sequence of the GS of the test molecule); [0472] 2- PS-CM (passenger strand, complete-match) vector containg one copy of the full target sequence (nucleotide sequence fully complementary to the whole 19-base sequence of the PS of the test molecule); [0473] 3- GS-SM (guide strand, seed-match) vector containing one copy or three copies of the seed region target sequence (sequence complementary to nucleotides 1-8 of the GS of the test molecule); [0474] 4- PS-SM (passenger strand, seed-match) vector containing one copy of the seed region target sequence (sequence complementary to nucleotides 1-8 of the PS of the test molecule). Nomenclature: [0475] guide strand: strand of siRNA that enters the RISC complex and guides cleavage/silencing of the complementary RNA sequence [0476] seed sequence: Nucleotides 2-8 from the 5'end of the guide strand. [0477] cm (complete match): DNA fragment fully complementary to the guide strand of siRNA. This DNA fragment is cloned in 3'UTR of a reporter gene and serves as a target for the straightforward RNA silencing. [0478] sm (seed match): 19-mer DNA fragment with nucleotides ns 12-18 fully complementary to the ns 2-8 of the guide strand of siRNA. This DNA fragment is cloned in 3'UTR of a reporter gene and serves as a target for the "off-target" silencing. [0479] X1: A single copy of cm or sm cloned in 3'UTR of a reporter gene. 137 WO 2011/072082 PCT/US2010/059578 [0480] X3 Three copies of cm or sm cloned in 3'UTR of a reporter gene, separated with 4 nucleotides one from another. Table 4 non-limiting examples of psiCHECK cloning targets Nomenclature Description structure S2a cm Xl SERPINHI 2, antisense CTCGAGGAGACACATGGGTGCTATAG complete match = fully CGGCCGC SEQIDNO:2724 clone name complimentary to the SERPINHI_2 antisense strand, XhoI SERPINH1_2 sense strand NotI a single copy. S2acmS_Xl The sense strand = the strand of 5' the S2acm_Xl clone to be TCGAGGAGACACATGGGTGCTATAGC expressed in the vector, with SEQIDNO:2725 XhoI and NotI sticky ends. S2acmA_Xl The complimentary (antisense) 5' strand of the S2acm_Xl GGCCGCTATAGCACCCATGTGTCTCC clone, with XhoI and NotI SEQIDNO:2726 sticky ends. S2asm_Xl SERPINHI_2, antisense seed CTCGAGTCTCAAACGTTGTGCTATCG match, a single copy, CGGCCGC SEQIDNO:2727 clone name nucleotides 12-18 are complimentary to the AS(3'-CTCTGTGTACCCACGATAT) nucleotides 2-8 of the SEQIDNO:2728 SERPINH1_2 antisense strand. seed S2scm_Xl SERPINH1_2, sense complete CTCGAGTATAGCACCCATGTGTCTCG match = fully complimentary to CGGCCGC SEQIDNO:2729 clone name the SERPINH 1_2 sense strand - antisense strand, a single XhoI SERPINHI_2 antisense strand NotI copy. S2ssm_Xl SERPINHI_2, sense seed CTCGAGGCGATACAAACTGTGTCTAG match, a single copy, CGGCCGC SEQIDNO:2730 clone name nucleotides 12-18 are complimentary to the S(3'- ATATCGTGGGTACACAGAG) nucleotides 2-8 of the SEQID NO:2731 SERPINH1_2 sense strand. seed S2a_sm_X3 SERPINH1_2, antisense seed CTCGAGTCTCAAACGTTGTGCTATCttc match, a triple copy cTCTCAAACGTTGTGCTATCttccTCTCA clone name AACGTTGTGCTATCGCGGCCGC SEQIDNO:2732 138 WO 2011/072082 PCT/US2010/059578 (ttcc - a spacer) S2s sm X3 SERPINHI 2, sense seed CTCGAGGCGATACAAACTGTGTCTAtt match, a triple copy ccGCGATACAAACTGTGTCTAttccGCG clone name ATACAAACTGTGTCTAGCGGCCGC SEQIDNO:2733 (ttcc - a spacer) [0481] The target sequences are cloned using the XhoI and NotI compatible restriction enzyme sites. Annealing mixtures are prepared in tightly closed 0.5ml Eppendorf tubes, heated in a water bath to 850C, submerged into the boiling water bath and finally gradually cooled to room temperature. [0482] Ligation: The double stranded oligonucleotide generated by the annealing procedure is ligated to the linearized (by XhoI and NotI) psiCHECKTM_2, and transfected into cells using standard techniques. Positive colonies were identified and sequenced for verification of insert sequence. Table 5 shows nucleotide sequences of inserted oligonucleotides. Table 5 siRNA Clone Full SEQ ID Oligonucleotide sequence (5'>3') name NO: S I1s_cm_X1 2734 GGCCGCCGGACAGGCCTCTACAACAC 2735 TCGAGTGTTGTAGAGGCCTGTCCGGC S1 1a_cm_X1 2736 GGCCGCTGTTGTAGAGGCCTGTCCGC 2737 TCGAGCGGACAGGCCTCTACAACAGC S1is_sm_X1 2738 GGCCGCAGGACAGGAAGAGCACCACC 2739 TCGAGGTGGTGCTCTTCCTGTCCTGC S1 1a_sm_X1 2740 GGCCGCGGTTGTAGCTTAAGGGAATC SERPIN 2741 TCGAGATTCCCTTAAGCTACAACCGC Hi_1 S I1s_smX3 2742 GGCCGCAGGACAGGAAGAGCACCACGGAAAGGACAG GAAGAGCACCACGGAAAGGACAGGAAGAGCACCACC 2743 TCGAGGTGGTGCTCTTCCTGTCCTTTCCGTGGTGCTCT TCCTGTCCTTTCCGTGGTGCTCTTCCTGTCCTGC S 11a_smX3 2744 GGCCGCGGTTGTAGCTTAAGGGAATGGAAGGTTGTAG CTTAAGGGAATGGAAGGTTGTAGCTTAAGGGAATC 2745 TCGAGATTCCCTTAAGCTACAACCTTCCATTCCCTTAA GCTACAACCTTCCATTCCCTTAAGCTACAACCGC SERPIN S30s_cm X1 2746 GGCCGCCGGACAGGCCTCTACAACTC 139 WO 2011/072082 PCT/US2010/059578 Hi_30 2747 TCGAGAGTTGTAGAGGCCTGTCCGGC S30acm_Xl 2748 GGCCGCAGTTGTAGAGGCCTGTCCGC 2749 TCGAGCGGACAGGCCTCTACAACTGC S2scm_Xl 2750 GGCCGCGAGACACATGGGTGCTATAC 2751 TCGAGTATAGCACCCATGTGTCTCGC S2acm_Xl 2752 GGCCGCTATAGCACCCATGTGTCTCC 2753 TCGAGGAGACACATGGGTGCTATAGC S2ssm_Xl 2754 GGCCGCTAGACACAGTTTGTATCGCC 2755 TCGAGGCGATACAAACTGTGTCTAGC S2asm_Xl 2756 GGCCGCGATAGCACAACGTTTGAGAC SERPIN 2757 TCGAGTCTCAAACGTTGTGCTATCGC H1_2 S2ssmX3 2758 GGCCGCTAGACACAGTTTGTATCGCGGAATAGACACA GTTTGTATCGCGGAATAGACACAGTTTGTATCGCC 2759 TCGAGGCGATACAAACTGTGTCTATTCCGCGATACAA ACTGTGTCTATTCCGCGATACAAACTGTGTCTAGC S2asmX3 2760 GGCCGCGATAGCACAACGTTTGAGAGGAAGATAGCA CAACGTTTGAGAGGAAGATAGCACAACGTTTGAGAC 2761 TCGAGTCTCAAACGTTGTGCTATCTTCCTCTCAAACGT TGTGCTATCTTCCTCTCAAACGTTGTGCTATCGC S4scm_XI 2762 GGCCGCGAGACACATGGGTGCTATTC SERPIN 2763 TCGAGAATAGCACCCATGTGTCTCGC H1_4 S4acm_Xl 2764 GGCCGCAATAGCACCCATGTGTCTCC 2765 TCGAGGAGACACATGGGTGCTATTGC S6scm_Xl 2766 GGCCGCACAAGATGCGAGACGAGTAC 2767 TCGAGTACTCGTCTCGCATCTTGTGC S6acm_Xl 2768 GGCCGCTACTCGTCTCGCATCTTGTC 2769 TCGAGACAAGATGCGAGACGAGTAGC S6ssm_Xl 2770 GGCCGCCCAAGATGATCTAATCTGCC 2771 TCGAGGCAGATTAGATCATCTTGGGC S6asm_Xl 2772 GGCCGCGACTCGTCGATACTAGGTGC SERPIN 2773 TCGAGCACCTAGTATCGACGAGTCGC H1_6 S6ssmX3 2774 TCGAGGCAGATTAGATCATCTTGGTTCCGCAGATTAG ATCATCTTGGTTCCGCAGATTAGATCATCTTGGGC 2775 GGCCGCCCAAGATGATCTAATCTGCGGAACCAAGATG ATCTAATCTGCGGAACCAAGATGATCTAATCTGCC S6asmX3 2776 GGCCGCGACTCGTCGATACTAGGTGGGAAGACTCGTC GATACTAGGTGGGAAGACTCGTCGATACTAGGTGC 2777 TCGAGCACCTAGTATCGACGAGTCTTCCCACCTAGTAT CGACGAGTCTTCCCACCTAGTATCGACGAGTCGC S12scm_X1 2778 GGCCGCACAAGATGCGAGACGAGTTC SERPIN 2779 TCGAGAACTCGTCTCGCATCTTGTGC H1_12 S12acm_X1 2780 GGCCGCAACTCGTCTCGCATCTTGTC 2781 TCGAGACAAGATGCGAGACGAGTTGC SERPIN S450scmXl 2782 GGCCGCACTCCAAGATCAACTTCCTC Hi45a 1 2783 TCGAGAGGAAGTTGATCTTGGAGTGC 140 WO 2011/072082 PCT/US2010/059578 (SERPI S450a_cmXl 2784 GGCCGCAGGAAGTTGATCTTGGAGTC NH1_45 2785 TCGAGACTCCAAGATCAACTTCCTGC _S450) S450s_smXl 2786 GGCCGCCCTCCAAGCGACCATGAAGC 2787 TCGAGCTTCATGGTCGCTTGGAGGGC S450asmXl 2788 GGCCGCCGGAAGTTTCGATGTTCTGC 2789 TCGAGCAGAACATCGAAACTTCCGGC S450ssmX3 2790 GGCCGCCCTCCAAGCGACCATGAAGGGAACCTCCAAG CGACCATGAAGGGAACCTCCAAGCGACCATGAAGC 2791 TCGAGCTTCATGGTCGCTTGGAGGTTCCCTTCATGGTC GCTTGGAGGTTCCCTTCATGGTCGCTTGGAGGGC S450a_smX3 2792 GGCCGCCGGAAGTTTCGATGTTCTGGGAACGGAAGTT TCGATGTTCTGGGAACGGAAGTTTCGATGTTCTGC 2793 TCGAGCAGAACATCGAAACTTCCGTTCCCAGAACATC GAAACTTCCGTTCCCAGAACATCGAAACTTCCGGC S51s_cm_X1 2794 GGCCGCTCCTGAGACACATGGGTGAC 2795 TCGAGTCACCCATGTGTCTCAGGAGC S51a_cm_Xl 2796 GGCCGCTCACCCATGTGTCTCAGGAC 2797 TCGAGTCCTGAGACACATGGGTGAGC S51s_sm_Xl 2798 GGCCGCGCCTGAGAACACGTGTGTCC 2799 TCGAGGACACACGTGTTCTCAGGCGC S51a_sm_X1 2800 GGCCGCGCACCCATTGTGATACTTCC SERPIN 2801 TCGAGGAAGTATCACAATGGGTGCGC H1_51 S51s_smX3 2802 GGCCGCGCCTGAGAACACGTGTGTCGGAAGCCTGAGA ACACGTGTGTCGGAAGCCTGAGAACACGTGTGTCC 2803 TCGAGGACACACGTGTTCTCAGGCTTCCGACACACGT GTTCTCAGGCTTCCGACACACGTGTTCTCAGGCGC S51a_smX3 GGCCGCGCACCCATTGTGATACTTCGGAAGCACCCAT 2804 TGTGATACTTCGGAAGCACCCATTGTGATACTTCC TCGAGGAAGTATCACAATGGGTGCTTCCGAAGTATCA 2805 CAATGGGTGCTTCCGAAGTATCACAATGGGTGCGC S86scm_Xl 2806 GGCCGCACAGGCCTCTACAACTACAC 2807 TCGAGTGTAGTTGTAGAGGCCTGTGC S86acm_Xl 2808 GGCCGCTGTAGTTGTAGAGGCCTGTC 2809 TCGAGACAGGCCTCTACAACTACAGC S86ssm_Xl 2810 GGCCGCACAGGCCTAGCACAAGCACC 2811 TCGAGGTGCTTGTGCTAGGCCTGTGC S86asm_Xl 2812 GGCCGCGGTAGTTGGCTCTGAAGTGC SERPIN 2813 TCGAGCACTTCAGAGCCAACTACCGC H1_86 S86ssmX3 GGCCGCACAGGCCTAGCACAAGCACGGAAACAGGCC 2814 TAGCACAAGCACGGAAACAGGCCTAGCACAAGCACC TCGAGGTGCTTGTGCTAGGCCTGTTTCCGTGCTTGTGC 2815 TAGGCCTGTTTCCGTGCTTGTGCTAGGCCTGTGC S86asmX3 GGCCGCGGTAGTTGGCTCTGAAGTGGGAAGGTAGTTG 2816 GCTCTGAAGTGGGAAGGTAGTTGGCTCTGAAGTGC TCGAGCACTTCAGAGCCAACTACCTTCCCACTTCAGA 2817 GCCAACTACCTTCCCACTTCAGAGCCAACTACCGC 141 WO 2011/072082 PCT/US2010/059578 S52scm_Xl 2818 GGCCGCGACAAGATGCGAGACGAGAC 2819 TCGAGTCTCGTCTCGCATCTTGTCGC S52acm_Xl 2820 GGCCGCTCTCGTCTCGCATCTTGTCC 2821 TCGAGGACAAGATGCGAGACGAGAGC S52ssm_X1 2822 GGCCGCTACAAGATTATCTCATCTCC 2823 TCGAGGAGATGAGATAATCTTGTAGC S52asm_Xl 2824 GGCCGCGCTCGTCTATACTAGGTGAC SERPIN 2825 TCGAGTCACCTAGTATAGACGAGCGC H1_52 S52ssmX3 GGCCGCTACAAGATTATCTCATCTCGGAATACAAGAT 2826 TATCTCATCTCGGAATACAAGATTATCTCATCTCC TCGAGGAGATGAGATAATCTTGTATTCCGAGATGAGA 2827 TAATCTTGTATTCCGAGATGAGATAATCTTGTAGC S52asmX3 GGCCGCGCTCGTCTATACTAGGTGAGGAAGCTCGTCT 2828 ATACTAGGTGAGGAAGCTCGTCTATACTAGGTGAC TCGAGTCACCTAGTATAGACGAGCTTCCTCACCTAGT 2829 ATAGACGAGCTTCCTCACCTAGTATAGACGAGCGC S58scm_Xl 2830 GGCCGCGACAAGATGCGAGACGAGTC SERPIN 2831 TCGAGACTCGTCTCGCATCTTGTCGC H1_58 S58acm_Xl 2832 GGCCGCACTCGTCTCGCATCTTGTCC 2833 TCGAGGACAAGATGCGAGACGAGTGC S95scm_Xl 2834 GGCCGCACTCCAAGATCAACTTCCGC SERPIN 2835 TCGAGCGGAAGTTGATCTTGGAGTGC H1_95 S95acm X1 2836 GGCCGCCGGAAGTTGATCTTGGAGTC 2837 TCGAGACTCCAAGATCAACTTCCGGC S96scm_Xl 2838 GGCCGCTCCTGAGACACATGGGTGCC SERPIN 2839 TCGAGGCACCCATGTGTCTCAGGAGC H1_96 S96acm_Xl 2840 GGCCGCGCACCCATGTGTCTCAGGAC 2841 TCGAGTCCTGAGACACATGGGTGCGC S97scm_Xl 2842 GGCCGCACAGGCCTCTACAACTACTC SERPIN 2843 TCGAGAGTAGTTGTAGAGGCCTGTGC H1_97 S97acm X1 2844 GGCCGCAGTAGTTGTAGAGGCCTGTC 2845 TCGAGACAGGCCTCTACAACTACTGC [0483] Relevant strands, as described above, were cloned in the 3'UTR of the reporter mRNA, Renilla Luciferase in the psiCHECKTM_2 (Promega) vector. XhoI and NotI were used as cloning sites using standard molecular biology techniques. Each strand was chemically synthesized and annealed by heating to 1 00"C and cooled to room temperature. Ligation was carried out for 3 hours using standard molecular biology techniques and transformed into E. coli DH5a cells. Resulting colonies were screened for presence of plasmid constructs by colony-PCR using relevant primers. Each of the plasmids (vectors) was purified from one positive colony and its sequence was verified. 142 WO 2011/072082 PCT/US2010/059578 [0484] About 1.3x106 human HeLa cells were inoculated in 10 cm dish. Cells were then incubated in 37r1C, 5% C02 incubator for 24 hours. Growth medium was replaced one day post inoculation by 8 mL fresh growth medium and each plate was transfected with one of the plasmids mentioned above, using LipofectamineTM2000 reagent according manufacturing protocol and incubated for 5 hours at 37+10C and 5% C02. Following incubation, cells were re-plated in a 96-well plate at final concentration of 5x103 cells per well in 80 pL growth medium. 16 hours later, cells were transfected with SERPINHI siRNA molecules using LipofectamineTM2000 reagent at different concentrations ranging from 0.00 1nM to 5nM in a 1OOgL final volume. Mock cells treated with LipofectaminCTM2000 reagent with the corresponding psiCHECKTM_2 plasmid defined as "Control not active samples" (negative control) and cells treated with a known active siRNA (HSP47-C) at final concentration of 5nM defined as "Control active samples" (positive control). Z' and controls fold {Fold=mean (Negative)/mean(Positive)} are the means to describe the assay efficiency. [04851 Cells were then incubated for 48 hours at 37±1 0 C and Renilla and FireFly Luciferase activities were measured in each of the siRNA transfected samples, using Dual Luciferase@ Assay kit (Promega, Cat#E 1960) according to manufacturer procedure. The activity of a synthetic siRNA toward this target sequence results either in cleavage and subsequent degradation of the fused mRNA or in translation inhibition of the encoded protein. Measuring the decrease in Renilla luciferase activity thus provides a convenient way of monitoring siRNA effect while Firefly luciferase, allows normalization of Renilla luciferase expression. Renilla Luciferase activity value was divided by Firefly Luciferase activity value for each sample (normalization). Renilla luciferase activity is finally expressed as the percentage of the normalized activity value in tested sample relative to "Control not active samples". [0486] Results of TNFa and IL-6 levels in peripheral blood mononuclear cells (PMNC) exposed to unmodified or modified siRNA/LipofectamineTM2000. Results are provided in pg/ml values calculated based on standard curve. "Control Lipofec2000" relates to level of cytokine secretion induced by the transfection reagent, LipofectamineTM2000. None of the modified compounds levels of cytokines TNFa or IL6 above those of the control transfection reagent. 143 WO 2011/072082 PCT/US2010/059578 Donor 11 TNFa IL-6 control 162+/-280 Control Lipofec2000 308+/-75 1303+/-440 dsRNA SEQ ID 860nM 610 2915 NOS:101 and 168) 287nM 6963 4021 unmodified 96nM 641 2278 32nM 1095 4126 Compound_4 860nM 660+/-227 1166+/-280 287nM 484+/- 84 1844+/-1072 96nM 571+/-170 2015+/-1667 32nM 865+/-90 2201+/-952 Donor I Donor II TNFa IL-6 TNFa IL-6 control 115+/-64 162+/-280 control Lipofec2000 427+/-87 1848+/- 194 308+/-75 1303+/-440 dsRNA SEQ ID 860nM 326 1014 873 4015 NOS:60 and 127) 287nM 305 638 909 3046 unmodified 96nM 546 1007 690 2451 32nM 707 1331 637 2159 Compound_1 860nM 491 1480 1017 4492 287nM 363 956 981 3126 96nM 294 840 952 2491 32nM 355 848 902 2779 Donor I TNFa IL-6 control 115+/-64 control Lipofec2000 427+/-87 1848+/- 194 dsRNA SEQ ID 860nM 228 553 NOS:63 and 130) 287nM 395 569 unmodified 96nM 561 966 32nM 737 1021 Compound_2 860nM 598 1560 287nM 621 1440 96nM 570 1825 32nM 517 1510 144 WO 2011/072082 PCT/US2010/059578 Donor I Donor 11 TNFa IL-6 TNFa IL-6 control 115+/-64 162+/-280 control Lipofec2000 427+/-87 1848+/- 194 308+/-75 1303+/-440 dsRNA SEQ ID 860nM 137 225 521 4223 NOS:98 and 165) 287nM 750 105 463 3755 unmodified 96nM 504 180 627 2784 32nM 312 442 711 3084 Compound_3 860nM 540 2170 1474 3896 287nM 698 2428 1000 1864 96nM 582 1876 1089 1760 32nM 614 1341 724 1044 Results are pg/ml Donor I Donor II TNFa [L-6 TNFa IL-6 Ctrl cells 115+/-64 162+/-280 CL075 (ug/ml) 2 13878 26464 0.67 8115 28471 17013 0.22 1575 10873 7589 22111 1 0.074 219 906 1389 7072 [0487] Data for induction of interferon (IFN) responsive genes, MX1 and IFITI, unmodified and modified double stranded nucleic acid compounds. Results shown are residual (fold of Ctrl Lipofectamine2000 treated cells) human IFITI and MX1 genes as tested in human PMNC. Data shows that all modified compounds induced negligible levels of IFN downstream genes, compared to unmodified (_S709) compounds. Donor II IFITI MX1 CtrI Lipo2000 1 1 dsRNA SEQ ID NOS:101 and 168) unmodified 32nM 5.5 3.3 96nM 7.5 4.3 297nM 3.9 3.8 860nM 0.8 0.8 Compound_4 32nM 1.2+/-0.5 1.7+/-0.35 96nM 1.1+/-0.3 1.5+/-0.06 297nM 0.7+/-0.3 0.9+/-0.7 860nM 0.6+/-0.1 0.9+/-0.5 145 WO 2011/072082 PCT/US2010/059578 Donor 1 Donor 11 IFITI MX1 IFIT1 MX1 Ctrl Lipo2000 1 1 1 1 dsRNA SEQ ID NOS:60 and 127) unmodified 32nM 27.9 - 2.2 2.7 96nM 42.1 18.3 4.0 5.0 297nM 53.8 18.0 3.4 2.8 860nM 39.4 16.3 3.3 3.6 Compound_1 32nM 1.2 0.2 0.8 1.3 96nM 1.3 0.8 1.5 1.1 297nM 1.1 0.3 1.2 1.6 860nM 1.0 0.3 0.3 0.3 Donor I Donor II IFITI MX1 IFIT1 MX1 Ctrl Lipo2000 1 1.00 1 1 dsRNA SEQ ID NOS:98 and 165) unmodified 32nM 29.7 18.5 4.3 4.1 96nM 39.1 19.2 3.5 297nM 25.1 9.3 4.8 5.2 860nM 3.8 3.7 Compound 3 32nM 1.4 0.4 1.0 1.4 96nM 1.7 1.3 1.3 1.1 297nM 1.9 1.4 1.1 1.4 860nM 5.2 2.5 1.1 1.4 Donor I IFITI MXl Ctrl Lipo2000 1 1 dsRNA SEQ ID NOS:63 and 130) unmodified 32nM 29.6 17.8 96nM 31.5 16.1 297nM 860nM 36.6 11.4 Compound_2 32nM 1.6 0.7 96nM 1.1 1.0 297nM 2.1 0.2 860nM 1.8 1.4 146 WO 2011/072082 PCT/US2010/059578 Donor I Donor 11 IFITI MX1 IFIT1 MX1 Ctrl cells 1 1 1 1 0.125 18 5.4 3.7 0.56 26 11 4.9 4.7 1.7 41 14 4.5 5.1 5 24 7 0.9 0.8 0.075 4 2 1.8 1.8 0.12 27 10 4.5 3.6 0.67 21 4.6 4.2 2 26 12 4.1 3.7 [0488] The tables below show activity of Compound 1, Compound 2, Compound 3 and Compound 4 compared to unmodified (_S709) compounds in rat cells. Results are shown as residual target (% of control LipofectamineTM2000 treated cells) rat SERPINHI gene in REF52 cells. Results of two separate experiments are shown. Knockdown to target gene in rat cells is relevant to testing compounds in animal models of human disease. Study 1 Study 2 Ctrl Lipo2000 100 100 dsRNA SEQ ID NOS:60 and 127) unmodified 0.8nM 52 36 2nM 25 31 lOnM 16 28 50nM 8 4 Compound_1 0.8nM 53 14 2nM 39 14 1OnM 19 24 50nM 7 4 Study_1 Study_2 Ctrl Lipo2000 100 100 dsRNA SEQ ID NOS:63 and 130) unmodified 0.8nM 45 15 2nM 28 18 1 OnM 13 12 50nM 12 8 Compound_2 0.8nM 76 78 2nM 61 68 lOnM 37 28 50nM 4 147 WO 2011/072082 PCT/US2010/059578 Study_1 Study_2 Ctrl Lipo2000 100 100 dsRNA SEQ ID NOS:98 and 165) unmodified 0.8nM 72 65 2_nM 43 41 l0nM 32 42 50nM 28 27 Compound 3 0.8nM 88 30 2nM 39 24 l0nM 24 23 50nM 6 23 Study_3 Study_4 CtrI Lipo2000 100 100 Compound 4 0.8nM 66 106 2nM 35 32 lOnM 10 12 j50nM 6 9 Serum Stability Assay [04891 The modified compounds according to the present invention are tested for duplex stability in human serum or human tissue extract, as follows: [0490] siRNA molecules at final concentration of 7uM are incubated at 370C in 100% human serum (Sigma Cat# H4522). (siRNA stock 1 OOuM diluted in human serum 1:14.29 or human tissue extract from various tissue types). Five ul (5ul) are added to 15ul 1.5xTBE loading buffer at different time points (for example 0, 30min, lh, 3h, 6h, 8h, 10h, 16h and 24h). Samples were immediately frozen in liquid nitrogen and kept at -20'C. [04911 Each sample is loaded onto a non-denaturing 20% acrylamide gel, prepared according to methods known in the art. The oligos were visualized with ethidium bromide under UV light. Exonuclease Stability Assay [0492] To study the stabilization effect of 3' non-nucleotide moieties on a nucleic acid molecule the sense strand, the antisense strand and the annealed siRNA duplex are incubated in cytosolic extracts prepared from different cell types. Extract: HCT1 16 cytosolic extract (12mg/ml). 148 Extract buffer: 25mM Hepes pH-7.3 at 37oC; 8mM MgCl; 150mM NaCl with 1mM DTT was added fresh immediately before use. [04931 Method: 3.5ml of test siRNA (100mM), were mixed with 46.5ml contain 120mg of HCTI 16 cytosolic extract. The 46.5ml consists of 12ml of HCTI 16 extract, and 34.5ml of the extract buffer supplemented with DTT and protease inhibitors cocktail/I 00 (Calbiochem, setIII-539134). The final concentration of the siRNA in the incubation tube is 7mM. The sample was incubated at 37oC, and at the indicated time point 5ml were moved to fresh tube, mixed with] 5ml of I XTBE-50% Glycerol loading buffer, and snap frozen in Liquid N2. The final concentration of the siRNA in the loading buffer is 1.75mM (21ng siRNA/ml). For Analyses by native PAGE and EtBr staining 50ng are loaded per lane. For Northern analyses Ing of tested siRNA was loaded per lane. Innate Immune response to SERPINHI siRNA molecules: [04941 Fresh human blood (at RT) was mixed at 1:1 ratio with sterile 0.9% NaCI at RT, and gently loaded (1:2 ratio) on Ficoll (Lymphoprep, Axis-Shield cat# 1114547). Samples were centrifuged at RT (22 0 C, 800g) in a swinging centrifuge for 30 minutes, washed with RPM11640 medium and centrifuged (RT, 250 g) for 10 minutes. Cells were counted and seeded at final concentration of 1.5X10 6 cell/ml in growth medium (RPMIl640+10%FBS+2mM L-glutamine + 1% Pen-Strep) and incubated for 1 hours at 37 0 C before siRNA treatment. [04951 Cells were then treated with the siRNAs being tested at different concentrations using the LipofectamineTM2000 reagent (Invitrogen) according manufacturer's instructions and incubated at 370C in a 5% C02 incubator for 24hours. [0496] As a positive control for IFN response, cells were treated with either poly(I:C), a synthetic analog of double strand RNA (dsRNA) which is a TLR3 ligand (InvivoGen Cat# tirl pic) at final concentrations of 0.25-5.0 gg/mL or to Thiazoloquinolone (CLO75), a TLR 7/8 ligand (InvivoGen Cat# tirl-c75) at final concentrations of 0.075-2 pg/mL. Cell treated with LipofectamineTM2000 reagent were used as negative (reference) control for IFN response. [0497] At about 24 hours following incubation, cells were collected and supernatant was transferred to new tubes. Samples were frozen immediately in liquid nitrogen and secretion of IL-6 and TNF-a cytokines was tested using IL-6, DuoSet ELISA kit (R&D System DY2060), 149 WO 2011/072082 PCT/US2010/059578 and TNF-a, DuoSet ELISA kit (R&D System DY210), according to manufacturer's instructions. RNA was extracted from the cell pellets and mRNA levels of human genes IFIT I (interferon-induced protein with tetratricopeptide repeats 1) and MX1 (myxovirus (influenza virus) resistance 1, interferon-inducible protein p78) were measured by qPCR. Measured mRNA quantities were normalized to the nRNA quantity of the reference gene peptidylprolyl isomerase A (cyclophilin A; CycloA). Induction of IFN-signaling was evaluated by comparing the quantity of mRNA from IFITI and MX1 genes from treated cells, relative to their quantities non-treated cells. The qPCR results are those that passed QC standards, i.e. the value of the standard curve slope was in the interval [-4, -3], R2 >0.99, no primer dimers. Results that did not pass the QC requirements were disqualified from analysis. [0498] Table 6 shows siSERPINHI compounds. Activity and stability data for some of the compounds is presented in Table 6. The code for the sense and antisense strand structures is presneted in Table 7, infra. Table 6: 1. Stability % % residual Sense strand 5->3 AntiSense strand 5->3 ame in residual 25nM code code plasma 5nM (h) 001 002 003 004 006, SERPINH1_2 10 16 10 9 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;mA;r S1356 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;mA;rU;mG;rU;mG p;rU2p;rA2p;rU2p;rA2p ;rU;mC;rU;mC;zc3p;zc3pS SERP1NH1_2_ zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S1357 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;mC;rA;mU;rG;mU;rG p;rU2p;rA2p;rU2p;rA2p ;mU;mC;mU;rC;zc3p;zc3p$ SERPINHI2 16 52 41 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S1358 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;rA;mU;rG;mU;rG; p;rU2p;rA2prU2p;rA2p mU;mC;mU;rC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S1359 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;rA;mU;rG;mU;rG;r p;rU2 p;rA2p;rU2p;rA2p U;mC;rU;mC;zc3p;zc3p$ SERPTNH1 2 10 47 31 8 20 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;n S1360 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;rC;mC;rA;mU;rG;mU;rG;r p;rU2p;rA2p;rU2p;rA2p U;mC;mU;rC;zc3p;zc3pS SERPINHI 2 8 31 34 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;rC2p;rA; S1361 ;rA;rU;rG;rG;rG;rU;rG;rC2 mC;mC;rC;rA;mU;rG;mU;r p;rU2p;rA2p;rU2p;rA2p G;rU;mC;rU;mC;zc3p;zc3p$ SERPINHI_2_ zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;LdC;rA;m S1362 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;rA;mU;rG;mU;rG;r p;rU2p;rA2p;rU2p;rA2p U;mC;rU;mC;zc3p;zc3p$ SERPINHI 2 17 10 15 25 zc3p;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;mA;r S1363 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;mA;rU;mG;rU;mG 150 WO 2011/072082 PCT/US2010/059578 p;rU2p;rA2p,-rU2p;rA2p ;rU;mC;rU;mC;zc3p;zc3pS SERP17NH1_2- zcpr~Ar~Ar~Ar mUr~Ur~r~Cr~ Si1364 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;mC;rA;mU;rG;mU;rG ____p;rU2p;rA2p;rU2p;rA2p ;miU;mC;miU;rC ;zc3p;zc3p$ SERPINHI-2-16 41 52 zc3p;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1365 ;r~Ur~Gr~Ur~C C~Cr~Am~Gm~G ____ ;rU2p;rA2p,-rU2p;rA2p mU;mC;mU;rC;zc3p;zc3pS SERP17NH1_2- zc3p;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1366 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;rA;mU;rG;mU;rG;r ____p~rU2p~rA2prU2p~rA2p UhmC~rU~mC~zc3p~zc3p$ SERPINHI-2-16 51 39 zc3p;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1367 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;rC;mC;rA;mU;rG;mU;rG;r ____p;rU2p;rA2p;rU2p;rA2p U;mC;mU;rC;zc3p;zc3pS SERPINH1_2- zc3p;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;rC2p-rA; S 1368 ,rA;rU;rG;rG;rG;rU;rG;rC2 mC;mC;rC;rA;mU;rG;mU;r ____p;rU2p;rA2prU2p;rA2p G;rU;mC;rU;mC;zc3p;zc3p$ SERPINH1_2- zc3p;rG ;rA;rG ;rA;rC ;rA ;rC rnU;rA;mlU;rA;rG;LdC;rA;m S 1369 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;rA;mU;rG;mU;rG;r ____p;rU2p;rA2p;rU2p;rA2p U;mC;rU;mC;zc3p;zc3p$ SERPINHI-2-17 15 61 20 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;mA;r S 1370 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;mA;rU;mG;rU;mG p;rU2p;rA2p-rU2p;rA2p;zc ;rU;mC ;rU;mC;zc3p;zc3p$ 3 pS SERPINHI_2- zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1371 ;rA;rU;rG;rG;rG ;rU;rG;rC2 C;imC;rnC;rA;imU;rG;rnU;rG p;rU2p;rA2p-rU2p;rA2p;zc ;mU;mC;mU;rC ;zc3p;zc3p$ 3 pS SERPINHI-2-16 74 66 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1372 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;iiC;rC;rA;mlU;rG;iiU;rG; p;rU2p;rA2p-rU2p;rA2p;zc mU;mC ;mU;rC ;zc3p;zc3p$ 3 pS SERPNH 1 -2 8 48 65 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1373 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;rA;mU;rG;mU;rG;r p;rU2p;rA2p-rU2p;rA2p;zc U;mC;rU;mC ;zc3p;zc3p$

____

3 pS ____________ SERPINHI-2-16 39 1106 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;mC;rA;m S 1374 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;rC;mC;rA;mU;rG;mU;rG;r p;rU2p;rA2p-rU2p;rA2p;zc U;mC;mU;rC;zc3p;zc3pS 3 pS SERPINHI_2- zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;rC2p,-rA; S 1375 ,rA;rU;rG;rG;rG;rU;rG;rC2 mC ;iC;rC ;rA;imU;rG;miU;r p;rU2p;rA2p-rU2p;rA2p;zc G;rU;mC;rU;mC;zc3p;zc3p$ 3 pS SERPINHI_2- zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;rG;LdC;rA;m S 1376 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;inC;rC;rA;iiiU;rG;iinU;rG;r p;rU2p;rA2p-rU2p;rA2p;zc U;mC;rU;mC ;zc3p;zc3p$

____

3 pS ____________ SERPINHI-2-3 25 5 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S 1377 mC ;rA;rU;rG;rG;rG;mU;r C ;mC;rC;niA;rU;mG;rU;mG G;mC;mU;rA;LdT;rA$ ;rU;mC ;rU;mC;zc3p;zc3p$ SERP1NH1_2- zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m IS1378 I I I I mC ;rA;rU;rG;rG;rG;imU;r C;mC;mnC;rA;lU;rG;llU;rGi 151 WO 2011/072082 PCT/US2010/059578 G;mC;mU;rA;LdT;rA$ ;mU;mC;mU;rC;zc3p;zc3pS SERPINHI_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1379 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;rA;mU;rG;mU;rG; G;mC;mU;rA;LdT;rA$ nU;mC;mU;rC;zc3p;zc3p$ SERPINH1_2 8 23 33 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1380 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;rA;mU;rG;mU;rG;r G;mC;mU;rA;LdT;rAS U;mC;rU;mC;zc3p;zc3pS SERPINHI2 16 25 56 12 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1381 mC;rA;rU;rG;rG;rG;mU;r C;rC;mC;rA;mU;rG;mU;rG;r G;mC;mU;rA;LdT;rA$ U;mC;mU;rC;zc3p;zc3pS SERPINH1 2_ 8 22 31 11 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;rC2p;rA; S1382 mC;rA;rU;rG;rG;rG;mU;r mC;mC;rC;rA;mU;rG;mU;r G;mC;mU;rA;LdT;rA$ G;rU;mC;rU;mC;zc3p;zc3p$ SERP1NH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;LdC;rA;m S1383 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;rA;mU;rG;mU;rG;r G;mC;mU;rA;LdT;rA$ U;mC;rU;mC;zc3p;zc3p$ SERP1NH1_2 16 7 20 7 4 zidB;rG;rA;rG;rA;mC;rA; nU;rA;mU;rA;mG;rC;nA;r S1384 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;mU;rA;zc3p$ ;rU;mC;rU;mC;zc3p;zc3p$ SERP1NH1_2 16 55 37 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1385 nC;rA;rU;rG;rG;rG;mU;r C;mC;mC;rA;mU;rG;mU;rG G;rC;mU;rA;mU;rA;zc3p$ ;mU;mC;mU;rC;zc3p;zc3p$ SERPINHI_2 16 42 45 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1386 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;rA;mU;rG;mU;rG; G;rC;mU;rA;mU;rA;zc3p$ mU;mC ;mU;rC;zc3p;zc3p$ SERP1NH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1387 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;rA;mU;rG;mU;rG;r G;rC;mU;rA;mU;rA;zc3p$ U;mC;rU;mC;zc3p;zc3pS SERP1NH1_2 16 21 39 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;mC;rA;m S1388 mC;rA;rU;rG;rG;rG;mU;r C;rC;mC;rA;mU;rG;mU;rG;r G;rC;mU;rA;mU;rA;zc3p$ U;mC;mU;rC;zc3p;zc3pS SERP1NH1 2 16 20 27 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;rC2p;rA; S1389 mC;rA;rU;rG;rG;rG;mU;r mC;mC;rC;rA;mU;rG;mU;r G;rC;mU;rA;mU;rA;zc3p$ G;rU;mC;rU;mC;zc3p;zc3p$ SERP1NH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;rG;LdC;rA;m S1390 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;rA;mU;rG;mU;rG;r G;rC;mU;rA;mU;rA;zc3p$ U;mC;rU;mC;zc3p;zc3p$ SERPINHi2_ zidB;rG;rA;rG;rA;rC;rA;mi mU;rA;mU;rA;mG;rC;mA;r S1687 C;rA;rU;rG;rG;rG;mU;rG;r C;mC;rC;mA;rU;mG;rU;mG C;mU;rA;mU;rA;zc3p$ ;rU;mC;rU;rC;zc3p;zc3p$ SERPINHI2 24 zidB;rG;rA;rG;rA;rC;rA;m mU;rA;mU;rA;mG;rC;rA2p; S1694 C;rA;rU2p;rG;rG;rG;mU;r rC;mC;rC;mA;rU;mG;rU;m G;rC;mU;rA;mU;rA;zc3p$ G;rU;mC;rU;mC;zc3p;zc3p$ SERPINHI_2 16 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;rA2p; S1700 mC;rA;rU;rG;rG;rG;mU;r rC;mC;rC;mA;rU;mG;rU;m G;rC;mU;rA;rU2p;rA;zc3p G;rU;mC;rU;mC;zc3p;zc3p$ s SERP1NH1 _2 10 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;rA2p; S1705 ;rA;rU;rG;rG;rG;rU;rG;rC2 rC;mC;rC;mA;rU;mG;rU;m p;rU2p;rA2p;rU2p;rA2p G;rU;mC;rU;mC;zc3p;zc3p$ 152 WO 2011/072082 PCT/US2O1O/059578 SERPINH 1 2- 10 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;rA2p; S 1707 ,rA;rU;rG;rG;rG;rU;rG;rC2 rC;mnC;rC;niA;rU;mG;rU;ni p;rU2p;rA2p-rU2p;rA2p;zc G;rU;mC;rU;mC;zc3p;zc3p$ 3 p$ SERPINH 1 2- 24 zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;rA2p; S 1754 ,rA;rU;rG;rG;rG;rU;rG;rC2 rC;mC;rC;niA;rU;mG;rU;m p;rU2p;rA2p-rU2p;rA2p;zc G;rU;mC;rU;mC;zc3p;zc3p$ 3 p SERPINH 1 2 24 zidB ;rG ;rA;rG ;rA;rC ;rA;iC rIJ2p;rA;mlU,-rA;mG;rC,-rA2 S 1755 ,rA;rU;rG;rG;rG;rU;rG;rC2 p;rC;mC;rC;mA;rU;mG;rU; p;rU2p;rA2p-rU2p;rA2p;zc mG-rU;mC;rU-mC;zc3p;zc3

____

3 p P$ SERPINHi_2- zidB;rG;rA;rG;rA;rC;rA;rC rIJ2p;rA;mU,-rA;mG;rC,-rA2 S 1756 ,rA;rU;rG;rG;rG;rU;rG;rC2 p;rC;mC;rC;mA;rU;mG;rU; p;rU2p;rA2p-rU2p;rA2p mG-rU;mC;rU-mC;zc3p;zc3 ___ ___ ___ ___ ___ __P$ SERPINHi_2- zidB;rG;rA;rG;rA;rC;rA;rC dU;rA;mU;rA;mG;rC;rA2p;r S 1787 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;niA;rU;mG;rU;mG p;rU2p;rA2p-rU2p;rA2p;zc ;rU;mC ;rU;mC;zc3p;zc3p$ 3 p SERPINHi 4 0 58 zidB;rG;rA;rG;rA;rC;rA;iC rA;mlA;rU;mlA;rG;mC;rA;m S139 1 ,rA;rU;rG;rG;rG;rU;rG;rC2 C;rC;rC;mA;rU;mG-rU;mG;r p;rU p;rA2p;rU2p;rU2p U;mC;rU;mC;zc3p;zc3p$ SERPINHi_4- zidB;rG;rA;rG;rA;rC;rA;rC rA;rA;mU;rA;mG;rC;rA2p;r S 1782 ,rA;rU;rG;rG;rG ;rU;rG;rC2 C;mC;rC;miA;rU;inG;rU;mG p;rU2p;rA2p-rU2p;rU2p;zc ;rU;mC ;rU;mC;zc3p;zc3p$ 3 p SERPINHI_6 zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU,-mC;rG;mU;r S 1356 ,rG;rC,-rG;rA;rG;rA;rC;rG2 C;mU;rC;mG;rC;miA;rU;mC ____p;rA2p;rG2p,-rU2p;rA2p ;rU;mU;rG;mU;zc3p;zc3pS SERPINHi_6- zc3p;rA~rC~rA~rA~rG;rA~rU mUr~Crm~Gm~ S 1363 ,rG;rC,-rG;rA;rG;rA;rC;rG2 C;mU;rC;mG;rC;miA;rU;mC ____ ;rA2p;rG2p;rU2p;rA2p ;rU;iiU;rG ;imU;zc3p;zc3pS SERP17NHI_6- zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;r~hmC;rG;mU;r S 1370 ,rG;rC;rG;rA;rG;rA;rC;rG2 C;mU;rC;mG;rC;miA;rU;mC p;rA2p;rG2p,-rU2p;rA2p;zc ;rU;mU;rG;mU;zc3p;zc3pS

____

3 p$__________ _____ SERP17NH1_6- zc3p;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1414 ;r~~Gr~r~Ar~G mCm~Cr~Cr~U p;rA2p;rG2p,-rU2p;rA2p mC;mU;mU;rG;rU;zc3p;zc3 ___ ___ ___ ___ ___ __P$ SERP17NH1_6- zc3p;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1415 ;r~~Gr~r~Ar~G mCm~Cr~m~Am ____p;rA2p;rG2p,-rU2p;rA2p C;mU;mU;rG;rU;zc3p;zc3pS SERP17NH1_6- zc3p;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S 1416 ,rG;rC~rG;rA;rG;rA;rC;rG2 mC;mU;rC;rG;mC;rA;rU;m ____p;rAp;rG2p;rU2p;rA2p C;mU;mU;rG;rU;zc3p;zc3p$ SERP17NH1_6- zc3p;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU-mC;rG;mU;m S 1417 ,rG;rC-rG;rA;rG;rA;rC;rG2 C;rU;mC;rG;mC;miA;rU;mC ____p; Ap;rG2prU2p;rA2p ;rU;mU;rG;rU;zc3p;zc3p$ SERP17NH1_6- zc3p;rA;rC ;rA;rA;rG;rA;rU mU;rA;mC;rU-mC;rG;LdT;r S 1418 ,rG;rC-rG;rA;rG;rA;rC;rG2 C;mU;rC;rG;mC;miA;rU;mC _________ _____ ____p;rA2p;rG2p,-rU2p;rA2p ;rU;mU;rG;rU;zc3p;zc3p$ 153 WO 2011/072082 PCT/US2010/059578 SERPINH1_6_ zc3p;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1419 ;rG;rC;rG;rA;rG;rA;rC;rG2 rC;mU;rC;rG;mC;mA;rU;m p;rA2p;rG2p;rU2p;rA2p C;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1420 ;rG;rC;rG;rA;rG;rA;rC;rG2 mC;mU;mC;rG;mC;rA;mU; p;rA2p;rG2p;rU2p;rA2p mC;mU;mU;rG;rU;zc3p;zc3 P$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1421 ;rG;rC;rG;rA;rG;rA;rC;rG2 mC;mU;rC;rG;mC;rA;mU;m p;rA2p;rG2p;rU2p;rA2p C;mU;mU;rG;rU;zc3p;zc3p$ SERPINHi_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1422 ;rG;rC;rG;rA;rG;rA;rC;rG2 mC;mU;rC;rG;mC;rA;rU;m p;rA2p;rG2p;rU2p;rA2p C;mU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6 zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;mU;m S1423 ;rG;rC;rG;rA;rG;rA;rC;rG2 C;rU;mC;rG;mC;mA;rU;mC p;rA2p;rG2p;rU2p;rA2p ;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;LdT;r S1424 ;rG;rC;rG;rA;rG;rA;rC;rG2 C;mU;rC;rG;mC;mA;rU;mC p;rA2p;rG2p;rU2p;rA2p ;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1425 ;rG;rC;rG;rA;rG;rA;rC;rG2 rC;mU;rC;rG;mC;mA;rU;m p;rA2p;rG2p;rU2p;rA2p C;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1426 ;rG;rC;rG;rA;rG;rA;rC;rG2 mC;mU;mC;rG;mC;rA;mU; p;rA2p;rG2p;rU2p;rA2p;zc mC;mU;mU;rG;rU;zc3p;zc3 3 p$ P$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1427 ;rG;rC;rG;rA;rG;rA;rC;rG2 mC;mU;rC;rG;mC;rA;mU;m p;rA2p;rG2p;rU2p;rA2p;zc C;mU;mU;rG;rU;zc3p;zc3p$ 3 p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;mU;mC;rG;mU; S1428 ;rG;rC;rG;rA;rG;rA;rC;rG2 mC;mU;rC;rG;mC;rA;rU;m p;rA2p;rG2p;rU2p;rA2p;zc C;mU;mU;rG;rU;zc3p;zc3p$ 3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;mU;m S1429 ;rG;rC;rG;rA;rG;rA;rC;rG2 C;rU;mC;rG;mC;mA;rU;mC p;rA2p;rG2p;rU2p;rA2p;zc ;rU;mU;rG;rU;zc3p;zc3p$ 3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;LdT;r S1430 ;rG;rC;rG;rA;rG;rA;rC;rG2 C;mU;rC;rG;mC;mA;rU;mC p;rA2p;rG2p;rU2p;rA2p;zc ;rU;mU;rG;rU;zc3p;zc3p$ 3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1431 ;rG;rC;rG;rA;rG;rA;rC;rG2 rC;mU;rC;rG;mC;mA;rU;m p;rA2p;rG2p;rU2p;rA2p;zc C;rU;mU;rG;rU;zc3p;zc3p$ 3p$ SERPINHi6 0 6 19 15 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;mU;r S1432 mU;rG;rC;rG;rA;rG;rA;mC C;mU;rC;mG;rC;mA;rU;mC ;rG;rA;rG;LdT;rA$ ;rU;mU;rG;mU;zc3p;zc3pS SERPTNH1 6 6 37 46 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;mU;mC;rG;mU; S1435 mU;rG;rC;rG;rA;rG;rA;mC mC;mU;rC;rG;mC;rA;rU;m ;rG;rA;rG;LdT;rA$ C;mU;mU;rG;rU;zc3p;zc3p$ 154 WO 2011/072082 PCT/US2010/059578 SERPINH1 _6 3 10 17 5 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;mU;m S1436 nU;rG;rC;rG;rA;rG;rA;mC C;rU;rnC;rG;mC;rnA;rU;mC ;rG;rA;rG;LdT;rA$ ;rU;mU;rG;rU;zc3p;zc3p$ SERPINHi_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;LdT;r S1437 mU;rG;rC;rG;rA;rG;rA;mC C;mU;rC;rG;mC;mA;rU;mC ;rG;rA;rG;LdT;rA$ ;rU;mU;rG;rU;zc3p;zc3p$ SERPINH 1_6_ 3 15 17 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1438 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;rG;mC;mA;rU;m ;rG;rA;rG;LdT;rA$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPINHi6 24 12 23 11 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;mU;r S1439 mU;rG;rC;rG;rA;rG;rA;mC C;mU;rC;mG;rC;mA;rU;mC ;rG;rA;rG;mU;rA;zc3p$ ;rU;mU;rG;mU;zc3p;zc3pS SERP1NH1_6_24 29 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;mU;mC;rG;mU; S1442 mU;rG;rC;rG;rA;rG;rA;mC mC;mU;rC;rG;mC;rA;rU;m ;rG;rA;rG;mU;rA;zc3p$ C;mU;mU;rG;rU;zc3p;zc3p$ SERP1NH1_6 24 9 22 7 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;mU;m S1443 mU;rG;rC;rG;rA;rG;rA;mC C;rU;mC;rG;mC;mA;rU;mC ;rG;rA;rG;mU;rA;zc3p$ ;rU;mU;rG;rU;zc3p;zc3p$ SERP1NH1_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;LdT;r S1444 mU;rG;rC;rG;rA;rG;rA;mC C;mU;rC;rG;mC;mA;rU;mC ;rG;rA;rG;mU;rA;zc3p$ ;rU;mU;rG;rU;zc3p;zc3p$ SERPTNH1 _6_ 24 19 18 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1445 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;rG;mC;mA;rU;m ;rG;rA;rG;mU;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPINHi6 24 11 zidB;rA;mC;rA;rA;rG;rA;r mU;rA;mC;rU;mC;rG;rU2p; S1739 U;rG;rC;rG;rA;rG;rA;mC;r rC;mU;rC;mG;rC;mA;rU;m G;rA;rG;mU;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPINHi6 24 12 zidB;rA;mC;rA;rA;rG;rA;r mU;rA;mC;rU;mC;rG;rU2p; S1741 U;rG;rC;rG;rA;rG;rA;mC;r rC;mU;rC;rG;mC;mA;rU;rC; G;rA;rG ;mU;rA;zc3p$ rU;mU;rG;rU;zc3p;zc3pS SERP1NH1_6 0 zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1744 ;rG;rC;rG;rA;rG;rA;mC;rG rC;mU;rC;rG;mC;mA;rU;m ;rA;rG;mU;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERP1NH1_6 0 zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1746 ;rG;rC;rG;rA;rG;rA;mC;rG rC;mU;rC;mG;rC;mA;rU;m ;rA;rG;mU;rA;zc3p$ C;rU;mU;rG;mU;zc3p;zc3p$ SERP1NH1_6_ zidB;rA;mC;rA;rA;rG;rA;r dU;rA;mC;rU;mC;rG;rU2p;r S1785 U;rG;rC;rG;rA;rG;rA;mC;r C;mU;rC;rG;mC;mA;rU;rC;r G;rA;rG;mU;rA;zc3p$ U;mU;rG;rU;zc3p;zc3p$ SERP1NH1_11 zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;rU;mG;rU;mA;r _S1356 ;rG;rC;rC;rU;rC;rU;rA;rC2 G;mA;rG;mG;rC;mC;rU;mG p;rA2p;rA2p;rC2p;rA2p ;rU;mC;rC;mG;zc3p;zc3p$ SERPINH1 11 zc3p;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;rU;mG;rU;mA;r _S1363 ;rG;rC;rC;rU;rC;rU;rA;rC2 G;mA;rG;mG;rC;mC;rU;mG p;rA2p;rA2p;rC2p;rA2p ;rU;mC;rC;mG;zc3p;zc3p$ SERPINHI_11 zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;rU;mG;rU;mA;r _S1370 ;rG;rC;rC;rU;rC;rU;rA;rC2 G;mA;rG;rnG;rC;mC;rU;mG p;rA2p;rA2p;rC2p;rA2p;zc ;rU;mC;rC;mG;zc3p;zc3p$ 3 p$ SERP1NH1_11 zc3p;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG;mU;rA;r _S1446 ;rG;rC;rC;rU;rC;rU;rA;rC2 G;rA;rG;rG;mC;mC;mU;rG; I _p;rA2p;rA2p;rC2p;rA2p mU;mC;mC;rG;zc3p;zc3p$ 155 WO 2011/072082 PCT/US2O1O/059578 SERPINHI_11I zc3p;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG,-rU2p;rA _S1449 ,rG;rC,-rC;rU;rC;rU;rA;rC2 rG;rA;rG;rG;iiC;rC;miU;rG;r p;rA2p;rA2p,-rC2p;rA2p U;mC;mC;rG;zc3p;zc3pS SERPINHI 1_11 zc3p;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG;LdT;rA;r -S1450 ,rG;rC,-rC;rU;rC;rU;rA;rC2 G;rA;rG;rG;mC;rC,-mU;rG;r ____p;rA2p;rA2p;rC2p;rA2p U;mC;mC;rG;zc3p;zc3pS SERP17NHI_-11 ziBr~Gr~Ar~Ar mUr~Um~~Ur~ -S1451 ,rG;rC,;rC;rU ;rC;rU ;rA;rC2 G;rA;rG;rG;mC;mC ;mU ;rG; ____ ;rA2p;rA2p;rC2p;rA2p rnU;mC ;mC;rG ;zc3p;zc3p$ SERP17NH1_11I zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rGrU2p;rA -S1454 ;r~~Cr~r~Ur~C rGr~Gr~Cr~Ur~ ____p;rA2p;rA2prC2p;rA2p U;mC;mC;rG;zc3p;zc3pS SERP17NH1_11 zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG;LdT;rA;r S1455 ,rG;rC-rC;rU;rC;rU;rA;rC2 G;rA;rG;rG;mC;rC-mU;rG;r ____p~rA2p~rA2p~rC2p~rA2p UhmC~mC~rG~zc3p~zc3pS SERP17NH1_I1I zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG-mU;rA;r S1456 ,rG;rC-rC;rU;rC;rU;rA;rC2 G;rA;rG;rG;mC;mC;mU;rG; p;rA2p;rA2p-rC2p;rA2p;zc mU;mC ;mC;rG-zc3p;zc3p$

____

3 p$ ____________ SERP17NH1_11 zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG-mU;rA;r -S1457 ,rG;rC-rC;rU;rC;rU;rA;rC2 G;rA;rG;rG;rC;mC-mU;rG; p;rA2p;rA2p,-rC2p;rA2p;zc mU;mC ;mC;rG,-zc3p;zc3p$

____

3 p$_________ ____ SERP17NH1_11 zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG-rU2p;rA; S1459 ,rG;rC-rC;rU;rC;rU;rA;rC2 rG;rA;rG;rG;mC;rC;mU;rG;r p~rA2p~rA2p,rC2p~rA2p~zc U~mC~mC~rG~zc3p~zc3pS

____

3 p$_____________ SERP17NH1_11 zidB;rC;rG;rG;rA;rC;rA;rG mU;rG;mU;mU;rG;LdT;rA;r S1460 ,rG;rC-rC;rU;rC;rU;rA;rC2 G;rA;rG;rG;mC;rC-mU;rG;r p;rA2p;rA2p-rC2p;rA2p;zc U;mC;mC;rG;zc3p;zc3pS

____

3 p$_____________ SERP17NH1_11 zidB;mC;rG;rG;rA;mC;rA; mU;rG;mU;rU;mG;rU;mA;r S 1461 rG;rG;rC;mC;rU;rC;mU;rA G;mA;rG;mG;rC;mC;rU;mG ,mC;rA;rA;LdC;rA$ ;rU;mC ;rC ;mG;zc3p;zc3p$ SERP17NH1_I1I zidB;mC;rG;rG;rA;mC;rA; mU;rG;mU;mU;rG-mU;rA;r -S1462 rG;rG;rC;mC;rU;rC;mU;rA G;rA;rG;rG;mC;mC;mU;rG; ,mC;rA;rA;LdC;rA$ mU;mC;mC;rG;zc3p;zc3p$ SERPTNH1 11 45 43 zidB;iiC;rG;rG;rA;mlC;rA; mU;rG;inU;mU;rG;mU;rA;r -S1464 rG;rG;rC;mC;rU;rC;mU;rA G;rA;rG;rG;mC;rC-mU;rG;r ,mC;rA;rA;LdC;rA$ U;mC;mC;rG;zc3p;zc3pS SERPINHII1I zidB;mC;rG;rG;rA;mC;rA;- mU;rG;mU;rU;mG;rU;mA;r _S1467 rG ;rG;rC;rC;rU;rC;niU;rA; G;im-A;rG;im-G;rC;imC;rU;mG mC;rA;rA;mC;rA;zc3p$ ;rU;mC;rC;mG;zc3p;zc3p$ SERPINHI_11 zidB;mC;rG;rG;rA;mC;rA; mU;rG;mU;mU;rG;mU;rA;r -S1468 rG;rG;rC;rC;rU;rC;mU;rA;- G;rA;rG;rG;mC;mC;mU;rG; mC ;rA;rA ;mC ;rA;zc3p$ rnU;mC ;imC;rG ;-zc3p;zc3p$ SERPI7NHI_11 zidB;mC;rG;rG;rA;mC;rA, mU;rG;mU;mU;rGmU;rA;r -S1469 rG;rG;rC;rC;rU;rC;mU;rA;- G;rA;rG;rG;rC;mC,-mU;rG; mC ;rA;rA;mC ;rA;zc3p$ mU;mC ;mC;rG;zc3p;zc3p$ SERP17NH1II1 zidB;mC;rG;rG;rA;mC;rA;- mU;rG;mU;mU;rG,-mU;rA;r -S1470 rG;rG;rC;rC;rU;rC;mU;rA, G;rA;rG;rG;mC;rCmU;rG;r ________________mC;rA;rA;mC;rA;zc3p$ U;mC;mC;rG;zc3p;zc3pS 156 WO 2011/072082 PCT/US2010/059578 SERPINHI_11 zidB;mC;rG;rG;rA;mC;rA; mU;rG;mU;mU;rG;rU2p;rA; _S1471 rG;rG;rC;rC;rU;rC;mU;rA; rG;rA;rG;rG;mC;rC ;mU;rG;r mC;rA;rA;mC;rA;zc3p$ U;mC;mC;rG;zc3p;zc3pS SERPINHI_11 zidB;mC;rG;rG;rA;mC;rA; mU;rG;mU;mU;rG;LdT;rA;r _S1472 rG;rG;rC;rC;rU;rC;mU;rA; G;rA;rG;rG;mC;rC;mU;rG;r mC;rA;rA;mC;rA;zc3p$ U;mC;mC;rG;zc3p;zc3pS SERP1NH 1_12 zidB;rA;rC;rA;rA;rG;rA;rU rA;nA;rC;mU;rC;mG;rU;m _S1391 ;rG;rC;rG;rA;rG;rA;rC;rG2 C;rU;rC;mG;rC;mA;rU;mC;r p;rA2p;rG2p;rU2p;rU2p U;mIU;rG ;mU;zc3p;zc3p$ SERP1NH1_12 zidB;rA;mC;rA;mA;rG;rA; rA;rA;mC;rU;mC;rG;rU2p;r _S1780 rU;rG;rC;rG;rA;rG;rA;mC; C;mU;rC;rG;mC;mA;rU;rC;r rG;rA;rG;mU;rU;zc3p$ U;mU;rG;rU;zc3p;zc3pS SERP1NH1_30 zidB;rC;rG;rG;rA;rC;rA;rG rA;mG;rU;mU;rG;mU;rA;m S1391 ;rG;rC;rC;rU;rC;rU;rA;rC2 G;rA;rG;mG;rC;mC;rU;mG; p;rA2p;rA2p;rC2p;rU2p rU;mC;rC mG;zc3p;zc3p$ SERPINHI_45 174 40 rA;rC;rU;rC;rC;rA;rA;rG;r yrA;rG;rG;rA;rA;rG;rU;rU;r _S1354 A;rU;rC;rA;rA;rC;rU;rU;r G;rA;rU;rC;rU;rU;rG;rG;rA; C;rC;yrU;zdT;zdT$ rG;rU;zdT;zdT$ SERPINHI_45 16 96 54 zidB;rA;rC;rU;rC;rC;rA;rA ymA;rG;rG;rA;rA;rG;mU;m _S1500 ;rG;rA;rU;rC;rA;rA;rC;rU2 U;rG;rA;mU;mC;mU;mU;rG _ p;rU2p;rC2p;rC2p;yrU2p ;rG;rA;rG;rU;zc3p;zc3p$ SERPTNH1_45 zidB;rA;rC;rU;rC;rC;rA;rA ymA;rG;mG;rA;mA;rG;mU; _S1501 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;mU;r p;rU2p;rC2p;rC2p;yrU2p G;mG;rA;mG;rU;zc3p;zc3p$ SERPINHI_45 zidB;rA;rC;rU;rC;rC;rA;rA ymA;rG;mG;rA;mA;rG;mU; _S1502 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;rUi;mC;mU;mU;r p;rU2p;rC2p;rC2p;yrU2p G;mG;rA;mG;rU;zc3p;zc3p$ SERPINHI_45 16 22 17 zidB;rA;rC;rU;rC;rC;rA;rA yrA;mGrG;mA;rA;mGrU; _S1505 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;rU;m p;rU2p;rC2p;rC2p;yrU2p G;rG;mA;rG ;mU;zc3p;zc3p$ SERPINHI_45 zc3p;rA;rC;rU;rC;rC;rA;rA ymA;rG;rG;rA;rA;rG;mU;m _S1506 ;rG;rA;rU;rC;rA;rA;rC;rU2 U;rG;rA;mUmC;mU;mU;rG p;rU2p;rC2p;rC2p;yrU2p ;rG;rA;rG;rU;zc3p;zc3p$ SERPINHI_45 zc3p;rA;rC;rU;rC;rC;rA;rA ymA;rG;mG;rA;mA;rG;mU; _S1507 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;mU;r _ p;rU2p;rC2p;rC2p;yrU2p G;mG;rA;mG;rU;zc3p;zc3p$ SERPINHI_45 zc3p;rA;rC;rU;rC;rC;rA;rA ymA;rG;mG;rA;mA;rG;mU; S1508 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;rU;mC;mU;mU;r p;rU2p;rC2p;rC2p;yrU2p G;mG;rA;mG;rU;zc3p;zc3p$ SERPINHI_45 16 zc3p;rA;rC;rU;rC;rC;rA;rA ymA;rG;rG;rA;rA;rG;rU2p; _S1509 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;mU;r p;rU2p;rC2p;rC2p;yrU2p G;mG;rA;mG;rU;zc3p;zc3p$ SERPINH 1_45 zc3p;rA;rC;rU;rC;rC;rA;rA ymA;rG;rG;rA;rA;rG;LdT;m _S1510 ;rG;rA;rU;rC;rA;rA;rC;rU2 U;rG;rA;mU;rC;mU;mU;rG; p;rU2p;rC2p;rC2p;yrU2p mG;rA;mG;rU;zc3p;zc3p$ SERPINHI_45 8 27 zc3p;rA;rC;rU;rC;rC;rA;rA yrA;mG;rG;mA;rA;mG;rU; _S1511 ;rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;rU;n p;rU2p;rC2p;rC2p;yrU2p G;rG;mA;rG;mU;zc3p;zc3p$ SERPINH1_45 zidB;rA;rC;rU;rC;rC;rA;rA ymA;rG;rG;rA;rA;rG;mU;m _S1512 ;rG;rA;rU;rC;rA;rA;rC;rU2 U;rG;rA;mU;mC;mU;mU;rG p;rU2p;rC2p;rC2p;yrU2p;z ;rG;rA;rG;rU;zc3p;zc3p$ c3p$ 157 WO 2011/072082 PCT/US2O1O/059578 SERPINHI_-45 zidB;rA;rC;rU;rC;rC;rA;rA ymiA;rG;mG;rA;miA;rG,-mU; 5S1513 ,rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mlU;inU;r p;rU2p;rC2p;rC2p;vrU2p;z G;mG;rA;mG;rU;zc3p;zc3p$ c3p$ SERPINHI_-45 zidB;rA;rC;rU;rC;rC;rA;rA ymiA;rG;mG;rA;miA;rG,-mU; 5S1514 ,rG;rA;rU;rC;rA;rA;rC ;rU2 mU;rG;rA;rU;mC ;mU;mU;r p;rU2p;rC2p;rC2p;vrU2p;z G;mG;rA;mG;rU;zc3p;zc3p$ c3p$ SERPINHI_-45 zidB;rA;iC;rU;rC;rC;rA;rA ymiA;rG;rG;rA;rA;rG;rU2p; 5S1515 ,rG;rA;rU;rC;rA;rA;rC ;rU2 mU;rG;rA;mU;rC;mU;mU;r p;rU2p;rC2p;rC2p;yrU2p;z G;mG;rA;mG;rU;zc3p;zc3p$ c3p$ _____________ SERPINHI_-45 zidB;rA;rC;rU;rC;rC;rA;rA ymiA;rG;rG;rA;rA;rG;LdT;m 5S1516 ,rG;rA;rU;rC;rA;rA;rC ;rU2 U;rG;rA;mU-rC;mU;mU;rG; p;rU2p;rC2p;rC2p;yrU2p;z mG;rA;mG;rU;zc3p;zc3p$ c3p$ _____________ SERPINHi1_45 24 22 31 7 11 14 zidB;rA;rC;rU;rC;rC;rA;rA yrA;mG,-rG;miA;rA;mG,-rU; 5S1517 ,rG;rA;rU;rC;rA;rA;rC ;rU2 mU;rG;rA;mU;rC ;mU;rU;m p;rU2p;rC2p;rC2p;yrU2p;z G;rG;miA;rG-mU;zc3p;zc3p$ c3p$ SERPINHi1_45 8 90 47 zidB;rA;iC;rU;mC;miC;rA; ymiA;rG;rG;rA;rA;rG;iiU;rn -S1518 rA;rG;rA;rU;mC;rA;rA;mC U;rG;rA;mU-mC;mU;mU;rG ;mU;rU;rC;LdC;yrU$ ;rG;rA;rG;rU;zc3p;zc3p$ SERPINHi1_45 3 17 30 16 zidB;rA;rC;rU;mC;mC;rA; yrA;mG,-rG;mA;rA;mG,-rU; Si1523 rA;rG;rA;rU;mC;rA;rA;mC rnU;rG;rA;mlU;rC;mlU;rU;m ;mU;rU;rC;LdC;yrU$ G;r G;miA;rG,-mU;zc3p;zc3p$ SERPINHI_45 ziBr~Cr~Cmr~ ym~Gr~Ar~Gm~ S1524 A;rG;rA;rU;mC;rA;rA;rC; U;rG;rA;mU,-mC;mU;mU;rG mU;rU;mC;mCl-yrU-zc3p$ ;rG;rA;rG;rU;zc3p;zc3p$ SERPI7NHI_45 zidB;rA;rC;rU;rC;mC-rA;r ymA;rG;mG;rA;mA;rG-mU; 5S1525 A~Gr~Um~Ar~C mUr~Am~r~Um~ mU;rU;mC;mC;yrU;zc3p$ G;mG;rA;mG;rU;zc3p;zc3p$ SERP17NH1_-4524 17 33 zidB;rA;rC;rU;rC;mC-rA;r yrA;mG-rG;mA;rA;mG-rU; S1529 A;rG;rA;rIJ;mC;rA;rA;rC; mU;rG;rA;mU;rC;mU;rU;m mU;rU;mC;mC;yrU;zc3p$ G;rG;mA;rG;mU;zc3p;zc3p$ SERPINHI_-45 24 14 zidB;rA;rC;rU;rC;rC;rA;rA yrA;mG-rG;mA;rA;mG-rU2 S1684 ,rG;rA;rU;rC;rA;rA;rC;rU2 p;mU;rG;rA;mU;rC;mU;rU; p;rU2p;rC2p;rC2p;yrU2p;z mGrG;niA;rG;mU;zc3p;zc3 c3p$ P$ SERP17NH 1_45 8 15 zidB;rA;rC;rU;mC;mC;rA; yrA;mG~rG;mA;rA;mG,-rU2 S1685 rA;rG;rA;rU;mC;rA;rA;mC p;mU;rG;rA;mU;rC;mU;rU; ,mIJ;rU;rC;LdC;yrU$ mGrG;niA;rG;mU;zc3p;zc3 ___ ___ ___ ___ ___ __P$ SERPINHI_-45 zidB;rA;rC;rU;rC;rC;rA;rA rU;rG;rG;miA;rA;mG;rU2p; S1781 ,rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;rU;m p;rU2p;rC2p;rC2p;yrU2p;z G;rG;mA;rG~mU;zc3p;zc3p$ ____c3pS _____________ SERP17NH1_-45 zidB;rA;rC;rU;rC;rC;rA;rA dU;rG;rG;mA;rA;mG;rU2p; S1786 ,rG;rA;rU;rC;rA;rA;rC;rU2 mU;rG;rA;mU;rC;mU;rU;m p;rU2p;rC2p;rC2p;rA2p;zc G;rG;mA;rGmU;zc3p;zc3p$

____

3 p$ ____________ SERPINHI1_51 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;miA;rC;mC;rC ;miA;r ISI1356 I I I I ;rA;rC-,rA;rC;rA;rU;rG;rG2,U;mG;rU;mG;rU;mC;rU;mC 158 WO 2011/072082 PCT/US2O1O/059578 p;rG2p;rU2p,-rG2p;rA2p ;rA;mG;rG;miA;zc3p;zc3pS SERPINHI1_51 zc3p;rU~rC :rC~rU~rG~rA~rG mUr~i r~Cr;iA~r -Si363 ,rA;rC,-rA;rC;rA;rU;rG;rG2 U;mG;rU;mG;rU;mC;rU;mC ____p;rG2p;rU2p;rG2p;rA2p ;rA;mG;rG ;imA;zc3p;zc3pS SERPINHI 151 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;miA;rC;mC;rC ;miA;r -S1370 ;r~~Ar~r~Ur~G U~Gr~GrUm~U p;rG2p;rU2p,-rG2p;rA2p;zc ;rA;mG;rG;miA;zc3p;zc3pS

____

3 p$_______________ SERP17NHI 151 zc3p;rU;rC ;rC;rU;rG;rA;rG m~hmC;rA;mC ;mC;mC;rA; -S1473 ;r~~Ar~r~Ur~G mUr~Ur~Um~U ____p;rG2p;rU2p,-rG2p;rA2p mC ;rA;rG;rG;rA;zc3p;zc3pS SERP17NHI 151 zc3p;rU;rC ;rC;rU;rG;rA;rG mU;rC;rA;mC ;mC;mC ;rA;m -S1474 ,rA;rCrA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;mU;mC ____ ;rG2p;rU2p;rG2p;rA2p ;rA;rG;rG;rA;zc3p;zc3p$ SERP17NHI 151 zc3p;rU;rC ;rC;rU;rG;rA;rG mU;rC;rA;mC ;mC;mC ;rA;m S1475 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU-mC; I___ p)rG2p;rU2p;rG2p;rA2p rA;rG;rG;rA;zc3p;zc3p$ SERPINHI 151 zc3p;rU;rC ;rC;rU;rG;rA;rG mU;rC;rA;mC ;rC;rC2p;rA;m -S1476 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU-mC; ____ ;rG2p;rU2p,-rG2p;rA2p rA;rG;rG;rA;zc3p;zc3p$ SERPTNH 1 51 zc3p;rU;rC ;rC;rU;rG;rA;rG iiU;rC;rA;rnC ;rC;LdC;rA;ml -S1477 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU-mC; p;rG p;rU2p;rG2p;rA2p rA;rG;rG;rA;zc3p;zc3p$ SERPINHI 151 zidB ;rU;rC;rC ;rU;rG;rA;rG mU,-mC;rA;mC ;mC;mC;rA; _S1478 ;rA;rC-rA ;rC;rA ;rU;rG ;rG2 rnU;rG;mU;rG;mU;mC;im-U; p;rG2p;rU2p,-rG2p;rA2p mC ;rA;rG;rG;rA;zc3p;zc3p$ SERPINHI1_51 zidB ;rU ;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;mC;mC ;rA;m -S1479 ,rA;rC,-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;mU;mC ____p;rG2p;rU2p;rG2p;rA2p ;rA;rG;rG;rA;zc3p;zc3p$ SERP7NHI _51 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;mC;mC ;rA;m -S1480 ,rA;rC;rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU;mC; ____p;rG2p;rU2p;rG2p;rA2p rA;rG;rG;rA;zc3p;zc3p$ SERPINHI1_51 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;rC;rC2p;rA;m S1481 ;r~~Ar~r~Ur~G U~Gr~GmUm~~ ____p;rG2p;rU2prG2p;rA2p rA;rG;rG;rA;zc3p;zc3p$ SERP17NHI 151 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;rC;LdC;rA;m -S1482 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU-mC; ____p~rG2p~rU2p~rG2p~rA2p rAr~Gr~z~~cp SERP17NHI 151 zidB ;rU;rC;rC ;rU;rG;rA;rG mU-mC;rA;mC ;mC;mC;rA; S1483 ,rA;rC-rA;rC;rA;rU;rG;rG2 mU;rG;mU;rG;mU;mC;mU; p;rG2p;rU2p-rG2p;rA2p;zc mC ;rA;rG;rG;rA;zc3p;zc3p$

____

3 p$_________ ____ SERP17NHI 151 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;mC;mC ;rA;m -S1484 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;mU;mC p;rG2p;rU2p,-rG2p;rA2p;zc ;rA;rG;rG;rA;zc3p;zc3p$

____

3 p$_____________ SERP17NHI 151 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;mC;mC ;rA;m -S1485 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU-mC; p;rG2p;rU2p-rG2p;rA2p;zc rA;rG;rG;rA;zc3p;zc3p$ ____________ _______ 3 p$__ ___________ 159 WO 2011/072082 PCT/US2O1O/059578 SERPINHI 1_51 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;rC;rC2p;rA;m _S1486 ,rA;rC-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mnC;rU;mC; p;rG2p;rU2p-rG2p;rA2p;zc rA;rG;rG;rA;zc3p;zc3p$ 3 p$ SERPINHI 1_51 zidB ;rU;rC;rC ;rU;rG;rA;rG mU;rC;rA;mC ;rC;LdC;rA;m -S1487 ,rA;rC,-rA;rC;rA;rU;rG;rG2 U;rG;rU;rG;mU;mC;rU-mC; p;rG2p;rU2p-rG2p;rA2p;zc rA;rG;rG;rA;zc3p;zc3p$ 3 pS SERPINH 1 51 zidB ;rU;mC ;rC ;mlU;rG;rA;- rnU;rC;rnA;rC;mC ;rC ;miA;r -S1488 frG;rA;rC ;rA;mC;rA;mU;rG U;mG;rU;mG;rU;mC;rU;mC ,rG;rG;rU;LdG;rA$ ;rA;mG;rG;mA;zc3p;zc3pS SERP1NH1_-51 8 25 zidB;rU;mC;rC;mU;rG;rA;- mU,-mC;rA;mC;mC;mC;rA; -S1489 rG;rA;rC;rA;mC;rA;mU;rG mU;rG;mU;rG;mU;mC;mU; ;rG;rG;rU;LdG;rA$ mC ;rA;rG;r G;rA;zc3 p;zc3 p$ SERPINHI 151 zidB ;rU~mC~rC ~mU~rG~rA, mU~rC~rA~mC~mC~mC :rA~m -S1490 rG;rA;rC ;rA;mC ;rA;mU ;rG U ;rG;rU;rG;mU;mC;mU;mC ____ rG;rG;rU;LdG;rA$ ;rA;rG;rG;rA;zc3p;zc3pS SERP7NHI 151 zidB ;rU;mC ;rC ;mU;rG;rA; mU;rC;rA;mC ;mC;mC ;rA;m -S1491 rGr~Cr~Cr~Ur U~Gr~GmUm~~C ;rG;rG;rU;LdG;rA$ rA;rG;rG;rA;zc3p;zc3p$ SERP7NHI 151 zidB ;rU;mC;rC ;mU;rG;rA;- mU;rC;rA;mC ;rC;rC2p;rA;m -S1492 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;rG;mU;mC;rUmC; ____ rG;rG;rU;LdG;rA$ rA;rG;rG;rA;zc3p;zc3p$ SERP17NHI 151 zidB ;rU;mC ;rC ;mU;rG;rA;- mU;rC;rA;mC ;rC;LdC;rA;m S1493 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;rG;mU;mC;rU-mC; ,rG;rG;rU;LdG;rA$ rA;rG;rG;rA;zc3p;zc3p$ SERP17NHI 151 zidB ;rU;mC;rC ;mU;rG;rA;- mU;rC;mA;rC;mC ;rC;mA;r S1494 rG;rA;rC;rA;mC;rA;mU;rG U;mG;rU;mG;rU;mC;rU;mC ____ rG;rG;mU;rG;rA;zc3p$ ;rA;mG;rG;mA;zc3p;zc3pS SERPINH 1 51 zidB ;rU;mC ;rC ;mlU;rG;rA;- rnUmC;rA;mC ;mC;mC;rA; S1495 rG;rA;rC ;rA;mC;rA;mU;rG mU;rG;mU;rG;mU; mC ;mU; ,rG;rG;mU;rG;rA;zc3p$ mC ;rA;rG;rG;rA;zc3p;zc3p$ SERP1NHI 151 zidB ;rU;mC ;rC ;mU;rG;rA;- mU;rC;rA;mC ;mC;mC ;rA;m _S1496 rG;rA;rC;rA;mlC;rA;iiU;rG U;rG;rU;rG;mU;mnC;mU;mnC ,rG;rG;mU;rG;rA;zc3p$ ;rA;rG;rG;rA;zc3p;zc3p$ SERPINHI_51 zidB;rU;mC;rC;mU;rG;rA;- mU;rC;rA;mC;mC;mC;rA;m -S1497 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;rG;mU;mC;rU,-mC; ,rG;rG;miU;rG;rA;zc3p)$ rA ;rG;rG;rA;zc3li;zc3p)$ SERPINHI_51 24 22 10 7 zidB;rU;mC;rC;mU;rG;rA, mU;rC;rA;mC;rC;rC2p;rA;m -S1498 rG;rA;rC ;rA;mC ;rA;mU ;rG U ;rG;rU;rG;mU;mC;rU;mC; ____ rG;rG;mU;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3pS SERPINHI_51 24 25 31 18 28 zidB;rU;mC;rC;mU;rG;rA;- mU;rC;rA;mC;rC;LdC;rA;m -S1499 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;rG;mU;mC;rUmC; ,rG;rG;mU ;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERPINHI 151 zidB ;rU;rC ;rC;mU;rG;rA;r mU;rC;rA;mC ;rC;rC2p;rA;m S 1666 G;rA;rC2p;rA;mC;rA;mU;r U;rG;rU;rG;mU;mC;rU-mC; ____G;rG;rG;mU~rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERP17NH1_51 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;LdC;rA;m S1667 G;rA;rC2p;rA;mC;rA;mU;r U;rG;rU;rG;mU;mC;rU-mC; ___G;rG rG;mU,-rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERPINH 1 _51 16 14 IzidB ;rU;rC ;rC;mU;rG;rA;r ImU;rC;rA;mC ;rC;rC2p;rA;m S 1668 ___ G;rA;rC2p;rA;mC;rA;mU;rlU;rG;rU;rG;rU;mC;rU;mC;r 160 WO 2011/072082 PCT/US21/059578 G;rG;rG;mU,-rG;rA;zc3pS A;rG;rG;rA;zc3p;zc3pS SERPINHI_-51 24 18 ziBr~CrCm~Gr~ mUr~Am~r~Cpr -Si669 G;rA;rC2p;rA;mC;rA;mU;r U;rG;rU;mG-rU;rC;rU;mC;r ____C;rG;rG ;rnU;rG ;rA;zc3p$ A;rG ;rG ;rA;zc3p;zc3p$ SERPINHI_-5116 13 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;mA;rC;rC;rC2p;rA;m -S1670 G~Ar~~Am~Am~ U~Gr~GmUm~~C ____G;rG;rG;mU,-rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3pS SERPINHI_51 24 22 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;rC2p;rA;m -S1673 G;rA;rCrA;mC;rA;mU;rG; U;rG;rU;rG;rU;mC;rU;mC;r rGr~UrGr~cp A~Gr~Az~~cp SERPINHI_-5116 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;rC2p;rA;m S1674 G;rA;rC-rA;mC;rA;mU;rG; U;rG;rU;mG-rU;rC;rU;mC;r rG;rG;mU;rG;rA;zc3p$ A;rG;rG;rA;zc3p;zc3p$ SERPINHI_-5116 35 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;mA;rC;rC;rC2p;rA;m -S1675 G;rA;rC-rA;mC;rA;mU;rG; U;rG;rU;rG;mU;mC;rU-mC; rG;rG;mU;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERPINHI 1_5110 zidB ;rU;iC ;rC ;mlU;rG ;rA;r rnU;rC;rA;mC ;rC;rC2p;rA;rn -S1676 G;rA;rC-rA;mC;rA;mU;rG; U;rG;rU;rG;mU;mC;rU-mC; rG;rG;rU2p;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERPINHI_5110 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;LdC;rA;m _S1677 G;rA;rC-rA;mlC;rA;miU;rG; U;rG;rU;rG;mU;mnC;rU;mC; rG;rG;rU2p;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERPINHI 15110 zidB ;rU ;rC ;rC ;mU;rG;rA;r mU;rC;rA;mC ;rC;rC2p;rA;m -S1678 G;rA;rC,-rA;mC;rA;mU;rG; U;rG;rU;rG;rU;mC;rU;mC;r rG ;rG;rU2p;rG;rA;zc3p$ A;rG ;rG ;rA;zc3p;zc3p$ SERPINHI_5110 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;rC2p;rA;m -S1679 G;rA;rC;rA;mC;rA;mU;rG; U;rG;rU;mG;rU;rC;rU;mC;r rG;rG;rU2p;rG;rA;zc3pS A;rG;rG;rA;zc3p;zc3pS SERPINHI_51 10 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;mA;rC;rC;rC2p;rA;m -S1680 G;rA;rCrA;mC;rA;mU;rG; U;rG;rU;rG;mU;mC;rUmC; rG;rG;rU2p;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERPINHI_-51 8 16 zidB;rU;mC;rC;mU;rG;rA; mU;rC;rA;mC;rC;rC2p;rA;m S1682 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;mG-rU;rC;rU;mC;r ;rG~rG~mU;rG~rA~zc3p$ A~Gr~Az~~cp SERPINHI 1_51 zidB ;rU;rC ;rC;mU;rG;rA;r yrA;rC ;rA;mC;rC;rC2p;rA;m -S1778 G;rA;rC2p;rA;mC;rA;mU;r U;rG;rU;mG-rU;rC;rU;mC;r ________________ _____G;rG;rG;mU,-rG;yrU;zc3p$ A;rG;rG;rA;zc3p;zc3p$ SERPINH 1 51 zidB ;rU;mC ;rC ;inlU;rG;rA;- yrA;rC ;rA;mC;rC;rC2p;rA;m -S1779 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;mG-rU;rC;rU;mC;r ,rG;rG;mU;rG;yrU;zc3p$ A;rG;rG;rA;zc3p;zc3p$ SERPINHI 151 zidB ;rU;rC ;rC;mU;rG;rA;r dU;rC;rA;mC;rC;rC2p;rA;m _S1783 G;rA;rC2p;rA;i-nC;rA;iniU;r U;rG;rU;iiG-rU;rC;rU;iiC;r G;rG;rG;mU,-rG;rA;zc3p$ A;rG;rG;rA;zc3p;zc3p$ SERPINHI_51 zidB;rU;mC;rC;mU;rG;rA;- dU;rC;rA;mC;rC;rC2p;rA;m _S1784 rG;rA;rC;rA;iiC;rA;im-U;i-G U;rG;rU;mG-rU;i-C;rU;iinC;r ____ ,G;rG;mU;r G;rA;zc3p$ A;rG;rG;rA;zc3p;zc3p$ SERPINHI_52 zidB~r~Ar~Ar~Gr mUr~U Cm~r~~ -S1356 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;rC;mU ____p;rG2p;rA2p;rG2p;rA2p ;rU;mG;rU;mC;zc3p;zc3p$ SERPINHI 152 zc3p;rG;rA;rC ;rA;rA;rG;rA mU;rC;mU;rC;mG;rU;mC~r IS1363 ;rrCGArrC2Umcr m~A UrCm 161 WO 2011/072082 PCT/US2O1O/059578 p;rG2p;rA2p,-rG2p;rA2p ;rU;mG;rU;mC;zc3p;zc3pS SERP17NHI_-52 zidB~r~Ar~Ar~Gr mUr~U Cm~r~~ -Si370 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;rC;mU p;rG2p;rA2p,-rG2p;rA2p;zc ;rU;mG;rU;mC;zc3p;zc3p$

____

3 p$_________ ____ SERPI7NHI1_52 zc3p;rG~rA~rC ~rA~rA;rG~rA mUr~Um~Gm~C -S1552 ,rU;rG;rC;rG;rA;rG;rA;rC2 mU,-mC;rG;mC;rA;mU;mC; p;rG2p;rA2p-rG2p;rA2p mU;mU;rG;mU;rC;zc3p;zc3 SERPINHI 1_52 zc3p;rG~rA~rC ~rA~rA;rG~rA mUr~m :r~U~Cr -S1553 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;mC;rU ____p;rG p;rA2p;rG2p;rA2p ;ii-U;rG ;inU;rC ;zc3p;zc3p$ SERP17NHI 1_52 zc3p;rG;rA;rC ;rA;rA;rG;rA mU;rC;mU;mCrG;mU;mC ;r -S1554 ,rU;rG;rC ;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU ____p;rG2p;rA2prG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERP17NHI 152 zc3p;rG;rA;rC ;rA;rA;rG;rA mU;rC;mU;mC-rG;mU;mC ;r -S1555 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;rC;mU ____p;rG2p;rA2p;rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERP17NHI 152 zc3p;rG;rA;rC ;rA;rA;rG;rA mU;rC;mU;mC,-rG;rU;LdC;r -S1556 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU ____p;rG2p;rA2p~rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERPINHI 152 zc3p;rG;rA;rC ;rA;rA;rG;rA mU;rC;mU;mC,-rG;rU;rC2p;r -S1557 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU ____p;rG2p;rA2p,-rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERPTNH 1 52 zidB ;rG ;rA;rC;rA;rA ;rG ;rA rnU;rC;rnU;mC-rG;im-U;mC; -S1558 ,rU;rG;rC;rG;rA;rG;rA;rC2 mU-mC;rG;mC;rA;mU;mC; p;rG2p;rA2p-rG2p;rA2p mU;mU;rG;mU;rC;zc3p;zc3 ___ ___ ___ ___ ___ __P$ SERPTNH 1 52 zidB ;rG;rA;rC;rA;rA;rG;rA imU;rC;imU;miC-rG;liU;mlC ;r -S1559 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;mC;rU p;rG p;rA2p;rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERPINH1_52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;mU;mC;r -S1560 ,rU;rG;rC ;rG;rA;rG;rA;rC2 U;mC;rG;mC ;rA;rU;mC;mU p;rG2p;rA2p,-rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERPINHI_52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;mU;mC;r S1561 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;rC;mU ____p;rG2p;rA2p;rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERP17NHI_52 ziBr~Ar~Ar~Gr mUr~UmrGr;d~ -S1562 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU ____p;rG2p;rA2p,-rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3pS SERPINHI_52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;rU;rC2p;r S1563 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU ____p;rG2p;rA2p;rG2p;rA2p ;mU;rG;mU;rC;zc3p;zc3p$ SERP17NH1_52 16 94 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC-rG;mU;mC; S1564 ,rU;rG;rC;rG;rA;rG;rA;rC2 mUmC;rG;mC;rA;mU;mC; p~rG2p~rA2p,-rG2p~rA2p~zc mUm~Gm~Cz~~c

____

3 pS PS SERP17NH1_52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;mU;mC;r -S1565 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;mU;mC;rU p~rG2p~rA2p,-rG2p~rA2p~zc ;m1JrG~mU~rC ~zc3p~zc3p$ ___________ ________ __ 3 p$ ____________ 162 WO 2011/072082 PCT/US2O1O/059578 SERP1NH1_-52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;mU;mC;r _S1566 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU p;rG2p;rA2p-rG2p;rA2p;zc ;mU;rG;mU;rC ;zc3p;zc3p$ 3 p$ SERPINHI_52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;mU;mC;r -S1567 ,rU;rG;rC ;rG;rA;rG;rA;rC2 U;mC;rG;mC ;rA;mU;rC;mU p;rG2p;rA2p-rG2p;rA2p;zc ;mU;rG;mU;rC ;zc3p;zc3p$ 3 pS SERPINHI 152 zidB ;rG ;rA;rC ;rA;rA;rG ;rA niU;rC;inU;mC,-rG;rU;LdC;r -S1568 ,rU;rG;rC ;rG;rA;rG;rA;rC2 U;mC;rG;mC ;rA;rU;mC;mU p;rG2p;rA2p-rG2p;rA2p;zc ;mU;rG;mU;rC ;zc3p;zc3p$

____

3 p$_________ ____ SERPINHI_52 zidB;rG;rA;rC;rA;rA;rG;rA mU;rC;mU;mC,-rG;rU;rC2p;r -S1569 ,rU;rG;rC ;rG;rA;rG;rA;rC2 U;mC;rG;mC ;rA;rU;mC;mU p;rG2p;rA2p-rG2p;rA2p;zc ;mU;rG;mU;rC ;zc3p;zc3p$

____

3 p$_________ ____ SERPINHI_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;rC;mG;rU;mC,-r S1570 A;mU;rG;mC-rG;rA;rG;rA; U;mC;rG;mC ;rA;mU;rC;mU mC;rG;rA;LdG;rA$ ;rU;mG;rU;mC;zc3p;zc3p$ SERP1NH1_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC,-rG;mU;mC; -S1571 A;mlU;rG;mC,-rG ;rA;rG ;rA; nUnC;rG;mC;rA;mlU;mC; mC ;rG;rA;LdG;rA$ mU;mU;G;mU;rC;zc3p;zc3 P$ SERPINHI_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC,-rG;mU;mC;r 5S1572 A;mlU;rG;mC-rG;rA;rG;rA; U;mC;rG;mC;rA;iiU;rnC;rU mC ;rG;rA;LdG;rA$ ;mU;rG;mU;rC ;zc3p;zc3p$ SERPINHI_52 ziBr~AmCr~Ar~ mUr~Umr~Um~ S1573 A;mU;rG;mC,-rG;rA;rG;rA; U;mC;rG;mC;rA;rU;mC;mU mC;rG;rA;LdG;rAS$ ;mU;rG;mU;rC;zc3p;zc3pS$ SERP17NH1_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC~rG;mU;mC;r 5S1574 A~Ur~~G~Ar~A U~Cr~CrAm~C mC;rG;rA;LdG;rAS ;mU;rG;mU;rC;zc3p;zc3pS SERP17NH1_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC,-rG;rU;LdC;r -S1575 A;mU;rG;mCrG;rA;rG;rA; U;mC;rG;mC;rA;rU;mC;mU mC;rG;rA;LdG;rA$ ;mU;rG;mU;rC;zc3p;zc3p$ SERP17NH1_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC-rG;rU;rC2p;r S1576 A;mU;rG;mC-rG;rA;rG;rA; U;mC;rG;mC;rA;rU;mC;mU mC;rG;rA;LdG;rA$ ;mU;rG;mU;rC;zc3p;zc3p$ SERP17NH1_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;rC;mG;rU;mC-r -S1577 A;mU;rG;mC-rG;rA;rG;rA; U;mC;rG;mC;rA;mU;rC;mU mC ;rG;rA;rG;rA;zc3p$ ;rU;mG;rU;mC;zc3p;zc3p$ SERPTNH1 52 zidB ;rG ;rA;i-C ;rA;rA;rG ;r rnU;rC;rnU;mC,-rG;im-U;niC; -S1578 A;mU;rG;mC-rG;rA;rG;rA; mU-mC;rG;mC;rA;mU;mC; mC;rG;rA;rG;rA;zc3p$ mU;mU;rG;mU;rC;zc3p;zc3 ___ ___ ___ ___ ___ __P$ SERPTNH 1 52 zidB ;rG ;rA;imC ;rA ;rA;rG ;r rnU;rC;inU;imC-rG;iniU;mC;r S1579 A;mU;rG;mC-rG;rA;rG;rA; U;mC;rG;mC;rA;mU;mC;rU mC;rG;rA;rG;rA;zc3p$ ;mU;rG;mU;rC;zc3p;zc3p$ SERPINHI_52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC,-rG;mU;mC;r S1580 A;iiU;rG;i-nC-rG;rA;rG;rA; U;mC;rG;mC;rA;rU;mC;mU mC;rG;rA;rG;rA;zc3p$ ;mU;rG;mU;rC;zc3p;zc3p$ SERPINHi_52 I zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC,-rG;mU;mC;r S1581 _ __A;mU;rG;mC,-rG;rA;rG;rA; U;mC;rG;mC;rA;mU;rC;mU 163 WO 2011/072082 PCT/US201O/059578 mC;rG;rA;rG;rA;zc3pS ;mU;rG;mU;rC;zc3p;zc3pS SERPI7NHI1_52 ziBr~AmCr~Ar~ mUr~UmrGr;d -Si582 A;mU;rG;mC,-rG;rA;rG;rA; U;mC;rG;mC;rA;rU;mC;mU mC ;rG ;rA;rG;rA;zc3p$ ;miU;rG;rnU;rC;zc3p;zc3p$ SERP17NH1_-52 zidB;rG;rA;mC;rA;rA;rG;r mU;rC;mU;mC,-rG;rU;rC2p;r -S1583 A~Ur~~G~Ar~A U~Cr~CrAr~C mC;rG;rA;rG;rA;zc3p$ ;mU;rG;mU;rC;zc3p;zc3p$ SERPI7NHI_58 zidB;rG;rA;rC;rA;rA;rG;rA rA;mC;rU;mC;rG;mU;rC;m -S1391 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;rC;rGmC;rA;mU;rC;mU;r ____p~rG2p~rA2prG2p~rU2p UhmG~rU~mC;zc3p~zc3p$ SERP17NH1_-58 zidB;rG;rA;rC;rA;rA;rG;rA rA;mC;rU;mC;rG;mU;mC-r S1584 ,rU;rG;rC;rG;rA;rG;rA;rC2 U;mC;rG;mC;rA;rU;mC;mU ____p;rG2p;rA2p;rG2p;rU2p ;m1;rG;mU;rC;zc3p;zc3p$ SERPINHI_-86 16 68 65 zidB;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;mG;rU;mU;r S1356 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;mG;rA;mG;rG;mC ____p;rU2p;rA2prC2p;rA2p ;rC;mU;rG;mU;zc3p;zc3p$ SERPINHI 1 86 zc3p;rA;rC ;rA;rG;rG;rC;rC rnU;rG ;mlU;rA;mG ;rU;mlU;r S1363 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;mG;rA;mG;rG;mC ____p;rU2p;rA2p;rC2p;rA2p ;rC;mU;rG;mU;zc3p;zc3p$ SERPINHI_-86 zidB;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;mG;rU;mU;r S1370 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;mG;rA;mG;rG;rnC p;rU2p;rA2p-rC2p;rA2p;zc ;rC;mU;rG;mU;zc3p;zc3p$ 3 pS SERPINHI_-86 zc3p;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;rG;mU;mU;r _S1530 ;rIJ;rC-rU;rA;rC;rA;rA ;rC2 G;im-U;rA;rG-rA;-G ;rG ;iiC; p;rU2p;rA2p,-rC2p;rA2p mC;mU;rGj;rUI-zc3p;zc3p$ SERPINHI_86 52 31 zc3p;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;rG;mU;mU;r -S1531 ,rU;rC,-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG,-rA;rG;rG,-mC;r ____p;rU2p;rA2p;rC2p;rA2p C ;iiU;rG;rU;zc3lp;zc3pi$ SERPINHI 1_86 zc3p;rA;rC;rA;rG;rG;rC;rC m~hrG;mU;rA;rG;rU;LdT;r S1532 ,rU;rC;rU;rA;rC;rA;rA;rC2 G;mU;rA;rG;rA;rG;rG;mC; ____p;rU2p;rA2p,-rC2p;rA2p mC;mU;rG;rU;zc3p;zc3pS SERPINHI_86 8 70 74 zc3p;rA;rC;rA;rG;rG;rC;rC mU,-rG;mU;rA;rG;rU;rU2p;r -S1533 ;r~~Ur~r~Ar~C G~Ur~~A~Gr~ ____p;rU2p;rA2p,-rC2p;rA2p mC ;mU ;rG;rU ;zc3p ;zc3p$ SERP17NH1_-86 zidB;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;rG;mU;mU;r S1534 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG-rA;rG;rG;mC; ____p~rU p~rA2p~rC2p~rA2p mC~mU~rG~rUhzc3p~zc3p$ SERPINHI 1_86 zidB ;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;rG;mU;mU;r -S1535 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG-rA;rG;rG-mC;r ____p;rU2p;rA2prC2p;rA2p C ;mU;rG;rU;zc3p;zc3p$ SERPTNHI 1 86 zidB ;rA ;rC;rA ;rG;rG;rC;rC iiU-rG;mlU;rA;rG;rU;LdT;r -S1536 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG-rA;rG;rG;mC; p;rU2p;rA2p;rC2p;rA2p mC;mU;rG;rU;zc3p;zc3p$ SERPTNHI 1 86 zidB ;rA ;rC;rA ;rG;rG ;rC;rC rnU-rG;mU;rA;rG;rU;rU2p;r -S1537 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG-rA;rG;rG;mC; p;rU2p;rA2p,-rC2p;rA2p mC;mU;rG;rUI-zc3p;zc3p$ SERPINHI_86 zidB;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;rG;mU;mU;r -S1538 ;rU;rC,-rU;rA;rC;rA;rA;rC2 G;mlU;rA;rG-rA;rG;rG;mC; p;rU2p;rA2p-rC2p;rA2p;zc mC ;mU;rG;rU-zc3p ;zc3p$ ____________ _______ 3 p$__ ___________ 164I WO 2011/072082 PCT/US2O1O/059578 SERPIhJH1_-86 zidB;rA;rC;rA;rG;rG;rC;rC mU;rG;mU;rA;rG;mU;mU;r _S1539 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG;rA;rG;rG;mC;r p;rU2p;rA2p-rC2p;rA2p;zc C ;mU;rG;rU;zc3p;zc3p$ 3 p$ SERPINHI_86 zidB;rA;rC;rA;rG;rG;rC;rC mU,-rG;mU;rA;rG;rU;LdT;r -S1540 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG-rA;rG;rG;mC; p;rU2p;rA2p-rC2p;rA2p;zc mC;mU;rG;rU-zc3p;zc3p$ 3 p$ SERPINHI 186 zidB ;rA;rC ;rA;rG;rG ;rC ;rC rnU,-rG;mlU;rA;rG;rU;rU2p;r 5S1541 ,rU;rC-rU;rA;rC;rA;rA;rC2 G;mU;rA;rG-rA;rG;rG;mC; p;rU2p;rA2p-rC2p;rA2p;zc mC;mU;rG;rU-zc3p;zc3p$

____

3 p$_________ ____ SERPINHI_86 zidB;rA;mC;rA;rG;rG;mC; mU;rG;mU;rA;mG;rU;mU;r -S1542 rC;rU;rC;mU;rA;mC;rA;rA G;mU;rA;mG;rA;mG;rG;mC ,rC;mU;rA;LdC;rA$ ;rC;mU;rG;mU;zc3p;zc3p$ SERPINHI_86 8 44 42 zidB;rA;mC;rA;rG;r;mC; mU;rG;mU;rA;rG;mU;mU;r 5S1543 rC;rU;rC;mU;rA;mC;rA;rA G;mU;rA;rG,-rA;rG;rG;mC; ,rC;mU;rA;LdC;rA$ mC;mU;rG;rUI-zc3p;zc3p$ SERP17NHI_86 8 29 36 zidB;rA;mC;rA;rG;rG;mC; mU;rG;mU;rA;rG;mU;mU;r S1544 rC;rU;rC;mU;rA;mC;rA;rA G;mU;rA;rG,-rA;rG;rG,-mC;r ____ rC;miU;rA;LdC;rA$ C ;mlU;rG ;rU;zc3p;zc3p$ SERP17NH1_86 zidB;rA;mC;rA;rG;rG;mC; mUrG;mU;rA;rG;rU;LdT;r 5S1545 rC;rU;rC;mU;rA;mC;rA;rA G;mU;rA;rG;rA;rG;rG;mC; ,rC;mU;rA;LdC;rA$ mC;mU;rG;rU,-zc3p;zc3pS SERPINHI_86 16 67 63 zidB;rA;mC;rA;rG;rG;mC; mU,-rG;mU;rA;rG;rU;rU2p;r 5S1546 rC;rU;rC;mU;rA;mC;rA;rA G;mU;rA;rGrA;rG;rG;mC; ;rC;mU;rA;LdC;rA$ mC;mU;rG;rUhzc3p;zc3p$ SERPINHI_86 16 24 63 zidB;rA;mC;rA;rG;rG;rC;r mU;rG;mU;rA;mG;rU;mU;r S1547 C;rU;rC;mU;rA;mC;rA;rA; G;mU;rA;mG;rA;mG;rG;mC rC;mU;rA;mC;rA;zc3p$ ;rC;mU;rG;mU;zc3p;zc3p$ SERPINHI_86 16 39 67 zidB;rA;mC;rA;rG;rG;rC;r mU;rG;mU;rA;rG;mU;mU;r S1548 C;rU;rC;mU;rA;mC;rA;rA; G;mU;rA;rG-rA;rG;rG;mC; rC;mU;rA;mC;rA;zc3p$ mC;mU;rG;rU;zc3p;zc3p$ SERPTNH1 86 16 20 68 zidB;rA;iniC;rA;rG;rG;rC;r iiU;rG;mlU;rA;rG;iiU;mlU;r S1549 C;rU;rC;mU;rA;mC;rA;rA; G;mU;rA;rG-rA;rG;rG-mC;r rC;mU;rA;mC;rA;zc3p$ C ;mU;rG;rU;zc3p;zc3p$ SERPINHI_86 16 96 92 zidB;rA;mC;rA;rG;rG;rC;r mU,-rG;mU;rA;rG;rU;LdT;r S1550 C;rU;rC;iiU;rA;iiC;rA;rA; G;mU;rA;rG;rA;rG;rG;mC; rC;mU;rA;mC;rA;zc3p$ mC;mU;rG;rU;zc3p;zc3p$ SERPINHI_86 16 70 51 zidB;rA;mC;rA;rG;rG;rC;r mU;rG;mU;rA;rG;rU;rU2p;r -S1551 C;rU;rC;mU;rA;mC;rA;rA; G;mU;rA;rG,-rA;rG;rG;mC; rC;ml-U;rA ;rC;rA;zc3p$ rnC ;imU;-G ;rU.z~ ;cp SERP17NH1_2- zidB ;rG;rA;rG;rA;rC ;rA;m mU;rA;mU;rA;mG;rC;mA;r S 1686 C;rA;rU-rG;rG;rG;mU;rG;r C;mC;rC;miA;rU;mG;rU;mG __ _C ;mU;rA;mU;rA;zc3p$ ;rU;mC ;rU;mC;zc3p;zc3p$ SERP17NH1_2- zidB ;rG;rA;rG;rA;rC ;rA;m mU;rA;mU;rA;mG;rC;rA2p; S 1688 C;rA;rU-rG;rG;rG;mU;rG;r rC;mC;rC;miA;rU;mG;rU;m __ _C ;mU;rA;mU,-rA;zc3p$ G;rU;mC;rU;mC;zc3p;zc3p$ SERPINHi_2- zidB;rG;rA;rG;rA;rC;rA;m mU;rA;mU;rA;mG;rC;miA;r S 1689 C ;rA;rU-rG;rG;rG;mU;rG;r C ;mC;rC;niA;rU;mG;rU;mG ___________ _____C ;mU;rA;mU,-rA;zc3p;zc3 ;rU;mC ;rU;mC;zc3p;zc3p$ 165 WO 2011/072082 PCT/US2010/059578 PS SERPINHI_2_ zidB;rG;rA;rG;rA;rC;rA;m mU;rA;mU;rA;mG;rC;mA;r S1690 C;rA;rU;rG;rG;rG;mU;rG;r C;mC;rC;mA;rU;mG;rU;mG C ;mU;rA;nU;rA;zc3p;zc3 ;rU;mC;rU;rC;zc3p;zc3p$ P$ SERP1NH1_2_ zidB;rG;rA;rG;rA;rC;rA;m mU;rA;mU;rA;mG;rC;rA2p; S1691 C;rA;rU;rG;rG;rG;mU;rG;r rC;mC;rC;mA;rU;mG;rU;m C ;mU;rA;mU;rA;zc3p;zc3 G;rU;mC;rU;mC;zc3p;zc3p$ p$ SERPINHi_2_ zidB;rG;rA;rG;rA;rC;rA;m mU;rA;mU;rA;mG;rC;mA;r S1692 C;rA;rU2p;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;mU;rA;zc3p$ ;rU;mC;rU;mC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;rC;rA;m mU;rA;mU;rA;mG;rC;mA;r S1693 C;rA;rU2p;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;mU;rA;zc3p$ ;rU;mC;rU;rC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S1695 mC;rA;rU;rG;rG;rG;rU;rG; C;mC;rC;mA;rU;mG;rU;mG rC;mU;rA;mU;rA;zc3p$ ;rU;mC;rU;mC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S1696 mC;rA;rU;rG;rG;rG;rU;rG; C;mC;rC;mA;rU;mG;rU;mG rC;mU;rA;mU;rA;zc3p$ ;rU;mC;rU;rC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;rA2p; S1697 mC;rA;rU;rG;rG;rG;rU;rG; rC;mC;rC;mA;rU;mG;rU;m rC;mU;rA;mU;rA;zc3p$ G;rU;mC;rU;mC;zc3p;zc3p$ SERPTNH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S1698 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;rU2p;rA;zc3p ;rU;mC;rU;mC;zc3p;zc3p$ SERPTNH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;nG;rC;mA;r S1699 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;rU2p;rA;zc3p ;rU;mC;rU;rC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S1701 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;LdT;rA;zc3p$ ;rU;mC;rU;mC;zc3p;zc3p$ SERPINHi_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S1702 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG G;rC;mU;rA;LdT;rA;zc3p$ ;rU;mC;rU;rC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;rA2p; S1703 mC;rA;rU;rG;rG;rG;mU;r rC;mC;rC;mA;rU;mG;rU;m G;rC;mU;rA;LdT;rA;zc3p$ G;rU;mC;rU;mC;zc3p;zc3p$ SERPINH1_2_ zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;mA;r S1704 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;mA;rU;mG;rU;mG p;rU2p;rA2p;rU2p;rA2p ;rU;mC;rU;rC;zc3p;zc3p$ SERPINHi_2_ zidB;rG;rA;rG;rA;rC;rA;rC mU;rA;mU;rA;mG;rC;mA;r S1706 ;rA;rU;rG;rG;rG;rU;rG;rC2 C;mC;rC;mA;rU;mG;rU;mG p;rU2p;rA2p;rU2p;rA2p;zc ;rU;mC;rU;rC;zc3p;zc3p$ 3 p$ SERPINH1_2 zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S1708 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;mA;rU;mG;rU;mG I IG;mC;mU;rA;LdT;rA$ ;rU;mC;rU;rC;zc3p;zc3p$ 166 WO 2011/072082 PCT/US2O1O/059578 SERPINHi_2- zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;rA2p; S 1709 rnC;rA;rU;rG;rG;rG;iiiU;r rC;mnC;rC;niA;rU;mG;rU;ni G;mC;mU;rA;LdT;rA$ G;rU;mC;rU;mC;zc3p;zc3p$ SERPINHI_2- zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;mA;r S 1710 mC;rA;rU;rG;rG;rG;mU;r C;mC;rC;miA;rU;mG;rU;mG ____G;rC;mU;rA;mU;rA;zc3 p$ ;rU;mC ;rU;rC;zc3 p;zc3 p$ SERP7NH1_2- zidB;rG;rA;rG;rA;mC;rA; mU;rA;mU;rA;mG;rC;rA2p; S 1711 mC ;rA;rU ;rG;rG;rG;mU ;r rC;mC;rC;mA;rU;mG;rU;m _____C;rC;miU;rA;mlU;rA;zc3p$ G ;rU;mC;rU;mC;zc3p;zc3p$ SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rUmC;rG;mU;r S 1712 mUhrG;rC;rG;rA;rG;rA;mC C;mU;rC;mG;rC;miA;rU;mC ____ rG;rA;rG;LdT;rA;zc3pS ;rU;mU;rG;mU;zc3p;zc3pS SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU-mC;rG;mU;m S 1713 mUrG;rC;rG;rA;rG;rA;mC C;rU;mC;rG;mC;miA;rU;mC ;rG;rA;rG;LdT;rA;zc3p$ ;rU;mU;rG;rU;zc3p;zc3p$ SERP17NH1_6 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,-mC;rG;rU2p; S 1714 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC -rG;mC;mnA;rU;m ____ rG;rA;rG;LdT;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6- zidB ;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU-mC;rG;rU2p; S 1715 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC-mG;rC;mA;rU;m ;rG;rA;rG;LdT;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPTNH1 6- zidB ;rA ;iiC;rA ;rA;rG;rA; mU;rA;mnC;rU;mC;rG;rU2p; S 1716 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC ;mG;rC;mA;rU;m ,rG;rA;rG;LdT;rA;zc3p$ C;rU;mU;rG;mU;zc3p;zc3p$ SERPINHi_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,-mC;rG;rU2p; S 1717 mUrG ;rC;rG ;rA;rG ;rA ;mC rC;niU;rC-rG;niC;im-A;rU;rC; ,r G;rA;r G;LdT;rA;zc3p$ rU;mU;rG;rUI-zc3p;zc3pS SERPINHi_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;r~hmC;rG;mU;r S 1718 mUrG;rC;rG;rA;rG;rA;mC C;mU;rC;mG;rC;miA;rU;mC ,rG;rA;rG ;LdT;rA;zc3p;zc3 ;rU;iiU;rG ;imU;zc3p;zc3pS ____P$ ______________ SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;r~hmC;rG;mU;m S 1719 mUrG;rC;rG;rA;rG;rA;mC C;rU;mC;rG;mC;miA;rU;mC ,rG;rA;rG;LdT;rA;zc3p;zc3 ;rU;mlU;rG;rU;zc3p;zc3p$ SERPINHI_6 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,-mC;rG;rU2p; S 1720 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC -rG;mC;mnA;rU;m ,rG;rA;rG;LdT;rA;zc3p;zc3 C ;rU;i-nU;rG;rU;zc3p;zc3p$ 13$ SERPINHi_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S 1721 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC,-mG;rC;miA;rU;m ;rG ;rA ;rG ;LdT;rA;zc3p;zc3 C;rU;im-U;rG;rU;zc3p;zc3p$ ____P$ ___________ SERPINHi_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S 1722 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC,-mG;rC;miA;rU;m ;rG ;rA ;rG ;LdT;rA;zc3p;zc3 C;rU;miU;rG;iiU;zc3p;zc3p$ SERPINHI_6 zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,-mC;rG;rU2p; S 1723 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC -rG;mC;mnA;rU;rC; ,rG;rA;rG;LdT;rA;zc3p;zc3 rU;iiU;rG;rU-zc3p;zc3pS PS FSERPINHI 16 zidB ;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,mC;rG;mU ;r S l 174___ UrG;rC;rG;rA;rG;rA;mC C;mU;rC;mG;rC;miA;rU;mC 167 WO 2011/072082 PCT/US2O1O/059578 ,rG;rA;rG;rU2p;rA;zc3pS ;rU;mU;rG;mU;zc3p ;zc3pS SERP17NHI_6- zidB;rA;mC;rA;rA;rG~rA; mU;rA;mC;rUmC;rG;mU;m Si1725 mUrG;rC;rG;rA;rG;rA;mC C;rU;mC;rG;mC;miA;rU;mC ____ rG;rA;rG ;rU2p;rA;zc3pS ;rU;iiU;rG ;rU;zc3p;zc3pS SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rUmC;rG;rU2p; S 1726 mU,,rG;rC;rG;rA;rG;rA;mC rC;mU;rCrG;mC;miA;rIJ;m ;rG;rA;rG;rU2p;rA;zc3pS C ;rU;mU;rG;rU;zc3p;zc3pS SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU~mC;rG;rU2p; S 1727 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rCmG;rC;miA;rIJ;m ,rG;rA;rG;rU2p;rA;zc3pS C ;rU;mU~rG;rU;zc3p;zc3p$ SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU-mC;rG;rU2p; S 1728 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC-mG;rC;miA;rU;m ;rG;rA;rG;rU2p;rA;zc3pS C ;rU;mU;rG;mU;zc3p;zc3p$ SERP17NH1_6- zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU-mC;rG;rU2p; S 1729 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC -rG;mC;mnA;rU;rC; ____ rG;rA;rG;rU2p;rA;zc3pS rU;mU;rG;rUI-zc3p;zc3pS SERPINHI 6- zidB;rA;mC;rA;rA;rG;rA; rnU;rA;mC;rUniC;rG;miU;r S 1730 mUrG;rC;rG;rA;rG;rA;mC C;mU;rC;mG;rC;miA;rU;mC ,rG;rA;rG;rU2p;rA;zc3p;zc ;rU;mU;rG;mU;zc3p;zc3pS

____

3 pS ____________ SERPTNH1 6- zidB ;rA ;iiC;rA ;rA;rG;rA; iniU;rA;mlC;rU-imC;rG;miU;ml S1731 mUrG;rC;rG;rA;rG;rA;mC C;rU;mC;rG;mC;miA;rU;mC ,rG;rA;rG;rU2p;rA;zc3p;zc ;rU;mU;rG;rU;zc3p;zc3p$

____

3 pS ____________ SERPTNH 1 6 zidB ;rA ;imC;rA ;rA ;i-G;rA; rnU;rA;mC;rU,-mC;rG;rU2p; S 1732 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC-rG;mC;mA;rU;m ,rG;rA;rG;rU2p;rA;zc3p;zc C;rU;mU;rG;rU;zc3p;zc3p$ 3 p$_____________ SERPTNH 1 6 zidB ;rA ;iiC;rA ;rA;rG;rA; mU;rA;mnC;rUI-mC;rG;rU2p; S 1733 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC-mG;rC;mA;rU;m ,rG;rA;rG;rU2p;rA;zc3p;zc C;rU;mU;rG;rU;zc3p;zc3p$

____

3 pS ____________ SERPINHI 16 zidB ;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,-mC;rG;rU2p; S 1734 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC-mG;rC;mA;rU;m ,rG;rA;rG;rU2p;rA;zc3p;zc C;rU;mU;rG;mU;zc3p;zc3p$

____

3 p$_________ ____ SERPINHI 16 zidB ;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU,-mC;rG;rU2p; S 1735 mUrG;rC;rG;rA;rG;rA;mC rC;mU;rC-rG;mC;mA;rU;rC; ,rG;rA;rG;rU2p;rA;zc3p;zc rU;mU;rG;rU-zc3p;zc3pS

____

3 p$_________ ____ SERPINHI 6 zidB;rA;mC;rA;rA;rG;rA;r iinU;rA;mC;rUinC;rG;iiU;r S 1736 U;rG;rC-rG;rA;rG;rA;mC;r C;mU;rC;mG;rC;mA;rU;mC G;rA;rG;mU,-rA;zc3p$ ;rU;mU;rG;mU;zc3p;zc3pS SERPINHI_6 zidB;rA;mC;rA;rA;rG;rA;r mU;rA;mC;rU,-mC;rG;mU;m S 1737 U;rG;rC ;rG;rA;rG;rA;miC;r C;rU;rnC;rG;inC;inA;rU;inC G;rA;rG;mU;rA;zc3p$ ;rU;mU;rG;rU;zc3p;zc3p$ SERPINHI_6- zidB;rA;mC;rA;rA;rG;rA;r mU;rA;mC;rU,-mC;rG;rU2p; S 1738 U;rG;rC,-rG;rA;rG;rA;mC;r rC;mU;rC,-rG;mC;miA;rU;m ____G;rA;rG;mU,-rA;zc3p$ C ;rU;mU;rG;rU;zc3p;zc3p$ SERP7NH1_6- zidB;rA;mC;rA;rA;rG~rA;r mU;rA;mC;rUmC;rG;rU2p; S 1740 U;rG;rC,-rG;rA;rG;rA;mC;r rC;mU;rC,-mG;rC;miA;rU;m __________ _____ C;rA;rG ;rnU;rA;zc3p$ C ;rU;liU;rG ;iiU;zc3p;zc3p$ 168 WO 2011/072082 PCT/US2010/059578 SERPINHi_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;mU;r S1742 ;rG;rC;rG;rA;rG;rA;mC ;rG C;mU;rC;mG;rC;rnA;rU;mC ;rA;rG;mU;rA;zc3p$ ;rU;mU;rG;mU;zc3p;zc3pS SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;mU;m S1743 ;rG;rC;rG;rA;rG;rA;mC;rG C;rU;mC;rG;mC;mA;rU;mC ;rA;rG;mU;rA;zc3p$ ;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1745 ;rG;rC;rG;rA;rG;rA;mC;rG rC;mU;rC;mG;rC;mA;rU;m ;rA;rG;nU;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;rC;rA;rA;rG;rA;rU mU;rA;mC;rU;mC;rG;rU2p; S1747 ;rG;rC;rG;rA;rG;rA;mC;rG rC;mU;rC;rG;mC;nA;rU;rC; ;rA;rG;mU;rA;zc3p$ rU;mU;rG;rU;zc3p;zc3pS SERP1NH1_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1748 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;mG;rC;mA;rU;m ;rG;rA;rG;LdT;rA$ C;rU;mU;rG;rU;zc3p;zc3p$ SERP1NH1_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1749 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;mG;rC;mA;rU;m ;rG;rA;rG;LdT;rA$ C;rU;mU;rG;mU;zc3p;zc3p$ SERPINH1_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1750 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;rG;mC;mA;rU;rC; ;rG;rA;rG;LdT;rA$ rU;mU;rG;rU;zc3p;zc3pS SERPTNH1_6_ zidB;rA ;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1751 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;mG;rC;mA;rU;m ;rG;rA;rG;mU;rA;zc3p$ C;rU;mU;rG;rU;zc3p;zc3p$ SERPINHi_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1752 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;mG;rC;mA;rU;m ;rG;rA;rG;mU;rA;zc3p$ C;rU;mU;rG;mU;zc3p;zc3p$ SERPINHi_6_ zidB;rA;mC;rA;rA;rG;rA; mU;rA;mC;rU;mC;rG;rU2p; S1753 mU;rG;rC;rG;rA;rG;rA;mC rC;mU;rC;rG;mC;mA;rU;rC; ;rG;rA;rG ;mU;rA;zc3p$ rU;mU;rG;rU;zc3p;zc3pS SERPINHI 42 rG;rA;rC;rA;rG;rG;rC;rC;r yrA;rU;rA;rG;rU;rU;rG;rU;r _S1354 U;rC;rU;rA;rC;rA;rA;rC;r A;rG;rA;rG;rG;rC;rC;rU;rG; U;rA;yrU;zdT;zdT$ rU;rC;zdT;zdT$ SERPINH1_51 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;rC2p;rA;m _S1671 G;rA;rC;rA;mC;rA;mU;rG; U;rG;rU;rG;mU;mC;rU;mC; rG;rG;mU;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERP1NH 1_51 zidB;rU;rC;rC;mU;rG;rA;r mU;rC;rA;mC;rC;LdC;rA;m S1672 G;rA;rC;rA;mC;rA;mU;rG; U;rG;rU;rG;mU;mC;rU;mC; rG;rG;mU;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ SERP1NH1_51 zidB;rU;mC;rC;mU;rG;rA; mU;rC;rA;mC;rC;rC2p;rA;m _S1681 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;rG;rU;mC;rU;mC;r ;rG;rG;mU;rG;rA;zc3p$ A;rG;rG;rA;zc3p;zc3p$ SERPINH1 51 zidB;rU;mC;rC ;mU;rG;rA; nU;rC;nA;rC;rC;rC2p;rA;m _S1683 rG;rA;rC;rA;mC;rA;mU;rG U;rG;rU;rG;mU;mC;rU;mC; ;rG;rG;mU;rG;rA;zc3p$ rA;rG;rG;rA;zc3p;zc3p$ 169 WO 2011/072082 PCT/US2010/059578 Table 7: Code of the modified nucleotides/unconventional moieties as used in the Tables herein. Code Description rA riboadenosine-3'-phosphate; 3'-adenylic acid rC ribocytidine-3'-phosphate; 3'-cytidylic acid rG riboguanosine-3'-phosphate; 3'-guanylic acid rU ribouridine-3'-phosphate; 3-uridylic acid mA 2'-O-methyladenosine-3'-phosphate; 2'-O-methyl-3'-adenylic acid mC 2'-O-methylcytidine-3'-phosphate; 2'-O-methyl-3'-cytidylic acid mG 2'-O-methylguanosine-3'-phosphate; 2'-O-methyl-3'-guanylic acid mU 2'-O-methyluridine-3'-phosphate; 2'-O-methyl-3'-uridylic acid dA deoxyriboadenosine-3'-phosphate; 2'-deoxyribo-3'-adenylic acid dC deoxyribocytidine-3'-phosphate; 2'-deoxyribo-3'-cytidylic acid dG deoxyriboguanosine-3'-phosphate; 2'-deoxyribo-3'-guanylic acid dT thymidine-3'-phosphate; 3'-thymidylic acid rA2p riboadenosine-2'-phosphate; 2'-adenylic acid (2'5' A) rC2p ribocytidine-2'-phosphate; 2'-cytidylic acid (2'5' C) rG2p riboguanosine-2'-phosphate; 2'-guanylic acid (2'5' G) rU2p ribouridine-2'-phosphate; 2'-uridylic acid (2'5'U) LdA L-deoxyriboadenosine-3'-phosphate (mirror image dA) LdC L-deoxyribocytidine-3'-phosphate (mirror image dC) LdG L-deoxyriboguanosine-3'-phosphate (mirror image dG) LdT L-deoxyribothymidine-3'-phosphate (mirror image dT) abasic deoxyribose-3'-phosphate; 1,2-dideoxy-D-ribofuranose-3 -phosphate; 1,4 dB 2-deoxy-D-ribitol-3 -phosphate zidB Inverted abasic deoxyribose-5'-phosphate; At 5'= 5'-5' idAb; At 3'= 3-3' idAb z Prefix to indicate moiety covalently attached to 3' terminus or 5' terminus psiU pseudouridne p 5' phosphate s 5' phosphorothioate C3 C3 non-nucleotide $ lacking a 3' linker (used together with above nucleotides at the 3' end of the sequence) 170 WO 2011/072082 PCT/US2010/059578 [0499] siRNA oligonucleotides useful in generating double stranded RNA molecules are disclosed in Tables A-18, A-19 and B-E below. SERPINHI oligonucleotide sequence useful in the preparation of siRNA compounds. Table A-18: Narne SEQ Sense (5' > 3') SEQ Antisense (5' > 3') Cross Ident Human ID ID Species gi"32454740 NO NO SEN AS SERPINHI 2 60 GAGACACAUGGGUGCUAUA 127 UAUAGCACCCAUGUGUCUC H, Rt, Rh, [1533-1551] 1_ 1_ M, D (18/19) SERPINH1_3 61 GGGAAGAUGCAGAAGAAGA 128 UCUUCUUCUGCAUCUUCCC H, Rt, Rh, [1112-1130] Rb (18/19) SERPINH1_5 62 GAAGAAGGCUGUUGCCAUA 129 UAUGGCAACAGCCUUCUUC H, Rt [1123-1141] (18/19) SERPINH1_6 63 ACAAGAUGCGAGACGAGUA 130 UACUCGUCUCGCAUCUUGU H, Rt, Rh, [1464-1482] 1_ __ 1(18/19) SERPINH1_7 64 GGACAACCGUGGCUUCAUA 131 UAUGAAGCCACGGUUGUCC H, Rb, M [886-904] (18/19) SERPTNH1_8 65 UGCAGUCCAUCAACGAGUA 132 UACUCGUUGAUGGACUGCA H, Rt, Rh, [738-756] M (18/19) SERPINH1_9 66 GCCUCAUCAUCCUCAUGCA 133 UGCAUGAGGAUGAUGAGGC H, Rt, Rh, [1026-1044] 1 1__ M, D (18/19) SERPINH1_10 67 CGCGCUGCAGUCCAUCAAA 134 UUUGAUGGACUGCAGCGCG H, Rt, Rh [733-751] (18/19) SERPINH1_11 68 CGGACAGGCCUCUACAACA 135 UGUUGUAGAGGCCUGUCCG H, Rt, Rh, [944-962] P (18/19) SERPINHI_13 69 UGACAAGAUGCGAGACGAA 136 UUCGUCUCGCAUCUUGUCA H, Rh [1462-1480] 1_ __ 1(18/19) SERPINH1_14 70 CCAGCCUCAUCAUCCUCAA 137 UUGAGGAUGAUGAGGCUGG H, M, Rt, [1023-1041] Rh, D- (18/19) SERPINH1_15 71 GCUGCAGUCCAUCAACGAA 138 UUCGUUGAUGGACUGCAGC H, Rt, Rh [736-754] (18/19) SERPINH1_16 72 GCAGCGCGCUGCAGUCCAA 139 UUGGACUGCAGCGCGCUGC H, Rt, Rh [729-747] (18/19) SERPINH1_17 73 UGAGACACAUGGGUGCUAA 140 AGCACCCAUGUGUCUCA H, Rt, Rh [1532-1550] 1 _ _M, D (18/19) SERPINH1_19 74 GGUGGAGGUGACCCAUGAA 141 UUCAUGGGUCACCUCCACC H, Rt, Rh, [1159-1177] M (18/19) SERPTNH1_20 75 CUUUGACCAGGACAUCUAA 142 UUAGAUGUCCUGGUCAAAG H, Rt, Rh [1324-1342] (18/19) SERPINH1_21 76 GGAGGUGACCCAUGACCUA 143 UAGGUCAUGGGUCACCUCC H, Rt, Rh, [1162-1180] 1 __ M, D (18/19) SERPINH1_22 77 CUCCUGAGACACAUGGGUA 144 UACCCAUGUGUCUCAGGAG H, D [1528-1546] (18/19) SERPINH1_23 78 AGAAGAAGGCUGUUGCCAA 145 UGGCAACAGCCUUCUUCU H, Rt [1122-1140] (18/19) SERPINHI_24 79 AGCUCUCCAGCCUCAUCAA 146 UUGAUGAGGCUGGAGAGCU H, Rt, D, [1017-1035] 1_ _M, P, Rh (18/19) SERPINH1_25 80 CUGCAGUCCAUCAACGAGA 147 UCUCGUUGAUGGACUGCAG H, Rt, Rh [737-755] M (18/19) SERPINH1_26 81 CCGGACAGGCCUCUACAAA 148 UUUGUAGAGGCCUGUCCGG H, Rt, Rh, [943-961] Rb, P (18/19) 171 WO 2011/072082 PCT/US2010/059578 SERPINH1_27 82 GCACCGGACAGGCCUCUAA 149 UUAGAGGCCUGUCCGGUGC H, Rt, Rh, [940-958] Rb, P (18/19) SERPINH1_28 83 GCAGAAGAAGGCUGUUGCA 150 UGCAACAGCCUUCUUCUGC H, Rt [1120-1138] (18/19) SERPINH1_31 84 AGAAGGCUGUUGCCAUCUA 151 UAGAUGGCAACAGCCUUCU H, Rt [1125-1143] 1_ __ 1(18/19) SERPINH1_32 85 AGCGCAGCGCGCUGCAGUA 152 UACUGCAGCGCGCUGCGCU H, Rt, Rh, [726-744] (18/19) SERPTNHI_33 86 GACACAUGGGUGCUAUUGA 153 UCAAUAGCACCCAUGUGUC H, Rt, Rh, [1535-1553] M (18/19)| SERPINH1_34 87 GGGCCUGACUGAGGCCAUA 154 UAUGGCCUCAGUCAGGCCC H, Rt [1201-1219] 1_ __ 1(18/19) SERPINH1_35 88 AGACACAUGGGUGCUAUUA 155 UAAUAGCACCCAUGUGUCU H, Rt, Rh, [1534-1552] M (18/19) SERPINH1_36 89 CCAUGACCUGCAGAAACAA 156 UUGUUUCUGCAGGUCAUGG H, Rt, Rh, [1171-1189] M (18/19) SERPINHI 37 90 AGAUGCAGAAGAAGGCUGA 157 UCAGCCUUCUUCUGCAUCU H, Rt, Rh, [1116-1134] 1_ ___M 1(18/19) SERPINH1_38 91 CAAGCUCUCCAGCCUCAUA 158 UAUGAGGCUGGAGAGCUUG H, Rt, Rh, [1015-1033] M, P, D (18/19) SERPINH1_39 92 UGCAGAAGAAGGCUGUUGA 159 UCAACAGCCUUCUUCUGCA H, Rt [1119-1137] (18/19) SERPINH1_41 93 CAGCCUCAUCAUCCUCAUA 160 UAUGAGGAUGAUGAGGCUG H, Rt, Rh, [1024-1042] M, D (18/19) SERPINH1_42 94 GACAGGCCUCUACAACUAA 161 AGUUGUAGAGGCCUGUC H, Rt, Rh, [946-964] 1_ __ 1Rb, P (18/19) SERPINH1_43 95 GAUGCAGAAGAAGGCUGUA 162 UACAGCCUUCUUCUGCAUC H, Rt, Rh, [1117-1135] M (18/19) SERPINH1_44 96 ACCCAUGACCUGCAGAAAA 163 UUUUCUGCAGGUCAUCiGGU H, Rt, Rh, [1169-1187] M (18/19) SERPINII_45 97 ACUCCAAGAUCAACUUCCA 164 UGGAAGUUGAUCUUGGAGU II, Rt, Rh, [702-720] 1_ 1iM, D (18/19) SERPINH1_45 98 ACUCCAAGAUCAACUUCCU 165 AGGAAGUUGAUCUUGGAGU H, Rt, Rh, [702-720] a _M, D (18/19) SERPINH1_48 99 AGGCCUCUACAACUACUAA 166 UUAGUAGUUGUAGAGGCCU H, Rt, Rh, [949-967] Rb, P, D (18/19) SERPINHI_49 100 CACUCCAAGAUCAACUUCA 167 UGAAGUUGAUCUUGGAGUG H, Rt, Rh, [701-719] 1_ __ 1M, D (18/19) SERPINHI_51 101 UCCUGAGACACAUGGGUGA 168 UCACCCAUGUGUCUCAGGA H, Rt, D, [1529-1547] M (18/19) SERPINH1_52 102 GACAAGAUGCGAGACGAGA 169 UCUCGUCUCGCAUCUUGUC H, Rt, Rh, [1463-1481] (18/19) SERPINH1_53 103 GGUGACCCAUGACCUGCAA 170 UUGCAGGUCAUGGGUCACC H, Rt, Rh, [1165-1183] M (18/19) SERPINH1_59 104 CCGAGGUGAAGAAACCUGA 171 CAGGUUUCUUCACCUCGG H, Rt, Rh, [285-303] 1 1_ 1(18/19) SERPINH1_51 105 UCCUGAGACACAUGGGUGU 172 ACACCCAUGUGUCUCAGGA H, Rt, D, [1529-1547] a _M (18/19) SERPTNH1_61 106 GCACUCCAAGAUCAACUUA 173 UAAGUUGAUCUUGGAGUGC H, Rh, D [700-718] (18/19) SERPINH1_62 107 GUGGUGGAGGUGACCCAUA 174 UAUGGGUCACCUCCACCAC H, Rt, Rh, [1157-1175] 1_ liM, Rb (18/19) SERPINII_64 108 GCCGAGGUGAAGAAACCUA 175 UAGGUUUCUUCACCUCGGC II, Rt, Rh, [284-302] (18/19) SERPINH1_65 109 GCUCUCCAGCCUCAUCAUA 176 UAUGAUGAGGCUGGAGAGC H, Rt, D, [1018-1036] M, P, Rh (18/19) SERPINHI_66 110 GAUGCACCGGACAGGCCUA 177 UAGGCCUGUCCGGUGCAUC H, Rt, Rh, [937-955] 1__ 1_ IM, Rb, P (18/19) 172 WO 2011/072082 PCT/US2010/059578 SERPINH1_68 111 CUCUCCAGCCUCAUCAUCA 178 UGAUGAUGAGGCUGGAGAG H, Rt, D, [1019-1037] M, P, Rh (18/19) SERPINH1_69 112 GCAGACCACCGACGGCAAA 179 UUUGCCGUCGGUGGUCUGC H, Rt, D [763-781] (18/19) SERPINH1_70 113 AGUCCAUCAACGAGUGGGA 180 UCCCACUCGUUGAUGGACU H, Rt, Rh, [741-759] 1_ __M 1 (18/19) SERPINH1_71 114 ACCGUGGCUUCAUGGUGAA 181 UUCACCAUGAAGCCACGGU H, Rt, Rh, [891-909] M (18/19) SERPTNH1_74 115 GAAGGCUGUUGCCAUCUCA 182 UGAGAUGGCAACAGCCUUC H, Rt, [1126-1144] (18/19) SERPINH1_75 116 GAAGAUGCAGAAGAAGGCA 183 UGCCUUCUUCUGCAUCUUC H, Rt, Rh, [1114-1132] 1_ 1 Rb (18/19) SERPINH1_77 117 UGAUGAUGCACCGGACAGA 184 UCUGUCCGGUGCAUCAUCA H, Rh, [933-951] (18/19) SERPINH1_78 118 CCCUUUGACCAGGACAUCA 185 UGAUGUCCUGGUCAAAGGG H, Rt, Rh, [1322-1340] (18/19) SERPINHI 80 119 CAGUCCAUCAACGAGUGGA 186 UCCACUCGUUGAUGGACUG H, Rt, Rh, [740-758] 1_ __M 1(18/19) SERPINH1_82 120 CAACCGUGGCUUCAUGGUA 187 UACCAUGAAGCCACGGUUG H, Rt, Rh, [889-907] M (18/19) SERPINH1_83 121 CGACAAGCGCAGCGCGCUA 188 UAGCGCGCUGCGCUUGUCG H [721-739] (18/19) SERPINH1_84 122 GCAGUCCAUCAACGAGUGA 189 UCACUCGUUGAUGGACUGC H, Rt, Rh, [739-757] M (18/19) SERPINH1_86 123 ACAGGCCUCUACAACUACA 190 GUAGUUGUAGAGGCCUGU H, Rt, Rh, [947-965] 1_ __ 1Rb, P, D (18/19) SERPINH1_87 124 AAGAUGCAGAAGAAGGCUA 191 UAGCCUUCUUCUGCAUCUU H, Rt, Rh, [1115-1133] M (18/19) SERPINH1_89 125 CAGCGCGCUGCAGUCCAUA 192 UAUGCACUGCAGCGCGCUG H, Rt, Rh, [730-748] (18/19) SERPINII_90 126 GCGCAGCGCGCUGCAGUCA 193 UGACUGCAGCGCGCUGCGC II, Rt, Rh, [727-745] 1__ 1_ 1 1 1(18/19) Table A-18 Select siRNAs siRNA SEQ ID SEQ ID Activity Activity Activity IC50 Length SEN AS 0.lnM 0.5nM 5nM (nM) SERPINHi 2 60 127 65 48 7 .008 19 SERPINHI_6 63 130 164 39 5 .019 19 SERPINHI_11 68 135 119 54 6 .05 19 SERPINHI_13 69 136 91 24 4 19 SERPINHI_45 97 164 156 38 8 .07 19 SERPINHI_45a 98 165 19 SERPINHI_51 101 168 68 39 5 .05 19 SERPINHI 52 102 169 149 37 9 0.06 19 SERPINH1 86 123 190 121 61 0.27 19 173 WO 2011/072082 PCT/US2010/059578 siRNA SEQ SEQ Activity Activity Activity Activity Activity Activity Activity ID ID 0.026nM 0.077nM 0.23nM 0.69nM 2.1nM 6.25nM 25 nM SEN AS SERPINHI 45 97 164 102 81 55 41 28 22 16 SERPINHI 45a 98 165 107 98 84 69 36 24 16 Table A-19: Name SEQ Sense (5' > 3') SEQ Antisense (5 ' > 3') Species L Ident ID ID Human gi NO NO 32454740 SEN AS SERPINH1I 194 GGACAGGCCUCUACAACUA 219 UAGUUGUAGAGGCCUGUCC H, Rt, Rh, 19 [945-963] 1_ 1 Rb, P (19/19) SERPINHI_4 195 GAGACACAUGGGUGCUAUU 220 AAUAGCACCCAUGUGUCUC H, Rt, Rh, 19 [1533-1551] M, D (19/19) SERPINH1_12 196 ACAAGAUGCGAGACGAGUU 221 AACUCGUCUCGCAUCUUGU H, Rt, Rh, 19 [1464-1482] (19/19) SERPINH1_18 197 CCUUUGACCAGGACAUCUA 222 UAGAUGUCCUGGUCAAAGG H, Rt, Rh, 19 [1323-1341] (19/19) SERPINHI_29 198 GACCCAUGACCUGCAGAAA 223 UUUCUGCAGGUCAUGGGUC H, Rt, Rh, 19 [1168-1186] 1 1 M (19/19) SERPINH1_30 199 CGCACAGGCCUCUACAACU 224 AGUUGUAGATGCCUCUCCG H, Rt, Rh, 19 [944-962] Rb, P (19/19) SERPINH1_40 200 ACCGGACAGGCCUCUACAA 225 UUGUAGAGGCCUGUCCGGU H, Rt, Rh, 19 [942-960] Rb, P, (19/19) SERPINH1_46 201 GCAGCGCGCUGCAGUCCAU 226 AUGGACUGCAGCGCGCUGC H, Rt, Rh, 19 [729-747] 1 1 '(19/19) SERPINH1_47 202 GCGCGCUGCAGUCCAUCAA 227 UUGAUGGACUGCAGCGCGC H, Rt, Rh, 19 [732-750] (19/19) SERPINHI_50 203 CUGAGACACAUGGGUGCUA 228 UAGCACCCAUGUGUCUCAG H, Rt, Rh, 19 [1531-1549] M, D (19/19) SERPINH1_54 204 ACAACAAGGCUCUUGCCAU 229 AUCTGCAACAGCCUUCUUCU H, Rt 19 [1122-1140] 1 1 '(19/19) SERPINHI_55 205 AGCUCUCCAGCCUCAUCAU 230 AUGAUGAGGCUGGAGAGCU H, Rt, D, 19 [1017-1035] M, P, Rh (19/19) SERPINH1_56 206 CUGCAGUCCAUCAACGAGU 231 ACUCGUUGAUGGACUGCAG H, Rt, Rh, 19 [737-755] M (19/19) SERPINH1_57 207 CGCUGCAGUCCAUCAACGA 232 UCGUUGAUGGACUGCAGCG H, Rt, Rh, 19 [735-753] 1__ _ 1(19/19) SERPINHI_58 208 GACAAGAUGCGAGACGAGU 233 ACUCGUCUCGCAUCUUGUC H, Rt, Rh, 19 [1463-1481] (19/19) SERPINH1_63 209 GGGCCUGACUGAGGCCAUU 234 AAUGGCCUCAGUCAGGCCC H, RL 19 [1201-1219] (19/19) SERPINH1_67 210 GAUGCAGAAGAAGGCUGUU 235 AACAGCCUUCUUCUGCAUC H, Rt, Rh, 19 [1117-1135] M (19/19) SERPINH1_72 211 CACCGGACAGGCCUCUACA 236 UGUAGAGGCCUGUCCGGUG H, Rt, Rh, 19 [941-959] 1_ 1 Rb, P (19/19) SERPINH1_73 212 AGAUGCAGAAGAAGGCUGU 237 ACAGCCUUCUUCUGCAUCU H, Rt, Rh 19 [1116-1134] M (19/19) SERPINHI_76 213 AGCGCGCUGCAGUCCAUCA 238 UGAUGGACUGCAGCGCGCU H, Rt, Rh 19 [731-749] (19/19) SERPINH1_79 214 GGAAGAUGCAGAAGAAGGC 239 GCCUUCUUCUGCAUCUUCC H, Rt, Rh, 19 [1113-1131] 1__ _ 1Rb (19/19) SERPINH1_81 215 GAAGAAGGCUGUUGCCAUC 240 GAUGGCAACAGCCUUCUUC H, Rt 19 [1123-1141] (19/19) SERPINH1_85 216 UGCAGUCCAUCAACGAGUG 241 CACUCGUUGAUGGACUGCA H, Rt, Rh, 19 [738-756] M (19/19) SERPINH1_88 217 CCUGAGACACAUGGGUGCU 242 AGCACCCAUGUGUCUCAGG H, Rt, D, 19 [1530-1548] 174 WO 2011/072082 PCT/US2010/059578 M (19/19) SERP1NH1_91 218 CGCAGCGCGCUGCAGUCCA 243 UGGACUGCAGCGCGCUGCG H, Rt, Rh, 19 [728-746] (19/19) Table A-19 Select siRNAs siRNA SEQ ID SEQ ID Activity Activity Activity IC50 (nM)Length NO SEN NO AS 0.1nM 0.5nM 5nM SERPINHI4 195 220 60 35 5 .006 19 SERPINHI 12 196 221 54 42 8 .065 19 SERPINHI18 197 222 139 43 9 19 SERPINHI_30 199 224 146 49 9 0.093 19 SERPINHI58 208 233 na na 8 19 SERPINHI88 217 242 105 43 9 19 Table B: Additional Active 19-mer SERPINH1 siRNAs No SEQ ID SEN Sense siRNA SEQ ID AS AntiSense siRNA Other human 1 244 GGCAGACUCUGGUCAAGAA 460 UUCUUGACCAGAGUCUGCC Rh [2009-2027] 2 245 CAGUGAGGCGGAUUGAGAA 461 UUCUCAAUCCGCCUCACUG [1967-1985] 3 246 AGCCUUUGUUGCUAUCAAU 462 AUUGAUAGCAACAAAGGCU Rh [2117-2135] 4 247 CCAUGUUCUUCAAGCCACA 463 UGUGGCUUGAAGAACAUGG Rh,Rb,D [837-855] 5 248 CCCUCUUCUGACACUAAAA 464 UUUUAGUGUCAGAAGAGGG [1850-1868] 6 249 CCUCAAUCAGUAUUCAUAU 465 AUAUGAAUACUTAUtUGAGG [1774-1792] 7 250 GAGACACAUGGGUGCUAUU 466 AAUAGCACCCAUGUGUCUC Rh,D,Rt,M [1533-1551] 8 251 GUGACAAGAUGCGAGACGA 467 UCGUCUCGCAUCUUGUCAC Rh [1461-1479] 9 252 GCCACACUGGGAUGAGAAA 468 UUUCUCAUCCCAGUGUGGC Rh,Rb,M [850-868] 10 253 AGAUGCGAGACGAGUUAUA 469 UAUAACUCGUCUCGCAUCU Rh [1467-1485] 11 254 ACGACGACGAGAAGGAAAA 470 UUUUCCUUCUCGUCGUCGU [966-984] 12 255 GCCUCUACAACUACUACGA 471 UCGUAGUAGUUGUAGAGGC Rb,D [951-969] 13 256 AiAUCAACUUCCGCGACAA 472 UUGUCGCGGAAGUUGAUCU D [708-726] 14 257 ACUACUACGACGACGAGAA 473 UUCUCGUCGUCGUAGUAGU Rb [960-978] 15 258 AGCCCUCUUCUGACACUAA 474 UUAGUGUCAGAAGAGGGCU [1848-1866] 16 259 ACAAGAUGCGAGACGAGUU 475 AACUCGUCUCGCAUCUUGU Rh,Rt [1464-1482] 17 260 AGCCACACUGGGAUGAGAA 476 UUCUCAUCCCAGUGUGGCU Rh,Rb,M [849-867] 18 261 AGGACCAGGCAGUGGAGAA 477 UUCUCCACUGCCUGGUCCU Rh [408-426] 19 262 CAGGCAAGAAGGACCUGUA 478 UACAGGUCCUUCUUGCCUG Rh,D [1251-1269] 20 263 ACCUGUGAGACCAAAUUGA 479 UCAAUUUGGUCUCACATGU Rh [1813-1831] 21 264 CUUUGUUGCUAUCAAUCCA 480 UGGAUUGAUAGCAACAAAG Rh [2120-2138] 22 265 GUGAGACCAAAUUGAGCUA 481 UAGCUCAAUUUGGUCUCAC Rh [1817-1835] 23 266 CCCUGAAAGUCCCAGAUCA 482 UGAUCUGGGACUUUCAGGG [1749-1767] 24 267 CCUUUGACCAGGACAUCUA 483 UAGAUGUCCUGGUCAAAGG Rh,Rt [1323-1341] 25 268 GACCAGGCAGUGGAGAACA 484 UGUUCUCCACUGCCUGGUC Rh [410-428] 26 269 CGCGCAACGUGACCUGGAA 485 UUCCAGGUCACGUUGCGCG M [597-615] 27 270 AUGAGAAAUUCCACCACAA 486 UUGUiGUGGAAUUUCUCAU Rh [861-879] 28 271 GAAGAAACCUGCAGCCGCA 487 UGCGGCUGCAGGUUUCUUC [292-310] 175 WO 2011/072082 PCT/US2010/059578 29 272 CUCUCGAGCGCCUUGAAAA 488 UUUUCAAGGCGCUCGAGAG [1059-1077] 30 273 GGAACAUGAGCCUUUGUUG 489 CAACAAAGGCUCAUGUUCC Rh [2109-2127] 31 274 CUCACCUGUGAGACCAAAU 490 AUUUGGUCUCACAGGUGAG Rh [1810-1828] 32 275 CUACGACGACGAGAAGGAA 491 UUCCUUCUCGUCGUCGUAG Rb [964-982] 33 276 ACCACAAGAUGGUGGACAA 492 UUGUCCACCAUCUUGUGGU Rh,Rb,M,P [873-891] 34 277 CUGGCACUGCGGAGAAGUU 493 AACUUCUCCGCAGIUGCCAG [318-336] 35 278 GGUCCUAUACCGUGGGUGU 494 ACACCCACGGUAUAGGACC Rh [912-930] 36 279 CCAACCUCUCCCAACUAUA 495 UAUAGUUGGGAGAGGUUGG Rh [1896-1914] 37 280 GAGAAGGAAAAGCUGCAAA 496 UUUGCAGCUUUUCCUUCUC Rh [974-992] 38 281 GCCUCUCGAGCGCCUUGAA 497 UUCAAGGCGCUCGAGAGGC [1057-1075] 39 282 AGGCCAUUGACAAGAACAA 498 UUGUUCUUGUCAAUGGCCU Rh,D [1212-1230] 40 283 GACCCAUGACCUGCAGAAA 499 UUUCUGCAGGUCAUGGGUC Rh,Rt,M [1168-1186] 41 284 CUCCUGGCACUGCGGAGAA 500 UUCUCCGCAGUGCCAGGAG [315-333] 42 285 CGGACAGGCCUCUACAACU 501 AGUUGUAGAGGCCUGUCCG Rh,Rb,Rt,P [944-962] 43 286 GAUGAGAAAUUCCACCACA 502 UGUGGUGGAAUUUCUCAUC Rh [860-878] 44 287 CACGCAUGUCAGGCAAGAA 503 UUCUUGCCUGACAUGCGUG Rh,D [1242-1260] 45 288 ACCUCUCCCAACUAUAAAA 504 UUUUAUAGUUGGGAGAGGU Rh [1899-1917] 46 289 ACCAGGCAGUGGAGAACAU 505 AUGUUCUCCACUGCCUGGU Rh [411-429] 47 290 GGGAACAUGAGCCUUUGUU 506 AACAAAGGCUCAUGUUCCC Rh [2108-2126] 48 291 AGAAUUCACUCCACUUGGA 507 UCCAAGUGGAGUGAAUUCU Rh [1653-1671] 49 292 GGGCAGACUCUGGUCAAGA 508 UCUUGACCAGAGUCUGCCC Rh [2008-2026] 50 293 AGAAGGAAAAGCUGCAAAU 509 AUUUGCAGCUUUUCCUUCU Rh [975-993] 51 294 GGCAGUGGAGAACAUCCUG 510 CAGGAUGUUCUCCACUGCC Rh [415-433] 52 295 GGGAUGAGAAAUUCCACCA 511 UGGUGGAAUUUCUCAUCCC Rh [858-876] 53 296 CCAAGCUGUUCUACGCCGA 512 UCGGCGUAGAACAGCUUGG Rh [1365-1383] 54 297 ACCGGACAGGCCUCUACAA 513 UUGUAGAGGCCUGUCCGGU Rh,Rb,Rt,P [942-960] 55 298 CUGCCUCAAUCAGUAUUCA 514 UGAAUACUGAUUGAGGCAG [1771-1789] 56 299 CAGCCCUCUUCUGACACUA 515 UAGUGUCAGAAGAGGGCUG [1847-1865] 57 300 CCAGCCUCAUCAUCCUCAU 516 AUGAGGAUGAUGAGGCUGG Rh,D,Rt,M [1023-1041] 58 301 AGGGUGACAAGAUGCGAGA 517 UCUCGCAUCUUGUCACCCU Rh,D [1458-1476] 59 302 GCiACCAGGCATUGCTAGAAC 518 GUUCUCCACUGCCUGCiUCC Rh [409-427] 60 303 GCAGCGCGCUGCAGUCCAU 519 AUGGACUGCAGCGCGCUGC Rh,Rt [729-747] 61 304 GCGCGCUGCAGUCCAUCAA 520 UUGAUGGACUGCAGCGCGC Rh,Rt [732-750] 62 305 CCAGAUACCAUGAUGCUGA 521 UCAGCAUCAUGGUAUCUGG Rh [1680-1698] 63 306 CUAGUGCGGGACACCCAAA 522 UUUGGGUGUCCCGCACUAG [1400-1418] 64 307 AGGCAGUGGAGAACAUCCU 523 AGGAUGUUCUCCACUGCCU Rh [414-432] 65 308 CUGAGACACAUGGGUGCUA 524 UAGCACCCAUGUGUCUCAG Rh,D,Rt,M [1531-1549] 66 309 GAUUGAGAAGGAGCUCCCA 525 UGGGAGCUCCUUCUCAAUC [1977-1995] 67 310 CGCAGACCACCGACGGCAA 526 UUGCCGUCGGUGGUCUGCG D,Rt [762-780] 68 311 CCACACUGGGAUGAGAAAU 527 AUUUCUCAUCCCAGUGUGG Rh [851-869] 69 312 GCUCAGUGAGCUUCGCUGA 528 UCAGCGAAGCUCACUGAGC [642-660] 70 313 CGCCUUUGAGUUGGACACA 529 UGUGUCCAACUCAAAGGCG Rh [1294-1312] 71 314 GGGUCAGCCAGCCCUCUUC 530 GAAGAGGGCUGGCUGACCC Rh [1839-1857] 72 315 GGGCUUCUGGGCAGACUCU 531 AGAGUCUGCCCAGAAGCCC Rh [2000-2018] 73 316 GCUACCUUCUCACCUGUGA 532 UCACAGGUGAGAAGGUACC Rh [1802-1820] 74 317 GCCUGCCUCAAUCAGUAUU 533 AAUACUGAUUGAGGCAGGC [1769-1787] 176 WO 2011/072082 PCT/US2010/059578 75 318 UCUACAACUACUACGACGA 534 UCGUCGUAGUAGUUGUAGA Rb [954-972] 76 319 GGGAAGAUGCAGAAGAAGG 535 CCUUCUUCUGCAUCUUCCC Rh,Rb,Rt [1112-1130] 77 320 CGAGAAGGAAAAGCUGCAA 536 UUGCAGCUUUUCCUUCUCG Rh [973-991] 78 321 AGAAGAAGGCUGUUGCCAU 537 AUGGCAACAGCCUUCUUCU Rt [1122-1140] 79 322 CACAAGCUCUCCAGCCUCA 538 UGAGGCUGGAGAGCUUGUG Rh,D,M,P [1013-1031] 80 323 GGGUGACAAGAUGCGAGAC 539 GUCUCGCAUCUUGUCACCC Rh,D [1459-1477] 81 324 UGUUGGAGCGUGGAAAAAA 540 UUUUUUCCACGCUCCAACA [2 190-2208] 82 325 CUUUGAGUUGGACACAGAU 541 AUCUGUGUCCAACUCAAAG Rh [1297-1315] 83 326 AGCUCUCCAGCCUCAUCAU 542 AUGAUGAGGCUGGAGAGCU Rh,D,Rt,M, [1017-1035] 84 327 AGCUGUUCUACGCCGACCA 543 UGGUCGGCGUAGAACAGCU Rh [1368-1386] 85 328 CUGCAGUCCAUCAACGAGU 544 ACUCGUUGAUGGACUGCAG Rh,Rt,M [737-755] 86 329 UACGACGACGAGAAGGAAA 545 UUUCCUUCUCGUCGUCGUA [965-983] 87 330 CCUAGUGCGGGACACCCAA 546 UUGGGUGUCCCGCACUAGG [1399-1417] 88 331 CUUCUCACCUGUGAGACCA 547 UGGUCUCACAGGUGAGAAG Rh [1807-1825] 89 332 AGUUGGACACAGAUGGCAA 548 UUGCCAUCUGUGUCCAACU [1302-1320] 90 333 CAGUGGAGAACAUCCUGGU 549 ACCAGGAUGUUCUCCACUG Rh [417-435] 91 334 CCAGCUAGAAUUCACUCCA 550 UGGAGUGAAUUCUAGCUGG Rh [1647-1665] 92 335 CGCUGCAGUCCAUCAACGA 551 UCGUUGAUGGACUGCAGCG Rh,Rt [735-753] 93 336 CCAAGGACCAGGCAGUGGA 552 UCCACUGCCUGGUCCUUGG Rh [405-423] 94 337 AGUUCUUCAAAGAUAGGGA 553 UCCCUAUCUUUGAAGAACU [2082-2100] 95 338 CGGACCUUCCCAGCUAGAA 554 UUCUAGCUGGGAAGGUCCG Rh [1638-1656] 96 339 GACAAGAUGCGAGACGAGU 555 ACUCGUCUCGCAUCUUGUC Rh,Rt [1463-1481] 97 340 CCAAGAUCAACUUCCGCGA 556 UCGCGGAAGUUGAUCUUGG D [705-723] 98 341 CCCAUCACGUGGAGCCUCU 557 AGAGGCUCCACGUGAUGGG Rh [1044-1062] 99 342 CCAUGAUGCUGAGCCCGGA 558 UCCGGGCUCAGCAUCAUGG [1687-1705] 100 343 AGCCUGCCUCAAUCAGUAU 559 AUACUGAUUGAGGCAGGCU [1768-1786] 101 344 CGGCCUAAGGGUGACAAGA 560 UCUUGUCACCCUUAGGCCG Rh [1451-1469] 102345 GGGCCUGACUGAGGCCAUU 561 AAUGGCCUCAGUCAGGCCC Rt [1201-1219] 103346 UCACCUGUGAGACCAAAUU 562 AAUUUGGUCUCACAGGUGA Rh [1811-1829] 104 347 GAGGCCAUUGACAAGAACA 563 UGUUCUUGUCAAUGGCCUC Rh,D [1211-1229] 105 348 GCUCCUGGCACUCGCiAGA 564 UCUCCGCAGUGCCAGGAGC [314-332] 106 349 GGCGCCUGGUCCGGCCUAA 565 UUAGGCCGGACCAGGCGCC Rh [1440-1458] 107 350 CCAGCCCUCUUCUGACACU 566 AGUGUCAGAAGAGGGCUGG [1846-1864] 108351 ACUACGACGACGAGAAGGA 567 UCCUUCUCGUCGUCGUAGU Rb [963-981] 109 352 CCUAUACCGUGGGUGUCAU 568 AUGACACCCACGGUAUAGG Rh,D,P [915-933] 1101353 GACCCAGCUCAGUGAGCUU 569 AAGCUCACUGAGCUGGGUC [636-654] 111 354 UGGGUGUCAUGAUGAUGCA 570 UGCAUCAUCAUGACACCCA Rh [924-942] 112355 CCAAGGGUGUGGUGGAGGU 571 ACCUCCACCACACCCUUGG Rh,D [1149-1167] 113 356 AGGUCACCAAGGACGUGGA 572 UCCACGUCCUUGGUGACCU Rh,D [789-807] 114 357 CCCUGGCCGCCGAGGUGAA 573 UUCACCUCGGCGGCCAGGG [276-294] 115 358 AGCACUCCAAGAUCAACUU 574 AAGUUGAUCUUGGAGUGCU Rh,D [699-717] 116 359 CCUGGCACUGCGGAGAAGU 575 ACUUCUCCGCAGUGCCAGG [317-335] 117360 GAUGCAGAAGAAGGCUGUU 576 AACAGCCUUCUUCUGCAUC Rh,Rt,M [1117-1135] 118 361 CCCACAAGCUCUCCAGCCU 577 AGGCUGGAGAGCUUGUGGG RhD,P [1011-1029] 119362 CUCUUCUGACACUAAAACA 578 UGUUUUAGUGUCAGAAGAG [1852-1870] 120 363 ACGAGAAGGAAAAGCUGCA 579 UGCAGCUUUUCCUUCUCGU Rh [972-990] 177 WO 2011/072082 PCT/US2010/059578 121364 UGAAAAGCUGCUAACCAAA 580 UUUGGUUAGCAGCUUUUCA [1072-1090] 122365 UCUCACCUGUGAGACCAAA 581 UUUGGUCUCACAGGUGAGA Rh [1809-1827] 123 366 CAUGAUGAUGCACCGGACA 582 UGUCCGGUGCAUCAUCAUG Rh [931-949] 124 367 GGAUUGAGAAGGAGCUCCC 583 GGGAGCUCCUUCUCAAUCC [1976-1994] 125 368 CCUUCAUCUUCCUAGUGCG 584 CGCACUAGGAAGAUGAAGG [1389-1407] 126369 GGCCUGGCCUUCAGCUUGU 585 ACAAGCUGAAGGCCAGGCC [374-392] 127 370 GGUCAGCCAGCCCUCUUCU 586 AGAAGAGGGCUGGCUGACC Rh [1840-1858] 128371 UUCUCACCUGUGAGACCAA 587 UUGGUCUCACAGGUGAGAA Rh [1808-1826] 129 372 CGCAGCAGCUCCUGGCACU 588 AGUGCCAGGAGCUGCUGCG [307-325] 130 373 GCCAUGUUCUUCAAGCCAC 589 GUGGCUUGAAGAACAUGGC Rh,Rb,D [836-854] 131 374 AGGCAGUGCUGAGCGCCGA 590 UCGGCGCUCAGCACUGCCU [510-528] 132375 CACCUGUGAGACCAAAUUG 591 CAAUUUGGUCUCACAGGUG Rh [1812-1830] 133 376 CACCGGACAGGCCUCUACA 592 UGUAGAGGCCUGUCCGGUG Rh,Rb,Rt,P [941-959] 134 377 AGCUAGAAUUCACUCCACU 593 AGUGGAGUGAAUUCUAGCU Rh [1649-1667] 1351378 AGAUGCAGAAGAAGGCUGU 594 ACAGCCUUCUUCUGCAUCU Rh,Rt,M [1116-1134] 136 379 CCCUGCUAGUCAACGCCAU 595 AUGGCGUUGACUAGCAGGG Rh [822-840] 137380 ACAACUACUACGACGACGA 596 UCGUCGUCGUAGUAGUUGU Rb [957-975] 138 381 GCUCCUGAGACACAUGGGU 597 ACCCAUGUGUCUCAGGAGC D [1527-1545] 139 382 UGGAGAACAUCCUGGUGUC 598 GACACCAGGAUGUUCUCCA Rh [420-438] 140 383 AGCGCGCUGCAGUCCAUCA 599 UGAUGGACUGCAGCGCGCU Rh,Rt [731-749] 141 384 CGCCUUGAAAAGCUGCUAA 600 UUAGCAGCUUUUCAAGGCG [1067-1085] 142385 GCCUUUGUUGCUAUCAAUC 601 GAUUGAUAGCAACAAAGGC Rh [2118-2136] 143386 CUCUACAACUACUACGACG 602 CGUCGUAGUAGUUGUAGAG Rb [953-971] 144 387 CGCUCACUCAGCAACUCCA 603 UGGAGUUGCUGAGUGAGCG Rh [575-593] 145388 GGUACCAGCCUUGGAUACU 604 AGUAUCCAAGGCUGGUACC Rh [1571-1589] 146 389 GCCUGACUGAGGCCAUUGA 605 UCAAUGGCCUCAGUCAGGC Rh [1203-1221] 147 390 UGAGCUUCGCUGAUGACUU 606 AAGUCAUCAGCGAAGCUCA Rh [648-666] 148391 CCAGCCUUGGAUACUCCAU 607 AUGGAGUAUCCAAGGCUGG Rh [1575-1593] 149392 AAAGGCUCCUGAGACACAU 608 AUGUGUCUCAGGAGCCUUU [1523-1541] 150 393 UGACCCAUGACCUGCAGAA 609 UUCUGCAGGUCAUGGGUCA Rh,Rt,M [1167-1185] 151 394 CCUGUGAGACCAAAUUCAG 610 CUCAAUUUGGUCUCACAGG Rh [1814-1832] 152395 GCGGACCUUCCCAGCUAGA 611 UCUAGCUGGGAAGGUCCGC Rh [1637-1655] 153 396 GGAAGAUGCAGAAGAAGGC 612 GCCUUCUUCUGCAUCUUCC Rh,Rb,Rt [1113-1131] 154 397 UGCCCAAGGGUGUGGUGGA 613 UCCACCACACCCUUGGGCA Rh,D [1146-1164] 155398 GGAGCCUCUCGAGCGCCUU 614 AAGGCGCUCGAGAGGCUCC [1054-1072] 1561399 GACUCUGGUCAAGAAGCAU 615 AUGCUUCUUGACCAGAGUC Rh [2013-2031] 157 400 CAGGCAGUGGAGAACAUCC 616 GGAUGUUCUCCACUGCCUG Rh [413-431] 158 401 CAAGCCUGCCUCAAUCAGU 617 ACUGAUUGAGGCAGGCUUG Rh [1766-1784] 159 402 CUGGAAGCUGGGCAGCCGA 618 UCGGCUGCCCAGCUUCCAG [610-628] 160 403 GAAGAAGGCUGUUGCCAUC 619 GAUGGCAACAGCCUUCUUC Rt [1123-1141] 161 404 GGGCGAGCUGCUGCGCUCA 620 UGAGCGCAGCAGCUCGCCC Rh [562-580] 162405 AAGCCACACUGGGAUGAGA 621 UCUCAUCCCAGUGUGGCUU Rh,Rb,M [848-866] 163 406 GUGUGGUGGAGGUGACCCA 622 UGGGUCACCUCCACCACAC Rh,D [1155-1173] 164 407 CCGCCUUUGAGUUGGACAC 623 GUGUCCAACUCAAAGGCGG Rh [1293-1311] 165408 GGCCAUUGACAAGAACAAG 624 CUUGUUCUUGUCAAUGGCC Rh,D [1213-1231] 166 409 UGCCUCAAUCAGUAUUCAU 625 AUGAAUACUGAUUGAGGCA [1772-1790] 178 WO 2011/072082 PCT/US2010/059578 167410 CCUUCCCAGCUAGAAUUCA 626 UGAAUUCUAGCUGGGAAGG Rh [1642-1660] 168 411 GGGACCUGGGCCAUAGUCA 627 UGACUAUGGCCCAGGUCCC [1721-1739] 169 412 CGAGGUGAAGAAACCUGCA 628 UGCAGGUUUCUUCACCUCG Rh [286-304] 170413 GCCUUUGAGUUGGACACAG 629 CUGUGUCCAACUCAAAGGC Rh [1295-1313] 1711414 AGCGGACCUUCCCAGCUAG 630 CUAGCUGGGAAGGUCCGCU Rh [1636-1654] 172415 CGCAUGUCAGGCAAGAAGG 631 CCUUCUUGCCUGACAUGCG Rh,D [1244-1262] 173 416 ACAACUGCGAGCACUCCAA 632 UUGGAGUGCUCGCAGUUGU Rh,D [690-708] 174417 GAGGCGGAUUGAGAAGGAG 633 CUCCUUCUCAAUCCGCCUC [1971-1989] 175 418 GGCCGCCGAGGUGAAGAAA 634 UUUCUUCACCUCGGCGGCC [280-298] 176 419 CAGCUCUAUCCCAACCUCU 635 AGAGGUUGGGAUAGAGCUG [1886-1904] 177420 AGCUGGGCAGCCGACUGUA 636 UACAGUCGGCUGCCCAGCU [615-633] 178 421 GCCAUUGACAAGAACAAGG 637 CCUUGUUCUUGUCAAUGGC Rh,D [1214-1232] 179 422 CGCCAUGUUCUUCAAGCCA 638 UGGCUUGAAGAACAUGGCG Rh,Rb,P [835-853] 180 423 CCGAGGUCACCAAGGACGU 639 ACGUCCUUGGUGACCUCGG Rh,D [786-804] 181 424 GGACCCAGCUCAGUGAGCU 640 AGCUCACUGAGCUGGGUCC [635-653] 182425 CCAAUGACAUUUUGUUGGA 641 UCCAACAAAAUGUCAUUGG [2178-2196] 183 426 AGUGAGGCGGAUUGAGAAG 642 CUUCUCAAUCCGCCUCACU [1968-1986] 184 427 UGCAGUCCAUCAACGAGUG 643 CACUCGUUGAUGGACUGCA Rh,Rt,M [738-756] 185 428 UGUCACGCAUGUCAGGCAA 644 UUGCCUGACAUGCGUGACA Rh,D [1239-1257] 186 429 CGACGACGAGAAGGAAAAG 645 CUUUUCCUUCUCGUCGUCG [967-985] 187 430 ACAAGAACAAGGCCGACUU 646 AAGUCGGCCUUGUUCUUGU Rh [1221-1239] 188431 CUUCAAGCCACACUGGGAU 647 AUCCCAGUGUGGCUUGAAG Rh,Rb,D [844-862] 189 432 CCUGGGCCAUAGUCAUUCU 648 AGAAUGACUAUGGCCCAGG [1725-1743] 190 433 UUUGUUGGAGCGUGGAAAA 649 UUUUCCACGCUCCAACAAA [2188-2206] 191 434 AGAACAUCCUGGUGUCACC 650 GGUGACACCAGGAUGUUCU [423-441] 192435 ACGCCACCGCCUUUGAGUU 651 AACUCAAAGGCGGUGGCGU Rh [1287-1305] 193 436 GUGAGGUACCAGCCUUGGA 652 UCCAAGGCUGGUACCUCAC Rh [1567-1585] 194437 GCGCCUUCUGCCUCCUGGA 653 UCCAGGAGGCAGAAGGCGC [252-270] 195438 GCCUGGCCUUCAGCUUGUA 654 UACAAGCUGAAGGCCAGGC [375-393] 196 439 CCCGGAAACUCCACAUCCU 655 AGGAUGUGGAGUUUCCGGG [1700-1718] 197 440 UCUUCAAGCCACACUGGGA 656 UCCCAGUGUGTCUUGAAGA Rh,Rb,D [843-861] 198 441 UGUUGCUAUCAAUCCAAGA 657 UCUUGGAUUGAUAGCAACA Rh [2123-2141] 199442 GAGUGGGCCGCGCAGACCA 658 UGGUCUGCGCGGCCCACUC [752-770] 200 443 CCUGAGACACAUGGGUGCU 659 AGCACCCAUGUGUCUCAGG D,Rt,M [1530-1548] 201 444 AGCCGACUGUACGGACCCA 660 UGGGUCCGUACAGUCGGCU [623-641] 2021445 GGGCCUCAGGGUGCACACA 661 UGUGUGCACCCUGAGGCCC [1486-1504] 203 446 ACUGGGAUGAGAAAUUCCA 662 UGGAAUUUCUCAUCCCAGU Rh [855-873] 204 447 AGAAUGACCUGGCCGCAGU 663 ACUGCGGCCAGGUCAUUCU [1952-1970] 205 448 CAUAUUUAUAGCCAGGUAC 664 GUACCUGGCUAUAAAUAUG Rh [1788-1806] 206 449 AGGUGACCCAUGACCUGCA 665 UGCAGGUCAUGGGUCACCU Rh,Rt,M [1164-1182] 207 450 GCGCUGCAGUCCAUCAACG 666 CGUUGAUGGACUGCAGCGC Rh,Rt [734-752] 208 451 GGUGACAAGAUGCGAGACG 667 CGUCUCGCAUCUUGUCACC Rh [1460-1478] 209 452 CUUCAAAGAUAGGGAGGGA 668 UCCCUCCCUAUCUUUGAAG [2086-2104] 210 453 AGCUGCAAAUCGUGGAGAU 669 AUCUCCACGAUUUGCAGCU Rh [984-1002] 211 454 GUGGAGAACAUCCUGGUGU 670 ACACCAGGAUGUUCUCCAC Rh [419-437] 2121455 GAACAAGGCCGACUUGUCA 671 UGACAAGUCGGCCUUGUUC Rh [1225-1243] 179 WO 2011/072082 PCT/US2010/059578 213456 CAUGAUGCUGAGCCCGGAA 672 UUCCGGGCUCAGCAUCAUG [1688-1706] 214457 GCGCCUUGAAAAGCUGCUA 673 UAGCAGCUUUUCAAGGCGC Rh [1066-1084] 215458 GCAGACUCUGGUCAAGAAG 674 CUUCUUGACCAGAGUCUGC Rh [2010-2028] 216 459 CCAGGCAGUGGAGAACAUC 675 GAUGUUCUCCACUGCCUGG Rh [412-430] Table C: Cross-Species 19-mer SERPINHI siRNAs No. SEQ ID SEN Sense siRNA SEQ ID AS AntiSense siRNA Other Species human 1 676 CACUACAACUGCGAGCACU 973 AGUGCUCGCAGUUGUAGUG Rh,D [686-704] 2 677 AACCGUGGCUUCAUGGUGA 974 UCACCAUGAAGCCACGGUU Rh,Rt,M [890-908] 3 678 GGCAAGAAGGACCUGUACC 975 GGUACAGGUCCUUCUUGCC Rh,D,M [1253 4 679 GGUGGACAACCGUGGCUUC 976 GAAGCCACGGUUGUCCACC Rh,M [883-901] 5 680 AGGCCAUGGCCAAGGACCA 977 UGGUCCUUGGCCAUGGCCU Rh,D [396-414] 6 681 CGCAGCGCGCUGCAGUCCA 978 UGGACUGCAGCGCGCUGCG Rh,Rt [728-746] 7 682 AGCAGCAAGCAGCACUACA 979 UGUAGUGCUGCUUGCUGCU Rh,D [674-692] 8 683 GGCCUCUACAACUACUACG 980 CGUAGUAGUUGUAGAGGCC Rb,D [950-968] 9 684 GAAGAUGCAGAAGAAGGCU 981 AGCCUUCUUCUGCAUCUUC Rh,Rb,Rt [1114 10 685 GGCUCCUGAGACACAUGGG 982 CCCAUGUGUCUCAGGAGCC D [1526 11 686 AGCAAGCAGCACUACAACU 983 AGUUGUAGUGCUGCUUGCU Rh,D [677-695] 12 687 GGAGGUGACCCAUGACCUG 984 CAGGUCAUGGGUCACCUCC Rh,Rt,M [1162 13 688 CCCUUUGACCAGGACAUCU 985 AGAUGUCCUGGUCAAAGGG Rh,Rt [1322 14 689 CUCCUGAGACACAUGGGUG 986 CACCCAUGUGUCUCAGGAG D [1528 15 690 AAGGCUCCUGAGACACAUG 987 CAUGUGUCUCAGGAGCCUU D [1524 16 691 CGCGCUGCAGUCCAUCAAC 988 GUUGAUGGACUGCAGCGCG Rh,Rt [733-751] 17 692 AGGGUGUGGUGGAGGUGAC 989 GUCACCUCCACCACACCCU Rh,D [1152 18 693 AGCACUACAACUGCGAGCA 990 UGCUCGCAGUUGUAGUGCU Rh,D [684-702] 19 694 GGCUCCCUGCUAUUCAUUG 991 CAAUGAAUAGCAGGGAGCC D [1421 20 695 GCGCGCAACGUGACCUGGA 992 UCCAGGUCACGUUGCGCGC M [596-614] 21 696 GCUGCAGUCCAUCAACGAG 993 CUCGUUGAUGGACUGCAGC Rh,Rt [736-754] 22 697 ACCAAAGAGCAGCUGAAGA 994 UCUUCAGCUGCUCUUUGGU Rh,Rb,P [1085 23 698 CCAAGGACGUGGAGCGCAC 995 GUGCGCUCCACGUCCUUGG Rh,D [795-813] 24 699 UGUUCUUCAAGCCACACUG 996 CAGUGUGGCUUGAAGAACA Rh,RbD [840-858] 25 700 GCCCAAGGGUGUGGUGGAG 997 CUCCACCACACCCUUGGGC Rh,D [1147 26 701 ACAGGCCUCUACAACUACU 998 AGUAGUUGUAGAGGCCUGU Rh,Rb,D,Rt,P [947-965] 27 702 UTCGCAGCAGCAAGCAGCA 999 UGCUGCUUGCUGCUGCCiCA Rh,D [669-687] 28 703 GGUGGAGGUGACCCAUGAC 1000 GUCAUGGGUCACCUCCACC Rh,Rt,M [1159 29 704 CUUUGACCAGGACAUCUAC 1001 GUAGAUGUCCUGGUCAAAG Rh,Rt [1324 30 705 AAGGGUGUGGUGGAGGUGA 1002 UCACCUCCACCACACCCUU Rh,D [1151 31 706 UCCUAUACCGUGGGUGUCA 1003 UGACACCCACGGUAUAGGA Rh,D,P [914-932] 32 707 GCGCAGACCACCGACGGCA 1004 UGCCGUCGGUGGUCUGCGC D [761-779] 33 708 CGCAGCAGCAAGCAGCACU 1005 AGUGCUGCUUGCUGCUGCG Rh,D [671-689] 34 709 GCCUCAUCAUCCUCAUGCC 1006 GGCAUGAGCTAUGAUGAGGC Rh,D,Rt,M [1026 35 710 UCUCCAGCCUCAUCAUCCU 1007 AGGAUGAUGAGGCUGGAGA Rh,D,Rt,M [1020 36 711 CCAUUGACAAGAACAAGGC 1008 GCCUUGUUCUUGUCAAUGG Rh,D [1215 37 712 GCAGCACUACAACUGCGA 1009 UCGCAGUUGUAGUGCUGCU Rh,D [681-699] 38 713 UGCACCGGACAGGCCUCUA 1010 UAGAGGCCUGUCCGGUGCA Rh,Rb,Rt,P [939-957] 180 WO 2011/072082 PCT/US2010/059578 39 714 ACUCCAAGAUCAACUUCCG 1011 CGGAAGUUGAUCUUGGAGU Rh,D,Rt,M [702-720] 40 715 UGGACAACCGUGGCUUCAU 1012 AUGAAGCCACGGUUGUCCA Rh,M [885-903] 41 716 GAGCAGCUGAAGAUCUGGA 1013 UCCAGAUCUUCAGCUGCUC Rh,D [1091 42 717 CAGAAGAAGGCUGUUGCCA 1014 UGGCAACAGCCUUCUUCUG Rt [1121 43 718 AGGCAAGAAGGACCUGUAC 1015 GUACAGGUCCUUCUUGCCU Rh,D [1252 44 719 CCUCUACAACUACUACGAC 1016 GUCGUAGUAGUUGUAGAGG Rb,D [952-970] 45 720 AGCAGCUGAAGAUCUGGAU 1017 AUCCAGAUCUUCAGCUGCU Rh,D [1092 46 721 AACUACUACGACGACGAGA 1018 UCUCGUCGUCGUAGUAGUU Rb [959-977] 47 722 GGCAAGCUGCCCGAGGUCA 1019 UGACCUCGGGCAGCUUGCC Rh,D [776-794] 48 723 CCGGACAGGCCUCUACAAC 1020 GUUGUAGAGGCCUGUCCGG Rh,Rb,Rt,P [943-961] 49 724 GCUCCCUGCUAUUCAUUGG 1021 CCAAUGAAUAGCAGGGAGC D [1422 50 725 AACUGCGAGCACUCCAAGA 1022 UCUUGGAGUGCUCGCAGUU Rh,D [692-710] 51 726 GACACAUGGGUGCUAUUGG 1023 CCAAUAGCACCCAUGUGUC Rh,Rt,M [1535 52 727 GCACCGGACAGGCCUCUAC 1024 GUAGAGGCCUGUCCGGUGC Rh,Rb,Rt,P [940-958] 53 728 AGCGCAGCGCGCUGCAGUC 1025 GACUGCAGCGCGCUGCGCU Rh,Rt [726-744] 54 729 GGACGUGGAGCGCACGGAC 1026 GUCCGUGCGCUCCACGUCC Rh,D [799-817] 55 730 CAGCCUCAUCAUCCUCAUG 1027 CAUGAGGAUGAUGAGGCUG Rh,D,Rt,M [1024 56 731 AAGAUCAACUUCCGCGACA 1028 UGUCGCGGAAGUUGAUCUU D [707-725] 57 732 GCGCAACGUGACCUGGAAG 1029 CUUCCAGGUCACGUUGCGC M [598-616] 58 733 ACUGCGAGCACUCCAAGAU 1030 AUCUUGGAGUGCUCGCAGU Rh,D [693-711] 59 734 GUGGACAACCGUGGCUUCA 1031 UGAAGCCACGGUUGUCCAC Rh,M [884-902] 60 735 CCACAAGCUCUCCAGCCUC 1032 GAGGCUGGAGAGCUUGUGG Rh,D,P [1012 61 736 CAAGAUGGUGGACAACCGU 1033 ACGGUUGUCCACCAUCUUG Rh,Rb,M,P [877-895] 62 737 CGAGCACUCCAAGAUCAAC 1034 GUUGAUCUUGGAGUGCUCG Rh,D [697-715] 63 738 AGCUGCCCGAGGUCACCAA 1035 UUGGUGACCUCGGGCAGCU Rh,D [780-798] 64 739 GGACAUCUACGGGCGCGAG 1036 CUCGCGCCCGUAGAUGUCC D [1333 65 740 AGGACAUCUACGGGCGCGA 1037 UCGCGCCCGUAGAUGUCCU D [1332 66 741 UGUCAGGCAAGAAGGACCU 1038 AGGUCCUUCUUGCCUGACA Rh,D [1248 67 742 GGGUGUGGUGGAGGUGACC 1039 GGUCACCUCCACCACACCC Rh,D [1153 68 743 CAAGCUCUCCAGCCUCAUC 1040 GAUGAGGCUGGAGAGCUUG Rh,D,MP [1015 69 744 GUGACCCAUGACCUGCAGA 1041 UCUGCAGGUCAUGGGUCAC Rh,Rt,M [1166 70 745 GUUCUUCAAGCCACACUGG 1042 CCAGUGUGGCUUGAAGAAC Rh,Rb,D [841-859] 71 746 ACAUCUACGGGCGCGAGGA 1043 UCCUCGCGCCCGUAGAUGU D,M [1335 72 747 UGGAGGUGACCCAUGACCU 1044 AGGUCAUGGGUCACCUCCA Rh,Rt,M [1161 73 748 UGCAGAAGAAGGCUGUUGC 1045 GCAACAGCCUUCUUCUGCA Rt [1119 74 749 UGUACCAGGCCAUGGCCAA 1046 UUGGCCAUGGCCUGGUACA Rh,D [390-408] 75 750 UGUGGUGGAGGUGACCCAU 1047 AUGGGUCACCUCCACCACA Rh,D [1156 76 751 AGAAGGACCUGUACCUGGC 1048 GCCAGGUACAGGUCCUUCU Rh,D [1257 77 752 AGCAGCUGCGCGACGAGGA 1049 UCCUCGUCGCGCAGCUGCU Rh,D [528-546] 78 753 ACGCCAUGUUCUUCAAGCC 1050 GGCUUGAAGAACAUGGCGU Rh,Rb,P [834-852] 79 754 ACAAGAUGGUGGACAACCG 1051 CGGUUGUCCACCAUCUUGU Rh,Rb,M,P [876-894] 80 755 CUGCGAGCACUCCAAGAUC 1052 GAUCUUGGAGUGCUCGCAG Rh,D [694-712] 81 756 GUCACGCAUGUCAGGCAAG 1053 CUUGCCUGACAUGCGUGAC Rh,D [1240 82 757 ACGCAUGUCAGGCAAGAAG 1054 CUUCUUGCCUGACAUGCGU Rh,D [1243 83 758 UGCUAUUCAUUGGGCGCCU 1055 AGGCGCCCAAUGAAUAGCA D [1428 84 759 UGCGCGACGAGGAGGUGCA 1056 UGCACCUCCUCGUCGCGCA Rh,D [534-552] 181 WO 2011/072082 PCT/US2010/059578 85 760 GCAGCUGAAGAUCUGGAUG 1057 CAUCCAGAUCUUCAGCUGC Rh,D [1093 86 761 CCAUGACCUGCAGAAACAC 1058 GUGUUUCUGCAGGUCAUGG Rh,Rt,M [1171 87 762 AAGCUCUCCAGCCUCAUCA 1059 UGAUGAGGCUGGAGAGCUU Rh,D,Rt,M,P [1016 88 763 CAGCAAGCAGCACUACAAC 1060 GUUGUAGUGCUGCUUGCUG Rh,D [676-694] 89 764 AUGUUCUUCAAGCCACACU 1061 AGUGUGGCUUGAAGAACAU Rh,Rb,D [839-857] 90 765 UCCUGAGACACAUGGGUGC 1062 GCACCCAUGUGUCUCAGGA D,Rt,M [1529 91 766 CACUCCAAGAUCAACUUCC 1063 GGAAGUUGAUCUUGGAGUG Rh,D,Rt,M [701-719] 92 767 AAGGGUGACAAGAUGCGAG 1064 CUCGCAUCUUGUCACCCUU Rh,D [1457 93 768 GACAGGCCUCUACAACUAC 1065 GUAGUUGUAGAGGCCUGUC Rh,Rb,Rt,P [946-964] 94 769 ACCCAUGACCUGCAGAAAC 1066 GUUUCUGCAGGUCAUGGGU Rh,Rt,M [1169 95 770 CACCACAAGAUGGUGGACA 1067 UGUCCACCAUCUUGUGGUG Rh,Rb,M,P [872-890] 96 771 GCAGAAGAAGGCUGUUGCC 1068 GGCAACAGCCUUCUUCUGC Rt [1120 97 772 GUGGUGGAGGUGACCCAUG 1069 CAUGGGUCACCUCCACCAC Rh,Rb,Rt,M [1157 98 773 AGGCCUCUACAACUACUAC 1070 GUAGUAGUUGUAGAGGCCU Rh,Rb,D,Rt,P [949-967] 99 774 GGUGACCCAUGACCUGCAG 1071 CUGCAGGUCAUGGGUCACC Rh,Rt,M [1165 100 775 GCCGAGGUGAAGAAACCUG 1072 CAGGUUUCUUCACCUCGGC Rh,Rt [284-302] 101 776 CAACUACUACGACGACGAG 1073 CUCGUCGUCGUAGUAGUUG Rb [958-976] 102777 CAAGAAGGACCUGUACCUG 1074 CAGGUACAGGUCCUUCUUG Rh,D,M [1255 103 778 UGUUCCACGCCACCGCCUU 1075 AAGGCGGUGGCGUGGAACA D [1281 1041779 CCCUGCUAUUCAUUGGGCG 1076 CGCCCAAUGAAUAGCAGGG D [1425 105 780 CCGUGGCUUCAUGGUGACU 1077 AGUCACCAUGAAGCCACGG Rh,Rt,M [892-910] 106781 CUACAACUACUACGACGAC 1078 GUCGUCGUAGUAGUUGUAG Rb [955-973] 107782 GCAGCACUACAACUGCGAG 1079 CUCGCAGUUGUAGUGCUGC Rh,D [682-700] 108 783 UGGUGGACAACCGUGGCUU 1080 AAGCCACGGUUGUCCACCA Rh,M [882-900] 109 784 AGACCACCGACGGCAAGCU 1081 AGCUUGCCGUCGGUGGUCU D,Rt [765-783] 110785 AGAAACACCUGGCUGGGCU 1082 AGCCCAGCCAGGUGUUUCU D [1182 111 786 ACCAAGGACGUGGAGCGCA 1083 UGCGCUCCACGUCCUUGGU Rh,D [794-812] 112787 CCGAGGUGAAGAAACCUGC 1084 GCAGGUUUCUUCACCUCGG Rh,Rt [285-303] 113788 ACUACAACUGCGAGCACUC 1085 GAGUGCUCGCAGUUGUAGU Rh,D [687-705] 1141789 ACAAGCUCUCCAGCCUCAU 1086 AUGAGGCUGGAGAGCUUGU Rh,D,M,P [1014 115790 AGCGACGUCTCAGCGCACGGA 1087 UCCGUGCCiCUCCACGUCCU Rh,D [798-816] 116791 GCUAUUCAUUGGGCGCCUG 1088 CAGGCGCCCAAUGAAUAGC D [1429 117792 AACUUCCGCGACAAGCGCA 1089 UGCGCUUGUCGCGGAAGUU D [713-731] 118 793 GCUCUCCAGCCUCAUCAUC 1090 GAUGAUGAGGCUGGAGAGC Rh,D,Rt,M,P [1018 119 794 AGAAGGCUGUUGCCAUCUC 1091 GAGAUGGCAACAGCCUUCU Rt [1125 120795 GGUCACCAAGGACGUGGAG 1092 CUCCACGUCCUUGGUGACC Rh,D [790-808] 121 796 AGCUGCGCGACGAGGAGGU 1093 ACCUCCUCGUCGCGCAGCU Rh,D [531-549] 122797 CCCGAGGUCACCAAGGACG 1094 CGUCCUUGGUGACCUCGGG Rh,D [785-803] 123 798 AUGUCAGGCAAGAAGGACC 1095 GGUCCUUCUUGCCUGACAU Rh,D [1247 124 799 CGAGGUCACCAAGGACGUG 1096 CACGUCCUUGGUGACCUCG Rh,D [787-805] 125800 GAUGCACCGGACAGGCCUC 1097 GAGGCCUGUCCGGUGCAUC Rh,Rb,Rt,M,P [937-955] 126 801 GCACUACAACUGCGAGCAC 1098 GUGCUCGCAGUUGUAGUGC Rh,D [685-703] 127802 CCACAAGAUGGUGGACAAC 1099 GUUGUCCACCAUCUUGUGG Rh,Rb,M,P [874-892] 128803 CAAGGGUGUGGUGGAGGUG 1100 CACCUCCACCACACCCUUG Rh,D [1150 1291804 AGCUGAAGAUCUGGAUGGG 1101 CCCAUCCAGAUCUUCAGCU RhD [1095 130 805 ACCAGGCCAUGGCCAAGGA 1102 UCCUUGGCCAUGGCCUGGU Rh,D [393-411] 182 WO 2011/072082 PCT/US2010/059578 131806 CAUGUUCUUCAAGCCACAC 1103 GUGUGGCUUGAAGAACAUG Rh,Rb,D [838-856] 132807 CAAGAUCAACUUCCGCGAC 1104 GUCGCGGAAGUUGAUCUUG D [706-724] 133 808 UCCAGCCUCAUCAUCCUCA 1105 UGAGGAUGAUGAGGCUGGA Rh,D,Rt,M [1022 134809 GCCCGAGGUCACCAAGGAC 1106 GUCCUUGGUGACCUCGGGC Rh,D [784-802] 135810 UCAAGCCACACUGGGAUGA 1107 UCAUCCCAGUGUGGCUUGA Rh,Rb [846-864] 136811 AGUCCAUCAACGAGUGGGC 1108 GCCCACUCGUUGAUGGACU Rh,Rt,M [741-759] 137812 GACUUCGUGCGCAGCAGCA 1109 UGCUGCUGCGCACGAAGUC Rh,D,M [662-680] 138813 CUCUCCAGCCUCAUCAUCC 1110 GGAUGAUGAGGCUGGAGAG Rh,D,Rt,M,P [1019 139814 GCAGACCACCGACGGCAAG 1111 CUUGCCGUCGGUGGUCUGC D,Rt [763-781] 140 815 AUGCAGAAGAAGGCUGUUG 1112 CAACAGCCUUCUUCUGCAU Rt [1118 141816 CAACCGUGGCUUCAUGGUG 1113 CACCAUGAAGCCACGGUUG Rh,Rt,M [889-907] 142817 UACUACGACGACGAGAAGG 1114 CCUUCUCGUCGUCGUAGUA Rb [962-980] 143 818 GAAGGCUGUUGCCAUCUCC 1115 GGAGAUGGCAACAGCCUUC Rt [1126 144 819 UCACCAAGGACGUGGAGCG 1116 CGCUCCACGUCCUUGGUGA Rh,D [792-810] 145820 CAGCUGAAGAUCUGGAUGG 1117 CCAUCCAGAUCUUCAGCUG Rh,D [1094 146 821 UGGGCCUGACUGAGGCCAU 1118 AUGGCCUCAGUCAGGCCCA Rt [1200 147 822 ACCGUGGCUUCAUGGUGAC 1119 GUCACCAUGAAGCCACGGU Rh,Rt,M [891-909] 148823 CAGUCCAUCAACGAGUGGG 1120 CCCACUCGUUGAUGGACUG Rh,Rt,M [740-758] 149 824 CCGACGGCAAGCUGCCCGA 1121 UCGGGCAGCUUGCCGUCGG D [771-789] 150 825 ACAAGCGCAGCGCGCUGCA 1122 UGCAGCGCGCUGCGCUUGU Rh,Rt [723-741] 151 826 GAAACACCUGGCUGGGCUG 1123 CAGCCCAGCCAGGUGUUUC D [1183 152827 AGGCUCCUGAGACACAUGG 1124 CCAUGUGUCUCAGGAGCCU D [1525 153 828 CAAGGACGUGGAGCGCACG 1125 CGUGCGCUCCACGUCCUUG Rh,D [796-814] 154 829 GCAGUCCAUCAACGAGUGG 1126 CCACUCGUUGAUGGACUGC Rh,Rt,M [739-757] 1551830 AGAUGGUGGACAACCGUGG 1127 CCACGGUUGUCCACCAUCU Rh,M [879-897] 156831 AAGCGCAGCGCGCUGCAGU 1128 ACUGCAGCGCGCUGCGCUU RhRt [725-743] 157832 CAUGUCAGGCAAGAAGGAC 1129 GUCCUUCUUGCCUGACAUG Rh,D [1246 158833 CAAGCCACACUGGGAUGAG 1130 CUCAUCCCAGUGUGGCUUG Rh,Rb [847-865] 159834 AAGAUGCAGAAGAAGGCUG 1131 CAGCCUUCUUCUGCAUCUU Rh,Rt,M [1115 160 835 GGCCAUGGCCAAGGACCAG 1132 CUGGUCCUUGGCCAUGGCC Rh,D [397-415] 161 836 GUGCGCAGCAGCAAGCAGC 1133 GCUGCUUGCUGCUGCGCAC Rh,D [668-686] 162837 CAACUGCGAGCACUCCAAG 1134 CUUGGAGUGCUCGCAGUUG Rh,D [691-709] 163 838 UACAACUGCGAGCACUCCA 1135 UGGAGUGCUCGCAGUUGUA Rh,D [689-707] 164839 CAUUGACAAGAACAAGGCC 1136 GGCCUUGUUCUUGUCAAUG Rh,D [1216 165 840 CAAGCAGCACUACAACUGC 1137 GCAGUUGUAGUGCUGCUUG Rh,D [679-697] 166841 GUGUUCCACGCCACCGCCU 1138 AGGCGGUGGCGUGGAACAC D [1280 167842 CCUGCUAUUCAUUGGGCGC 1139 GCGCCCAAUGAAUAGCAGG D [1426 168843 GCCCACAAGCUCUCCAGCC 1140 GGCUGGAGAGCUUGUGGGC Rh,DP [1010 169844 CAGCAGCAAGCAGCACUAC 1141 GUAGUGCUGCUUGCUGCUG Rh,D [673-691] 170 845 UGAUGCACCGGACAGGCCU 1142 AGGCCUGUCCGGUGCAUCA Rh,Rb,Rt,M,P [936-954] 171 846 UCAACUUCCGCGACAAGCG 1143 CGCUUGUCGCGGAAGUUGA D [711-729] 172847 UCAGGCAAGAAGGACCUGU 1144 ACAGGUCCUUCUUGCCUGA Rh,D [1250 173848 ACUUCGUGCGCAGCAGCAA 1145 UUGCUGCUGCGCACGAAGU Rh,D,M [663-681] 174849 ACAACCGUGGCUUCAUGGU 1146 ACCAUGAAGCCACGGUUGU Rh,Rt,M [888-906] 1751850 AAGGCUGUUGCCAUCUCCU 1147 AGGAGAUGGCAACAGCCUU D,Rt [1127 176 851 GCAGCUGCGCGACGAGGAG 1148 CUCCUCGUCGCGCAGCUGC Rh,D [529-547] 183 WO 2011/072082 PCT/US2010/059578 177852 UAUUCAUUGGGCGCCUGGU 1149 ACCAGGCGCCCAAUGAAUA D [1431 178 853 UCCACCACAAGAUGGUGGA 1150 UCCACCAUCUUGUGGUGGA Rh,Rb,D,P [870-888] 179 854 CCCUGGCCCACAAGCUCUC 1151 GAGAGCUUGUGGGCCAGGG Rh,D,P [1005 180 855 ACCAGGACAUCUACGGGCG 1152 CGCCCGUAGAUGUCCUGGU D,Rt [1329 1811856 GAUGAUGCACCGGACAGGC 1153 GCCUGUCCGGUGCAUCAUC Rh,Rb,Rt,M [934-952] 182857 CAACGCCAUCjUUCUUCAAG 1154 CUUGAAGAACAUGGCGUUG Rh,Rb,P [832-850] 183 858 ACGGCAAGCUGCCCGAGGU 1155 ACCUCGGGCAGCUUGCCGU Rh,D [774-792] 184859 CAGCGCGCUGCAGUCCAUC 1156 GAUGGACUGCAGCGCGCUG Rh,Rt [730-748] 185 860 CCCAAGGGUGUGGUGGAGG 1157 CCUCCACCACACCCUUGGG Rh,D [1148 186 861 CAUGGCCAAGGACCAGGCA 1158 UGCCUGGUCCUUGGCCAUG Rh,D [400-418] 187 862 CUCCAGCCUCAUCAUCCUC 1159 GAGGAUGAUGAGGCUGGAG Rh,D,Rt,M [1021 188863 UCUACGGGCGCGAGGAGCU 1160 AGCUCCUCGCGCCCGUAGA D,M [1338 189864 GGCCCACAAGCUCUCCAGC 1161 GCUGGAGAGCUUGUGGGCC Rh,D,P [1009 190 865 GUCAGGCAAGAAGGACCUG 1162 CAGGUCCUUCUUGCCUGAC Rh,D [1249 191866 CAUCUACGGGCGCGAGGAG 1163 CUCCUCGCGCCCGUAGAUG D,M [1336 192867 CGUGCGCAGCAGCAAGCAG 1164 CUGCUUGCUGCUGCGCACG Rh,D,M [667-685] 193 868 AGCCUCAUCAUCCUCAUGC 1165 GCAUGAGGAUGAUGAGGCU Rh,D,Rt,M [1025 194869 UUCAAGCCACACUGGGAUG 1166 CAUCCCAGUGUGGCUUGAA Rh,Rb [845-863] 195 870 AAGAAGGCUGUUGCCAUCU 1167 AGAUGGCAACAGCCUUCUU Rt [1124 196 871 GGUGUGGUGGAGGUGACCC 1168 GGGUCACCUCCACCACACC Rh,D [1154 197 872 GAGGUGACCCAUGACCUGC 1169 GCAGGUCAUGGGUCACCUC Rh,Rt,M [1163 198873 GUGGAGGUGACCCAUGACC 1170 GGUCAUGGGUCACCUCCAC Rh,Rt,M [1160 199 874 CACAAGAUGGUGGACAACC 1171 GGUUGUCCACCAUCUUGUG Rh,Rb,M,P [875-893] 200 875 CUGGCCCACAAGCUCUCCA 1172 UGGAGAGCUUGUGGGCCAG Rh,D,P [1007 201876 GAUGACUUCGUGCGCAGCA 1173 UGCUGCGCACGAAGUCAUC Rh,Rt,M [659-677] 2021877 ACUUCCGCGACAAGCGCAG 1174 CUGCGCUUGUCGCGGAAGU D [714-732] 203 878 AACGCCAUGUUCUUCAAGC 1175 GCUUGAAGAACAUGGCGUU Rh,Rb,P [833-851] 204879 GGACCUGUACCUGGCCAGC 1176 GCUGGCCAGGUACAGGUCC Rh,D [1261 205880 GCGACGAGGAGGUGCACGC 1177 GCGUGCACCUCCUCGUCGC D [537-555] 206881 GCAAGCUGCCCGAGGUCAC 1178 GUGACCUCGGGCAGCUUGC Rh,D [777-795] 207882 AUUCAUUGCTGCGCCUGTUC 1179 GACCAGGCGCCCAAUGAAU D [1432 208 883 GAGGUCACCAAGGACGUGG 1180 CCACGUCCUUGGUGACCUC Rh,D [788-806] 209884 AAGAAGGACCUGUACCUGG 1181 CCAGGUACAGGUCCUUCUU Rh,D [1256 210 885 GACAACCGUGGCUUCAUGG 1182 CCAUGAAGCCACGGUUGUC Rh,Rt,M [887-905] 211886 CUGGGCCUGACUGAGGCCA 1183 UGGCCUCAGUCAGGCCCAG Rt [1199 2121887 CUCCAAGAUCAACUUCCGC 1184 GCGGAAGUUGAUCUUGGAG Rh,D,Rt,M [703-721] 213 888 CAACUUCCGCGACAAGCGC 1185 GCGCUUGUCGCGGAAGUUG D [712-730] 214889 CUCCCUGCUAUUCAUUGGG 1186 CCCAAUGAAUAGCAGGGAG D [1423 215890 AAGCAGCACUACAACUGCG 1187 CGCAGUUGUAGUGCUGCUU Rh,D [680-698] 216 891 GCGCAGCAGCAAGCAGCAC 1188 GUGCUGCUUGCUGCUGCGC Rh,D [670-688] 2171892 CAGGCCAUGGCCAAGGACC 1189 GGUCCUUGGCCAUGGCCUG Rh,D [395-413] 218 893 GUACCAGGCCAUGGCCAAG 1190 CUUGGCCAUGGCCUGGUAC RhD [391-409] 219894 CUUCGUGCGCAGCAGCAAG 1191 CUUGCUGCUGCGCACGAAG Rh,D,M [664-682] 220 895 CAGCACUACAACUGCGAGC 1192 GCUCGCAGUUGUAGUGCUG Rh,D [683-701] 221 896 UACAACUACUACGACGACG 1193 CGUCiUCGCGUAGUAGUUGUA Rb [956-974] 2221897 GAUGGUGGACAACCGUGGC 1194 GCCACGGUUGUCCACCAUC Rh,M [880-898] 184 WO 2011/072082 PCT/US2010/059578 223898 CUACAACUGCGAGCACUCC 1195 GGAGUGCUCGCAGUUGUAG Rh,D [688-706] 224899 AAGGACCUGUACCUGGCCA 1196 UGGCCAGGUACAGGUCCUU Rh,D [1259 225 900 GCUGCCCGAGGUCACCAAG 1197 CUUGGUGACCUCGGGCAGC Rh,D [781-799] 226901 GACAUCUACGGGCGCGAGG 1198 CCUCGCGCCCGUAGAUGUC D,M [1334 227 902 CCACCACAAGAUGGUGGAC 1199 GUCCACCAUCUUGUGGUGG Rh,Rb,D,P [871-889] 228903 GCGCGACGAGGAGGUGCAC 1200 GUGCACCUCCUCGUCGCGC Rh,D [535-553] 229 904 CUAUUCAUUGGGCGCCUGG 1201 CCAGGCGCCCAAUGAAUAG D [1430 230 905 CCAGGACAUCUACGGGCGC 1202 GCGCCCGUAGAUGUCCUGG D,Rt [1330 231 906 AAGAUGGUGGACAACCGUG 1203 CACGGUUGUCCACCAUCUU Rh,M [878-896] 232907 CAGGACAUCUACGGGCGCG 1204 CGCGCCCGUAGAUGUCCUG D [1331 233 908 UCCAAGAUCAACUUCCGCG 1205 CGCGGAAGUUGAUCUUGGA D [704-722] 234 909 GUCACCAAGGACGUGGAGC 1206 GCUCCACGUCCUUGGUGAC Rh,D [791-809] 235 910 CUGCCCGAGGUCACCAAGG 1207 CCUUGGUGACCUCGGGCAG Rh,D [782-800] 236911 GACCAGGACAUCUACGGGC 1208 GCCCGUAGAUGUCCUGGUC D,Rt [1328 2371912 CCAUGGCCAAGGACCAGGC 1209 GCCUGGUCCUUGGCCAUGG Rh,D [399-417] 238913 CACCAAGGACGUGGAGCGC 1210 GCGCUCCACGUCCUUGGUG Rh,D [793-811] 239 914 GACAAGCGCAGCGCGCUGC 1211 GCAGCGCGCUGCGCUUGUC Rh,Rt [722-740] 240915 CAAGCGCAGCGCGCUGCAG 1212 CUGCAGCGCGCUGCGCUUG Rh,Rt [724-742] 241 916 CAGACCACCGACGGCAAGC 1213 GCUUGCCGUCGGUGGUCUG D,Rt [764-782] 2421917 GACCACCGACGGCAAGCUG 1214 CAGCUUGCCGUCGGUGGUC D,Rt [766-784] 243 918 AGGACCUGUACCUGGCCAG 1215 CUGGCCAGGUACAGGUCCU Rh,D [1260 244919 CUGCUAUUCAUUGGGCGCC 1216 GGCGCCCAAUGAAUAGCAG D [1427 245 920 UCAUUGGGCGCCUGGUCCG 1217 CGGACCAGGCGCCCAAUGA Rh,D [1434 246 921 GCUGCGCGACGAGGAGGUG 1218 CACCUCCUCGUCGCGCAGC RhD [532-550] 2471922 CGGCAAGCUGCCCGAGGUC 1219 GACCUCGGGCAGCUUGCCG Rh,D [775-793] 248 923 CCUCAUCAUCCUCAUGCCC 1220 GGGCAUGAGGAUGAUGAGG Rh,D,Rt,M [1027 249 924 CCAGGCCAUGGCCAAGGAC 1221 GUCCUUGGCCAUGGCCUGG Rh,D [394-412] 250 925 GCCAUGGCCAAGGACCAGG 1222 CCUGGUCCUUGGCCAUGGC Rh,D [398-416] 251 926 CCACCGACGGCAAGCUGCC 1223 GGCAGCUUGCCGUCGGUGG D,Rt [768-786] 2521927 AUGGUGGACAACCGUGGCU 1224 AGCCACGGUUGUCCACCAU Rh,M [881-899] 253 928 CUUCCGCCiACAAGCGCAGC 1225 GCUGCGCUUGUCGCGGAAG D [715-733] 254 929 CGCGACGAGGAGGUGCACG 1226 CGUGCACCUCCUCGUCGCG Rh,D [536-554] 255 930 UGGCCCACAAGCUCUCCAG 1227 CUGGAGAGCUUGUGGGCCA Rh,D,P [1008 256 931 GAGCAGCUGCGCGACGAGG 1228 CCUCGUCGCGCAGCUGCUC Rh,D [527-545] 2571932 UGACCAGGACAUCUACGGG 1229 CCCGUAGAUGUCCUGGUCA Rt [1327 258 933 ACCACCGACGGCAAGCUGC 1230 GCAGCUUGCCGUCGGUGGU D,Rt [767-785] 259 934 GAAGGACCUGUACCUGGCC 1231 GGCCAGGUACAGGUCCUUC Rh,D [1258 260935 CAUUGGGCGCCUGGUCCGG 1232 CCGGACCAGGCGCCCAAUG Rh,D [1435 261 936 AUGCACCGGACAGGCCUCU 1233 AGAGGCCUGUCCGGUGCAU Rh,Rb,Rt,P [938-956] 2621937 AUCAACUUCCGCGACAAGC 1234 GCUUGUCGCGGAAGUUGAU D [710-728] 263 938 CAGCUGCGCGACGAGGAGG 1235 CCUCCUCGUCGCGCAGCUG Rh,D [530-548] 264 939 CAGAAACACCUGGCUGGGC 1236 GCCCAGCCAGGUGUUUCUG D [1181 265 940 CUACGGGCGCGAGGAGCUG 1237 CAGCUCCUCGCGCCCGUAG D,M [1339 266 941 CGACGAGGAGGUGCACGCC 1238 GGCGUGCACCUCCUCGUCG D [538-556] 267942 UUUGACCAGGACAUCUACG 1239 CGUAGAUGUCCUGGUCAAA Rt [1325 268 943 GUCCAUCAACGAGUGGGCC 1240 GGCCCACUCGUUGAUGGAC Rh,Rt,M [742-760] 185 WO 2011/072082 PCT/US2010/059578 269944 AUGACUUCGUGCGCAGCAG 1241 CUGCUGCGCACGAAGUCAU Rh,Rt,M [660-678] 270 945 UCCCUGCUAUUCAUUGGGC 1242 GCCCAAUGAAUAGCAGGGA D [1424 271 946 CUGCGCGACGAGGAGGUGC 1243 GCACCUCCUCGUCGCGCAG Rh,D [533-551] 272947 CAAGCUGCCCGAGGUCACC 1244 GGUGACCUCGGGCAGCUUG Rh,D [778-796] 273 948 AAGCUGCCCGAGGUCACCA 1245 UGGUGACCUCGGGCAGCUU Rh,D [779-797] 274949 UCUUCAAGCCACACUGGG 1246 CCCACUGUGGCUUGAAGAA Rh,Rb,D [842-860] 275 950 ACACCUGGCUGGGCUGGGC 1247 GCCCAGCCCAGCCAGGUGU D [1186 276 951 UCCAUCAACGAGUGGGCCG 1248 CGGCCCACUCGUUGAUGGA Rt,M [743-761] 277 952 AUCUACGGGCGCGAGGAGC 1249 GCUCCUCGCGCCCGUAGAU D,M [1337 278 953 UCGUGCGCAGCAGCAAGCA 1250 UGCUUGCUGCUGCGCACGA Rh,D,M [666-684] 279 954 CGACGGCAAGCUGCCCGAG 1251 CUCGGGCAGCUUGCCGUCG D [772-790] 280 955 UUCAUUGGGCGCCUGGUCC 1252 GGACCAGGCGCCCAAUGAA Rh,D [1433 281 956 UUGACCAGGACAUCUACGG 1253 CCGUAGAUGUCCUGGUCAA Rt [1326 282957 CCUGGCCCACAAGCUCUCC 1254 GGAGAGCUUGUGGGCCAGG Rh,D,P [1006 283 958 UGACUUCGUGCGCAGCAGC 1255 GCUGCUGCGCACGAAGUCA Rh,Rt,M [661-679] 284 959 AUGAUGCACCGGACAGGCC 1256 GGCCUGUCCGGUGCAUCAU Rh,Rb,Rt,M,P [935-953] 285 960 CACCGACGGCAAGCUGCCC 1257 GGGCAGCUUGCCGUCGGUG D,Rt [769-787] 286 961 GACGGCAAGCUGCCCGAGG 1258 CCUCGGGCAGCUUGCCGUC Rh,D [773-791] 287 962 UACCAGGCCAUGGCCAAGG 1259 CCUUGGCCAUGGCCUGGUA Rh,D [392-410] 288 963 UCCGCGACAAGCGCAGCGC 1260 GCGCUGCGCUUGUCGCGGA D [717-735] 289 964 UUCCGCGACAAGCGCAGCG 1261 CGCUGCGCUUGUCGCGGAA D [716-734] 290 965 AAGGACGUGGAGCGCACGG 1262 CCGUGCGCUCCACGUCCUU Rh,D [797-815] 291 966 UUCCACCACAAGAUGGUGG 1263 CCACCAUCUUGUGGUGGAA Rh,Rb,D,P [869-887] 292967 UACGGGCGCGAGGAGCUGC 1264 GCAGCUCCUCGCGCCCGUA D,M [1340 293 968 AAACACCUGGCUGGGCUGG 1265 CCAGCCCAGCCAGGUGUUU D [1184 294 969 AACACCUGGCUGGGCUGGG 1266 CCCAGCCCAGCCAGGUGUU D [1185 295 970 AUUGGGCGCCUGGUCCGGC 1267 GCCGGACCAGGCGCCCAAU Rh,D [1436 296 971 ACCGACGGCAAGCUGCCCG 1268 CGGGCAGCUUGCCGUCGGU D [770-788] 297972 UUCGUGCGCAGCAGCAAGC 1269 GCUUGCUGCUGCGCACGAA Rh,D,M [665-683] Table D: SERPINHlI Active 18+1-mer siRNAs No SEQ ID Sense siRNA SEQ ID AntiSense siRNA Other Sp human 1 1270 AGCCUUUGUUGCUAUCAAA 1849 UUUGAUAGCAACAAAGGCU Rh [2117-2135] 2 1271 GCCUAAGGGUGACAAGAUA 1850 UAUCUUGUCACCCUUAGGC Rh [1453-1471] 3 1272 GGCCUAAGGGUGACAAGAA 1851 UUCUUGUCACCCUUAGGCC Rh [1452-1470] 4 1273 CCUCAAUCAGUAUUCAUAA 1852 UUAUGAAUACUGAUUGAG [1774-1792] 5 1274 GGCGGAUUGAGAAGGAGCA 1853 UGCUCCUUCUCAAUCCGCC [1973-1991] 6 1275 GGCAGUGGAGAACAUCCUA 1854 UAGGAUGUUCUCCACUGCC Rh [415-433] 7 1276 GGGUCAGCCAGCCCUCUUA 1855 UAAGAGGGCUGGCUGACCC Rh [1839-1857] 8 1277 GGGUGACAAGAUGCGAGAA 1856 UUCUCGCAUCUUGUCACCC Rh,D [1459-1477] 9 1278 GGACCAGGCAGUGGAGAAA 1857 UUUCUCCACUGCCUGGUCC Rh [409-427] 10 1279 GAGACACAUGGGUGCUAUA 1858 UAUAGCACCCAUGUGUCUC Rh,D,Rt, [1533-1551] 186 WO 2011/072082 PCT/US2010/059578 11 1280 GUUGGAGCGUGGAAAAAAA 1859 UUUUUUUCCACGCUCCAAC [2191-2208] 12 1281 GGAACAUGAGCCUUUGUUA 1860 UAACAAAGGCUCAUGUUCC Rh [2109-2127] 13 1282 GCCAUGUUCUUCAAGCCAA 1861 UUGGCUUGAAGAACAUGGC Rh,Rb,D [836-854] 14 1283 GGAUUGAGAAGGAGCUCCA 1862 UGGAGCUCCUUCUCAAUCC [1976-1994] 15 1284 GGGAUGAACUUUUUGUUUA 1863 UAAACAAAAAGUUCAUCCC Rh [2048-2066] 16 1285 GCCGCAGUGAGGCGGAUUA 1864 UAAUCCGCCUCACUGCGGC [1963-1981] 17 1286 GGACCUUCCCAGCUAGAAA 1865 UUUCUAGCUGGGAAGGUCC Rh [1639-1657] 18 1287 GACCUUCCCAGCUAGAAUA 1866 UAUUCUAGCUGGGAAGGUCRh [1640-1658] 191288 CCUGUGAGACCAAAUUGAA 1867 UUCAAUUUGGUCUCACAGG Rh [1814-1832] 20 1289 UGGAGAACAUCCUGGUGUA 1868 UACACCAGGAUGUUCUCCA Rh [420-438] 21 1290 GCCUUUGUUGCUAUCAAUA 1869 UAUUGAUAGCAACAAAGGC Rh [2118-2136] 22 1291 CCGCCUUUGAGUUGGACAA 1870 UUGUCCAACUCAAAGGCGG Rh [1293-1311] 23 1292 CAGGCAGUGGAGAACAUCA 1871 UGAUGUUCUCCACUGCCUG Rh [413-431] 24 1293 CACCUGUGAGACCAAAUUA 1872 UAAUUUGGUCUCACAGGUG Rh [1812-1830] 25 1294 GGGAAGAUGCAGAAGAAGA 1873 UCUUCUUCUGCAUCUUCCC Rh,Rb,Rt [1112-1130] 26 1295 GGCCAUUGACAAGAACAAA 1874 UUUGUUCUUGUCAAUGGCC Rh,D [1213-1231] 27 1296 GCCUUUGAGUUGGACACAA 1875 UUGUGUCCAACUCAAAGGC Rh [1295-1313] 28 1297 AGCGGACCUUCCCAGCUAA 1876 UUAGCUGGGAAGGUCCGCU Rh [1636-1654] 29 1298 GAAGAAGGCUGUUGCCAUA 1877 UAUGGCAACAGCCUUCUUC Rt [1123-1141] 30 1299 ACAAGAUGCGAGACGAGUA 1878 UACUCGUCUCGCAUCUUGU Rh,Rt [1464-1482] 31 1300 GAGGCGGAUUGAGAAGGAA 1879 UUCCUUCUCAAUCCGCCUC [1971-1989] 32 1301 GGACAACCGUGGCUUCAUA 1880 UAUGAAGCCACGGUUGUCC Rh,M [886-904] 33 1302 CAUAUUUAUAGCCAGGUAA 1881 UUACCUGGCUAUAAAUAUG Rh [1788-1806] 34 1303 CGACGACGAGAAGGAAAAA 1882 UUUUUCCUUCUCGUCGUCG [967-985] 35 1304 CUCACCUGUGAGACCAAAA 1883 UUUUGGUCUCACAGGUGAG Rh [1810-1828] 36 1305 GCGGCUCCCUGCUAUUCAA 1884 UUGAAUAGCAGGGAGCCGC [1419-1437] 37 1306 AGAACAUCCUGGUGUCACA 1885 UGUGACACCAGGAUGUUCU [423-441] 38 1307 CACACUGGGAUGAGAAAUA 1886 UAUUUCUCAUCCCAGUGUG Rh [852-870] 39 1308 GCUAGAAUUCACUCCACUA 1887 UAGUGGAGUGAAUUCUAGCRh [1650-1668] 40 1309 CCUUCAUCUUCCUAGUGCA 1888 UGCACUAGGAAGAUGAAGG [1389-1407] 411310 UGCUAUCAAUCCAAGAACA 1889 UGUUCUUCTCAUUGAUAGCA Rh [2126-2144] 42 1311 GGAAGAUGCAGAAGAAGGA 1890 UCCUUCUUCUGCAUCUUCC Rh,Rb,Rt [1113-1131] 43 1312 CAUGAGCCUUUGUUGCUAA 1891 UUAGCAACAAAGGCUCAUG Rh [2113-2131] 44 1313 GCGGAUUGAGAAGGAGCUA 1892 UAGCUCCUUCUCAAUCCGC [1974-1992] 45 1314 UGCAGUCCAUCAACGAGUA 1893 UACUCGUUGAUGGACUGCA Rh,Rt,M [738-756] 46 1315 GCACUGCGGAGAAGUUGAA 1894 UUCAACUUCUCCGCAGUGC [321-339] 47 1316 CCAGGCAGUGGAGAACAUA 1895 UAUGUUCUCCACUGCCUGG Rh [412-430] 48 1317 GGCAAGAAGGACCUGUACA 1896 UGUACAGGUCCUUCUUGCC Rh,D,M [1253-1271] 49 1318 CUCUACAACUACUACGACA 1897 UGUCGUAGUAGUUGUAGA Rb [953-971] 50 1319 CUUCCCAGCUAGAAUUCAA 1898 UUGAAUUCUAGCUGGGAAG Rh [1643-1661] 511320 AGGCGGAUUGAGAAGGAGA 1899 UCUCCUUCUCAAUCCGCCU [1972-1990] 52 1321 GGUCCUAUACCGUGGGUGA 1900 UCACCCACGGUAUAGGACC Rh [912-930] 53 1322 GCAAGAAGGACCUGUACCA 1901 UGGUACAGGUCCUUCUUGC Rh,D,M [1254-1272] 54 1323 CCGUGGGUGUCAUGAUGAA 1902 UUCAUCAUGACACCCACGG Rh [921-939] 55 1324 GAUGCGAGACGAGUUAUAA 1903 UUAUAACUCGUCUCGCAUC Rh [1468-1486] 56 1325 GGCAGUGCUGAGCGCCGAA 1904 UUCGGCGCUCAGCACUGCC [511-529] 187 WO 2011/072082 PCT/US2010/059578 57 1326 CAGCUAGAAUUCACUCCAA 1905 UUGGAGUGAAUUCUAGCUG Rh [1648-1666] 58 1327 GAGCUUCGCUGAUGACUUA 1906 UAAGUCAUCAGCGAAGCUC Rh [649-667] 59 1328 CUUUGAGUUGGACACAGAA 1907 UUCUGUGUCCAACUCAAAG Rh [1297-1315] 60 1329 GGUGGACAACCGUGGCUUA 1908 UAAGCCACGGUUGUCCACC Rh,M [883-901] 611330 GCCUCAUCAUCCUCAUGCA 1909 UGCAUGAGGAUGAUGAGGC Rh,D,Rt, [1026-1044] 62 1331 ACCAGGCAGUGGAGAACAA 1910 UUGUUCUCCACUGCCUGGU Rh [411-429] 63 1332 CCUGCCUCAAUCAGUAUUA 1911 UAAUACUGAUUGAGGCAGG [1770-1788] 64 1333 GAUCAAGCCUGCCUCAAUA 1912 UAUUGAGGCAGGCUUGAUCRh [1763-1781] 65 1334 CAGACUCUGGUCAAGAAGA 1913 UCUUCUUGACCAGAGUCUG Rh [2011-2029] 66 1335 CGCGCUGCAGUCCAUCAAA 1914 UUUGAUGGACUGCAGCGCG Rh,Rt [733-751] 67 1336 CUGGCACUGCGGAGAAGUA 1915 UACUUCUCCGCAGUGCCAG [318-336] 68 1337 CCAGCUCUAUCCCAACCUA 1916 UAGGUUGGGAUAGAGCUG [1885-1903] 69 1338 AGGGUGUGGUGGAGGUGAA 1917 UUCACCUCCACCACACCCU Rh,D [1152-1170] 70 1339 AGUGAGGCGGAUUGAGAAA 1918 UUUCUCAAUCCGCCUCACU [1968-1986] 711340 CGGACAGGCCUCUACAACA 1919 UGUUGUAGAGGCCUGUCCG Rh,Rb,Rt, [944-962] 72 1341 CGACGAGAAGGAAAAGCUA 1920 UAGCUUUUCCUUCUCGUCG Rh [970-988] 73 1342 AGGCCAAGGCAGUGCUGAA 1921 UUCAGCACUGCCUUGGCCU Rh [504-522] 74 1343 GCCUCAGGGUGCACACAGA 1922 UCUGUGUGCACCCUGAGGC [1488-1506] 75 1344 GGAUGAGAAAUUCCACCAA 1923 UUGGUGGAAUUUCUCAUCC Rh [859-877] 76 1345 AGAAGGAAAAGCUGCAAAA 1924 UUUUGCAGCUUUUCCUUCU Rh [975-993] 77 1346 AGCUCUAUCCCAACCUCUA 1925 UAGAGGUUGGGAUAGAGC Rh [1887-1905] 78 1347 UGACAAGAUGCGAGACGAA 1926 UUCGUCUCGCAUCUUGUCA Rh [1462-1480] 79 1348 AGAAGGAGCUCCCAGGAGA 1927 UCUCCUGGGAGCUCCUUCU [1982-2000] 80 1349 CCUUCUCACCUGUGAGACA 1928 UGUCUCACAGGUGAGAAGG Rh [1806-1824] 811350 GGCUUCUGGGCAGACUCUA 1929 UAGAGUCUGCCCAGAAGCC Rh [2001-2019] 82 1351 CCAGCCUCAUCAUCCUCAA 1930 UUGAGGAUGAUGAGGCUG Rh,D,Rt, [1023-1041] 83 1352 CCAAAGGCUCCUGAGACAA 1931 UUGUCUCAGGAGCCUUUGG [1521-1539] 84 1353 GGACCUGGGCCAUAGUCAA 1932 UUGACUAUGGCCCAGGUCC [1722-1740] 85 1354 GGGUGUCAUGAUGAUGCAA 1933 UUGCAUCAUCAUGACACCC Rh [925-943] 86 1355 GUACCAGCCUUGGAUACUA 1934 UAGUAUCCAAGGCUGGUAC Rh [1572-1590] 87 1356 GGCUGUUGCCAUCUCCUUA 1935 UAAGGAGAUGGCAACAGCC [1129-1147] 88 1357 CGCAGUGAGGCGGAUUGAA 1936 UUCAAUCCGCCUCACUGCG [1965-1983] 89 1358 CCAAGGACGUGGAGCGCAA 1937 UUGCGCUCCACGUCCUUGG Rh,D [795-813] 90 1359 GGCUCCUGAGACACAUGGA 1938 UCCAUGUGUCUCAGGAGCC D [1526-1544] 91 1360 GCUGCAGUCCAUCAACGAA 1939 UUCGUUGAUGGACUGCAGC Rh,Rt [736-754] 92 1361 CCAGGUACCUUCUCACCUA 1940 UAGGUGAGAAGGUACCUGG Rh [1799-1817] 93 1362 GCAGCGCGCUGCAGUCCAA 1941 UUGGACUGCAGCGCGCUGC Rh,Rt [729-747] 94 1363 GAGACCAAAUUGAGCUAGA 1942 UCUAGCUCAAUUUGGUCUC Rh [1819-1837] 95 1364 GCCGCCGAGGUGAAGAAAA 1943 UUUUCUUCACCUCGGCGGC [281-299] 96 1365 GCAGACUCUGGUCAAGAAA 1944 UUUCUUGACCAGAGUCUGC Rh [2010-2028] 97 1366 CUAGAAUUCACUCCACUUA 1945 UAAGUGGAGUGAAUUCUA Rh [1651-1669] 98 1367 GCAGUGGAGAACAUCCUGA 1946 UCAGGAUGUUCUCCACUGC Rh [416-434] 99 1368 CGCAUGUCAGGCAAGAAGA 1947 UCUUCUUGCCUGACAUGCG Rh,D [1244-1262] 10 1369 CGGAUUGAGAAGGAGCUCA 1948 UGAGCUCCUUCUCAAUCCG [1975-1993] 10 1370 AGGUGAGGUACCAGCCUUA 1949 UAAGGCUGGUACCUCACCU Rh [1565-1583] 10 1371 CCACACUGGGAUGAGAAAA 1950 UUUUCUCAUCCCAGUGUGG Rh [851-869] 188 WO 2011/072082 PCT/US2010/059578 10 1372 GCCAUUGACAAGAACAAGA 1951 UCUUGUUCUUGUCAAUGGC Rh,D [1214-1232] 10 1373 GCGCUGCAGUCCAUCAACA 1952 UGUUGAUGGACUGCAGCGC Rh,Rt [734-752] 10 1374 CUCCCAACUAUAAAACUAA 1953 UUAGUUUUAUAGUUGGGA Rh [1903-1921] 10 1375 GGUGACAAGAUGCGAGACA 1954 UGUCUCGCAUCUUGUCACC Rh [1460-1478] 10 1376 GGCCGACUUGUCACGCAUA 1955 UAUGCGUGACAAGUCGGCC Rh [1231-1249] 10 1377 CCUAAGGGUGACAAGAUGA 1956 UCAUCUUGUCACCCUUAGG Rh [1454-1472] 10 1378 UGAGACACAUGGGUGCUAA 1957 UUAGCACCCAUGUGUCUCA Rh,D,Rt, [1532-1550] 111379 GGGUGGAAAAACAGACCGA 1958 UCGGUCUGUUUUUCCACCC [1601-1619] 111380 GGUGGAGGUGACCCAUGAA 1959 UUCAUGGGUCACCUCCACC Rh,Rt,M [1159-1177] 1111381 CUUUGACCAGGACAUCUAA 1960 UUAGAUGUCCUGGUCAAAG Rh,Rt [1324-1342] 111382 GAACAUGAGCCUUUGUUGA 1961 UCAACAAAGGCUCAUGUUC Rh [2110-2128] 11 1383 AGCCUUGGAUACUCCAUGA 1962 UCAUGGAGUAUCCAAGGCU Rh [1577-1595] 11 1384 GGAGGUGACCCAUGACCUA 1963 UAGGUCAUGGGUCACCUCC Rh,Rt,M [1162-1180] 11 1385 AGAUCAAGCCUGCCUCAAA 1964 UUUGAGGCAGGCUUGAUCURh [1762-1780] 111386 GCCCAAGGGUGUGGUGGAA 1965 UUCCACCACACCCUUGGGC Rh,D [1147-1165] 111387 AGAACAAGGCCGACUUGUA 1966 UACAAGUCGGCCUUGUUCU Rh [1224-1242] 111388 GUGGCUUCAUGGUGACUCA 1967 UGAGUCACCAUGAAGCCAC Rh [894-912] 12 1389 CUCCUGAGACACAUGGGUA 1968 UACCCAUGUGUCUCAGGAG D [1528-1546] 12 1390 CAGCCUUGGAUACUCCAUA 1969 UAUGGAGUAUCCAAGGCUG Rh [1576-1594] 12 1391 AAGGCUCCUGAGACACAUA 1970 UAUGUGUCUCAGGAGCCUU D [1524-1542] 12 1392 AGAAGAAGGCUGUUGCCAA 1971 UUGGCAACAGCCUUCUUCU Rt [1122-1140] 12 1393 CUACUACGACGACGAGAAA 1972 UUUCUCGUCGUCGUAGUAG Rb [961-979] 12 1394 CCUUUGUUGCUAUCAAUCA 1973 UGAUUGAUAGCAACAAAGGRh [2119-2137] 12 1395 AGGCAGUGGAGAACAUCCA 1974 UGGAUGUUCUCCACUGCCU Rh [414-432] 12 1396 CCAUCACGUGGAGCCUCUA 1975 UAGAGGCUCCACGUGAUGG Rh [1045-1063] 12 1397 AGCUCUCCAGCCUCAUCAA 1976 UUGAUGAGGCUGGAGAGCU Rh,D,Rt, [1017-1035] 12 1398 GGCUCCCUGCUAUUCAUUA 1977 UAAUGAAUAGCAGGGAGCC D [1421-1439] 13 1399 GGGAACAUGAGCCUUUGUA 1978 UACAAAGGCUCAUGUUCCC Rh [2108-2126] 13 1400 GGGCCAUAGUCAUUCUGCA 1979 UGCAGAAUGACUAUGGCCC [1728-1746] 13 1401 CCAAAGAGCAGCUGAAGAA 1980 UUCUUCAGCUGCUCUUUGG Rh,Rb,P [1086-1104] 13 1402 GACGAGAAGGAAAAAGCUGA 1981 UCAGCUUUUCCUUCUCGUC Rh [971-989] 13 1403 GGGCUUCUGGGCAGACUCA 1982 UGAGUCUGCCCAGAAGCCC Rh [2000-2018] 13 1404 CAAGGACCAGGCAGUGGAA 1983 UUCCACUGCCUGGUCCUUG Rh [406-424] 13 1405 CUGUGAGACCAAAUUGAGA 1984 UCUCAAUUUGGUCUCACAG Rh [1815-1833] 13 1406 GACUGAGGCCAUUGACAAA 1985 UUUGUCAAUGGCCUCAGUC Rh [1207-1225] 131407 GACUUGUCACGCAUGUCAA 1986 UUGACAUGCGUGACAAGUC Rh [1235-1253] 13 1408 GAGGUGAGGUACCAGCCUA 1987 UAGGCUGGUACCUCACCUC [1564-1582] 14 1409 CAGAUACCAUGAUGCUGAA 1988 UUCAGCAUCAUGGUAUCUG Rh [1681-1699] 14 1410 AGGCAAGAAGGACCUGUAA 1989 UUACAGGUCCUUCUUGCCU Rh,D [1252-1270] 14 1411 CUGGGAUGAGAAAUUCCAA 1990 UUGGAAUUUCUCAUCCCAG Rh [856-874] 14 1412 AGGUACCAGCCUUGGAUAA 1991 UUAUCCAAGGCUGGUACCU Rh [1570-1588] 14 1413 CAGCCAGCCCUCUUCUGAA 1992 UUCAGAAGAGGGCUGGCUG [1843-1861] 14 1414 GUGUCAUGAUGAUGCACCA 1993 UGGUGCAUCAUCAUGACAC Rh [927-945] 14 1415 CCUCUACAACUACUACGAA 1994 UUCGUAGUAGUUGUAGAG Rb,D [952-970] 14 1416 CCGCCGAGGUGAAGAAACA 1995 UCjUUUCUUCACCUCGGCGG Rh [282-300] 14 1417 GCUAUCAAUCCAAGAACUA 1996 UAGUUCUUGGAUUGAUAGC Rh [2127-2145] 189 WO 2011/072082 PCT/US2010/059578 14 1418 AGCCUGCCUCAAUCAGUAA 1997 UUACUGAUUGAGGCAGGCU [1768-1786] 15 1419 GGUCCGGCCUAAGGGUGAA 1998 UUCACCCUUAGGCCGGACC Rh [1447-1465] 15 1420 GAAGGAAAAGCUGCAAAUA 1999 UAUUUGCAGCUUUUCCUUC Rh [976-994] 15 1421 GGCCUCUACAACUACUACA 2000 UGUAGUAGUUGUAGAGGCCRb,D [950-968] 15 1422 UGUUCUUCAAGCCACACUA 2001 UAGUGUGGCUUGAAGAACA Rh,Rb,D [840-858] 15 1423 GGCCAAGGCACjUGCUGAGA 2002 UCUCAGCACUGCCUUGGCC Rh [505-523] 15 1424 AGAAAUUCCACCACAAGAA 2003 UUCUUGUGGUGGAAUUUCU Rh [864-882] 15 1425 CUGCAGUCCAUCAACGAGA 2004 UCUCGUUGAUGGACUGCAG Rh,Rt,M [737-755] 15 1426 CCAGCGUGUUCCACGCCAA 2005 UUGGCGUGGAACACGCUGG [1275-1293] 15 1427 GCUCCCUCCUGCUUCUCAA 2006 UUGAGAAGCAGGAGGGAGC [234-252] 15 1428 CCGGACAGGCCUCUACAAA 2007 UUUGUAGAGGCCUGUCCGG Rh,Rb,Rt, [943-961] 16 1429 CCCAUCACGUGGAGCCUCA 2008 UGAGGCUCCACGUGAUGGG Rh [1044-1062] 16 1430 CCGGCCUAAGGGUGACAAA 2009 UUUGUCACCCUUAGGCCGG Rh [1450-1468] 16 1431 CCUAUACCGUGGGUGUCAA 2010 UUGACACCCACGGUAUAGG Rh,D,P [915-933] 16 1432 CAGUGGAGAACAUCCUGGA 2011 UCCAGGAUGUUCUCCACUG Rh [417-435] 16 1433 CACUGGGAUGAGAAAUUCA 2012 UGAAUUUCUCAUCCCAGUG Rh [854-872] 16 1434 AUCCAAAGGCUCCUGAGAA 2013 UUCUCAGGAGCCUUUGGAU [1519-1537] 16 1435 UGAGAAAUUCCACCACAAA 2014 UUUGUGGUGGAAUUUCUCARh [862-880] 16 1436 GGUGGAAAAACAGACCGGA 2015 UCCGGUCUGUUUUUCCACC [1602-1620] 16 1437 GCUGGGCAGCCGACUGUAA 2016 UUACAGUCGGCUGCCCAGC [616-634] 16 1438 CCAUAGUCAUUCUGCCUGA 2017 UCAGGCAGAAUGACUAUGG [1731-1749] 17 1439 GCACCGGACAGGCCUCUAA 2018 UUAGAGGCCUGUCCGGUGC Rh,Rb,Rt, [940-958] 17 1440 GUUGGACACAGAUGGCAAA 2019 UUUGCCAUCUGUGUCCAAC [1303-1321] 17 1441 GCCUGCCUCAAUCAGUAUA 2020 UAUACUGAUUGAGGCAGGC [1769-1787] 17 1442 GAUCAACUUCCGCGACAAA 2021 UUUGUCGCGGAAGUUGAUC D [709-727] 17 1443 GGCCGCAGUGAGGCGGAUA 2022 UAUCCGCCUCACUGCGGCC [1962-1980] 17 1444 CUGCGGAGAAGUUGAGCCA 2023 UGGCUCAACUUCUCCGCAG [324-342] 17 1445 GCAUCCAAAGGCUCCUGAA 2024 UUCAGGAGCCUUUGGAUGC [1517-1535] 17 1446 GCUUCUGGGCAGACUCUGA 2025 UCAGAGUCUGCCCAGAAGC Rh [2002-2020] 17 1447 CCAGCCCUCUUCUGACACA 2026 UGUGUCAGAAGAGGGCUGG [1846-1864] 17 1448 GCUCUAUCCCAACCUCUCA 2027 UGAGAGGUUGGGAUAGAG Rh [1888-1906] 18 1449 GGACGUGGAGCGCACGGAA 2028 UUCCGUGCGCUCCACGUCC Rh,D [799-817] 18 1450 CCAAGGCAGUGCUGAGCGA 2029 UCGCUCAGCACUGCCUUGG Rh [507-525] 18 1451 GCAGAAGAAGGCUGUUGCA 2030 UGCAACAGCCUUCUUCUGC Rt [1120-1138] 18 1452 GACAUUUUGUUGGAGCGUA 2031 UACGCUCCAACAAAAUGUC [2183-2201] 18 1453 CGAGCACUCCAAGAUCAAA 2032 UUUGAUCUUGGAGUGCUCG Rh,D [697-715] 18 1454 UCAUGAUGAUGCACCGGAA 2033 UUCCGGUGCAUCAUCAUGA Rh [930-948] 18 1455 CCUGCUUCUCAGCGCCUUA 2034 UAAGGCGCUGAGAAGCAGG [241-259] 18 1456 CCCAACCUCUCCCAACUAA 2035 UUAGUUGGGAGAGGUUGG Rh [1895-1913] 18 1457 UGGGCAGACUCUGGUCAAA 2036 UUUGACCAGAGUCUGCCCA Rh [2007-2025] 18 1458 CUCUGGUCAAGAAGCAUCA 2037 UGAUGCUUCUUGACCAGAG Rh [2015-2033] 19 1459 GAGCCUCUCGAGCGCCUUA 2038 UAAGGCGCUCGAGAGGCUC [1055-1073] 19 1460 AGAAGGCUGUUGCCAUCUA 2039 UAGAUGGCAACAGCCUUCU Rt [1125-1143] 19 1461 CCCUGCUAGUCAACGCCAA 2040 UUGGCGUUGACUAGCAGGG Rh [822-840] 19 1462 GCCUUCAGCUUGUACCAGA 2041 UCUGCjUACAAGCUGAAGGC [380-398] 19 1463 GCUGCUAACCAAAGAGCAA 2042 UUGCUCUUUGGUUAGCAGC [1078-1096] 190 WO 2011/072082 PCT/US2010/059578 19 1464 CCCACAAGCUCUCCAGCCA 2043 UGGCUGGAGAGCUUGUGGG Rh,D,P [1011-1029] 19 1465 GCUCCCUGCUAUUCAUUGA 2044 UCAAUGAAUAGCAGGGAGC D [1422-1440] 19 1466 GUUCUUCAAAGAUAGGGAA 2045 UUCCCUAUCUUUGAAGAAC [2083-2101] 19 1467 GUCAGCCAGCCCUCUUCUA 2046 UAGAAGAGGGCUGGCUGAC Rh [1841-1859] 19 1468 GCGGGACACCCAAAGCGGA 2047 UCCGCUUUGGGUGUCCCGC [1405-1423] 20 1469 AGCGCAGCGCGCUGCAGUA 2048 UACUGCAGCGCGCUGCGCU Rh,Rt [726-744] 20 1470 CCGGAAACUCCACAUCCUA 2049 UAGGAUGUGGAGUUUCCGG [1701-1719] 20 1471 CCAUUGACAAGAACAAGGA 2050 UCCUUGUUCUUGUCAAUGG Rh,D [1215-1233] 20 1472 GGACAUCUACGGGCGCGAA 2051 UUCGCGCCCGUAGAUGUCC D [1333-1351] 20 1473 GACACAUGGGUGCUAUUGA 2052 UCAAUAGCACCCAUGUGUC Rh,Rt,M [1535-1553] 20 1474 CCUGGCACUGCGGAGAAGA 2053 UCUUCUCCGCAGUGCCAGG [317-335] 20 1475 GGGCCUGACUGAGGCCAUA 2054 UAUGGCCUCAGUCAGGCCC Rt [1201-1219] 20 1476 ACACUGGGAUGAGAAAUUA 2055 UAAUUUCUCAUCCCAGUGU Rh [853-871] 20 1477 GGUCAGCCAGCCCUCUUCA 2056 UGAAGAGGGCUGGCUGACC Rh [1840-1858] 20 1478 GUGAGGCGGAUUGAGAAGA 2057 UCUUCUCAAUCCGCCUCAC [1969-1987] 211479 UCACCUGUGAGACCAAAUA 2058 UAUUUGGUCUCACAGGUGA Rh [1811-1829] 21 1480 AGCUGCAAAUCGUGGAGAA 2059 UUCUCCACGAUUUGCAGCU Rh [984-1002] 21 1481 GGUGCACACAGGAUGGCAA 2060 UUGCCAUCCUGUGUGCACC Rh [1495-1513] 21 1482 GGGUGUGGUGGAGGUGACA 2061 UGUCACCUCCACCACACCC Rh,D [1153-1171] 211483 CCAGCCUUGGAUACUCCAA 2062 UUGGAGUAUCCAAGGCUGG Rh [1575-1593] 21 1484 CCACAAGCUCUCCAGCCUA 2063 UAGGCUGGAGAGCUUGUGG Rh,D,P [1012-1030] 21 1485 AAAGGCUCCUGAGACACAA 2064 UUGUGUCUCAGGAGCCUUU [1523-1541] 21 1486 AGGAAAAGCUGCAAAUCGA 2065 UCGAUUUGCAGCUUUUCCU Rh [978-996] 21 1487 CGCAGCAGCUCCUGGCACA 2066 UGUGCCAGGAGCUGCUGCG [307-325] 21 1488 GGUGUCAUGAUGAUGCACA 2067 UGUGCAUCAUCAUGACACC Rh [926-944] 22 1489 CCUCUUCUGACACUAAAAA 2068 UUUUUAGUGUCAGAAGAG [1851-1869] 22 1490 AGCUAGAAUUCACUCCACA 2069 UGUGGAGUGAAUUCUAGCURh [1649-1667] 22 1491 CGCUGGGCGGCAAGGCGAA 2070 UUCGCCUUGCCGCCCAGCG [474-492] 22 1492 GGCCUGGCCUUCAGCUUGA 2071 UCAAGCUGAAGGCCAGGCC [374-392] 22 1493 AGACACAUGGGUGCUAUUA 2072 UAAUAGCACCCAUGUGUCU Rh,Rt,M [1534-1552] 22 1494 CGUGGGUGUCAUGAUGAUA 2073 UAUCAUCAUGACACCCACC Rh [922-940] 22 1495 GUGGGUGUCAUGAUGAUGA 2074 UCAUCAUCAUGACACCCAC Rh [923-941] 22 1496 GAGAAGGAGCUCCCAGGAA 2075 UUCCUGGGAGCUCCUUCUC [1981-1999] 22 1497 GACUCUGGUCAAGAAGCAA 2076 UUGCUUCUUGACCAGAGUC Rh [2013-2031] 22 1498 CACUAAAACACCUCAGCUA 2077 UAGCUGAGGUGUUUUAGU [1861-1879] 23 1499 IGGAGGCAUCCAAAGGCUCA 2078 UGAGCCUUUGGAUGCCUCC [1513-1531] 23 1500 GACCCAGCUCAGUGAGCUA 2079 UAGCUCACUGAGCUGGGUC [636-654] 23 1501 CCAUGACCUGCAGAAACAA 2080 UUGUUUCUGCAGGUCAUGG Rh,Rt,M [1171-1189] 23 1502 AGAUGCAGAAGAAGGCUGA 2081 UCAGCCUUCUUCUGCAUCU Rh,Rt,M [1116-1134] 23 1503 CAGCAAGCAGCACUACAAA 2082 UUUGUAGUGCUGCUUGCUG Rh,D [676-694] 23 1504 CAAGCUCUCCAGCCUCAUA 2083 UAUGAGGCUGGAGAGCUUG Rh,D,M,P [1015-1033] 23 1505 UGCAGAAGAAGGCUGUUGA 2084 UCAACAGCCUUCUUCUGCA Rt [1119-1137] 23 1506 GGCGCGAGGAGCUGCGCAA 2085 UUGCGCAGCUCCUCGCGCC Rh,D,M [1344-1362] 23 1507 GGUACCAGCCUUGGAUACA 2086 UGUAUCCAAGGCUGGUACC Rh [1571-1589] 23 1508 GCAGCCGACUGUACGGACA 2087 UGUCCGUACAGUCGGCUGC [621-639] 24 1509 CAGCCUCAUCAUCCUCAUA 2088 UAUGAGGAUGAUGAGGCU Rh,D,Rt, [1024-1042] 191 WO 2011/072082 PCT/US2010/059578 24 1510 GCCACCGCCUUUGAGUUGA 2089 UCAACUCAAAGGCGGUGGC Rh [1289-1307] 24 1511 AGAAGGACCUGUACCUGGA 2090 UCCAGGUACAGGUCCUUCU Rh,D [1257-1275] 24 1512 GGUGAAGAAACCUGCAGCA 2091 UGCUGCAGGUUUCUUCACC Rh [289-307] 24 1513 GUACCUUCUCACCUGUGAA 2092 UUCACAGGUGAGAAGGUAC Rh [1803-1821] 24 1514 GGCCAAGGACCAGGCAGUA 2093 UACUGCCUGGUCCUUGGCC Rh [403-421] 24 1515 GGCGGCAAGGCGACCACGA 2094 UCGUGGUCGCCUUGCCGCC [479-497] 24 1516 AGCACUCCAAGAUCAACUA 2095 UAGUUGAUCUUGGAGUGCU Rh,D [699-717] 24 1517 AUAUUUAUAGCCAGGUACA 2096 UGUACCUGGCUAUAAAUAU Rh [1789-1807] 24 1518 GGCAGCCGACUGUACGGAA 2097 UUCCGUACAGUCGGCUGCC [620-638] 25 1519 GUCACGCAUGUCAGGCAAA 2098 UUUGCCUGACAUGCGUGAC Rh,D [1240-1258] 25 1520 GACAGGCCUCUACAACUAA 2099 UUAGUUGUAGAGGCCUGUC Rh,Rb,Rt, [946-964] 25 1521 GAUGCAGAAGAAGGCUGUA 2100 UACAGCCUUCUUCUGCAUC Rh,Rt,M [1117-1135] 25 1522 ACCCAUGACCUGCAGAAAA 2101 UUUUCUGCAGGUCAUGGGU Rh,Rt,M [1169-1187] 25 1523 GGCUUCAUGGUGACUCGGA 2102 UCCGAGUCACCAUGAAGCC Rh [896-914] 25 1524 UGCCUCAAUCAGUAUUCAA 2103 UUGAAUACUGAUUGAGGCA [1772-1790] 25 1525 GUUCUUCAAGCCACACUGA 2104 UCAGUGUGGCUUGAAGAAC Rh,Rb,D [841-859] 25 1526 ACUCCAAGAUCAACUUCCA 2105 UGGAAGUUGAUCUUGGAG Rh,D,Rt, [702-720] 25 1527 GCUGUUCUACGCCGACCAA 2106 UUGGUCGGCGUAGAACAGC Rh [1369-1387] 25 1528 UAGUCAACGCCAUGUUCUA 2107 UAGAACAUGGCGUUGACUA Rh [828-846] 26 1529 CCGUGUGCCUGAGCGGACA 2108 UGUCCGCUCAGGCACACGG Rh [1625-1643] 26 1530 AGGCCUCUACAACUACUAA 2109 UUAGUAGUUGUAGAGGCCU Rh,Rb,D, [949-967] 26 1531 GCUUCAUGGUGACUCGGUA 2110 UACCGAGUCACCAUGAAGC Rh [897-915] 26 1532 GGUCAAGAAGCAUCGUGUA 2111 UACACGAUGCUUCUUGACC Rh [2019-2037] 26 1533 CUGCGAGCACUCCAAGAUA 2112 UAUCUUGGAGUGCUCGCAG Rh,D [694-712] 26 1534 GUCCUAUACCGUGGGUGUA 2113 UACACCCACGGUAUAGGAC Rh [913-931] 26 1535 GGCCUGACUGAGGCCAUUA 2114 UAAUGGCCUCAGUCAGGCC Rh [1202-1220] 26 1536 CACUCCAAGAUCAACUUCA 2115 UGAAGUUGAUCUUGGAGU Rh,D,Rt, [701-719] 26 1537 GCGUCGCAGGCCAAGGCAA 2116 UUGCCUUGGCCUGCGACGC [497-515] 26 1538 AAGGGUGACAAGAUGCGAA 2117 UUCGCAUCUUGUCACCCUU Rh,D [1457-1475] 27 1539 CAAGCUGUUCUACGCCGAA 2118 UUCGGCGUAGAACAGCUUG Rh [1366-1384] 27 1540 CCUGCUAGUCAACGCCAUA 2119 UAUGCiCGUUGACUAGCAGG Rh [823-841] 27 1541 CCAAGGGUGUGGUGGAGGA 2120 UCCUCCACCACACCCUUGG Rh,D [1149-1167] 27 1542 CACACAGGAUGGCAGGAGA 2121 UCUCCUGCCAUCCUGUGUG Rh [1499-1517] 27 1543 UCCUGAGACACAUGGGUGA 2122 UCACCCAUGUGUCUCAGGA D,Rt,M [1529-1547] 27 1544 CUACAACUACUACGACGAA 2123 UUCGUCGUAGUAGUUGUAG Rb [955-973] 27 1545 GACAAGAUGCGAGACGAGA 2124 UCUCGUCUCGCAUCUUGUC Rh,Rt [1463-1481] 27 1546 CCUGGAAGCUGGGCAGCCA 2125 UGGCUGCCCAGCUUCCAGG [609-627] 27 1547 CUUCAAGCCACACUGGGAA 2126 UUCCCAGUGUGGCUUGAAG Rh,Rb,D [844-862] 27 1548 GCGAGACGAGUUAUAGGGA 2127 UCCCUAUAACUCGUCUCGC Rh [1471-1489] 28 1549 GAAGCUGGGCAGCCGACUA 2128 UAGUCGGCUGCCCAGCUUC [613-631] 28 1550 GUGCCUGAGCGGACCUUCA 2129 UGAAGGUCCGCUCAGGCAC Rh [1629-1647] 28 1551 GGUGACCCAUGACCUGCAA 2130 UUGCAGGUCAUGGGUCACC Rh,Rt,M [1165-1183] 28 1552 AUGAGCCUUUGUUGCUAUA 2131 UAUAGCAACAAAGGCUCAU Rh [2114-2132] 28 1553 CAACUACUACGACGACGAA 2132 UUCGUCGUCGUAGUAGUUG Rb [958-976] 28 1554 GCUGCGCUCACUCAGCAAA 2133 UUUGCUGAGUGAGCGCAGC Rh [571-589] 28 1555 GAGAACAUCCUGGUGUCAA 2134 UUGACACCAGGAUGUUCUC [422-440] 192 WO 2011/072082 PCT/US2010/059578 28 1556 CCCAAGCUGU UCUACGCCA 2135 UGGCGUAGAACAGCUUGGG Rh [1364-1382] 28 1557 CAGCUCUAUCCCAACCUCA 2136 UGAGGUUGGGAUAGAGCU [1886-1904] 28 1558 UGAGCUUCGCUGAUGACUA 2137 UAGUCAUCAGCGAAGCUCA Rh [648-666] 29 1559 CCCAAGGCGGCCACGCUUA 2138 UAAGCGUGGCCGCCUUGGG Rh [341-359] 29 1560 CUAUACCGUGGGUGUCAUA 2139 UAUGACACCCACGGUAUAG Rh [916-934] 29 1561 CAUUGACAAGAACAAGGCA 2140 UGCCUUGUUCUUGUCA AUG Rh,D [1216-1234] 29 1562 GGACCCAGCUCAGUGAGCA 2141 UGCUCACUGAGCUGGGUCC [635-653] 29 1563 GACGACGAGAAGGAAAAGA 2142 UCUUUUCCUUCUCGUCGUC Rh [968-986] 29 1564 GCGGCAAGGCGACCACGGA 2143 UCCGUGGUCGCCUUGCCGC [480-498] 29 1565 GGGACACCCAAAGCGGCUA 2144 UAGCCGCUUUGGGUGUCCC [1407-1425] 29 1566 GGGAGGUGAGGUACCAGCA 2145 UGCUGGUACCUCACCUCCC [1562-1580] 29 1567 GCAGCACUACAACUGCGAA 2146 UUCGCAGUUGUAGUGCUGC Rh,D [682-700] 29 1568 GCGCAACGUGACCUGGAAA 2147 UUUCCAGGUCACGUUGCGC M [598-616] 30 1569 GGGCUGGGCCUGACUGAGA 2148 UCUCAGUCAGGCCCAGCCC [1196-1214] 30 1570 CCUGAGCGGACCUUCCCAA 2149 UUGGGAAGGUCCGCUCAGG Rh [1632-1650] 30 1571 GCAGCUGAAGAUCUGGAUA 2150 UAUCCAGAUCUUCAGCUGC Rh,D [1093-1111] 30 1572 AGUGGAGAACAUCCUGGUA 2151 UACCAGGAUGUUCUCCACU Rh [418-436] 30 1573 GCAAGCAGCACUACAACUA 2152 UAGUUGUAGUGCUGCUUGC Rh,D [678-696] 30 1574 AGCUCAGUGAGCUUCGCUA 2153 UAGCGAAGCUCACUGAGCU [641-659] 301575 CCGACUUGUCACGCAUGUA 2154 UACAUGCGUGACAAGUCGG Rh [1233-1251] 30 1576 CCGAGGUCACCAAGGACGA 2155 UCGUCCUUGGUGACCUCGG Rh,D [786-804] 30 1577 GGAGCCUCUCGAGCGCCUA 2156 UAGGCGCUCGAGAGGCUCC [1054-1072] 30 1578 GGCCGCGCAGACCACCGAA 2157 UUCGGUGGUCUGCGCGGCC [757-775] 31 1579 GGAAACUCCACAUCCUGUA 2158 UACAGGAUGUGGAGUUUCC Rh [1703-1721] 31 1580 CAAAGCGGCUCCCUGCUAA 2159 UUAGCAGGGAGCCGCUUUG [1415-1433] 311581 GCUCCUGAGACACAUGGGA 2160 UCCCAUGUGUCUCAGGAGC D [1527-1545] 31 1582 CCUGGGCCAUAGUCAUUCA 2161 UGAAUGACUAUGGCCCAGG [1725-1743] 31 1583 CGUGGAGCCUCUCGAGCGA 2162 UCGCUCGAGAGGCUCCACG [1051-1069] 31 1584 CCUCCUGCUUCUCAGCGCA 2163 UGCGCUGAGAAGCAGGAGG [238-256] 31 1585 AGUCCCAGAUCAAGCCUGA 2164 UCAGGCUUGAUCUGGGACU Rh [1756-1774] 311586 UACCGUGGGUGUCAUGAUA 2165 UAUCAUGACACCCACCTGUA Rh [919-937] 31 1587 GCCAGCCCUCUUCUGACAA 2166 UUGUCAGAAGAGGGCUGGC [1845-1863] 311588 CCGAGGUGAAGAAACCUGA 2167 UCAGGUUUCUUCACCUCGG Rh,Rt [285-303] 32 1589 UCCUGGCACUGCGGAGAAA 2168 UUUCUCCGCAGUGCCAGGA [316-334] 32 1590 CCCGGAAACUCCACAUCCA 2169 UGGAUGUGGAGUUUCCGGG [1700-1718] 32 1591 ACUCUGGUCAAGAAGCAUA 2170 UAUGCUUCUUGACCAGAGU Rh [2014-2032] 32 1592 CCCAGAUACCAUGAUGCUA 2171 UAGCAUCAUGGUAUCUGGGRh [1679-1697] 32 1593 CCUGAGACACAUGGGUGCA 2172 UGCACCCAUGUGUCUCAGG D,Rt,M [1530-1548] 32 1594 GCACUACAACUGCGAGCAA 2173 UUGCUCGCAGUUGUAGUGC Rh,D [685-703] 32 1595 CCACAAGAUGGUGGACAAA 2174 UUUGUCCACCAUCUUGUGG Rh,Rb,M, [874-892] 32 1596 GGACACAGAUGGCAACCCA 2175 UGGGUUGCCAUCUGUGUCC [1306-1324] 32 1597 GAAAAGCUGCUAACCAAAA 2176 UUUUGGUUAGCAGCUUUUC [1073-1091] 32 1598 ACUACAACUGCGAGCACUA 2177 UAGUGCUCGCAGUUGUAGU Rh,D [687-705] 33 1599 GCACUCCAAGAUCAACUUA 2178 UAAGUUGAUCUUGGAGUGC Rh,D [700-718] 33 1600 GCCUUGAAAAGCUGCUAAA 2179 UUUAGCAGCUUUUCAAGGC [1068-1086] 33 1601 GUGACUCGGUCCUAUACCA 2180 UGGUAUAGGACCGAGUCAC Rh [905-923] 193 WO 2011/072082 PCT/US2010/059578 33 1602 GUGGUGGAGGUGACCCAUA 2181 UAUGGGUCACCUCCACCAC Rh,Rb,Rt, [1157-1175] 33 1603 AUGCGAGACGAGUUAUAGA 2182 UCUAUAACUCGUCUCGCAU Rh [1469-1487] 33 1604 ACCUUCCCAGCUAGAAUUA 2183 UAAUUCUAGCUGGGAAGGU Rh [1641-1659] 33 1605 CCCAGCUAGAAUUCACUCA 2184 UGAGUGAAUUCUAGCUGGG Rh [1646-1664] 33 1606 GGUCACCAAGGACGUGGAA 2185 UUCCACGUCCUUGGUGACC Rh,D [790-808] 33 1607 GGCCUCAGGGUGCACACAA 2186 UUGUGUGCACCCUGAGGCC [1487-1505] 33 1608 UGAGGUACCAGCCUUGGAA 2187 UUCCAAGGCUGGUACCUCA Rh [1568-1586] 34 1609 CAUGGUGACUCGGUCCUAA 2188 UUAGGACCGAGUCACCAUG Rh [901-919] 34 1610 GGUGAGGUACCAGCCUUGA 2189 UCAAGGCUGGUACCUCACC Rh [1566-1584] 34 1611 GCCGAGGUGAAGAAACCUA 2190 UAGGUUUCUUCACCUCGGC Rh,Rt [284-302] 34 1612 GUACGGACCCAGCUCAGUA 2191 UACUGAGCUGGGUCCGUAC [631-649] 34 1613 CAAGAAGGACCUGUACCUA 2192 UAGGUACAGGUCCUUCUUG Rh,D,M [1255-1273] 34 1614 GAGCACUCCAAGAUCAACA 2193 UGUUGAUCUUGGAGUGCUC Rh,D [698-716] 34 1615 CAUGUUCUUCAAGCCACAA 2194 UUGUGGCUUGAAGAACAUG Rh,Rb,D [838-856] 34 1616 CCCUCCUGCUUCUCAGCGA 2195 UCGCUGAGAAGCAGGAGGG [237-255] 34 1617 AUGUCAGGCAAGAAGGACA 2196 UGUCCUUCUUGCCUGACAU Rh,D [1247-1265] 34 1618 CAAGAUCAACUUCCGCGAA 2197 UUCGCGGAAGUUGAUCUUGD [706-724] 35 1619 GCGUGUUCCACGCCACCGA 2198 UCGGUGGCGUGGAACACGC [1278-1296] 35 1620 CGGACCCAGCUCAGUGAGA 2199 UCUCACUGAGCUGGGUCCG [634-652] 35 1621 CCUUCAGCUUGUACCAGGA 2200 UCCUGGUACAAGCUGAAGG [381-399] 35 1622 GCUCUCCAGCCUCAUCAUA 2201 UAUGAUGAGGCUGGAGAGC Rh,D,Rt, [1018-1036] 35 1623 CCCUGGCCCACAAGCUCUA 2202 UAGAGCUUGUGGGCCAGGG Rh,D,P [1005-1023] 35 1624 GCCCGAGGUCACCAAGGAA 2203 UUCCUUGGUGACCUCGGGC Rh,D [784-802] 35 1625 GUGGAGAACAUCCUGGUGA 2204 UCACCAGGAUGUUCUCCAC Rh [419-437] 35 1626 GCUCACUCAGCAACUCCAA 2205 UUGGAGUUGCUGAGUGAGC Rh [576-594] 35 1627 ACGCCAUGUUCUUCAAGCA 2206 UGCUUGAAGAACAUGGCGU Rh,Rb,P [834-852] 35 1628 ACACAUGGGUGCUAUUGGA 2207 UCCAAUAGCACCCAUGUGU Rh [1536-1554] 36 1629 CCAGCUCAGUGAGCUUCGA 2208 UCGAAGCUCACUGAGCUGG [639-657] 36 1630 CCCAGCUCAGUGAGCUUCA 2209 UGAAGCUCACUGAGCUGGG [638-656] 36 1631 GGGCGGCAAGGCGACCACA 2210 UGUGGUCGCCUUGCCGCCC [478-496] 36 1632 CAGGGUGCACACAGGAUGA 2211 UCAUCCUGUGUGCACCCUG [1492-1510] 36 1633 AGGUGAAGAAACCUGCAGA 2212 UCUGCAGGUUUCUUCACCU Rh [288-306] 36 1634 CCUCUCCCAACUAUAAAAA 2213 UUUUUAUAGUUGGGAGAG Rh [1900-1918] 36 1635 GACUGUACGGACCCAGCUA 2214 UAGCUGGGUCCGUACAGUC [627-645] 36 1636 GAAGGAGCUCCCAGGAGGA 2215 UCCUCCUGGGAGCUCCUUC [1983-2001] 36 1637 ACGCAUGUCAGGCAAGAAA 2216 UUUCUUGCCUGACAUGCGU Rh,D [1243-1261] 36 1638 GACUCGGUCCUAUACCGUA 2217 UACGGUAUAGGACCGAGUC Rh [907-925] 37 1639 CACUACAACUGCGAGCACA 2218 UGUGCUCGCAGUUGUAGUG Rh,D [686-704] 37 1640 AGCUCCUGGCACUGCGGAA 2219 UUCCGCAGUGCCAGGAGCU [313-331] 37 1641 CUAAGGGUGACAAGAUGCA 2220 UGCAUCUUGUCACCCUUAG Rh [1455-1473] 37 1642 UGUGAGACCAAAUUGAGCA 2221 UGCUCAAUUUGGUCUCACA Rh [1816-1834] 37 1643 GCCGACUUGUCACGCAUGA 2222 UCAUGCGUGACAAGUCGGC Rh [1232-1250] 37 1644 CAGGAUGGCAGGAGGCAUA 2223 UAUGCCUCCUGCCAUCCUG [1503-1521] 37 1645 ACAAGAACAAGGCCGACUA 2224 UAGUCGGCCUUGUUCUUGU Rh [1221-1239] 37 1646 UGCGCUCCCUCCUGCUUCA 2225 UGAAGJCAGGAGGGAGCGCA [231-249] 37 1647 GGCGAGCUGCUGCGCUCAA 2226 UUGAGCGCAGCAGCUCGCC Rh [563-581] 194 WO 2011/072082 PCT/US2010/059578 37 1648 GAUGCACCGGACAGGCCUA 2227 UAGGCCUGUCCGGUGCAUC Rh,Rb,Rt, [937-955] 38 1649 CGUGUCGCUGGGCGGCAAA 2228 UUUGCCGCCCAGCGACACG [469-487] 38 1650 AUCCCAACCUCUCCCAACA 2229 UGUUGGGAGAGGUUGGGA Rh [1893-1911] 38 1651 UGUUCUACGCCGACCACCA 2230 UGGUGGUCGGCGUAGAACARh [1371-1389] 38 1652 CGGCCUGGCCUUCAGCUUA 2231 UAAGCUGAAGGCCAGGCCG [373-391] 38 1653 GUCGCAGGCCAAGGCAGJUA 2232 UACUGCCUUGGCCUGCGAC [499-517] 38 1654 AGUCAUUCUGCCUGCCCUA 2233 UAGGGCAGGCAGAAUGACU [1735-1753] 38 1655 CCCAGAAUGACCUGGCCGA 2234 UCGGCCAGGUCAUUCUGGG [1949-1967] 38 1656 ACAAGAUGGUGGACAACCA 2235 UGGUUGUCCACCAUCUUGU Rh,Rb,M, [876-894] 38 1657 GCUAGUCAACGCCAUGUUA 2236 UAACAUGGCGUUGACUAGC Rh [826-844] 38 1658 ACGCCACCGCCUUUGAGUA 2237 UACUCAAAGGCGGUGGCGU Rh [1287-1305] 39 1659 GCCGCGCAGACCACCGACA 2238 UGUCGGUGGUCUGCGCGGC [758-776] 39 1660 GCUAUUCAUUGGGCGCCUA 2239 UAGGCGCCCAAUGAAUAGC D [1429-1447] 39 1661 CUCAGUGAGCUUCGCUGAA 2240 UUCAGCGAAGCUCACUGAG [643-661] 39 1662 IGGAGGUGAGGUACCAGCCA 2241 UGGCUGGUACCUCACCUCC [1563-1581] 39 1663 GCCAAGGCAGUGCUGAGCA 2242 UGCUCAGCACUGCCUUGGC Rh [506-524] 39 1664 CUCUCCAGCCUCAUCAUCA 2243 UGAUGAUGAGGCUGGAGA Rh,D,Rt, [1019-1037] 39 1665 GAAUGACCUGGCCGCAGUA 2244 UACUGCGGCCAGGUCAUUC [1953-1971] 39 1666 UGGUGACUCGGUCCUAUAA 2245 UUAUAGGACCGAGUCACCA Rh [903-921] 39 1667 CAGGUACCUUCUCACCUGA 2246 UCAGGUGAGAAGGUACCUG Rh [1800-1818] 39 1668 GUUCCACGCCACCGCCUUA 2247 UAAGGCGGUGGCGUGGAAC D [1282-1300] 40 1669 CCGACUGUACGGACCCAGA 2248 UCUGGGUCCGUACAGUCGG [625-643] 40 1670 GCAGACCACCGACGGCAAA 2249 UUUGCCGUCGGUGGUCUGC D,Rt [763-781] 40 1671 AAGAUGCGAGACGAGUUAA 2250 UUAACUCGUCUCGCAUCUU Rh [1466-1484] 40 1672 CAAAGAGCAGCUGAAGAUA 2251 UAUCUUCAGCUGCUCUUUG Rh [1087-1105] 40 1673 ACGACGAGAAGGAAAAGCA 2252 UGCUUUUCCUUCUCGUCGU Rh [969-987] 40 1674 CACUCCACUUGGACAUGGA 2253 UCCAUGUCCAAGUGGAGUG Rh [1659-1677] 40 1675 AGUCCAUCAACGAGUGGGA 2254 UCCCACUCGUUGAUGGACU Rh,Rt,M [741-759] 40 1676 GCGCCGGCCUGGCCUUCAA 2255 UUGAAGGCCAGGCCGGCGC Rh [369-387] 40 1677 GGAAAAGCUGCAAAUCGUA 2256 UACGAUUUGCAGCUUUUCC Rh [979-997] 40 1678 ACAUUUUGUUGGAGCGUGA 2257 UCACGCUCCAACAAAAUGU [2184-2202] 41 1679 ACCGUGGCUUCAUGGUGAA 2258 UUCACCAUGAAGCCACGGU Rh,Rt,M [891-909] 41 1680 CCCUUCAUCUUCCUAGUGA 2259 UCACUAGGAAGAUGAAGGG [1388-1406] 41 1681 GAAAUUCCACCACAAGAUA 2260 UAUCUUGUGGUGGAAUUUC Rh [865-883] 41 1682 CUAUAAAACUAGGUGCUGA 2261 UCAGCACCUAGUUUUAUAG Rh [1910-1928] 411683 IGGAGGUGCACGCCGGCCUA 2262 UAGGCCGGCGUGCACCUCC [544-562] 41 1684 GCAGGCCAAGGCAGUGCUA 2263 UAGCACUGCCUUGGCCUGC [502-520] 41 1685 UGAGACCAAAUUGAGCUAA 2264 UUAGCUCAAUUUGGUCUCA Rh [1818-1836] 41 1686 GCCAUAGUCAUUCUGCCUA 2265 UAGGCAGAAUGACUAUGGC [1730-1748] 41 1687 AGCUGAAGAUCUGGAUGGA 2266 UCCAUCCAGAUCUUCAGCU Rh,D [1095-1113] 411688 CCAUCUCCUUGCCCAAGGA 2267 UCCUUGGGCAAGGAGAUGG Rh [1137-1155] 42 1689 CCCAGAUCAAGCCUGCCUA 2268 UAGGCAGGCUUGAUCUGGG Rh [1759-1777] 42 1690 GCUGUUGCCAUCUCCUUGA 2269 UCAAGGAGAUGGCAACAGC [1130-1148] 42 1691 CGAGGUCACCAAGGACGUA 2270 UACGUCCUUGGUGACCUCG Rh,D [787-805] 42 1692 CAACUAUAAAACUAGGUGA 2271 UCACCUAGUUUUAUAGUUG Rh [1907-1925] 42 1693 GAAGGCUGUUGCCAUCUCA 2272 UGAGAUGGCAACAGCCUUC Rt [1126-1144] 195 WO 2011/072082 PCT/US2010/059578 42 1694 UGCGGAGAAGUUGAGCCCA 2273 UGGGCUCAACUUCUCCGCA [325-343] 42 1695 CUCCUUGCCCAAGGGUGUA 2274 UACACCCUUGGGCAAGGAG Rh [1141-1159] 42 1696 GCCCUGAAAGUCCCAGAUA 2275 UAUCUGGGACUUUCAGGGC [1748-1766] 42 1697 CAAGGGUGUGGUGGAGGUA 2276 UACCUCCACCACACCCUUG Rh,D [1150-1168] 42 1698 AAGAGCAGCUGAAGAUCUA 2277 UAGAUCUUCAGCUGCUCUU Rh [1089-1107] 43 1699 GAAGAUGCAGAAGAAGGCA 2278 UGCCUUCUUCUGCAUCUUC Rh,Rb,RL [1114-1132] 43 1700 CGGAAACUCCACAUCCUGA 2279 UCAGGAUGUGGAGUUUCCG [1702-1720] 43 1701 AGUCAACGCCAUGUUCUUA 2280 UAAGAACAUGGCGUUGACU Rh [829-847] 43 1702 CGAGCGCCUUGAAAAGCUA 2281 UAGCUUUCAAGGCGCUCG [1063-1081] 43 1703 AUACCGUGGGUGUCAUGAA 2282 UUCAUGACACCCACGGUAU Rh [918-936] 43 1704 GACCUGGGCCAUAGUCAUA 2283 UAUGACUAUGGCCCAGGUC [1723-1741] 43 1705 CAUGUCAGGCAAGAAGGAA 2284 UUCCUUCUUGCCUGACAUG Rh,D [1246-1264] 43 1706 UGCGAGACGAGUUAUAGGA 2285 UCCUAUAACUCGUCUCGCA Rh [1470-1488] 43 1707 CGCAACGUGACCUGGAAGA 2286 UCUUCCAGGUCACGUUGCG [599-617] 43 1708 AGCAAGCAGCACUACAACA 2287 UGUUGUAGUGCUGCUUGCU Rh,D [677-695] 44 1709 GCUGCUGCGCUCACUCAGA 2288 UCUGAGUGAGCGCAGCAGC Rh [568-586] 44 1710 UGAUGAUGCACCGGACAGA 2289 UCUGUCCGGUGCAUCAUCA Rh [933-951] 44 1711 UUGUUGCUAUCAAUCCAAA 2290 UUUGGAUUGAUAGCAACAA Rh [2122-2140] 44 1712 CCUUGAAAAGCUGCUAACA 2291 UGUUAGCAGCUUUUCAAGG [1069-1087] 44 1713 CCCUUUGACCAGGACAUCA 2292 UGAUGUCCUGGUCAAAGGG Rh,Rt [1322-1340] 44 1714 GAGGUGAAGAAACCUGCAA 2293 UUGCAGGUUUCUUCACCUC Rh [287-305] 44 1715 CCCAAGGGUGUGGUGGAGA 2294 UCUCCACCACACCCUUGGG Rh,D [1148-1166] 44 1716 CCCUGCUAUUCAUUGGGCA 2295 UGCCCAAUGAAUAGCAGGG D [1425-1443] 44 1717 CUGAAAGUCCCAGAUCAAA 2296 UUUGAUCUGGGACUUUCAG [1751-1769] 44 1718 GCUGCAAAUCGUGGAGAUA 2297 UAUCUCCACGAUUUGCAGC Rh [985-1003] 45 1719 CAAGCCUGCCUCAAUCAGA 2298 UCUGAUUGAGGCAGGCUUG Rh [1766-1784] 45 1720 CGAGCAGCUGCGCGACGAA 2299 UUCGUCGCGCAGCUGCUCG [526-544] 45 1721 AGGCCGACUUGUCACGCAA 2300 UUGCGUGACAAGUCGGCCU Rh [1230-1248] 45 1722 GCAGCAGCUCCUGGCACUA 2301 UAGUGCCAGGAGCUGCUGC [308-326] 45 1723 GGCCAUAGUCAUUCUGCCA 2302 UGGCAGAAUGACUAUGGCC [1729-1747] 45 1724 CCCGUGUGCCUGAGCGGAA 2303 UUCCGCUCAGGCACACGGG Rh [1624-1642] 45 1725 CAGCUGAAGAUCUGGAUGA 2304 UCAUCCAGAUCUUCAGCUG Rh,D [1094-1112] 45 1726 CAAGCCACACUGGGAUGAA 2305 UUCAUCCCAGUGUGGCUUG Rh,Rb [847-865] 45 1727 GAAUUCACUCCACUUGGAA 2306 UUCCAAGUGGAGUGAAUUC Rh [1654-1672] 45 1728 CGGCGCCCUGCUAGUCAAA 2307 UUUGACUAGCAGGGCGCCG Rh [817-835] 46 1729 UGGAAGCUGGGCAGCCGAA 2308 UUCGGCUGCCCAGCUUCCA [611-629] 46 1730 GGCAAGGCGACCACGGCGA 2309 UCGCCGUGGUCGCCUUGCC Rh [482-500] 46 1731 CACUGCGGAGAAGUUGAGA 2310 UCUCAACUUCUCCGCAGUG [322-340] 46 1732 GGCAGGAGGCAUCCAAAGA 2311 UCUUUGGAUGCCUCCUGCC [1509-1527] 46 1733 GGUGACUCGGUCCUAUACA 2312 UGUAUAGGACCGAGUCACC Rh [904-922] 46 1734 UUUAUAGCCAGGUACCUUA 2313 UAAGGUACCUGGCUAUAAA Rh [1792-1810] 46 1735 GGCCAUGGCCAAGGACCAA 2314 UUGGUCCUUGGCCAUGGCC Rh,D [397-415] 46 1736 CAAAGAUAGGGAGGGAAGA 2315 UCUUCCCUCCCUAUCUUUG [2089-2107] 46 1737 UCUUCUGACACUAAAACAA 2316 UUGUUUUAGUGUCAGAAG [1853-1871] 46 1738 CUUCUGACACUAAAACACA 2317 UCUGUUUUAGUGUCAGAA [1854-1872] 47 1739 UCACGUGGAGCCUCUCGAA 2318 UUCGAGAGGCUCCACGUGA [1048-1066] 196 WO 2011/072082 PCT/US2010/059578 47 1740 CAGUCCAUCAACGAGUGGA 2319 UCCACUCGUUGAUGGACUG Rh,Rt,M [740-758] 47 1741 AGACCAAAUUGAGCUAGGA 2320 UCCUAGCUCAAUUUGGUCU [1820-1838] 47 1742 GGGUUCCCGUGUGCCUGAA 2321 UUCAGGCACACGGGAACCC Rh [1619-1637] 47 1743 UUGCUAUCAAUCCAAGAAA 2322 UUUCUUGGAUUGAUAGCAA Rh [2125-2143] 47 1744 CAACCGUGGCUUCAUGGUA 2323 UACCAUGAAGCCACGGUUG Rh,Rt,M [889-907] 47 1745 CUGUACGGACCCAGCUCAA 2324 UUGAGCUGGGUCCGUACAG [629-647] 47 1746 CAGCAGCAAGCAGCACUAA 2325 UUAGUGCUGCUUGCUGCUG Rh,D [673-691] 47 1747 CCUGCAGCCGCAGCAGCUA 2326 UAGCUGCUGCGGCUGCAGG [299-317] 47 1748 GACACUAAAACACCUCAGA 2327 UCUGAGGUGUUUUAGUGUC [1859-1877] 48 1749 CAACUGCGAGCACUCCAAA 2328 UUUGGAGUGCUCGCAGUUG Rh,D [691-709] 48 1750 ACUGCGGAGAAGUUGAGCA 2329 UGCUCAACUUCUCCGCAGU [323-341] 48 1751 GCGCCCUGCUAGUCAACGA 2330 UCGUUGACUAGCAGGGCGC Rh [819-837] 48 1752 GGAAGCUGGGCAGCCGACA 2331 UGUCGGCUGCCCAGCUUCC [612-630] 48 1753 AGGCUCCUGAGACACAUGA 2332 UCAUGUGUCUCAGGAGCCU D [1525-1543] 48 1754 CGACAAGCGCAGCGCGCUA 2333 UAGCGCGCUGCGCUUGUCG [721-739] 48 1755 UCAGUGAGCUUCGCUGAUA 2334 UAUCAGCGAAGCUCACUGA [644-662] 48 1756 UUGAGAAGGAGCUCCCAGA 2335 UCUGGGAGCUCCUUCUCAA [1979-1997] 48 1757 ACUGCGAGCACUCCAAGAA 2336 UUCUUGGAGUGCUCGCAGU Rh,D [693-7111 48 1758 CAUCCUGGUGUCACCCGUA 2337 UACGGGUGACACCAGGAUG [427-445] 49 1759 GUGCGCAGCAGCAAGCAGA 2338 UCUGCUUGCUGCUGCGCAC Rh,D [668-686] 49 1760 CACGCCACCGCCUUUGAGA 2339 UCUCAAAGGCGGUGGCGUG Rh [1286-1304] 49 1761 UCUCGAGCGCCUUGAAAAA 2340 UUUUUCAAGGCGCUCGAGA [1060-1078] 49 1762 GCUUCGCUGAUGACUUCGA 2341 UCGAAGUCAUCAGCGAAGC Rh [651-669] 49 1763 UCUCCUUGCCCAAGGGUGA 2342 UCACCCUUGGGCAAGGAGA Rh [1140-1158] 49 1764 GCAGUCCAUCAACGAGUGA 2343 UCACUCGUUGAUGGACUGC Rh,Rt,M [739-757] 49 1765 AGAUGGUGGACAACCGUGA 2344 UCACGGUUGUCCACCAUCU Rh,M [879-897] 49 1766 CGGCUCCCUGCUAUUCAUA 2345 UAUGAAUAGCAGGGAGCCG [1420-1438] 49 1767 AUACCAUGAUGCUGAGCCA 2346 UGGCUCAGCAUCAUGGUAU [1684-1702] 49 1768 AGCCAGGUACCUUCUCACA 2347 UGUGAGAAGGUACCUGGCU Rh [1797-1815] 50 1769 GAGCCCGGAAACUCCACAA 2348 UUGUGGAGUUUCCGGGCUC [1697-1715] 50 1770 GCAGCUCCUGGCACUGCGA 2349 UCGCAGUGCCAGGAGCUGC [311-329] 50 1771 CCCGAGGUCACCAAGGACA 2350 UGUCCUUGGUGACCUCGGG Rh,D [785-803] 50 1772 CCUGACUGAGGCCAUUGAA 2351 UUCAAUGGCCUCAGUCAGG Rh [1204-1222] 50 1773 UGCUGAGCCCGGAAACUCA 2352 UGAGUUUCCGGGCUCAGCA [1693-1711] 50 1774 GCCAUCUCCUUGCCCAAGA 2353 UCUUGGGCAAGGAGAUGGC Rh [1136-1154] 50 1775 CAAGCAGCACUACAACUGA 2354 UCAGUUGUAGUGCUGCUUG Rh,D [679-697] 50 1776 CAAGGCAGUGCUGAGCGCA 2355 UGCGCUCAGCACUGCCUUG Rh [508-526] 50 1777 CAAUGACAUUUUGUUGGAA 2356 UUCCAACAAAAUGUCAUUG [2179-2197] 50 1778 AGUGAGCUUCGCUGAUGAA 2357 UUCAUCAGCGAAGCUCACU [646-664] 51 1779 AUGAUGAUGCACCGGACAA 2358 UUGUCCGGUGCAUCAUCAU Rh [932-950] 511780 GAAACACCUGGCUGGGCUA 2359 UAGCCCAGCCAGGUGUUUC D [1183-1201] 51 1781 CCUGCUAUUCAUUGGGCGA 2360 UCGCCCAAUGAAUAGCAGG D [1426-1444] 51 1782 CGCCACCGCCUUUGAGUUA 2361 UAACUCAAAGGCGGUGGCG Rh [1288-1306] 51 1783 GCUUCUCAGCGCCUUCUGA 2362 UCAGAAGGCGCUGAGAAGC [244-262] 51 1784 UGAUGCUGAGCCCGGAAAA 2363 UUUUCCGGGCUCAGCAUCA [1690-1708] 51 1785 UGACCUGGCCGCAGUGAGA 2364 UCUCACUGCGGCCAGGUCA [1956-1974] 197 WO 2011/072082 PCT/US2010/059578 51 1786 UGCAGAAACACCUGGCUGA 2365 UCAGCCAGGUGUUUCUGCA [1179-1197] 51 1787 GCAGUGCUGAGCGCCGAGA 2366 UCUCGGCGCUCAGCACUGC [512-530] 511788 CGGCGCGCAACGUGACCUA 2367 UAGGUCACGUUGCGCGCCG [594-612] 52 1789 AGUGCUGAGCGCCGAGCAA 2368 UUGCUCGGCGCUCAGCACU [514-532] 52 1790 ACAGGCCUCUACAACUACA 2369 UGUAGUUGUAGAGGCCUGU Rh,Rb,D, [947-965] 52 1791 GCAGCUGCGCGACGAGGAA 2370 UUCCUCCiUCGCGCAGCUGC Rh,D [529-547] 52 1792 AUUGAGAAGGAGCUCCCAA 2371 UUGGGAGCUCCUUCUCAAU [1978-1996] 52 1793 CGCGCAGACCACCGACGGA 2372 UCCGUCGGUGGUCUGCGCG [760-778] 52 1794 CCUGUACCUGGCCAGCGUA 2373 UACGCUGGCCAGGUACAGG Rh [1264-1282] 52 1795 CUGAGCGGACCUUCCCAGA 2374 UCUGGGAAGGUCCGCUCAG Rh [1633-1651] 52 1796 GGCCUUCAGCUUGUACCAA 2375 UUGGUACAAGCUGAAGGCC [379-397] 52 1797 CACCCAAAGCGGCUCCCUA 2376 UAGGGAGCCGCUUUGGGUG [1411-1429] 52 1798 GCCAAGGACCAGGCAGUGA 2377 UCACUGCCUGGUCCUUGGC Rh [404-422] 53 1799 CUCAGGGUGCACACAGGAA 2378 UUCCUGUGUGCACCCUGAG [1490-1508] 53 1800 CGAGCUGCUGCGCUCACUA 2379 UAGUGAGCGCAGCAGCUCG Rh [565-583] 53 1801 GGCUGGGCCUGACUGAGGA 2380 UCCUCAGUCAGGCCCAGCC [1197-1215] 53 1802 CCGCAGCAGCUCCUGGCAA 2381 UUGCCAGGAGCUGCUGCGG [306-324] 53 1803 UGUGGGACCUGGGCCAUAA 2382 UUAUGGCCCAGGUCCCACA [1718-1736] 53 1804 AAGAUGCAGAAGAAGGCUA 2383 UAGCCUUCUUCUGCAUCUU Rh,Rt,M [1115-1133] 53 1805 CCACGGCGCGCAACGUGAA 2384 UUCACGUUGCGCGCCGUGG Rh [591-609] 53 1806 ACCUUCUCACCUGUGAGAA 2385 UUCUCACAGGUGAGAAGGU Rh [1805-1823] 53 1807 UGAAGAAACCUGCAGCCGA 2386 UCGGCUGCAGGUUUCUUCA [291-309] 53 1808 CAGCACUACAACUGCGAGA 2387 UCUCGCAGUUGUAGUGCUG Rh,D [683-701] 54 1809 GCGACAAGCGCAGCGCGCA 2388 UGCGCGCUGCGCUUGUCGC [720-738] 54 1810 UAGAAUUCACUCCACUUGA 2389 UCAAGUGGAGUGAAUUCUA Rh [1652-1670] 54 1811 GUGGAAAAACAGACCGGGA 2390 UCCCGGUCUGUUUUUCCAC [1603-1621] 54 1812 ACGUGGAGCCUCUCGAGCA 2391 UGCUCGAGAGGCUCCACGU [1050-1068] 54 1813 GGCGCGCAACGUGACCUGA 2392 UCAGGUCACGUUGCGCGCC [595-613] 54 1814 UGGACAACCGUGGCUUCAA 2393 UUGAAGCCACGGUUGUCCA Rh,M [885-903] 54 1815 CUAGUCAACGCCAUGUUCA 2394 UGAACAUGGCGUUGACUAG Rh [827-845] 54 1816 AGAAUGACCUGGCCGCAGA 2395 UCUGCGGCCAGGUCAUUCU [1952-1970] 54 1817 AGCUGCUGCGCUCACUCAA 2396 UUGAGUGAGCGCAGCAGCU Rh [567-585] 54 1818 CUCUAUCCCAACCUCUCCA 2397 UGGAGAGGUUGGGAUAGA Rh [1889-1907] 55 1819 GCGAGCUGCUGCGCUCACA 2398 UGUGAGCGCAGCAGCUCGC Rh [564-582] 55 1820 CGCAGCAGCAAGCAGCACA 2399 UGUGCUGCUUGCUGCUGCG Rh,D [671-689] 55 1821 GGCUGGGCUGGGCCUGACA 2400 UGUCAGGCCCAGCCCAGCC [1192-1210] 55 1822 UCUCCAGCCUCAUCAUCCA 2401 UGGAUGAUGAGGCUGGAG Rh,D,Rt, [1020-1038] 55 1823 CAACGCCAUGUUCUUCAAA 2402 UUUGAAGAACAUGGCGUUG Rh,Rb,P [832-850] 55 1824 UGGCACUGCGGAGAAGUUA 2403 UAACUUCUCCGCAGUGCCA [319-337] 55 1825 UUUGAGUUGGACACAGAUA 2404 UAUCUGUGUCCAACUCAAA [1298-1316] 55 1826 UGGGCGAGCUGCUGCGCUA 2405 UAGCGCAGCAGCUCGCCCA Rh [561-579] 55 1827 CUGCUAACCAAAGAGCAGA 2406 UCUGCUCUUUGGUUAGCAG [1079-1097] 55 1828 AACGUGACCUGGAAGCUGA 2407 UCAGCUUCCAGGUCACGUU [602-620] 56 1829 AUGACAUUUUGUUGGAGCA 2408 UGCUCCAACAAAAUGUCAU [2181-2199] 56 1830 CAGGAGGCAUCCAAAGGCA 2409 UGCCUUUGGAUGCCUCCUG [1511-1529] 56 1831 AUCUCCUUGCCCAAGGGUA 2410 UACCCUUGGGCAAGGAGAU Rh [1139-1157] 198 WO 2011/072082 PCT/US2010/059578 56 1832 UGGGAUGAGAAAUUCCACA 2411 UGUGGAAUUUCUCAUCCCA Rh [857-875] 56 1833 AAAGCUGCUAACCAAAGAA 2412 UUCUUUGGUUAGCAGCUUU [1075-1093] 56 1834 AGGAGGCAUCCAAAGGCUA 2413 UAGCCUUUGGAUGCCUCCU [1512-1530] 56 1835 CACCGCCUUUGAGUUGGAA 2414 UUCCAACUCAAAGGCGGUG Rh [1291-1309] 56 1836 CCAACUAUAAAACUAGGUA 2415 UACCUAGUUUUAUAGUUGGRh [1906-1924] 56 1837 CAAGAAGCAUCGUGUCUGA 2416 UCAGACACGAUGCUUCUUG Rh [2022-2040] 56 1838 AGCAGCUGAAGAUCUGGAA 2417 UUCCAGAUCUUCAGCUGCU Rh,D [1092-1110] 57 1839 GCGCUCCCUCCUGCUUCUA 2418 UAGAAGCAGGAGGGAGCGC [232-250] 57 1840 UGCUAGUCAACGCCAUGUA 2419 UACAUGGCGUUGACUAGCA Rh [825-843] 57 1841 CGCCGAGCAGCUGCGCGAA 2420 UUCGCGCAGCUGCUCGGCG [523-541] 57 1842 CCGCGCAGACCACCGACGA 2421 UCGUCGGUGGUCUGCGCGG [759-777] 57 1843 UAGCCAGGUACCUUCUCAA 2422 UUGAGAAGGUACCUGGCUA Rh [1796-1814] 57 1844 UGCUUCUCAGCGCCUUCUA 2423 UAGAAGGCGCUGAGAAGCA [243-261] 57 1845 CUCCCUCCUGCUUCUCAGA 2424 UCUGAGAAGCAGGAGGGAG [235-253] 57 1846 CGCAGGCCAAGGCAGUGCA 2425 UGCACUGCCUUGGCCUGCG [501-519] 57 1847 GCAAGGCGACCACGGCGUA 2426 UACGCCGUGGUCGCCUUGC Rh [483-501] 57 1848 GCAGCCGCAGCAGCUCCUA 2427 UAGGAGCUGCUGCGGCUGC [302-320] Table E: SERPINHI Cross-Species 18+1-mer siRNAs No. SEQ ID NO Sense siRNA SEQ AntiSense siRNA Other human 1 2428 UCACCAAGGACGUGGAGCA 2576 UGCUCCACGUCCUUGGU Rh,D [792-810] 2 2429 CAGCGCGCUGCAGUCCAUA 2577 UAUGGACUGCAGCGCGC Rh,Rt [730-748] 3 2430 CAUCUACGGGCGCGAGGAA 2578 UUCCUCGCGCCCGUAGA D,M [1336-1354] 4 2431 CUCCAGCCUCAUCAUCCUA 2579 UAGGAUGAUGAGGCUGG Rh,D,Rt,M [1021-1039] 5 2432 GACAUCUACGGGCGCGAGA 2580 UCUCGCGCCCGUAGAUG D,M [1334-1352] 6 2433 CGUGCGCAGCAGCAAGCAA 2581 UUGCUUGCUGCUGCGCA Rh,D,M [667-685] 7 2434 GUCACCAAGGACGUGGAGA 2582 UCUCCACGUCCUUGGUG Rh,D [791-809] 8 2435 CCGCGACAAGCGCAGCGCA 2583 UGCGCUGCGCUUGUCGC D [718-736] 9 2436 GCGCAGCGCGCUGCAGUCA 2584 UGACUGCAGCGCGCUGC Rh,Rt [727-745] 10 2437 GGCCCACAAGCUCUCCAGA 2585 UCUGGAGAGCUUGUGGG Rh,D,P [1009-1027] 11 2438 CAAGGACGUGGAGCGCACA 2586 UGUGCGCUCCACGUCCU Rh,D [796-814] 12 2439 AGCCUCAUCAUCCUCAUGA 2587 UCAUGAGGAUGAUGAGG Rh,D,Rt,M [1025-1043] 13 2440 GGUGUGGUGGAGGUGACCA 2588 UGGUCACCUCCACCACA Rh,D [1154-1172] 14 2441 GCAAGCUGCCCGACGGUCAA 2589 UUGACCUCGGGCAGCUU Rh,D [777-795] 15 2442 GUGGAGGUGACCCAUGACA 2590 UGUCAUGGGUCACCUCC Rh,Rt,M [1160-1178] 16 2443 CACAAGAUGGUGGACAACA 2591 UGUUGUCCACCAUCUUG Rh,Rb,M,P [875-893] 17 2444 GCGAGGAGCUGCGCAGCCA 2592 UGGCUGCGCAGCUCCUC D,M [1347-1365] 18 2445 UACUACGACGACGATAAGA 2593 UCUUCUCGUCGCUAG Rb [962-980] 19 2446 GAGGUGACCCAUGACCUGA 2594 UCAGGUCAUGGGUCACC Rh,Rt,M [1163-1181] 20 2447 ACUUCCGCGACAAGCGCAA 2595 UUGCGCUUGUCGCGGAA D [714-732] 21 2448 GCCCACAAGCUCUCCAGCA 2596 UGCUGGAGAGCUUGUGG Rh,D,P [1010-1028] 22 2449 GCGCAGCAGCAAGCAGCAA 2597 UUGCUGCUUGCUGCUGC Rh,D [670-688] 199 WO 2011/072082 PCT/US2010/059578 23 2450 CGAGGAGCUGCGCAGCCCA 2598 UGGGCUGCGCAGCUCCU D,M [1348-1366] 24 2451 AACGCCAUGUUCUUCAAGA 2599 UCUUGAAGAACAUGGCG Rh,Rb,P [833-851] 25 2452 GUCAGGCAAGAAGGACCUA 2600 UAGGUCCUUCUUGCCUG Rh,D [1249-1267] 26 2453 GCCUGGGCGAGCUGCUGCA 2601 UGCAGCAGCUCGCCCAG Rh,D [558-576] 27 2454 GAUGAUGCACCGGACAGGA 2602 UCCUGUCCGGUGCAUCA Rh,Rb,Rt,M [934-952] 28 2455 GGACCUGUACCUGGCCAGA 2603 UCUGGCCAGGUACAGGU Rh,D [1261-1279] 29 2456 GCGACGAGGAGGUGCACGA 2604 UCGUGCACCUCCUCGUC D [537-555] 30 2457 UGUGGUGGAGGUGACCCAA 2605 UUGGGUCACCUCCACCA Rh,D [1156-1174] 31 2458 UUCAAGCCACACUGGGAUA 2606 UAUCCCAGUGUGGCUUG Rh,Rb [845-863] 32 2459 CAAGAUGGUGGACAACCGA 2607 UCGGUUGUCCACCAUCU Rh,Rb,M,P [877-895] 33 2460 UCAACUUCCGCGACAAGCA 2608 UGCUUGUCGCGGAAGUU D [711-729] 34 2461 AUUCAUUGGGCGCCUGGUA 2609 UACCAGGCGCCCAAUGA D [1432-1450] 35 2462 CUCCAAGAUCAACUUCCGA 2610 UCGGAAGUUGAUCUUGG Rh,D,Rt,M [703-721] 36 2463 CAGGCCAUGGCCAAGGACA 2611 UGUCCUUGGCCAUGGCC Rh,D [395-413] 37 2464 GUACCAGGCCAUGGCCAAA 2612 UUUGGCCAUGGCCUGGU Rh,D [391-409] 38 2465 UGUCAGGCAAGAAGGACCA 2613 UGGUCCUUCUUGCCUGA Rh,D [1248-1266] 39 2466 CUUCGUGCGCAGCAGCAAA 2614 UUUGCUGCUGCGCACGA Rh,D,M [664-682] 40 2467 CAACUUCCGCGACAAGCGA 2615 UCGCUUGUCGCGGAAGU D [712-730] 41 2468 CCACCACAAGAUGGUGGAA 2616 UUCCACCAUCUUGUGGU Rh,Rb,D,P [871-889] 42 2469 GCGCGACGAGGAGGUGCAA 2617 UUGCACCUCCUCGUCGC Rh,D [535-553] 43 2470 CUACAACUGCGAGCACUCA 2618 UGAGUGCUCGCAGUUGU Rh,D [688-706] 44 2471 UGGAGGUGACCCAUGACCA 2619 UGGUCAUGGGUCACCUC Rh,Rt,M [1161-1179] 45 2472 GAGGUCACCAAGGACGUGA 2620 UCACGUCCUUGGUGACC Rh,D [788-806] 46 2473 AAGAAGGACCUGUACCUGA 2621 UCAGGUACAGGUCCUUC Rh,D [1256-1274] 47 2474 GACAACCGUGGCUUCAUGA 2622 UCAUGAAGCCACGGUUG Rh,Rt,M [887-905] 48 2475 ACCAGGACAUCUACGGGCA 2623 UGCCCGUAGAUGUCCUG D,Rt [1329-1347] 49 2476 GCUGCCCGAGGUCACCAAA 2624 UUUGGUGACCUCGGGCA Rh,D [781-799] 50 2477 AUGCAGAAGAAGGCUGUUA 2625 UAACAGCCUUCUUCUGC Rt [1118-1136] 51 2478 GGCCUGGGCGAGCUGCUGA 2626 UCAGCAGCUCGCCCAGG Rh,D [557-575] 52 2479 GAUGGUGGACAACCGUGGA 2627 UCCACGGUUGUCCACCA Rh,M [880-898] 53 2480 CUCCCUGCUAUUCAUUCiGA 2628 UCCAAUGAAUAGCAGGG D [1423-1441] 54 2481 GAAGGACCUGUACCUGGCA 2629 UGCCAGGUACAGGUCCU Rh,D [1258-1276] 55 2482 CCACCGACGGCAAGCUGCA 2630 UGCAGCUUGCCGUCGGU D,Rt [768-786] 56 2483 UGCUAUUCAUUGGGCGCCA 2631 UGGCGCCCAAUGAAUAG D [1428-1446] 57 2484 AUGUUCUUCAAGCCACACA 2632 UGUGUGGCUUGAAGAAC Rh,Rb,D [839-857] 58 2485 CCAGGACAUCUACGGGCGA 2633 UCGCCCGUAGAUGUCCU D,Rt [1330-1348] 59 2486 GCGCGAGGAGCUGCGCAGA 2634 UCUGCGCAGCUCCUCGC Rh,D,M [1345-1363] 60 2487 GAGCAGCUGCGCGACGAGA 2635 UCUCGUCGCGCAGCUGC Rh,D [527-545] 61 2488 CUAUUCAUUGGGCGCCUGA 2636 UCAGGCGCCCAAUGAAU D [1430-1448] 62 2489 ACAAGCUCUCCAGCCUCAA 2637 UUGAGGCUGGAGAGCUU Rh,D,M,P [1014-1032] 63 2490 GCUGAAGAUCUGGAUGGGA 2638 UCCCAUCCAGAUCUUCA Rh,D [1096-1114] 64 2491 GACCAGGACAUCUACGGGA 2639 UCCCGUAGAUGUCCUGG D,Rt [1328-1346] 65 2492 CAAGCGCAGCGCGCUGCAA 2640 UUGCAGCGCGCUGCGCU Rh,Rt [724-742] 66 2493 CCAUGGCCAAGGACCAGGA 2641 UCCUGGUCCUUGGCCAU Rh,D [399-417] 67 2494 CACCAAGGACGUGGAGCGA 2642 UCGCUCCACGUCCUUGG Rh,D [793-811] 68 2495 CCGUGGCUUCAUGGUGACA 2643 UGUCACCAUGAAGCCAC Rh,Rt,M [892-910] 200 WO 2011/072082 PCT/US2010/059578 69 2496 UGACCAGGACAUCUACGGA 2644 UCCGUAGAUGUCCUGGU Rt [1327-1345] 70 2497 AGACCACCGACGGCAAGCA 2645 UGCUUGCCGUCGGUGGU D,Rt [765-783] 71 2498 GACAAGCGCAGCGCGCUGA 2646 UCAGCGCGCUGCGCUUG Rh,Rt [722-740] 72 2499 AGAAACACCUGGCUGGGCA 2647 UGCCCAGCCAGGUGUUU D [1182-1200] 73 2500 AAGAUGGUGGACAACCGUA 2648 UACGGUUGUCCACCAUC Rh,M [878-896] 74 2501 CAGACCACCGACGGCAAGA 2649 UCUUGCCGUCGGUGGUC D,Rt [764-782] 75 2502 AGGACCUGUACCUGGCCAA 2650 UUGGCCAGGUACAGGUC Rh,D [1260-1278] 76 2503 CUGCUAUUCAUUGGGCGCA 2651 UGCGCCCAAUGAAUAGC D [1427-1445] 77 2504 GUCCAUCAACGAGUGGGCA 2652 UGCCCACUCGUUGAUGG Rh,Rt,M [742-760] 78 2505 CCAGGCCAUGGCCAAGGAA 2653 UUCCUUGGCCAUGGCCU Rh,D [394-412] 79 2506 AAGCAGCACUACAACUGCA 2654 UGCAGUUGUAGUGCUGC Rh,D [680-698] 80 2507 UGUUCCACGCCACCGCCUA 2655 UAGGCGGUGGCGUGGAA D [1281-1299] 81 2508 UACAACUACUACGACGACA 2656 UGUCGUCGUAGUAGUUG Rb [956-974] 82 2509 CCUCAUCAUCCUCAUGCCA 2657 UGGCAUGAGGAUGAUGA Rh,D,Rt,M [1027-1045] 83 2510 UGGUGGACAACCGUGGCUA 2658 UAGCCACGGUUGUCCAC Rh,M [882-900] 84 2511 GACCACCGACGGCAAGCUA 2659 UAGCUUGCCGUCGGUGG D,Rt [766-784] 85 2512 AGCUGCGCGACGAGGAGGA 2660 UCCUCCUCGUCGCGCAG Rh,D [531-549] 86 2513 CGGCAAGCUGCCCGAGGUA 2661 UACCUCGGGCAGCUUGC Rh,D [775-793] 87 2514 UGGCCCACAAGCUCUCCAA 2662 UUGGAGAGCUUGUGGGC Rh,D,P [1008-1026] 88 2515 CAGCUGCGCGACGAGGAGA 2663 UCUCCUCGUCGCGCAGC Rh,D [530-548] 89 2516 CUUCCGCGACAAGCGCAGA 2664 UCUGCGCUUGUCGCGGA D [715-733] 90 2517 UGGGCCUGACUGAGGCCAA 2665 UUGGCCUCAGUCAGGCC Rt [1200-1218] 91 2518 GCUGCGCGACGAGGAGGUA 2666 UACCUCCUCGUCGCGCA Rh,D [532-550] 92 2519 CAGGACAUCUACGGGCGCA 2667 UGCGCCCGUAGAUGUCC D [1331-1349] 93 2520 GCCAUGGCCAAGGACCAGA 2668 UCUGGUCCUUGGCCAUG Rh,D [398-416] 94 2521 UCCAAGAUCAACUUCCGCA 2669 UGCGGAAGUUGAUCUUG D [704-722] 95 2522 ACCACCGACGGCAAGCUGA 2670 UCAGCUUGCCGUCGGUG D,Rt [767-785] 96 2523 AUCUACGGGCGCGAGGAGA 2671 UCUCCUCGCGCCCGUAG D,M [1337-1355] 97 2524 CUGCCCGAGGUCACCAAGA 2672 UCUUGGUGACCUCGGGC Rh,D [782-800] 98 2525 AUCAACUUCCGCGACAAGA 2673 UCUUGUCGCGGAAGUUG D [710-728] 99 2526 UCAUUGGGCGCCUGTUCCA 2674 UGGACCAGGCGCCCAAU Rh,D [1434-1452] 100 2527 CAUUGGGCGCCUGGUCCGA 2675 UCGGACCAGGCGCCCAA Rh,D [1435-1453] 101 2528 GUGUUCCACGCCACCGCCA 2676 UGGCGGUGGCGUGGAAC D [1280-1298] 102 2529 AUGAUGCACCGGACAGGCA 2677 UGCCUGUCCGGUGCAUC Rh,Rb,Rt,M [935-953] 103 2530 CGACGAGGAGGUGCACGCA 2678 UGCGUGCACCUCCUCGU D [538-556] 104 2531 CAGAAACACCUGGCUGGGA 2679 UCCCAGCCAGGUGUUUC D [1181-1199] 105 2532 UGAUGCACCGGACAGGCCA 2680 UGGCCUGUCCGGUGCAU Rh,Rb,Rt,M [936-954] 106 2533 AAGGCUGUUGCCAUCUCCA 2681 UGGAGAUGGCAACAGCC D,Rt [1127-1145] 107 2534 AUGACUUCGUGCGCAGCAA 2682 UUGCUGCGCACGAAGUC Rh,Rt,M [660-678] 108 2535 UCAGGCAAGAAGGACCUGA 2683 UCAGGUCCUUCUUGCCU Rh,D [1250-1268] 109 2536 CUCAUCAUCCUCAUGCCCA 2684 UGGGCAUGAGGAUGAUG Rh,Rt,M [1028-1046] 110 2537 CGCGACGAGGAGGUGCACA 2685 UGUGCACCUCCUCGUCG Rh,D [536-554] 111 2538 ACAACCGUGGCUUCAUGGA 2686 UCCAUGAAGCCACGGUU Rh,Rt,M [888-906] 112 2539 UUGACCAGGACAUCUACGA 2687 UCGUAGAUGUCCUGGUC Rt [1326-1344] 113 2540 CAAGCUGCCCGAGGUCACA 2688 JUGUGACCUCGGGCAGCU Rh,D [778-796] 114 2541 UCCCUGCUAUUCAUUGGGA 2689 UCCCAAUGAAUAGCAGG D [1424-1442] 201 WO 2011/072082 PCT/US2010/059578 115 2542 UAUUCAUUGGGCGCCUGGA 2690 UCCAGGCGCCCAAUGAA D [1431-1449] 116 2543 CUGCGCGACGAGGAGGUGA 2691 UCACCUCCUCGUCGCGC Rh,D [533-551] 117 2544 CUACGGGCGCGAGGAGCUA 2692 UAGCUCCUCGCGCCCGU D,M [1339-1357] 118 2545 CGCGAGGAGCUGCGCAGCA 2693 UGCUGCGCAGCUCCUCG D,M [1346-1364] 119 2546 ACACCUGGCUGGGCUGGGA 2694 UCCCAGCCCAGCCAGGU D [1186-1204] 120 2547 UCUACGGGCGCGAGGAGCA 2695 UGCUCCUCGCGCCCGUA D,M [1338-1356] 121 2548 UUCUUCAAGCCACACUGGA 2696 UCCAGUGUGGCUUGAAG Rh,Rb,D [842-860] 122 2549 CCUGGGCGAGCUGCUGCGA 2697 UCGCAGCAGCUCGCCCA Rh,D [559-577] 123 2550 AAGAAGGCUGUUGCCAUCA 2698 UGAUGGCAACAGCCUUC Rt [1124-1142] 124 2551 CGACGGCAAGCUGCCCGAA 2699 UUCGGGCAGCUUGCCGU D [772-790] 125 2552 GACGGCAAGCUGCCCGAGA 2700 UCUCGGGCAGCUUGCCG Rh,D [773-791] 126 2553 UUCAUUGGGCGCCUGGUCA 2701 UGACCAGGCGCCCAAUG Rh,D [1433-1451] 127 2554 AAGCGCAGCGCGCUGCAGA 2702 UCUGCAGCGCGCUGCGC Rh,Rt [725-743] 128 2555 CCUGGCCCACAAGCUCUCA 2703 UGAGAGCUUGUGGGCCA Rh,D,P [1006-1024] 129 2556 ACGGCAAGCUGCCCGAGGA 2704 UCCUCGGGCAGCUUGCC Rh,D [774-792] 130 2557 UUUGACCAGGACAUCUACA 2705 UGUAGAUGUCCUGGUCA Rt [1325-1343] 131 2558 UGACUUCGUGCGCAGCAGA 2706 UCUGCUGCGCACGAAGU Rh,Rt,M [661-679] 132 2559 AAGGACGUGGAGCGCACGA 2707 UCGUGCGCUCCACGUCC Rh,D [797-815] 133 2560 UCCAUCAACGAGUGGGCCA 2708 UGGCCCACUCGUUGAUG Rt,M [743-761] 134 2561 CACCGACGGCAAGCUGCCA 2709 UGGCAGCUUGCCGUCGG D,Rt [769-787] 135 2562 ACGGGCGCGAGGAGCUGCA 2710 UGCAGCUCCUCGCGCCC D,M [1341-1359] 136 2563 UCCGCGACAAGCGCAGCGA 2711 UCGCUGCGCUUGUCGCG D [717-735] 137 2564 UUGGGCGCCUGGUCCGGCA 2712 UGCCGGACCAGGCGCCC Rh,D [1437-1455] 138 2565 AUGGUGGACAACCGUGGCA 2713 UGCCACGGUUGUCCACC Rh,M [881-899] 139 2566 AUUGGGCGCCUGGUCCGGA 2714 UCCGGACCAGGCGCCCA Rh,D [1436-1454] 140 2567 UACGGGCGCGAGGAGCUGA 2715 UCAGCUCCUCGCGCCCG D,M [1340-1358] 141 2568 AUGCACCGGACAGGCCUCA 2716 UGAGGCCUGUCCGGUGC Rh,Rb,Rt,P [938-956] 142 2569 UUCCACCACAAGAUGGUGA 2717 UCACCAUCUUGUGGUGG Rh,Rb,D,P [869-887] 143 2570 UUCCGCGACAAGCGCAGCA 2718 UGCUGCGCUUGUCGCGG D [716-734] 144 2571 UACCAGGCCAUGGCCAAGA 2719 UCUUGGCCAUGGCCUGG Rh,D [392-410] 145 2572 AAACACCUGGCUGGGCUGA 2720 UCAGCCCAGCCAGGUGU D [1184-1202] 146 2573 ACCGACGGCAAGCUGCCCA 2721 UGGGCAGCUUGCCGUCG D [770-788] 147 2574 ACACCUGGCUGGGCUGGA 2722 UCCAGCCCAGCCAGGUG D [1185-1203] 148 2575 UUCGUGCGCAGCAGCAAGA 2723 UCUUGCUGCUGCGCACG Rh,D,M [665-683] EXAMPLE 10: Animal models Modcl systems of fibrotic conditions [0500] Testing the active siRNAs of the invention may be done in predictive animal models. Rat diabetic and aging models of kidney fibrosis include Zucker diabetic fatty (ZDF) rats, aged fa/fa (obese Zucker) rats, aged Sprague-Dawley (SD) rats, and Goto Kakizaki (GK) rats; GK rats are an inbred strain derived from Wistar rats, selected for spontaneous 202 WO 2011/072082 PCT/US2010/059578 development of NIDDM (diabetes type II). Induced models of kidney fibrosis include the permanent unilateral ureteral obstruction (UUO) model which is a model of acute interstitial fibrosis occurring in healthy non-diabetic animals; renal fibrosis develops within days following the obstruction. Another induced model of kidney fibrosis is 5/6 nephrectomy. [0501] Two models of liver fibrosis in rats are the Bile Duct Ligation (BDL) with sham operation as controls, and CCl4 poisoning, with olive oil fed animals as controls, as described in the following references: Lotersztajn S, et al Hepatic Fibrosis: Molecular Mechanisms and Drug Targets. Annu Rev Pharmacol Toxicol. 2004 Oct 07; Uchio K, et al., Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen. 2004 Jan-Feb;12(1):60-6; Xu XQ, et al., Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics Proteornics. 2004 Oct;4(10):3235-45. [0502] Models for ocular scarring are well known in the art e.g. Sherwood MB et al., J Glaucoma. 2004 Oct;13(5):407-12. A new model of glaucoma filtering surgery in the rat; Miller MH et al., Ophthalmic Surg. 1989 May;20(5):350-7. Wound healing in an animal model of glaucoma fistulizing surgery in the Rb; vanBockxmccr FM ct al., Retina. 1985 Fall Winter; 5(4): 239-52. Models for assessing scar tissue inhibitors; Wiedemann P et al., J Pharmacol Methods. 1984 Aug; 12(1): 69-78. Proliferative vitreoretinopathy: the Rb cell injection model for screening of antiproliferative drugs. [0503] Models of cataract are described in the following publications: The role of Src family kinases in cortical cataract formation. Zhou J, Menko AS.Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2293-300; Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on solenite treated rats. Wang S, et al. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract& listuids=15370367 Curr Eye Res. 2004 Jul;29(1):51-8; and Long-term organ culture system to study the effects of UV-A irradiation on lens transglutaminase. Weinreb 0, Dovrat A.; Curr Eye Res. 2004 Jul;29(1):51-8. [0504] The compounds of Table A-18 and Table A-19 are tested in these models of fibrotic conditions, in which it is found that they are effective in treating liver fibrosis and other fibrotic conditions. 203 WO 2011/072082 PCT/US2010/059578 Model systems of glaucoma [0505] Testing the active siRNA of the invention for treating or preventing glaucoma is preformed in rat animal model for optic nerve crush described for example in: Maeda, K. et al., "A Novel Neuroprotectant against Retinal Ganglion Cell Damage in a Glaucoma Model and an Optic Nerve Crush Model in the rat", Investigative Ophthalmology and visual Science (IOVS), March 2004, 45(3)851. Specifically, for optic nerve transection the orbital optic nerve (ON) of anesthetized rats is exposed through a supraorbital approach, the meninges severed and all axons in the ON transected by crushing with forceps for 10 seconds, 2 mm from the lamina cribrosa. [0506] Nucleic acid molecules as disclosed herein are tested in this animal model and the results show that these siRNA compounds are useful in treating and/or preventing glaucoma. Rat Optic Nerve Crush (ONC) Model: intravitreal siRNA delivery and eye drop delivery [0507] For optic nerve transsection the orbital optic nerve (ON) of anesthetized rats is exposed through a supraorbital approach, the meninges severed and all axons in the ON transected by crushing with forceps for 10 seconds, 2 mm from the lamina cribrosa. [0508] The siRNA compounds are delivered alone or in combination in 5uL volume (1Oug/uL) as eye drops. Immediately after optic nerve crush (ONC), 20ug/lOul test siRNA or Oul PBS is administered to one or both eyes of adult Wistar rats and the levels of siRNA taken up into the dissected and snap frozen whole retinae at 5h and 1 d, and later at 2d, 4d, 7d, 14d and 21d post injection is determined. Similar experiments are performed in order to test activity and efficacy of siRNA administered via eye drops. Model systems of ischemia reperfusion injury following lung transplantation in rats [0509] Lung ischemia/reperfusion injury is achieved in a rat animal model as described in Mizobuchi et al., The Journal of Heart and Lung Transplantation, Vol 23 No. 7 (2004) and in Kazuhiro Yasufuku et al., Am. J. Respir. Cell Mol Biol, Vol 25, pp 26-34 (2001). [0510] Specifically, after inducing anesthesia with isofluorane, the trachea is cannulated with a 14-gauge Teflon catheter and the rat is mechanically ventilated with rodent ventilator using 100% oxygen, at a rate of 70 breaths per minute and 2 cm H20 of positive end respiratory pressure. The left pulmonary artery, veins and main stem bronchus are occluded 204 with a Castaneda clamp. During the operation, the lung is kept moist with saline and the incision is covered to minimize evaporative losses. The period of ischemia is 60 minutes long. At the end of the ischemic period the clamp is removed and the lung is allowed to ventilate and reperfuse for further 4h, 24h, and 5 d post induction of lung ischemia. At the end of the experiment, the lungs are gently harvested and either frozen for RNA extraction or fixed in glutaraldehyde cocktail for subsequent histological analysis. The bleomycin animal model as a model for idiopathic pulmonary fibrosis (IPF). [0511] Testing feasibility of lung and liver delivery of vitamin A-Coatsome formulated siRNA administered by intravenous injection and intratracheal administration of siRNA vitaminA-Coatsome complex to a healthy mice and bleomycine-treated mice [05121 Objective: To test two administration routes for feasibility of vitamin A-Coatsome formulated siRNA delivery to normal and fibrotic mouse lungs. The main hypothesis to be tested in the current study is whether systemic administration of vitamin A-Coatsome formulated modified siRNA provides efficient uptake and cell-specific distribution in the fibrotic and normal mouse lungs. Intratracheal route of vitaminA-Coatsome formulated modified siRNA will be tested in parallel. siRNA detection and cell-specific distribution in the lungs and liver will be performed by in situ hybridization (ISH) [05131 Background: The Bleomycin model of pulmonary fibrosis has been well developed and characterized over the last three decades (Moeller, et al. Int J Biochem Cell Biol, 40:362-382, 2008; Chua et al., Am J Respir Cell Mol Biol 33:9-13, 2005). Histological hallmarks, such as intra-alveolar buds, mural incorporation of collagen and obliteration of alveolar space are present in BLM-treated animals similar to [PF patients. Early studies demonstrated that C57/Bl mice were consistently prone to BLM-induced lung fibrosis, whereas Balb/C mice were inheritantly resistant. Depending on the route of administration, different fibrotic pattern develops. Intratracheal instillation of BLM results in bronchiocentric accentuated fibrosis, whereas intravenous or intraperitoneal administration induces subpleural scarring similar to human disease (Chua et al. ibid). A mouse model of usual interstitial pneumonia (UIP) is used. This model shows a heterogenous distribution of fibroproliferation, distributed mainly subpleurally, forming similar lesions to those observed in the lungs of patients with idiopathic pulmonary (IPF) (Onuma, et al., Tohoku J Exp Med 194: 147-156, 2001 and Yamaguchi and Ruoslahti, Nature 336: 244-246, 1988). UIP will be induced by intraperitoneal injection of bleomycin every other day for 7 days for a constant composition of 205 subpleural fibroproliferation in the mouse lung (Swiderski et al. Am J Pathol 152: 821-828, 1998 and Shimizukawa et al., Am J Physiol Lung Cell Mol Physiol 284: L526-L532, 2003). 10514] As was previously demonstrated, vitamin A-loaded liposomes containing siRNA interact with retinol- binding protein (RBP) and provide efficient delivery to the hepatic stellate cells via RBP receptor (Sato et al. Nat Biotechnol 26:431-442, 2008). This study is planned to test whether vitA-Coatsome-siRNA complex will be efficiently taken up by an RBP receptor-expressing activated myofibroblasts in the lungs of bleomycin-treated mice. In addition, local administration route (intratracheal instillation) will be tested. [05151 General study design Mice - C57 BI male Starting N (BLM I.P.) - 40 (6 for the first pilot group, 34 for the study, taking in consideration anticipated 25% mortality) Starting N (Total) - 60 Test siRNA: SERPINHI compounds disclosed herein. Group ps: No BLM BLM BLM siRNA siRNA siRNA Terminatio N (before dose, adm. regime dose, adm regime n, post last siRNA mg/kg route mg/kg route siRNA administration BW, in BW adm n 0.1 ml saline 1 0.75 I.P. dd 0, 2, 4, 6 4.5 I.V. 2 daily 2h 4 2 0.75 I.P. dd 0, 2, 4, 6 4.5 I.V. 2 daily 24 h 4 3 0.75 I.P. dd 0, 2, 4, 6 2.25 I.T. 2 daily 2 h 4 4 0.75 I.P. dd 0, 2, 4, 6 2.25 I.T. 2 daily 24 h 4 5 intact n/a 4.5 I.V. 2 daily 2h 4 6 intact n/a 4.5 I.V 2 daily 24h 4 7 intact n/a 2.25 I.T 2 daily 2h 4 8 intact n/a 2.25 I.T. 2 daily 24 h 4 9 0.75 I.P. dd 0, 2, 4, 6 n/a I.V. 2 daily 2h 3 vehicle 10 0.75 I.P. dd 0, 2, 4, 6 n/a I/T/vehic 2 daily 24 h 3 le Il Intact n/a n/a intact n/a Any time 3 206 [05161 Bleomycin-induced pulmonary fibrosis. Pulmonary fibrosis of 12-wk-old female C57BL/6 mice will be induced by intraperitoneal instillation of bleomycin sulfate: 0.75 mg/kg body weight dissolved in 0.1 ml of saline every other day for 7 days, on days 0, 2, 4, and 6. [0517] Model follow up and monitoring. The mice will be weighed before the BLM treatment, and twice weekly for the period of study duration. [0518] Pilot evaluation of the establishment of fibrosis. The mice (N=30) are subjected to BLM treatment in groups, to allow for a one week time interval between the first treated group (N=5) and the rest of the animals. On day 14, two mice from the first group are sacrificed and the lungs harvested for the fast HE stain and quick histopathological evaluation of fibrosis. When lung fibrosis is confirmed, the remaining rats are sorted into the groups and treated with siRNA on Day 14 after the first BLM treatment. In case that no sufficient fibrosis develops in the lungs by day 14, the remaining mice from the first treated group are sacrificed on day 21, followed by quick histopathology evaluation of fibrosis. The rest of the animals are treated with test siRNA complex starting from day 21 after the BLM treatment. 105191 siRNA administration. On day 14 or day 21 after the first BLM administration (TBD during the study, based on pilot evaluation of establishment of fibrosis), the animals are group sorted, according to BW. The animals from groups I and 2 are administered intravenously (tail vein injection) with siRNA/vitA/Coatsome complex, at an siRNA concentration of 4.5 mg/kg BW. Intact animals of the same age (Groups 5 and 6) are treated in the same manner. BLM treated animals (Group 9) will be used as vitA-coatsome vehicle control). In 24 hours, the injection is repeated to all the animals, as above. [05201 The BLM animals from the groups 3 and 4, and intact mice from groups 7 and 8 are anesthetized with isoflurane and subjected to intratracheal instillation of 2.25 mg/kg BW siRNA formulated in vitA-loaded liposomes. Mice from the BLM group 10 are administered with vitA/Coatsome vehicle only. The inttratracheal instillation is repeated after 24 hours. [0521] Study termination. The animals from the groups 1, 3, 5, 7, 9 are sacrificed at 2 hours after the second siRNA complex injection or instillation. The animals from the groups 2,4,6,8,10 are sacrificed at 24 hours after the second siRNA complex injection or instillation. 207 [05221 Upon animals sacrifice, the mice are perfused transcardially with 10% neutral buffered formalin. The lungs are inflated with 0.8-1.0 ml of 10% NBF, and the trachea ligated. The lungs are excised and fixed for 24 h in 10 % NBF. The liver is harvested from each animal and fixed in 10% NBF for 24 h. [0523] Sectioning and evaluation. Consequent sections are prepared from the lungs and livers. First consequent section are stained with hematoxylin and eosin for assessment of lung and liver morphology, second section are stained with Sirius Red (trichrome) to identify collagen The third consequent sections are subjected to in situ hybridization (ISH) for detection of siRNA. 10524] The compounds as described herein are tested in this animal model and the results show that these siRNA compounds are useful in treating and/or preventing pulmonary fibrosis. 208 WO 2011/072082 PCT11S2010/059578 CO -CIO L) L) _ ~ 00 _L "C H L)H L) -~ Q H L) L) (D0 L0C 0 )6 )L (j0 A 0 ~ 0) U 0) 0) L) 00 L) 0 C)C -D 0 C)C 0) o c ) 0 709 WO 2011/072082 PCT/US2010/059578 C>0 H~ H0 Cc 01 0 C0 H t 0 0 -o 00 21 WO 2011/072082 PCT/US2010/059578 CO Ct) C/) H 0 H H H H 0 -~ -o H H 0 H CI-SQ~0 IT0 21 WO 2011/072082 PCT/US2010/059578 cn* C 0 X 0 w 01 Ct c 0212 WO 2011/072082 PCT/US2010/059578 [05251 The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. [0526] Applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other physical and electronic documents. [0527] It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The present invention teaches one skilled in the art to test various combinations and/or substitutions of chemical modifications described herein toward generating nucleic acid constructs with improved activity for mediating RNAi activity. Such improved activity can include improved stability, improved bioavailability, and/or improved activation of cellular responses mediating RNAi. Therefore, the specific embodiments described herein are not limiting and one skilled in the art can readily appreciate that specific combinations of the modifications described herein can be tested without undue experimentation toward identifying nucleic acid molecules with improved RNAi activity. [0528] The inventions illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising", "having," "including," containing", etc. shall be read expansively and without limitation (e.g., meaning "including, but not limited to,"). Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary 213 WO 2011/072082 PCT/US2010/059578 language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. [0529] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. Other embodiments are within the following claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. 214

Claims (19)

1. A double- stranded nucleic acid compound having a structure (A2) set forth below: (A2) 5' N 1 -(N)x - Z 3' (antisense strand) 3' Z' 2 -(N')y -z" 5' (sense strand) wherein each of N 2 , N and N' is an unmodified or modified ribonucleotide, or an unconventional moiety; wherein each of (N)x and (N')y is an oligonucleotide in which each consecutive N or N' is joined to the adjacent N or N' by a covalent bond; wherein each of x and y is independently an integer between 17 and 39; wherein the sequence of (N')y has complementarity to the sequence of (N)x and the sequence of (N)x has complementarity to a consecutive sequence in a mRNA encoding hsp47 wherein said mRNA encoding hsp47 has a sequence set forth in SEQ ID NO: 1; wherein N 1 is covalently bound to (N)x and is mismatched to the mRNA encoding hsp47 or is a complementary DNA moiety to the mRNA encoding hsp47; wherein N 1 is a moiety selected from the group consisting of natural or modified uridine, deoxyribouridine, ribothymidine, deoxyribothymidine, adenosine or deoxyadenosine; wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of N 2 - (N')y; wherein each of Z and Z' is independently present or absent, but if present is independently 1-5 consecutive nucleotides, consecutive non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein the sense strand comprises a sequence set forth in SEQ ID NO: 60 and the antisense strand comprises a sequence set forth in SEQ ID NO: 127.

2. The double-stranded nucleic acid compound according to claim 1, wherein x =y=18. 215

3. The double-stranded nucleic acid compound according to claim 1 or 2, wherein said double stranded nucleic acid compound is SERPINH1_2 having the structure: 5' UAUAGCACCCAUGUGUCUC -Z 3' (antisense strand SEQ ID NO:127) 3' Z '-AUAUCGUGGGUACACAGAG - z" 5' (sense strand SEQ ID NO:60) wherein each " "represents base pairing; wherein each of A, C, G and U is independently an unmodified ribonucleotide, a modified ribonucleotide, or an unconventional moiety; wherein each of Z and Z' is independently present or absent, but if present is independently 1-5 consecutive nucleotide or non-nucleotide moieties or a combination thereof covalently attached at the 3' terminus of the strand in which it is present; and wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5' terminus of the sense strand.

4. The double-stranded nucleic acid compound according to claim 3, wherein each of Z and Z' is present, and wherein optionally each of Z and Z' independently comprises a nucleotide overhang or a non-nucleotide overhang.

5. The double-stranded nucleic acid compound according to claim 4, wherein each of Z and Z' comprise a non-nucleotide overhang, wherein Z' comprises C3Pi or C30H; and wherein Z comprises C3Pi-C3OH.

6. The double-stranded nucleic acid compound according to any one of claims 3 to 5, wherein the antisense strand comprises 2'-0-methyl sugar modified ribonucleotides, wherein the 2'-0 methyl sugar modified ribonucleotides are optionally present in positions (5'>3') 3, 5, 9, 11, 13, 15, 17 and 19, and optionally further comprises a 2'-O-methyl sugar modified ribonucleotide or a 2'5' ribonucleotide in position (5'>3') 1.

7. The double-stranded nucleic acid compound according to any one of claims 3 to 6, wherein the antisense strand comprises a 2'5' ribonucleotide in any one of positions (5'>3') 5, 6, 7, or 8.

8. The double-stranded nucleic acid compound according to claim 6 or 7, wherein the sense strand comprises 4 or 5 consecutive 2'5' ribonucleotides at the 3' terminal or penultimate position. 216

9. The double-stranded nucleic acid compound according to claim 8, wherein the sense strand comprises 2'5' ribonucleotides in positions (5'>3') 15, 16, 17, and 18, and optionally comprises a 2'5' ribonucleotide in position 19.

10. The double-stranded nucleic acid compound according to claim 3, wherein z" is present and wherein the capping moiety is selected from the group consisting of an abasic ribose moiety, an inverted abasic ribose moiety, an inverted abasic deoxyribose moiety, an abasic deoxyribose moiety and modifications thereof; a C6-imino-Pi moiety; a mirror nucleotide moiety; a 5'OMe nucleotide moiety; a 4',5'-methylene nucleotide moiety; a 1-(D-D-erythrofuranosyl) nucleotide moiety; a 4'-thio nucleotide moiety, a carbocyclic nucleotide moiety; a 5'-amino-alkyl phosphate moiety; a 1,3 diamino-2-propyl phosphate moiety, a 3-aminopropyl phosphate moiety; a 6-aminohexyl phosphate moiety; a 12-aminododecyl phosphate moiety; a hydroxypropyl phosphate moiety; a 1,5 anhydrohexitol nucleotide moiety; an alpha-nucleotide moiety; a threo-pentofuranosyl nucleotide moiety; an acyclic 3',4'-seco nucleotide moiety; a 3,4-dihydroxybutyl nucleotide moiety; a 3,5 dihydroxypentyl nucleotide moiety, a 5'-5'-inverted abasic moiety; a 1,4-butanediol phosphate moiety; a 5'-amino moiety; and bridging or non bridging methylphosphonate and 5'-mercapto moieties.

11. The double-stranded nucleic acid compound according to claim 3, wherein the antisense strand comprises: 2'-O-methyl sugar modified ribonucleotides at positions (5'>3') 3, 5, 9, 11, 13, 15, 17 and 19, and optionally comprises a 2'-O-methyl sugar modified ribonucleotide at position 1; a 2'5' ribonucleotide in at least one of positions (5'>3') 1, 5, 6 or 7; and a 3' terminal non-nucleotide moiety, optionally a C3Pi-C30H non-nucleotide moiety, covalently attached to the 3' terminus; and wherein the sense strand comprises: at least one 2'5' ribonucleotide and/or a 2'-0-methyl modified ribonucleotide; 5 consecutive 2'5' ribonucleotides in the 3' terminal positions (5'>3') 15, 16, 17, 18 and 19; a non-nucleotide moiety, optionally a C3Pi non-nucleotide moiety, covalently attached at the 3' terminus; and a cap moiety, optionally an inverted abasic deoxyribonucleotide, covalently attached at the 5' terminus. 217

12. The double-stranded nucleic acid compound according to claim 11, wherein the antisense strand comprises: 2'-O-methyl sugar modified ribonucleotides at positions (5'>3') 1, 3, 5, 9, 11, 13, 15, 17 and 19; a 2'5' ribonucleotide in position (5'>3') 7; and a C3Pi-C30H non-nucleotide moiety covalently attached to the 3' terminus; and wherein the sense strand comprises: 5 consecutive 2'5' ribonucleotides in the 3' terminal positions (5'>3') 15, 16, 17, 18 and 19; a C3Pi non-nucleotide moiety covalently attached at the 3' terminus; and an inverted abasic cap moiety covalently attached at the 5' terminus.

13. A composition comprising the double-stranded nucleic acid compound according to any one of claims 1 to 12 and a pharmaceutically acceptable carrier.

14. A method of treating a subject suffering from a disease or condition associated with hsp47 expression, said method comprising administering to the subject the double-stranded nucleic acid compound according to any one of claims 1 to 12, or the composition according to claim 13 in an amount effective to treat the disease or condition.

15. Use of the double-stranded nucleic acid compound of any one of claims 1 to 12 or the composition according to claim 13, in the manufacture of a medicament for treating a disease or condition associated with hsp47 expression.

16. The method according to claim 14 or the use according to claim 15, wherein the disease or condition is a fibrotic condition selected from the group consisting of liver fibrosis; kidney fibrosis for any reason (CKD including ESRD); lung fibrosis; peritoneal fibrosis; chronic hepatic damage; fibrillogenesis; myelofibrosis, abnormal scarring (keloids) associated with all possible types of skin injury accidental and iatrogenic (operations); scleroderma; cardiofibrosis, failure of glaucoma filtering operation; and intestinal adhesions.

17. The method according to claim 14 or the use according to claim 15, wherein the disease or condition is selected from the group consisting of liver fibrosis, liver cirrhosis, pulmonary fibrosis, kidney fibrosis, peritoneal fibrosis, chronic hepatic damage, cardiofibrosis, retinal fibrosis, retro orbital fibrosis, lacrimal gland fibrosis, myelofibrosis, intestinal fibrosis, vocal cord mucosal 218 fibrosis, laryngeal fibrosis, nephrogenic systemic fibrosis, congenital hepatic fibrosis and oral submucosal fibrosis.

18. The method according to claim 14 or the use according to claim 15, wherein the disease or condition is a fibrosis of skin, peritoneum, liver, pancreas, kidney, heart, lung, bone marrow, eye, intestine, vocal cord and/or vasculature.

19. The double-stranded nucleic acid compound of any one of claims 1 to 12 or the composition according to claim 13 or the method according to claim 14, 16 17 or 18 or the use according to claim 15, 16, 17 or 18, substantially as hereinbefore described with reference to the Figures and/or Examples. 219